0001493152-24-04497810-Q Cocrystal Pharma, Inc. 20241113202411130803037083038083038 0 0001493152-24-044978 10-Q 58 20240930 20241113 20241113 Cocrystal Pharma, Inc. 0001412486 2834 352528215 DE 1231 10-Q 34 001-38418 241451328 19805 N. CREEK PARKWAY BOTHELL WA 98011 (786) 459-1831 19805 N. CREEK PARKWAY BOTHELL WA 98011 BIOZONE PHARMACEUTICALS, INC. 20110304 International Surf Resorts, Inc. 20070917 10-Q 1 form10-q.htm false --12-31 Q3 0001412486 P3Y 0001412486 2024-01-01 2024-09-30 0001412486 2024-11-13 0001412486 2024-09-30 0001412486 2023-12-31 0001412486 2024-07-01 2024-09-30 0001412486 2023-07-01 2023-09-30 0001412486 2023-01-01 2023-09-30 0001412486 us-gaap:CommonStockMember 2023-12-31 0001412486 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001412486 us-gaap:RetainedEarningsMember 2023-12-31 0001412486 us-gaap:CommonStockMember 2024-03-31 0001412486 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001412486 us-gaap:RetainedEarningsMember 2024-03-31 0001412486 2024-03-31 0001412486 us-gaap:CommonStockMember 2024-06-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001412486 us-gaap:RetainedEarningsMember 2024-06-30 0001412486 2024-06-30 0001412486 us-gaap:CommonStockMember 2022-12-31 0001412486 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001412486 us-gaap:RetainedEarningsMember 2022-12-31 0001412486 2022-12-31 0001412486 us-gaap:CommonStockMember 2023-03-31 0001412486 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001412486 us-gaap:RetainedEarningsMember 2023-03-31 0001412486 2023-03-31 0001412486 us-gaap:CommonStockMember 2023-06-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001412486 us-gaap:RetainedEarningsMember 2023-06-30 0001412486 2023-06-30 0001412486 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001412486 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001412486 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001412486 2024-01-01 2024-03-31 0001412486 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001412486 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001412486 2024-04-01 2024-06-30 0001412486 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001412486 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001412486 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001412486 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001412486 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001412486 2023-01-01 2023-03-31 0001412486 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001412486 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001412486 2023-04-01 2023-06-30 0001412486 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001412486 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001412486 us-gaap:CommonStockMember 2024-09-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001412486 us-gaap:RetainedEarningsMember 2024-09-30 0001412486 us-gaap:CommonStockMember 2023-09-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001412486 us-gaap:RetainedEarningsMember 2023-09-30 0001412486 2023-09-30 0001412486 COCP:SweepAccountMember 2024-09-30 0001412486 COCP:SweepAccountMember 2023-12-31 0001412486 COCP:OutstandingOptionsToPurchaseCommonStockMember 2024-01-01 2024-09-30 0001412486 COCP:OutstandingOptionsToPurchaseCommonStockMember 2023-01-01 2023-09-30 0001412486 COCP:RestrictedStockUnitsForCommonStockMember 2024-01-01 2024-09-30 0001412486 COCP:RestrictedStockUnitsForCommonStockMember 2023-01-01 2023-09-30 0001412486 COCP:WarrantsToPurchaseCommonStockMember 2024-01-01 2024-09-30 0001412486 COCP:WarrantsToPurchaseCommonStockMember 2023-01-01 2023-09-30 0001412486 srt:MinimumMember 2024-09-30 0001412486 srt:MaximumMember 2024-09-30 0001412486 COCP:LabEquipmentMember 2024-09-30 0001412486 COCP:LabEquipmentMember 2023-12-31 0001412486 COCP:FinanceLeaseRightofUseLabEquipmentNetMember 2024-09-30 0001412486 COCP:FinanceLeaseRightofUseLabEquipmentNetMember 2023-12-31 0001412486 COCP:ComputerAndOfficeEquipmentMember 2024-09-30 0001412486 COCP:ComputerAndOfficeEquipmentMember 2023-12-31 0001412486 2024-06-27 0001412486 COCP:TwoThousandandFifteenEquityIncentivePlansMember 2024-09-30 0001412486 COCP:TwoThousandandFifteenEquityIncentivePlansMember 2024-01-01 2024-09-30 0001412486 2024-08-12 0001412486 2024-08-12 2024-08-12 0001412486 us-gaap:EmployeeStockOptionMember 2023-12-31 0001412486 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001412486 us-gaap:EmployeeStockOptionMember 2024-09-30 0001412486 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001412486 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001412486 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001412486 COCP:CollaborationAgreementMember srt:MaximumMember 2019-01-02 0001412486 COCP:MiamiFloridaMember 2024-01-01 2024-09-30 0001412486 COCP:BothellWashingtonMember 2024-01-01 2024-09-30 0001412486 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001412486 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001412486 COCP:NorthCreekTecLLCMember COCP:AmendedLeaseAgreementForExpansionMember 2023-09-21 0001412486 COCP:NorthCreekTecLLCMember COCP:AmendedLeaseAgreementForExpansionMember 2023-09-21 2023-09-21 0001412486 COCP:NorthCreekTecLLCMember COCP:AmendedLeaseAgreementForExtensionMember 2023-09-21 0001412486 COCP:NorthCreekTecLLCMember COCP:AmendedLeaseAgreementForExtensionMember 2023-09-21 2023-09-21 0001412486 COCP:NorthCreekTecLLCMember 2023-09-21 2023-09-21 0001412486 COCP:DrPhillipFrostMember 2024-08-14 2024-08-14 0001412486 us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0001412486 us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001412486 COCP:PhaseTwoAClinicalTrialMember 2022-08-03 0001412486 COCP:PhaseTwoAClinicalTrialMember 2024-01-01 2024-09-30 0001412486 COCP:PhaseTwoAClinicalTrialMember 2024-09-30 0001412486 COCP:AgreementMember COCP:HVIVOMember 2024-01-01 2024-09-30 0001412486 COCP:AgreementMember COCP:HVIVOMember 2024-05-21 0001412486 COCP:SecuritiesPurchaseAgreementMember 2023-04-04 2023-04-04 0001412486 COCP:SecuritiesPurchaseAgreementMember 2023-04-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft COCP:Segment Â Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Â FORM 10-Q Â â˜ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended September 30, 2024 Â OR Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period from to Â Commission file number: 001-38418 Â COCRYSTAL PHARMA, INC. (Exact name of registrant as specified in its charter) Â Delaware Â 35-2528215 (State or Other Jurisdiction of Â (I.R.S. Employer Incorporation or Organization) Â Identification No.) Â Â Â 19805 North Creek Parkway Bothell, WA Â 98011 (Address of Principal Executive Office) Â (Zip Code) Â Registrantâ€™s telephone number, including area code: 877-262-7123 Â Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜‘ No â˜ Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Sec.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜‘ No â˜ Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. (Check one): Â Large accelerated filer â˜ Accelerated filer â˜ Â Â Â Â Non-accelerated filer â˜‘ Smaller reporting company â˜‘ Â Â Â Â Emerging growth company â˜ Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes â˜ No â˜‘ Â Securities registered pursuant to Section 12(b) of the Act: Â Title of Each Class Â Trading Symbol(s) Â Name of each exchange on which registered Common Stock Â COCP Â The Nasdaq Stock Market LLC (The Nasdaq Capital Market) Â As of November 13, 2024, the number of outstanding shares of the registrantâ€™s common stock, par value $0.001 per share, was approximately 10,173,790. Â Â Â Â Â Â COCRYSTAL PHARMA, INC. Â FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2024 Â INDEX Â Part I - FINANCIAL INFORMATION Â Item 1. Â Condensed Consolidated Balance Sheets F-1 Condensed Consolidated Statements of Operations F-2 Condensed Consolidated Statements of Stockholdersâ€™ Equity F-3 Condensed Consolidated Statements of Cash Flows F-4 Notes to the Condensed Consolidated Financial Statements F-5 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 3 Item 3. Quantitative and Qualitative Disclosures About Market Risk 9 Item 4. Controls and Procedures 9 Part II - OTHER INFORMATION Â Item 1. Legal Proceedings 10 Item 1. A. Risk Factors 10 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 10 Item 3. Defaults Upon Senior Securities 10 Item 4. Mine Safety Disclosures 10 Item 5. Other Information 10 Item 6. Exhibits 11 SIGNATURES 12 Â 2 Â Â Part I â€“ FINANCIAL INFORMATION Â COCRYSTAL PHARMA, INC. Â CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except per share data) Â Â Â September 30, 2024Â Â December 31, 2023Â Â Â (unaudited)Â Â Â Â AssetsÂ Â Â Â Â Â Â Â Current assets:Â Â Â Â Â Â Â Â CashÂ $13,020Â Â $26,353Â Restricted cashÂ Â 75Â Â Â 75Â Tax credit receivableÂ Â 652Â Â Â 890Â Prepaid expenses and other current assetsÂ Â 509Â Â Â 1,773Â Total current assetsÂ Â 14,256Â Â Â 29,091Â Property and equipment, netÂ Â 181Â Â Â 271Â DepositsÂ Â 29Â Â Â 46Â Operating lease right-of-use assets, net (including $163 and $42 respectively, to related party)Â Â 1,767Â Â Â 1,851Â Total assetsÂ $16,233Â Â $31,259Â Â Â Â Â Â Â Â Liabilities and stockholdersâ€™ equityÂ Â Â Â Â Â Â Â Current liabilities:Â Â Â Â Â Â Â Accounts payable and accrued expensesÂ $1,655Â Â $3,022Â Current maturities of operating lease liabilities (including $55 and $42 respectively, to related party)Â Â 293Â Â Â 240Â Total current liabilitiesÂ Â 1,948Â Â Â 3,262Â Long-term liabilities:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Operating lease liabilities (including $163 and $0 respectively, to related party)Â Â 1,582Â Â Â 1,613Â Â Â Â Â Â Â Â Total liabilitiesÂ Â 3,530Â Â Â 4,875Â Â Â Â Â Â Â Â Â Commitments and contingencies (Note 8)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stockholdersâ€™ equity:Â Â Â Â Â Â Â Common stock, $0.001 par value 100,000 and 150,000 shares authorized as of September 30, 2024, and December 31, 2023; 10,174 shares issued and outstanding as of September 30, 2024 and December 31, 2023Â Â 10Â Â Â 10Â Additional paid-in capitalÂ Â 342,845Â Â Â 342,288Â Accumulated deficitÂ Â (330,152)Â Â (315,914) Total stockholdersâ€™ equityÂ Â 12,703Â Â Â 26,384Â Total liabilities and stockholdersâ€™ equityÂ $16,233Â Â $31,259Â Â See accompanying notes to condensed consolidated financial statements. Â F-1 Â Â COCRYSTAL PHARMA, INC. Â CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except per share data) Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Â Three months ended September 30,Â Â Â Nine months ended September 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Operating expenses:Â Â Â Â Â Â Â Â Â Â Â Â Research and developmentÂ Â 3,242Â Â Â 4,194Â Â Â 10,500Â Â Â 10,902Â General and administrativeÂ Â 1,800Â Â Â 1,849Â Â Â 4,148Â Â Â 4,591Â Legal settlementÂ Â -Â Â Â (1,600)Â Â -Â Â Â (1,600) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total operating expensesÂ Â 5,042Â Â Â 4,443Â Â Â 14,648Â Â Â 13,893Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Loss from operationsÂ Â (5,042)Â Â (4,443)Â Â (14,648)Â Â (13,893) Other income (expense):Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest income (expense), netÂ Â 111Â Â Â 320Â Â Â 482Â Â Â 460Â Foreign exchange lossÂ Â (8)Â Â (42)Â Â (72)Â Â (87) Total other expense, netÂ Â 103Â Â Â 278Â Â Â 410Â Â Â 373Â Net lossÂ $(4,939)Â $(4,165)Â Â (14,238)Â Â (13,520) Net loss per common share, basic and dilutedÂ $(0.49)Â $(0.41)Â Â (1.40)Â Â (1.43) Weighted average number of common shares, basic and dilutedÂ Â 10,174Â Â Â 10,153Â Â Â 10,174Â Â Â 9,461Â Â See accompanying notes to condensed consolidated financial statements. Â F-2 Â Â COCRYSTAL PHARMA, INC. Â CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (unaudited) (in thousands) Â Â Â SharesÂ Â AmountÂ Â CapitalÂ Â DeficitÂ Â EquityÂ Â Â Common StockÂ Â Additional Paid-inÂ Â AccumulatedÂ Â Total Stockholdersâ€™Â Â Â SharesÂ Â AmountÂ Â CapitalÂ Â DeficitÂ Â EquityÂ Balance as of December 31, 2023Â Â 10,174Â Â Â $10Â Â Â $342,288Â Â Â $(315,914)Â Â $26,384Â Stock-based compensationÂ Â -Â Â Â -Â Â Â 157Â Â Â -Â Â Â 157Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (3,956)Â Â (3,956) Balance as of March 31, 2024Â Â 10,174Â Â Â $10Â Â Â $342,445Â Â Â $(319,870)Â Â $22,585Â Stock-based compensationÂ Â -Â Â Â -Â Â Â 148Â Â Â -Â Â Â 148Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (5,343)Â Â (5,343) Balance as of June 30, 2024Â Â 10,174Â Â Â $10Â Â Â $342,593Â Â Â $(325,213)Â Â $17,390Â Stock-based compensationÂ Â -Â Â Â -Â Â Â 252Â Â Â -Â Â Â 252Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (4,939)Â Â (4,939) Balance as of September 30, 2024Â Â 10,174Â Â Â $10Â Â Â $342,845Â Â Â $(330,152)Â Â $12,703Â Â Â Â Â Common StockÂ Â Additional Paid-inÂ Â AccumulatedÂ Â Total Stockholdersâ€™Â Â Â SharesÂ Â AmountÂ Â CapitalÂ Â DeficitÂ Â EquityÂ Balance as of December 31, 2022Â Â 8,143Â Â Â $8Â Â Â $337,489Â Â Â $(297,930)Â Â $39,567Â Stock-based compensationÂ Â -Â Â Â -Â Â Â 291Â Â Â -Â Â Â 291Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (5,189)Â Â (5,189) Balance as of March 31, 2023Â Â 8,143Â Â Â $8Â Â Â $337,780Â Â Â $(303,119)Â Â $34,669Â Stock-based compensationÂ Â -Â Â Â -Â Â Â 179Â Â Â -Â Â Â 179Â Â Â Sale of common stock to related entities, net of transaction costsÂ Â 2,031Â Â Â 2Â Â Â 3,998Â Â Â -Â Â Â 4,000Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (4,166)Â Â (4,166) Balance as of June 30, 2023Â Â 10,174Â Â Â $10Â Â Â $341,957Â Â Â $(307,285)Â Â $34,682Â BalanceÂ Â 10,174Â Â Â $10Â Â Â $341,957Â Â Â $(307,285)Â Â $34,682Â Stock-based compensationÂ Â -Â Â Â -Â Â Â 173Â Â Â -Â Â Â 173Â Net lossÂ Â -Â Â Â -Â Â Â -Â Â Â (4,165)Â Â (4,165) Balance as of September 30, 2023Â Â 10,174Â Â Â $10Â Â Â $342,130Â Â Â $(311,450)Â Â $30,690Â BalanceÂ Â 10,174Â Â Â $10Â Â Â $342,130Â Â Â $(311,450)Â Â $30,690Â Â See accompanying notes to condensed consolidated financial statements. Â F-3 Â Â COCRYSTAL PHARMA, INC. Â CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (in thousands) Â Â Â 2024Â Â 2023Â Â Â Nine months ended September 30,Â Â Â 2024Â Â 2023Â Operating activities:Â Â Â Â Â Â Â Â Net lossÂ $(14,238)Â $(13,520) Adjustments to reconcile net loss to net cash used in operating activities:Â Â Â Â Â Â Â Depreciation and amortization expenseÂ Â 98Â Â Â 149Â Right of use assetsÂ Â 247Â Â Â 163Â Stock-based compensationÂ Â 558Â Â Â 643Â Operating lease liabilitiesÂ Â (142)Â Â (172) Changes in operating assets and liabilities:Â Â Â Â Â Â Â Â Prepaid expenses and other current assetsÂ Â 1,281Â Â Â 401Â Tax credit receivableÂ Â 238Â Â Â 166Â Accounts payable and accrued expensesÂ Â (1,367)Â Â 830Â Â Â Â Â Â Â Â Net cash used in operating activitiesÂ Â (13,325)Â Â (11,340) Â Â Â Â Â Â Â Â Investing activities:Â Â Â Â Â Â Â Purchases of property and equipmentÂ Â (8)Â Â (59) Net cash used in investing activitiesÂ Â (8)Â Â (59) Â Â Â Â Â Â Â Financing activities:Â Â Â Â Â Â Â Payments on finance lease liabilitiesÂ Â -Â Â Â (7) Proceeds from sale of common stock to related entities, net of transaction costsÂ Â -Â Â Â 4,000Â Net cash provided by financing activitiesÂ Â -Â Â Â 3,993Â Â Â Â Â Â Â Â Net decrease in cash and restricted cashÂ Â (13,333)Â Â (7,406) Cash and restricted cash at beginning of periodÂ Â 26,428Â Â Â 37,219Â Cash and restricted cash at end of periodÂ $13,095Â Â $29,813Â Â Â Â Â Â Â Â Supplemental disclosure:Â Â Â Â Â Â Â Non-cash investing and financing activitiesÂ Â Â Â Â Â Â Â Initial recognition of right-of-use assets and lease liabilitiesÂ $163Â Â $-Â Â Â See accompanying notes to condensed consolidated financial statements. Â F-4 Â Â COCRYSTAL PHARMA, INC. Â NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 and 2023 (unaudited) Â 1. Organization and Business Â Cocrystal Pharma, Inc. (â€œweâ€, the â€œCompanyâ€ or â€œCocrystalâ€), a clinical stage biopharmaceutical company incorporated in Delaware, has been developing novel technologies and approaches to create first-in-class or best-in-class antiviral drug candidates. Our focus is to pursue the development and commercialization of broad-spectrum antiviral drug candidates that will transform the treatment and prophylaxis of viral diseases in humans. By concentrating our research and development efforts on viral replication inhibitors, we plan to leverage our infrastructure and expertise in these areas. Â The Companyâ€™s activities since inception have principally consisted of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Companyâ€™s development programs, obtaining regulatory approvals of its products and, ultimately, the attainment of profitable operations is dependent on future events, including, among other things, its ability to access potential markets, secure financing, develop a customer base, attract, retain and motivate qualified personnel, and develop strategic alliances. Â Liquidity Â The Companyâ€™s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative operating cash flows since inception. For the nine months ended September 30, 2024, the Company recorded a net loss of approximately $14,238,000 and used approximately $13,325,000 of cash in operating activities. Â On September 30, 2024, the Company had cash and restricted cash of approximately $13,095,000. Restricted cash represents amounts pledged as collateral for financing arrangements that are currently limited to the issuance of business credit cards. The restriction will end upon the conclusion of these financing arrangements. We believe that our current resources will be sufficient to fund our operations beyond the next 12 months. This estimate is based, in part, upon our currently projected expenditures. Â The Companyâ€™s activities since inception have principally consisted of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Companyâ€™s development programs, obtaining regulatory approvals of its products and, ultimately, the attainment of profitable operations is dependent on future events, including, among other things, its ability to access potential markets, secure financing, develop a customer base, attract, retain and motivate qualified personnel, and develop strategic alliances. Through September 30, 2024, the Company has primarily funded its operations through equity offerings. Â The Company will need to continue obtaining adequate capital to fund operating losses until it becomes profitable. The

Company can give no assurances that the additional capital it is able to raise, if any, will be sufficient to meet its needs, or that any such financing will be obtainable on acceptable terms. Our future cash requirements, and the timing of those requirements, will depend on a number of factors, including economic conditions, the approval and success of our products in development, the continued progress of research and development of our product candidates, the timing and outcome of clinical trials and regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims and other intellectual property rights, the status of competitive products, the availability of financing, our success in developing markets for our product candidates and legal proceedings that may arise. We have historically not generated sustained positive cash flow and if we are not able to secure additional funding when needed, we may have to delay, reduce the scope of, or eliminate one or more of our clinical trials or research and development programs. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its drug development activities. The Company expects to continue incurring substantial operating losses and negative cash flows from operations over the next several years during its pre-clinical and clinical development phases. Â 2. Basis of Presentation and Significant Accounting Policies Â Basis of Presentation Â The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (â€œU.S. GAAPâ€) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X set forth by the Securities and Exchange Commission (â€œSECâ€). They do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire fiscal year. For further information, refer to the consolidated financial statements and footnotes thereto included in the Companyâ€™s annual report on Form 10-K for the year ended December 31, 2023 filed on March 28, 2024 (â€œAnnual Reportâ€). Â Principles of Consolidation Â The consolidated financial statements include the accounts of Cocrystal Pharma, Inc. and its wholly owned subsidiaries: Cocrystal Discovery, Inc., Cocrystal Pharma Australia Pty Ltd. (â€œCocrystal Australiaâ€), RFS Pharma, LLC and Cocrystal Merger Sub, Inc. Intercompany transactions and balances have been eliminated. Â F-5 Â Â Segments Â The Company operates in only one segment. Management uses cash flows as the primary measure to manage its business and does not segment its business for internal reporting or decision-making. Â Use of Estimates Â Preparation of the Companyâ€™s consolidated financial statements in conformance with U.S. GAAP requires the Companyâ€™s management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Companyâ€™s consolidated financial statements and accompanying notes. The significant estimates in the Companyâ€™s consolidated financial statements relate to the valuation of equity awards and warrant liabilities, recoverability of deferred tax assets, estimated tax credit receivable and estimated useful lives of fixed assets. The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions. Â Concentrations of Credit Risk Â Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash deposited in accounts held at two U.S. financial institutions, which may, at times, exceed federally insured limits of $250,000 for each institution where accounts are held. At September 30, 2024 and December 31, 2023, our primary operating accounts held approximately $13,020,000 and $26,353,000, respectively, and our restricted cash collateral account balance was $75,000 and $75,000 at a different institution. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risks thereof. Â Foreign Currency Transactions Â The Company and its subsidiaries use the U.S. dollar as functional currency. Foreign currency transactions are initially measured and recorded in the functional currency using the exchange rate on the date of the transaction. Foreign exchange gains and losses arising from settlement of foreign currency transactions are recognized in profit and loss. Â Cocrystal Australia maintains its records in Australian dollars. The monetary assets and liabilities of Cocrystal Australia are remeasured into the functional currency using the closing rate at the end of every reporting period. All nonmonetary assets and liabilities and related profit and loss accounts are remeasured into the functional currency using the historical exchange rates. Profit and loss accounts, other than those that are remeasured using the historical exchange rates, are remeasured into the functional currency using the average exchange rate for the period. Foreign exchange gains and losses arising from the remeasurement into the functional currency is recognized in profit and loss. Â Fair Value Measurements Â FASB Accounting Standards Codification (â€œASCâ€) 820 defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: Â Â Level 1 â€” quoted prices in active markets for identical assets or liabilities. Â Â Â Level 2 â€” other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date. Â Â Â Level 3 â€” significant unobservable inputs that reflect managementâ€™s best estimate of what market participants would use to price the assets or liabilities at the measurement date. Â F-6 Â Â At September 30, 2024 and December 31, 2023, the carrying amounts of financial assets and liabilities, such as cash, tax receivable, other assets, and accounts payable and accrued expenses approximate their fair values due to their short-term nature. The carrying values of leases payable approximate their fair values due to the fact that the interest rates on these obligations are based on prevailing market interest rates. Â Long-Lived Assets Â The Company regularly reviews the carrying value and estimated lives of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include managementâ€™s estimate of the assetâ€™s ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Companyâ€™s business objective. Should an impairment exist, the impairment loss would be measured based on the excess of the carrying amount over the assetâ€™s fair value. Â Research and Development Expenses Â Research and development costs consist primarily of fees paid to consultants and outside service providers, and other expenses relating to the acquisition, design, development and testing of the Companyâ€™s clinical products. All research and development costs are expensed as incurred. Research and development costs are presented net of tax credits. Â The Companyâ€™s Australian subsidiary is entitled to receive government assistance in the form of refundable and non-refundable research and development tax credits (â€œRefundable Tax Creditsâ€) from the federal and provincial taxation authorities, based on qualifying expenditures incurred during the fiscal year. The Refundable Tax Credits are from the provincial taxation authorities and are not dependent on its ongoing tax status or tax position and accordingly are not considered part of income taxes. The Company records Refundable Tax Credits as a reduction of research and development expenses when the Company can reasonably estimate the amounts and it is more likely than not, they will be received. As of December 31, 2023, balance of Refundable Tax Credits was approximately $786,000, which was received in full as of September 30, 2024. The Company estimated and accrued Refundable Tax Credits for the nine months ended September 30, 2024 of approximately $652,000 and a tax payable of $15,000, resulting in a net balance of Refundable Tax Credits receivable of approximately $637,000. Â Income Taxes Â The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Realization of deferred tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred tax asset will not be realized based on the weight of available evidence, including expected future earnings. The Company recognizes an uncertain tax position in its financial statements when it concludes that a tax position is more likely than not to be sustained upon examination based solely on its technical merits. Only after a tax position passes the first step of recognition will measurement be required. Under the measurement step, the tax benefit is measured as the largest amount of benefit that is more likely than not to be realized upon effective settlement. This is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. The Company elects to accrue any interest or penalties related to income taxes as part of its income tax expense. Â F-7 Â Â As of September 30, 2024, the Company assessed its income tax expense based on its projected future taxable income for the year ending December 31, 2024 and therefore recorded no amount for income tax expense for the nine months ended September 30, 2024. In addition, the Company has significant deferred tax assets available to offset income tax expense due to net operating loss carry forwards which are currently subject to a full valuation allowance based on the Companyâ€™s assessment of future taxable income. Refer to our Annual Report on Form 10-K for the year ended December 31, 2023 for more information. Â Stock-Based Compensation Â The Company recognizes compensation expense using a fair value-based method for costs related to stock-based payments, including stock options. The fair value of options awarded to employees is measured on the date of grant using the Black-Scholes option pricing model and is recognized as expense over the requisite service period on a straight-line basis. Â Use of the Black-Scholes option pricing model requires the input of subjective assumptions including expected volatility, expected term, and a risk-free interest rate. The Company estimates volatility using a blend of its own historical stock price volatility as well as that of market comparable entities since the Companyâ€™s common stock has limited trading history and limited observable volatility of its own. The expected term of the options is estimated by using the SEC Staff Bulletin No. 107â€™s Simplified Method for Estimate Expected Term. The risk-free interest rate is estimated using comparable published federal funds rates. Â Net Income (Loss) per Share Â The Company accounts for and discloses net income (loss) per common share in accordance with FASB ASC Topic 260, Earnings Per Share. Basic income (loss) per common share is computed by dividing income (loss) attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common stock for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants and the conversion of convertible notes payable. Â The following table sets forth the number of potential common shares excluded from the calculations of net loss per diluted share because their inclusion would be anti-dilutive (in thousands): Â Schedule of Anti-dilutive Securities Excluded from Calculations of Net Loss Per Share Â Â 2024Â Â 2023Â Â Â September 30,Â Â Â 2024Â Â 2023Â Outstanding options to purchase common stockÂ 555Â Â Â 559Â Restricted stock units for common stockÂ Â 256Â Â Â -Â Warrants to purchase common stockÂ Â -Â Â Â 13Â TotalÂ Â 811Â Â Â 572Â Â F-8 Â Â Recent Accounting Pronouncements Â Authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC did not, or are not expected to, have a material impact on the Companyâ€™s consolidated financial statements and related disclosures. Â 3. Property and Equipment Â Property and equipment are recorded at cost and depreciated over the estimated useful lives of the underlying assets (three to five years) using the straight-line method. As of September 30, 2024, and December 31, 2023, property and equipment consists of (table in thousands): Â Schedule of Property and Equipment Â Â September 30, 2024Â Â December 31, 2023Â Lab equipmentÂ $1,765Â Â $1,757Â Finance lease right-of-use lab equipmentÂ Â 162Â Â Â 162Â Computer and office equipmentÂ Â 155Â Â Â 155Â Total property and equipmentÂ Â 2,082Â Â Â 2,074Â Less: accumulated depreciation and amortizationÂ Â (1,901)Â Â (1,803) Property and equipment, netÂ $181Â Â $271Â Â Total depreciation and amortization expense were approximately $98,000 and $149,000 for the nine months ended September 30, 2024 and 2023, which includes amortization expense of $0 and $7,164 for the nine months ended September 30, 2024 and 2023, respectively, related to assets under finance lease. For additional finance leases information, refer to Note 8 â€“ Commitments and Contingencies. Â 4. Accounts Payable and Accrued Expenses Â Accounts payable and accrued expenses consisted of the following (in thousands) as of: Â Schedule of Accounts Payable and Accrued Expenses Â Â September 30, 2024Â Â December 31, 2023Â Accounts payableÂ $859Â Â $1,222Â Accrued compensationÂ Â 185Â Â Â 109Â Accrued other expensesÂ Â 611Â Â Â 1,691Â Total accounts payable and accrued expensesÂ $1,655Â Â $3,022Â Â Accounts payable and accrued expenses contain unpaid general and administrative expenses and costs related to research and development that have been billed and estimated unbilled, respectively, as of period-end. Â 5. Equity Â As of September 30, 2024, the Company has authorized 100,000,000 shares of common stock, $0.001 par value per share, and 1,000,000 shares of preferred stock, $0.001 par value per share. Â On June 27, 2024, the Company, following approval of the Companyâ€™s stockholders at the 2024 Annual Meeting of Stockholders filed an amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware (the â€œAmendmentâ€) to decrease the number of shares of authorized capital stock of the Company from 155,000,000 shares of capital stock, consisting of 150,000,000 shares of common stock and 5,000,000 shares of preferred stock, to 101,000,000 shares of capital stock consisting of 100,000,000 shares of common stock and 1,000,000 shares of preferred stock. The Amendment became effective on June 27, 2024. Â The Company had 10,174,000 shares of common stock and no shares of preferred stock issued and outstanding as of September 30, 2024, and December 31, 2023. Â The holders of common stock are entitled to one vote for each share of common stock held. Â F-9 Â Â 6. Stock Based Awards Â Equity Incentive Plans Â The Company adopted an equity incentive plan in 2015 (the â€œ2015 Planâ€) under which 833,333 shares of common stock have been reserved for issuance to employees, and non-employee directors and consultants of the Company. Recipients of incentive stock options granted under the 2015 Plan shall be eligible to purchase shares of the Companyâ€™s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the 2015 Plan is ten years. As of September 30, 2024, 22,000 shares remain available for future grants under the 2015 Plan. Â Common Stock Reserved for Future Issuance Â The following table presents information concerning common stock available for future issuance (in thousands) as of September 30, 2024: Â Schedule of Common Stock Available for Future Issuance Â Â Shares Available for GrantÂ Balance at December 31, 2023Â Â 275Â Restricted Stock Units (RSU) GrantedÂ Â (256) Cancelled or returnedÂ Â 3Â Balance at September 30, 2024Â Â 22Â Â Stock Options Â The following table summarizes stock option transactions for the 2015 Plan, collectively, for the nine months ended September 30, 2024 (in thousands, except per share amounts): Â Schedule of Stock Option Transactions Â Â Total Options OutstandingÂ Â Weighted Average Exercise PriceÂ Â Aggregate Intrinsic ValueÂ Balance at December 31, 2023Â Â 558Â Â $10.37Â Â $-Â ExercisedÂ Â -Â Â Â -Â Â Â -Â GrantedÂ Â -Â Â Â -Â Â Â -Â CancelledÂ Â (3)Â Â Â -Â Â Â -Â Balance at September 30, 2024Â Â 555Â Â $10.40Â Â $-Â Â Restricted Stock Units Â On August 12, 2024, the Companyâ€™s Compensation Committee approved the issuance of 256,000 restricted stock unit (â€œRSUâ€) awards to non-employee directors, officers, consultants and employees. The aggregate fair value of the restricted stock unit awards granted was estimated to be $451,000 using the market price of the stock on the date of the grant which is expensed using the straight-line method over the vesting period. Â Schedule of Restricted Stock Units Â Â Total Options OutstandingÂ Â Weighted Average Fair ValueÂ Â Aggregate Intrinsic ValueÂ Unvested December 31, 2023Â Â -Â Â $-Â Â $-Â GrantedÂ Â 256Â Â Â -Â Â Â -Â ForfeitedÂ Â -Â Â Â -Â Â Â -Â VestedÂ Â 92Â Â Â 1.76Â Â Â -Â Unvested and expected to vest at September 30, 2024Â Â 164Â Â $1.76Â Â $-Â Â F-10 Â Â The Company accounts for share-based awards to employees and nonemployee directors and consultants in accordance with the provisions of ASC 718, Compensationâ€”Stock Compensation., and under the recently issued guidance following FASBâ€™s pronouncement, ASU 2018-07, Compensationâ€“Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. Under ASC 718, and applicable updates adopted, share-based awards are valued at fair value on the date of grant and that fair value is recognized over the requisite service, or vesting, period. The Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur. For the three and nine months ended September 30, 2024 and 2023, equity-based compensation expense recorded on vested options and RSU was $252,000 and $557,000 and $173,000 and $643,000 respectively. Â As of September 30, 2024, there was approximately $321,000 of total unrecognized compensation expense related to non-vested stock options that is expected to be recognized over a weighted average period of 0.8 years. For options granted and outstanding, there were 555,000 options outstanding which were fully vested or expected to vest, with an aggregate intrinsic value of $0.00, a weighted average exercise price of $10.40 and weighted average remaining contractual term of 7.47 years at September 30, 2024. For vested and exercisable options, outstanding shares totaled 435,000, with an aggregate intrinsic value of $0.00. These options had a weighted average exercise price of $12,38 per share and a weighted-average remaining contractual term of 7.16 years at September 30, 2024. Â The aggregate intrinsic value of outstanding and exercisable options at September 30, 2024 was calculated based on the closing price of the Companyâ€™s common stock as reported on The Nasdaq Capital Market on September 30, 2024 of $1.76 per share less the exercise price of the options. The aggregate intrinsic value is calculated based on the positive difference between the closing fair market value of the Companyâ€™s common stock and the exercise price of the underlying options. Â F-11 Â Â 7. Licenses and Collaborations Â On January 2, 2019, the Company entered into an Exclusive License and Research Collaboration Agreement (the â€œCollaboration Agreementâ€) with Merck Sharp & Dohme LLC (â€œMerckâ€) to discover and develop certain proprietary influenza A/B antiviral agents. Under

the terms of the Collaboration Agreement, Merck funded research and development for the program, including clinical development, and was responsible for worldwide commercialization of any products derived from the collaboration. Under the Collaboration Agreement Cocrystal was eligible to receive payments related to designated development, regulatory and sales milestones with the potential to earn up to $156,000,000, as well as royalties on product sales. The Collaboration Agreement provided that Merck may terminate the Collaboration Agreement at any time prior to the first commercial sale of the first product developed under the Collaboration Agreement, in its sole discretion, without cause. Â On December 15, 2023, the Company received written notice from Merck of Merckâ€™s election to terminate the Collaboration Agreement. The termination of the Collaboration Agreement took effect on March 14, 2024. According to Merckâ€™s termination notice, Merck determined there were no existing conditions to continue the collaboration. The termination resulted from the inability to develop the compounds to meet a specific aspect of Merckâ€™s program. The pending patent applications on compounds covered by the Collaboration Agreement and previously filed by Merck on behalf of both companies remain in place. Â Kansas State University Research Foundation Â Cocrystal entered into two License Agreement with Kansas State University Research Foundation (the â€œFoundationâ€) on February 18, 2020 to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of norovirus and coronavirus infections. Â On February 28, 2024, the Company provided notice to the Foundation of the Companyâ€™s election to terminate the 2020 License Agreements. The terminations, which were made due to the Companyâ€™s determination that further development efforts under the License Agreements would be futile, took effect on March 29, 2024. Â 8. Commitments and Contingencies Â Commitments Â In the ordinary course of business, the Company enters into non-cancellable leases to purchase equipment and for its facilities, including related party leases (see Note 9 â€” Transactions with Related Parties). Leases are accounted for as operating leases or finance leases, in accordance with ASC 842, Leases. Â Operating Leases Â The Company leases office space in Miami, Florida and research and development laboratory space in Bothell, Washington under operating leases that expire on September 30, 2027 and January 31, 2031, respectively. For operating leases, the weighted average discount rate is 6.4% and the weighted average remaining lease term is 5.5 years. Â The following table summarizes the Companyâ€™s maturities of operating lease liabilities, by year and in aggregate, as of September 30, 2024 (table in thousands): Â Schedule of Maturities of Operating Lease Liabilities Â Â Â Â Â 2024 (excluding the nine months ended September 30, 2024)Â $99Â 2025Â Â 407Â 2026Â Â 419Â 2027Â Â 415Â 2028Â Â 376Â 2029 and ThereafterÂ Â 513Â Total operating lease paymentsÂ Â 2,229Â Less: present value discountÂ Â (354) Total operating lease liabilitiesÂ $1,875Â Â As of September 30, 2024, the total operating lease liability of $293,000 is classified as a current operating lease liability. Â F-12 Â Â The operating lease liabilities summarized above do not include variable common area maintenance (the â€œCAMâ€) charges, which are contractual liabilities under the Companyâ€™s Bothell, Washington lease. CAM charges for the Bothell, Washington facility is calculated annually based on actual common expenses for the building incurred by the lessor and proportionately billed to tenants based on leased square footage. For the nine months ended September 30, 2024 and 2023, approximately $134,000 and $76,000 of CAM was included in general and administrative operating expenses on the condensed consolidated statements of operations, respectively. Â The minimum lease payments above include the amounts that would be paid if the Company maintains its Bothell lease for the five-year term, starting February 2024. Â On September 21, 2023, the Company amended the lease agreement with a North Creek Tec LLC, to expand its laboratory facility in Bothell â€“ WA, with additional 6,000 sq ft for a period of 5 years that expires on January 31, 2029, with monthly lease payments under this lease totaling $660,000. In addition, the Company amended the lease agreement to extend the original laboratory facility for an additional 7 years with monthly lease payments under this lease totaling $1,498,000. Through January 2031, the minimum lease payment combined totals approximately $380,000 annually. Â On August 14, 2024, the Company entered into a three-year lease extension with a limited liability company controlled by Dr. Phillip Frost, a director and a principal stockholder of the Company. On an annualized basis, straight-line rent expense is approximately $64,000 including fixed and estimable fees and taxes. Â For the nine months ended September 30, 2024 and 2023, operating lease expense, excluding short-term leases, finance leases and CAM charges, totaled approximately $291,000 and $175,000, respectively, of which $46,000 and $47,000 for each period was to a related party. Â Phase 2a Clinical Trial Â On August 3, 2022 the Company engaged hVIVO, a subsidiary of London-based Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organization (â€œCROâ€), to conduct a Phase 2a clinical trial with the Companyâ€™s novel, broad-spectrum, orally administered antiviral influenza candidate. The Company prepaid a reservation fee of $1.7 million upon execution of the agreement. As of September 30, 2024, the Company expensed $1.7 million leaving no balance in prepaid expenses. In addition, the Company incurred additional costs of $2.2 million on this agreement during the period ended September 30, 2024. Â The total estimated cost of the agreement (including the reservation fee) is approximately $6.9 million. Â On May 21, 2024, the Company entered into a new agreement with hVIVO, as a follow-on to CPI-CST-001 Influenza virus challenge study, in which potential resistance to CC-42344 antiviral compound will be genotypically characterized. The Company incurred $45,000 on this agreement for nine months ended September 30, 2024. The total estimated cost of this agreement is approximately $227,000. Â Contingencies Â From time to time, the Company is a party to, or otherwise involved in, legal proceedings arising in the normal course of business. As of the date of this report, except as described below, the Company is not aware of any proceedings, threatened or pending, against it which, if determined adversely, would have a material effect on its business, results of operations, cash flows or financial position. Â 9. Transactions with Related Parties Â On April 4, 2023, the Company entered into a Securities Purchase Agreement with two accredited investors (the â€œPurchasersâ€) whereby the Purchasers agreed to purchase a total of 2,030,458 shares of unregistered common stock at a price of $1.97 per share for a total purchase price of $4,000,000 in two equal $2,000,000 investments. The Purchasers were an entity controlled by a director and another investor who subsequently joined the Companyâ€™s Board of Directors. Â On August 14, 2024, the Company entered a three-year lease extension with a limited liability company controlled by Dr. Phillip Frost, a director and a principal stockholder of the Company. On an annualized basis, straight-line rent expense is approximately $64,000 including fixed and estimable fees and taxes. Â F-13 Â Â ITEM 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Â Overview Â Cocrystal Pharma, Inc. (the â€œCompanyâ€ or â€œCocrystalâ€) is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We have identified promising preclinical and clinical-stage antiviral compounds for unmet medical needs including influenza virus, coronavirus, norovirus and hepatitis C virus (â€œHCVâ€). Â Research and Development Update Â During the nine months ended September 30, 2024 the Company continued to focus its research and development efforts primarily in three areas. Â Â Influenza Program Â We have several candidates under development for the treatment of influenza infection. CC-42344, a novel PB2 inhibitor, was selected as a preclinical lead as an oral or inhaled treatment of pandemic and seasonal influenza A. This candidate binds to a highly conserved PB2 site of influenza polymerase complex (PB1: PB2: PA) and exhibits a novel mechanism of action. CC-42344 showed excellent in vitro antiviral activity against influenza A strains, including avian pandemic strains and TamifluÂ® and XofluzaÂ® resistant strains, and has favorable pharmacokinetic and drug resistance profiles. Oral CC-42344 is being evaluated in a Phase 2a human challenge study. In addition, the inhaled CC-42344 is being developed for the potential prophylactic treatment of pandemic and seasonal influenza infections. Dry powder inhalation development and toxicology studies have been evaluated. Â We received authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) to conduct a Phase 2a human challenge study with oral CC-42344 as a potential treatment for pandemic and seasonal influenza A. This ongoing randomized, double-blind, placebo-controlled study is evaluating the safety, tolerability, viral and clinical measurements of influenza A infection in subjects dosed with oral CC-42344 treatment. In May 2024 we announced completion of enrollment of 77 subjects. Â In June 2024 we reported the potential efficacy of CC-42344 against the new Texas avian flu strain from in vitro studies with the recently published genome sequence for H5N1. Using our proprietary structure-based platform technology, the Company reported a high-resolution cocrystal structure of this avian PB2 protein complexed with CC-42344 and confirmed that CC-42344 binds to its highly conserved PB2 region. The in vitro data using purified Texas avian H5N1 PB2 protein further showed in vitro affinity of CC-42344similar to that of the previously data using pandemic avian and seasonal influenza A PB proteins. We also continue developing novel broad-spectrum influenza antivirals targeting replication enzymes of seasonal and pandemic influenza A and B strains. Â 3 Â Â Norovirus and Coronavirus Programs Â We developed the novel protease inhibitor CDI-988 as an oral pan-viral treatment of noroviruses and coronaviruses, including SARS-CoV-2 and its variants. CDI-988 was specifically designed and developed using our proprietary structure-based drug discovery platform technology as a broad-spectrum antiviral inhibitor to a highly conserved region in the active site of noroviruses, coronaviruses and other 3CL viral proteases. We believe CDI-988 represents a first-in-class pan-viral antiviral for the treatment of viral gastroenteritis and COVID-19 caused by noroviruses and coronaviruses, respectively. Â Oral CDI-988 is being clinically evaluated for safety, tolerability and pharmacokinetics including a food-effect cohort in healthy volunteers in a single-center, randomized, double-blind, placebo-controlled Phase 1 study being conducted in Australia. Â We previously announced favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study with CDI-988 in July 2024. Study participants in the SAD cohorts received CDI-988 in doses ranging from 100 mg to 600 mg. All participants completed the study with no discontinuations. There were no serious adverse events or severe treatment-emergent adverse events. No clinically significant observations were noted in laboratory assessments, physical exams or electrocardiograms. Â In September 2024 we initiated dosing of the first subjects in the multiple-ascending dose (MAD) portion of the Phase 1 study with CDI-988. Â Therapeutic Targets Â Influenza: A worldwide public health problem, including the potential for pandemic disease. Â Influenza is a severe respiratory illness, caused primarily by influenza A or B virus. Influenza A viruses are the only influenza viruses known to cause influenza pandemics. Each year there are approximately 1 billion cases of seasonal influenza worldwide, with 3-5 million severe illnesses and up to 650,000 deaths, according to the World Health Organization (â€œWHOâ€). On average about 8% of the U.S. population contracts influenza each season, according to the Centers for Disease Control and Prevention (â€œCDCâ€). In addition to the health risk, influenza is responsible for approximately $10.4 billion in direct medical costs in the U.S. annually, according to the National Institutes of Health (â€œNIHâ€). Â Currently approved antiviral treatments for influenza are effective but burdened with significant viral resistance. Strains of influenza virus that are resistant to the approved treatments oseltamivir phosphate (TamifluÂ®), zanamavir (RelenzaÂ®) and baloxavir marboxil (XofluzaÂ®) have appeared and in some cases are predominant. For example, the predominant strain of the 2009 swine influenza pandemic was resistant to oseltamivir. Oseltamivir inhibits influenza neuraminidase enzymes, which are not highly conserved between viral strains. According to the WHO, approximately 15% of the H1N1 isolates circulating worldwide were oseltamivir resistant. Also, treatment-emergent resistance to recently approved baloxavir has been observed during clinical trials and the potential transmission of resistant influenza variants could significantly diminish baloxavir effectiveness. Â Coronavirus: COVID-19 continues to be a global pandemic fueled by an emergence of new strains. Â COVID-19 is a global pandemic with approximately 777 million confirmed cases globally, including 7 million deaths, as of October 2024, according to data reported by the WHO. Â Coronaviruses (CoV) are a large family of RNA viruses that historically have been associated with illness ranging from mild symptoms similar to the common cold to more severe respiratory disease. Infection with the novel SARS-CoV-2 has been associated with a wide range of responses, from no symptoms to more severe disease that has included pneumonia, severe acute respiratory syndrome, kidney failure, and death. The incubation period for SARS-CoV-2 is believed to be within 14 days after exposure, with most illness occurring within about five days after exposure. SARS-CoV-2, like other RNA viruses, is prone to mutate over time, resulting in the emergence of multiple variants. Adaptive mutations in the viral genome can alter the virusâ€™s pathogenic potential. Even a single amino acid exchange can drastically affect a virusâ€™s ability to evade the immune system and complicate the vaccine and antibody therapeutics development against the virus. Based on the recent epidemiological update by the WHO, five SARS-CoV-2 VOCs (variants of concern) have been identified since the beginning of the pandemic. Also, as demonstrated in the Delta, Omicron and other variants, some variations allow the virus to spread more easily and make it resistant to the treatments and vaccines. Â 4 Â Â On October 22, 2020, the U.S. Food and Drug Administration (â€œFDAâ€) approved the antiviral drug VekluryÂ® (remdesivir) for the treatment of COVID-19 requiring hospitalization. Remdesivir is a nucleotide prodrug that inhibits viral replication and was previously evaluated in clinical trials for Ebola treatment in 2014. On May 25, 2023, the FDA approved Paxlovidâ„¢ (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. For certain hospitalized adults with COVID-19, the FDA has also approved OlumiantÂ® (baricitinib) and ActemraÂ® (tocilizumab). In addition, the FDA issued emergency use authorization (EUA) for several antibody and antiviral therapeutics, including and Lagevrioâ„¢ (molnupiravir). Â We continue pursuing the development of novel antiviral compounds for the treatment of coronavirus infections using our established proprietary drug discovery platform. By targeting the viral replication enzymes and protease, we believe it is possible to develop an effective treatment for all coronavirus diseases including COVID-19, Severe Acute Respiratory Syndrome (SARS), and Middle East Respiratory Syndrome (MERS). Â Norovirus: A worldwide public health problem responsible for close to 90% of epidemic, non-bacterial outbreaks of gastroenteritis around the world with no effective treatment. Â Norovirus is a very common and highly contagious virus that causes symptoms of acute gastroenteritis among people of all ages. Norovirus infection can be significantly more severe and prolonged in specific risk groups including infants, children, the elderly and people with immunodeficiency. In immunosuppressed patients, chronic norovirus infection can lead to a debilitating illness with extended periods of nausea, vomiting and diarrhea. Symptoms include nausea, vomiting, stomach pain and diarrhea as well as fatigue, fever and dehydration. Norovirus outbreaks occur most commonly in semi-closed communities and have become notorious for their occurrence in hospitals, nursing homes, childcare facilities, cruise ships, schools, disaster relief sites and military settings. In the U.S. alone, noroviruses are responsible for an estimated 21 million cases annually, including 109,000 hospitalizations, 465,000 emergency department visits and nearly 900 deaths, according to the CDC. The NIH estimates the annual burden to the United States at $10.6 billion. Noroviruses are responsible for up to 1.1 million hospitalizations and 218,000 deaths annually in children in the developing world. Â There is currently no effective treatment or effective vaccine for norovirus, and the ability to curtail outbreaks is limited. We are developing a novel norovirus antiviral candidate for the prophylactic and therapeutic treatment of norovirus infection that is currently in a Phase 1 clinical study. A few companies have been developing vaccines and are in stages of clinical testing, including Vaxart Pharmaceutical, Moderna, Hillevax, Takeda Pharmaceuticals, Anhui Zhifei Longcom Biopharmaceutical (China) and National Vaccine and Serum Institute (China). Â By targeting viral replication enzymes and a viral protease, we believe it is possible to develop an effective treatment for all genogroups of norovirus. Also, because of the significant unmet medical need and the possibility of chronic norovirus infection in immunocompromised individuals, new antiviral therapeutic and prophylactic approaches may warrant an accelerated path to market. We are developing inhibitors of the RNA-dependent RNA polymerase and protease of norovirus. These enzymes are essential to viral replication and are highly conserved between all noroviral genogroups. Therefore, an inhibitor of these enzymes might be an effective treatment or short-term prophylactic agent, when administered during a cruise or nursing home stay, for example. We have developed X-ray quality norovirus polymerase and protease crystals and have identified promising inhibitors. We are implementing our proprietary drug discovery platform technology and approaches that have proven successful in our other antiviral programs. Â Hepatitis C: A large competitive market with opportunity for shorter treatment regimens. Â HCV is a highly competitive and changing market. Since 2014, several combinations of direct-acting antiviral agents (â€œDAAsâ€) have been approved for the treatment of HCV infection. These include HarvoniÂ® (sofosbuvir/ledipasvir) 12 weeks of treatment, Viekira Pakâ„¢ (ombitasvir/paritaprevir/ritonavir, dasabuvir) 12 weeks of treatment, EpclusaÂ® (sofosbuvir/velpatasvir) 12 weeks of treatment, Zepatierâ„¢ (elbasvir/grazoprevir) 12 weeks of treatment and MavyretÂ® (glecaprevir/pibrentasvir) eight weeks of treatment. We believe the next improvements in HCV treatment will be ultra-short combination oral treatments of four to six weeks, which is the goal of our program. Â 5 Â Â We anticipate a significant global HCV market opportunity that will persist through at least 2036, given the large prevalence of HCV infection worldwide. The 2024 World Health Organization Global Hepatitis Report estimates that 50 million people worldwide have chronic HCV infections with about 1 million new infections occurring per year and an estimated 3.2 million adolescents and children with chronic HCV infection. Â We are targeting the viral NS5B polymerase with a non-nucleoside inhibitor (â€œNNIâ€), which could be developed as part of an all-oral, pan-genotypic combination regimen. Our focus is on developing what is now called ultrashort treatment regimens from four to six weeks in length. Combining CC-31244 with different classes of approved direct-acting antivirals (â€œDAAsâ€) has the potential to change the paradigm of treatment for HCV by shortening the duration of treatment. Combination strategies with approved drugs could allow us to expand CC-31244 into the HCV antiviral therapeutic area globally and could lead to a high and fast cure rate, to improved compliance, and to reduced treatment duration. To our knowledge no competing company has yet developed a short HCV treatment of less than 8 weeks with a high (>95%) sustained virologic response (SVR) at week 12. Â CC-31244, an HCV NNI, is a potential best in class pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV. We completed a randomized, double-blinded Phase 1a/b study in healthy volunteers and HCV-infected subjects in Canada in September 2016, with favorable safety results. We completed a Phase 2a study in HCV genotype 1

subjects in the U.S. in 2017. HCV-infected subjects treated with CC-31244 had a rapid and marked decline in HCV RNA levels, and slow viral rebound after treatment. Results of this study suggest that CC-31244 could be an important component in a shortened duration all-oral HCV combination therapy. We have completed the Phase 2a final study report as filed with the FDA. See â€œItem 1 â€“ Business â€“ Research and Development Update â€“ Hepatitis Câ€ in our Annual Report on Form 10-K for the year ended December 31, 2023 for more information. Â We have been seeking a partner for further clinical development of CC-31244 since completing Phase 2a trials. Â Results of Operations for the Three and Nine Months Ended September 30, 2024 compared to the Three and Nine Months Ended September 30, 2023 Â Research and Development Expense Â Research and development expense consists primarily of compensation-related costs for our employees dedicated to research and development activities and clinical trials, as well as lab supplies, lab services, and facilities and equipment costs related to our research and development programs. Â Total research and development expenses for the three months ended September 30, 2024, and 2023 were $3,242,000 and $4,194,000, respectively. The decrease of $952,000 was primarily due to our Influenza CC-42344 product candidate moving out of Phase 2a clinical trial and the finalizing of the Phase 1 clinical trial of norovirus and coronavirus candidate CDI-988. Â Total research and development expenses for the nine months ended September 30, 2024 and 2023 were $10,500,000 and $10,902,000, respectively. The decrease of $402,000 was primarily due to a decrease in preclinical trial costs of $1.7 million and manufacturing development costs of $1.2 million, partially offset with an increase of $2.5 million related to CC-42344 Phase 2a clinical study costs. Â General and Administrative Expense Â General and administrative expenses include compensation-related costs for our employees dedicated to general and administrative activities, legal fees, audit and tax fees, consultants and professional services, and general corporate expenses. Â General and administrative expenses for the three months ended September 30, 2024, and 2023 were $1,800,000 and $1,849,000, respectively, remaining relatively stable between periods. Â General and administrative expenses for the nine months ended September 30, 2024 and 2023 were $4,148,000 and $4,591,000, respectively. The decrease of $443,000 was primarily due to reduction of legal litigation fees, insurance cost and other general and administrative expenses. Â 6 Â Â Legal settlement Â The Company paid $1.6 million into the registry of the court in 2022 that was expensed as legal settlement. Following a favorable appeal ruling, the Company received a refund of the $1.6 million from the registry of the court during the period ended September 30, 2023. Â Interest Income, Net Â Interest income (expense) for the three months ended September 30, 2024 and 2023 was $111,000 and $320,000, respectively, and for the nine months ended September 30, 2024 and 2023 was $482,000 and $460,000, respectively. The interest income was primarily earned on cash held in interest bearing bank accounts. Â Foreign Exchange Loss Â In 2022, the Company established a wholly owned subsidiary in Australia, making it subject to foreign exchange rate fluctuations. Foreign exchange loss during the nine months ended September 30, 2024 and 2023 was $ 72,000 and $87,000, respectively. Â Income Taxes Â No income tax benefit or expense was recognized for the three and nine months ended September 30, 2024 and 2023. The Companyâ€™s effective income tax rate was 0.00% for the three and nine months ended September 30, 2024 and 2023. As a result of the Companyâ€™s cumulative losses, management has concluded that a full valuation allowance against the Companyâ€™s net deferred tax assets is appropriate. Â Net Loss Â As a result of the above factors, net loss for the three and nine months ended September 30, 2024 was $ 4,939,000 and $14,238,000, respectively, compared with a net loss for the three and nine months ended September 30, 2023 was $4,165,000 and $13,520,000, respectively, as a result of developments related to our expenses described above. Â Liquidity and Capital Resources Â Net cash used in operating activities was $13,325,000 for the nine months ended September 30, 2024 compared with net cash used in operating activities of $11,340,000 for the same period in 2023. This increase was primarily related to period expenses of our Influenza A Phase 2a clinical trial and preparation for our anticipated Influenza A Phase 1 inhaler administer medicine clinical trial and completion of our COVID-19 Phase 1 clinical trial. Â We used $8,000 net cash for investing activities during the nine months ended September 30, 2024 compared with $59,000 net cash used for the same period in 2023. For the nine months ended September 30, 2024 the level of investments decreased compared with September 30, 2023 due to comparative reduction in purchases of laboratory equipment in 2024. Â Net cash provided by financing activities totaled $0 for the nine months ended September 30, 2024 compared with net cash provided by financing activities of $3,993,000 for the same period in 2023. Â The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs. The Company had $13,020,000 unrestricted cash on September 30, 2024. The Company believes it has sufficient cash to maintain planned operations for more than the next 12 months. Â We have focused our efforts on research and development activities, including through collaborations with suitable partners. We have been profitable on a quarterly basis but have never been profitable on an annual basis. We have no products approved for sale and have incurred operating losses and negative operating cash flows on an annual basis since inception. Â The Companyâ€™s interim consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Historically, public and private equity offerings have been our principal source of liquidity. Â 7 Â Â The Company is party to the At-The-Market Offering Agreement, dated July 1, 2020 (â€œATM Agreementâ€) with H.C. Wainwright & Co., LLC (â€œWainwrightâ€), pursuant to which the Company may issue and sell over time and from time to time, to or through Wainwright, up to $10,000,000 of shares of the Companyâ€™s common stock. There were no sales under the ATM Agreement during the nine months ended September 30, 2024. Â As the Company continues to incur losses, achieving profitability is dependent upon the successful development, approval and commercialization of its product candidates, and achieving a level of revenues adequate to support the Companyâ€™s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional capital. Management intends to fund future operations through additional private or public equity offerings and through arrangements with strategic partners or from other sources. There can be no assurances, however, that additional funding will be available on terms acceptable to the Company, or at all, and any equity financing may be very dilutive to existing stockholders. Â Cautionary Note Regarding Forward-Looking Statements Â This Quarterly Report on Form 10-Q contains â€œforward-looking statements,â€ as that term is defined under the Private Securities Litigation Reform Act of 1995 (â€œPSLRAâ€), SectionÂ 27A of the Securities Act of 1933, as amended (the â€œSecurities Actâ€), and SectionÂ 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). Forward-looking statements include statements about our expectations, beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies or prospects, operating results, cash flows and/or financial condition. You can identify forward-looking statements by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described below and in â€œItem 1A-Risk Factorsâ€ of our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, and described from time to time in our other filings with the Securities and Exchange Commission (the â€œSECâ€). We do not undertake any obligation to update forward-looking statements, except to the extent required by applicable law. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Â Risks and uncertainties, the occurrence of which could adversely affect our business, include the following: Â Â â—we have had a history of losses and may not generate sustained positive cash flow sufficient to fund our operations and research and development programs; Â â—our need for, and ability to obtain, additional financing when needed on favorable terms, or at all; Â â—the risks inherent in developing, obtaining regulatory approvals for and commercializing new, commercially viable and competitive products and treatments; Â â—our research and development activities may not result in commercially viable products; Â â—risks related to our development efforts, including the risk that clinical studies may not yield favorable results, or that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results; Â â—our ability to manage our growth and our expanded operations; Â â—the performance of our third-party distribution partners, licensees and manufacturers over which we have limited control, including the ability of our clinical research organizations to recruit volunteers for clinical studies; Â â—changes in regulation and policies in the U.S. and other countries, including increasing downward pressure on government spending on healthcare in the wake of the recent election in the U.S.; Â â—increased competition, including the possibility that competitors may develop effective and/or less costly treatments or vaccines, including as part of the programs financed by the U.S. government; Â â—our success is dependent on the involvement and continued efforts of our Chairman and Co-Chief Executive Officers; Â â—the information technology systems that we rely on may be subject to unauthorized tampering, cyberattack or other data security or privacy incidents that could impact our billing processes or disrupt our operations; Â â—failure to maintain the security of patient-related information; Â â—our ability to obtain and maintain intellectual property protection for our products; Â â—our ability to defend our intellectual property rights with respect to our products; Â â—our ability to operate our business without infringing the intellectual property rights of others; Â â—our ability to attract and retain key scientific and management personnel; Â â—failure to obtain and maintain regulatory approval for our products and services; Â â—legal, economic, political, regulatory, currency exchange, and other risks associated with international operations; and Â â—disruptions to operations, including impact on employees, facilities or technology, or on the industry or economy, from uncontrollable events such as geopolitical conflicts. Â 8 Â Â Critical Accounting Policies and Estimates Â In our Annual Report on Form 10-K for the year ended December 31, 2023, we disclosed our critical accounting policies and estimates upon which our financial statements are derived. Â Accounting estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates. Â Readers are encouraged to review these disclosures in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 in conjunction with the review of this report. Â ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Â Not applicable. Â ITEM 4. CONTROLS AND PROCEDURES Â Evaluation of Disclosure Controls and Procedures Â We carried out an evaluation, under the supervision and with the participation of our management, including our Co-Chief Executive Officers and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the â€œExchange Actâ€) as of the end of the period covered by this report. Based on that evaluation, our Co-Chief Executive Officers and Chief Financial Officer have concluded that our disclosure controls and procedures as of September 30, 2024 were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commissionâ€™s rules and forms. Â Changes in Internal Control over Financial Reporting Â There were no material changes in our internal controls over financial reporting or in other factors that could materially affect, or are reasonably likely to affect, our internal controls over financial reporting during the quarter ended September 30, 2024. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Â 9 Â Â PART II â€“ OTHER INFORMATION Â ITEM 1. LEGAL PROCEEDINGS Â From time to time, the Company is a party to, or otherwise involved in, legal proceedings arising in the normal course of business. During the reporting period, there have been no material changes to the description of legal proceedings set forth in our Annual Report on Form 10-Q for the year ended September 30, 2024. Â ITEM 1.A RISK FACTORS Â None. Â ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Â All recent sales of unregistered securities have been previously reported. Â ITEM 3. DEFAULTS UPON SENIOR SECURITIES Â None. Â ITEM 4. MINE SAFETY DISCLOSURES Â Not applicable. Â ITEM 5. OTHER INFORMATION Â During the nine months ended September 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any â€œnon-Rule 10b5-1 arrangementâ€ as defined in Item 408(c) of Regulation S-K. Â 10 Â Â ITEM 6. EXHIBITS Â The exhibits listed in the accompanying â€œExhibit Indexâ€ are filed or incorporated by reference as part of this Form 10-Q. Â EXHIBIT INDEX Â Exhibit Â Â Â Incorporated by Reference Â Filed or Furnished No. Â Exhibit Description Â Form Â Date Â Number Â Herewith 3.1 Â Certificate of Incorporation, as amended Â Â Â Â Â Â Â Filed 3.2 Â Amended and Restated Bylaws Â 8-K Â 2/19/21 Â 3.1 Â Â 31.1 Â Certification of Principal Executive Officer (302) Â Â Â Â Â Â Â Filed 31.2 Â Certification of Principal Executive Officer (302) Â Â Â Â Â Â Â Filed 31.3 Â Certification of Principal Financial Officer (302) Â Â Â Â Â Â Â Filed 32.1 Â Certification of Principal Executive and Principal Financial Officer (906) Â Â Â Â Â Â Â Furnished* 101.INS Â Inline XBRL Instance Document Â Â Â Â Â Â Â Filed 101.SCH Â Inline XBRL Taxonomy Extension Schema Document Â Â Â Â Â Â Â Filed 101.CAL Â Inline XBRL Taxonomy Extension Calculation Linkbase Document Â Â Â Â Â Â Â Filed 101.DEF Â Inline XBRL Taxonomy Extension Definition Linkbase Document Â Â Â Â Â Â Â Filed 101.LAB Â Inline XBRL Taxonomy Extension Label Linkbase Document Â Â Â Â Â Â Â Filed 101.PRE Â Inline XBRL Taxonomy Extension Presentation Linkbase Document Â Â Â Â Â Â Â Filed 104 Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) Â Â Â Â Â Â Â Filed Â Â * This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K. Â ** Certain schedules and other attachments have been omitted. The Company undertakes to furnish the omitted schedules and attachments to the Securities and Exchange Commission upon request. Â Copies of this report (including the financial statements) and any of the exhibits referred to above will be furnished at no cost to our stockholders who make a written request to our Corporate Secretary at Cocrystal Pharma, Inc., 4400 Biscayne Blvd, Suite 101, Miami, FL 33137. Â 11 Â Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â Â Cocrystal Pharma, Inc. Â Â Â Dated: November 13, 2024 By: /s/ Sam Lee Â Â Sam Lee Â Â President and Co-Chief Executive Officer Â Â (Principal Executive Officer) Â Â Â Dated: November 13, 2024 By: /s/ James Martin Â Â James Martin Â Â Chief Financial Officer and Co-Chief Executive Officer Â Â (Principal Executive Officer and Principal Financial Officer) Â 12 EX-3.1 2 ex3-1.htm Â Exhibit 3.1 Â CERTIFICATE OF INCORPORATION OF COCRYSTAL PHARMA, INC. Â (Conformed copy incorporating all amendments through November 13, 2024) Â 1. The name of the corporation is Cocrystal Pharma, Inc. (the â€œCompanyâ€). Â 2. The address of its registered office in the State of Delaware, County of New Castle, is 3411 Silverside Road, Rodney Building #104, Wilmington, Delaware 19810. The name of its registered agent at such address is Corporate Creations Network, Inc. Â 3. The nature of the business or purposes to be conducted or promoted are to engage in any lawful act or activity for which corporations may be organized under the Delaware General Corporation Law. Â 4. The total number of shares of stock of all classes and series the Company shall have authority to issue is 101,000,000 shares consisting of (i) 100,000,000 shares of common stock, par value of $0.001 per share and (ii) 1,000,000 shares of preferred stock, par value $0.001 per share with such rights, preferences and limitations as may be set from time to time by resolution of the board of directors and the filing of a certificate of designation as required by the Delaware General Corporation Law.1 Â 5. The name and mailing address of the incorporator is as follows: Â Michael D. Harris 1645 Palm Beach Lakes Blvd. Suite 1200 West Palm Beach, FL 33401 Â 6. The name and mailing address of each person who is to serve as a director until the first annual meeting of the shareholders or until a successor is elected and qualified, is as follows: Â Name Â Mailing Address Â Â Â Dr. Gary Wilcox Â 4018 Via Laguna Â Â Santa Barbara, CA 93110 Â 7. The Company is to have perpetual existence. In furtherance and not in limitation of the powers conferred by statute, the board of directors is expressly authorized to make, amend, alter or repeal the bylaws of the Company. Â 8. Elections of directors need not be by written ballot unless the bylaws of the Company shall so provide. Â Meetings of shareholders may be held within or without the State of Delaware as the bylaws may provide. The books of the Company may be kept (subject to any provision contained in the statutes) outside the State of Delaware at such place or places as may be designated from time to time by the board of directors or in the bylaws of the Company. Â Â 1 Does not include language from reverse stock splits which occurred on January 18, 2018 and October 11, 2022. Â 1 Â Â 9. The Company reserves the right to amend, alter, change or repeal any provision contained in this certificate of incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon shareholders herein are granted subject to this reservation. Â 10. No director of this Company shall be personally liable to the Company or its shareholders for monetary damages for breach of fiduciary duty as a director. Nothing in this paragraph shall serve to eliminate or limit the liability of a director (a) for any breach of the directorâ€™s duty of loyalty to this Company or its shareholders, (b) for acts or omissions not in good faith or which involves intentional misconduct or a knowing violation of law, (c) under Section 174 of the Delaware General Corporation Law, or (d) for any transaction from which the director derived an improper personal benefit. If the Delaware General Corporation Law is amended after approval by the shareholders of this article to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Company shall be eliminated or limited to the fullest extent permitted by the

Delaware General Corporation Law, as so amended. Â Any repeal or modification of the foregoing paragraph by the shareholders of the Company shall not adversely affect any right or protection of a director of the Company existing at the time of such repeal or modification. Â 11. (a) Each person who was or is made a party or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding (except as provided in Section 11 (f)) whether civil, criminal or administrative, (a â€œProceedingâ€), or is contacted by any governmental or regulatory body in connection with any investigation or inquiry (an â€œInvestigationâ€), by reason of the fact that he or she is or was a director or executive officer (as such term is utilized pursuant to interpretations under Section 16 of the Securities Exchange Act of 1934) of the Company or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans (an â€œIndemniteeâ€), whether the basis of such Proceeding or Investigation is alleged action in an official capacity or in any other capacity as set forth above shall be indemnified and held harmless by the Company to the fullest extent authorized by the Delaware General Corporation Law, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Company to provide broader indemnification rights than such law permitted the Company to provide prior to such amendment), against all expense, liability and loss (including attorneysâ€™ fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by such Indemnitee in connection therewith and such indemnification shall continue as to an Indemnitee who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the Indemniteeâ€™s heirs, executors and administrators. The right to indemnification conferred in this Section shall be a contract right and shall include the right to be paid by the Company the expenses incurred in defending any such Proceeding in advance of its final disposition (an â€œAdvancement of Expensesâ€); provided, however, that an Advancement of Expenses shall be made only upon delivery to the Company of an undertaking, by or on behalf of such Indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such Indemnitee is not entitled to be indemnified for such expenses under this Section or otherwise (an â€œUndertakingâ€). Â (b) If a claim under paragraph (a) of this Section is not paid in full by the Company within 60 days after a written claim has been received by the Company, except in the case of a claim for an Advancement of Expenses, in which case the applicable period shall be 20 days, the Indemnitee may at any time thereafter bring suit against the Company to recover the unpaid amount of the claim. If successful in whole or in part in any such suit or in a suit brought by the Company to recover an Advancement of Expenses pursuant to the terms of an Undertaking, the Indemnitee shall be entitled to be paid also the expense of prosecuting or defending such suit. In Â (i) any suit brought by the Indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by the Indemnitee to enforce a right to an Advancement of Expenses) it shall be a defense that, and Â 2 Â Â (ii) any suit by the Company to recover an Advancement of Expenses pursuant to the terms of an Undertaking the Company shall be entitled to recover such expenses upon a final adjudication that, the Indemnitee has not met the applicable standard of conduct set forth in the Delaware General Corporation Law. Neither the failure of the Company (including its board of directors, independent legal counsel, or its shareholders) to have made a determination prior to the commencement of such suit that indemnification of the Indemnitee is proper in the circumstances because the Indemnitee has met the applicable standard of conduct set forth in the Delaware General Corporation Law, nor an actual determination by the Company (including its board of directors, independent legal counsel, or its shareholders) that the Indemnitee has not met such applicable standard of conduct or, in the case of such a suit brought by the Indemnitee, be a defense to such suit. In any suit brought by the Indemnitee to enforce a right hereunder, or by the Company to recover an Advancement of Expenses pursuant to the terms of an undertaking, the burden of proving that the Indemnitee is not entitled to be indemnified or to such Advancement of Expenses under this Section or otherwise shall be on the Company. Â (c) The rights to indemnification and to the Advancement of Expenses conferred in this Section shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, this certificate of incorporation, bylaw, agreement, vote of shareholders or disinterested directors or otherwise. Â (d) The Company may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Company or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Company would have the power to indemnify such person against such expense, liability or loss under the Delaware General Corporation Law. Â (e) The Company may, to the extent authorized from time to time by the board of directors, grant rights to indemnification and to the Advancement of Expenses, to any employee or agent of the Company to the fullest extent of the provisions of this Section with respect to the indemnification and Advancement of Expenses of directors, and executive officers of the Company. Â (f) Notwithstanding the indemnification provided for by this Section 11, the Companyâ€™s bylaws, or any written agreement, such indemnity shall not include any Advancement of Expenses incurred by such Indemnitees relating to or arising from any Proceeding in which the Company asserts a direct claim against an Indemnitee, or an Indemnitee asserts a direct claim against the Company, whether such claim is termed a complaint, counterclaim, crossclaim, third-party complaint or otherwise. Following the termination of any Proceeding referred to in this Section 11(f), the Company may provide indemnification in accordance with this Section 11, the Companyâ€™s bylaws, any written agreement or the Delaware General Corporation Law. Â 12. This Certificate of Incorporation and the internal affairs of the Company shall be governed by and interpreted under the laws of the State of Delaware, excluding its conflict of laws principles. Unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director or officer (or affiliate of any of the foregoing) of the Company to the Company or the Companyâ€™s shareholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or the Companyâ€™s Certificate of Incorporation or Bylaws, or (iv) any other action asserting a claim arising under, in connection with, and governed by the internal affairs doctrine. Â I, THE UNDERSIGNED, being the incorporator hereinbefore named, for the purpose of forming a corporation pursuant to the Delaware General Corporation Law, do make this certificate, hereby declaring and certifying that this is my act and deed and the facts herein stated are true, and accordingly have hereunto set my hand this 21st day of November, 2014. Â /s/ Michael Harris Michael D. Harris Â 3 Â Â EX-31.1 3 ex31-1.htm Â Exhibit 31.1 Â CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER Â I, Sam Lee, certify that: Â 1. I have reviewed this quarterly report on Form 10-Q of Cocrystal Pharma, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 13, 2024 Â /s/ Sam Lee Â Sam Lee Â President and Co-Chief Executive Officer Â (Principal Executive Officer) Â Â Â Â EX-31.2 4 ex31-2.htm Â Exhibit 31.2 Â CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER Â I, James Martin, certify that: Â 1. I have reviewed this quarterly report on Form 10-Q of Cocrystal Pharma, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 13, 2024 Â /s/ James Martin Â James Martin Â Co-Chief Executive Officer Â (Principal Executive Officer) Â Â Â Â EX-31.3 5 ex31-3.htm Â Exhibit 31.3 Â CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER Â I, James Martin, certify that: Â 1. I have reviewed this quarterly report on Form 10-Q of Cocrystal Pharma, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 13, 2024 Â /s/ James Martin Â James Martin Â Chief Financial Officer Â (Principal Financial Officer) Â Â Â Â EX-32.1 6 ex32-1.htm Â Exhibit 32.1 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the quarterly report of Cocrystal Pharma, Inc. (the â€œCompanyâ€) on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof, I, Sam Lee, certify, pursuant to 18 U.S.C. Sec.1350, as adopted pursuant to Sec.906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: Â 1. The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and Â 2. The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â /s/ Sam Lee Â Sam Lee Â President and Co-Chief Executive Officer Â (Principal Executive Officer) Â Â Dated: November 13, 2024 Â In connection with the quarterly report of Cocrystal Pharma, Inc. (the â€œCompanyâ€) on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof, I, James Martin, certify, pursuant to 18 U.S.C. Sec.1350, as adopted pursuant to Sec.906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: Â 1. The quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and Â 2. The information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â /s/ James Martin Â James Martin Â Chief Financial Officer and Co-Chief Executive Officer Â (Principal Executive Officer and Principal Financial Officer) Â Â Dated: November 13, 2024 Â Â Â Â GRAPHIC 7 form10-q_001.jpg begin 644 form10-q_001.jpg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

@>849%>DIXM&JM:6<(G>",Y4OS\OTXZ5%I$^D>+WO M-,?0[6Q=4+136X&X$>O I_65:Z3VN_(GV%G9NVMCSNC->AZ;I5KHGAVTNCI4 M.JZE?R[(XI<;<--'CU'P[:Z=$^\>2@5EEX/)
]*I5TVTMM? MP$Z,DM=S@U6E(&\1T]^U9WA#2=-@"T"UN- M2L4N9=1FV1EHM^Q>GIQSGFH6*3@Y6[?B.5!J2C?O^!YQ17?^%=#MK7Q;JEC? MVT5RENI*B6,$$>H!JY8^%[.W\;:A-
<6T3Z9%&)41E!3+G@ =/6J>(BG;RN2J M,FGY.QYI170^.+:"S\6W4%M#'#$JIA(U"@?+Z"N>K:$N>*EW,YQY9./8**** MLD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@
I#]T_2EI#]T_2@#:\3?\A.W P"O"V_]%+6- M6SXF_P"0G;_]>%M_Z*6L:HI_"BY_$PHHIT8S*@/0L/YUHE=D#QNZ+3LGV_'8\VS17I>CVEA_PBEK/H^CV.KW76XCG(\P'VR.E4--M
MM/L=#U#Q'?:5#+*9S%'9N/DC]L$?TJW75VK;:$QI.2BT]_Z_I'!T9'K7::7] M@\)9>(K6W;2[?3X($>21;;CS<8X)P*T["_P!%US7;C0G\/6=O$Q>..>)0'&.A MZ#ZXZT?6()%W_5[C]A);_UK
M:QYAD49'K7IOB&PMHKFTB&G:+'$UXBYMSF4C/1EVCCUK80\ 1-.>>]M;C0;* MVT\0;EO4VHV[T&.16?UN-D[?UI_F5]7?-RW/&J*[[0-+TWQ7H2VBQ06U]92* M7E5 IFC]\+KNPGUEK?
3;6"&UMAY0:) #(1U)]>:V56\^2VO]?F9N MG:/-? A^Q@4445L9$MM_Q^6__75/_0A5[Q'_,C1JW_7W+_Z$:HVW_'Y;_\M75/_$(5>\1_\C1JW_7W+_Z$:C[?R_4K[/S,RBBK>EHLFK6:.H9&F4,I&01F
MK)*F1ZT9'K7L]YH>GR75S:S:!9P:=]GW?;4"HP;T'WXK^NATO#M=?Z_4\HHS7INEZ-HX^(.IVL5O;S MVJV_F+&X#HCDC./3^E1ZKH<&I:YIFGO:Z5;122L6;3WRS* 3AN!BK^LQYDK; MJ_Y_Y"=!I-
WV/-LCUHKM=-U_3+.XO=+MO#=@%C!B2G_\+"TNU^PV_P!G>SWM%Y8VL=O4CUJI M8V&FZ3I&IZ]=6$5VRW+0PP./D4?2E]85KV_J[7Z_J#:T?]6NI[UQE:0
MFIJZ]/N,Y1Y;!6SX3_Y&O3O^NA_]!-8U;/A/_D:]._ZZ' T$T5/@?H.'Q(Q1 MTI:0=*6K("BBB@ HR/6BO4M%TZ(>%-+GMO#UGJ,\L@69I%4%4[MD]<5G4JI'I@_E4-GX2CTOPWK)BM_+\3=X>2V=];?
A<\KHXT3P=I-A;Z#8>ZCIZW3 MW]PL4>Z/?L3^]{56T#1=+T_Q??Z?J8B+KL_95N/N/G9INO%.2[?TS/V3Y5+O M^IPF11D5Z,+45U/@JVT:?4D_M+,MP9%2&V*Y5
ML]S]/2J'BV"&V\47\,$211+)A41< ?05K[3W^2QDH7@Y=C%HHHK0@**** -C M0/N:Q_V#)OYK6/6QH'W-8_[!DW\UK'J(_$_E^1;^%!1115D!112K]X?44)D M>M%>QQ:1:XTJ)/#EE-:3P9N;HJH,7R]?
4YKG]'\/V&H:5XBMK9;4-'=;+>XG MYV*,?Q=:Y5B8V;MM_G8Z88=R2=]_\KGGE%=]]OAR'1OA],9197%X)UQ<0#<< M$CC=C-:UKX;TT:)#HLEFAU&XM6E^U>5DJW;YL:
IFG+$Q2YEKK:];D1HR;2V_MX>QY71FN_P#!ECISZ1>#['9WFL)(0+>[.,@=,9!YZU-X?M8M0\9WL6H:%:6A MCM,BU9 45@1\W3'XTW72=9HS79>.($@CM56STF#+'FP?)/^
M]P*;X1O;622WTQ/#MM>W$DF9IYOFVIZ\CC'I5*K>'.D3*GRSY6SCZ*V/%,-E M;^([R+3\"!7QA>@/<#VK'K2$N:*EW(G'EDX]@HHHJB0K8LO^13UC_KXMO_9Z MQZV++_D4]8_Z^+;_-GJ)
[+U7YE0W^\QZ***LD**** "C(]:M::BR:G:HZAE M:0 @C@BO6K_1K%KJ]M9_#UE;Z:ML76^0*K;_$XY'UK"K65.UT:4J?M&UZ?B M>-T5Z))X6AU?
P7IK636%I/O)>>Y"XYXR!D]JA\8:#!;6NA6=K!;I<3$1O+" MH^P_9/EYNKEG T9KU#7M TR70KVQLK%8KS3XDD:98<&3N M1NQS4&@6>GMX2AFTW2;'5-
0&3<0W!&\'OC(_^M2^LQY>:W7^F7["5TG_ %Y' MFV117I_AFQM;S3]6N9MTZ.Y6X(6*Z4!(N?NYP<#*XSQ;&(]=D18+*$!%^6 MR;,?3MP.:N%92GR6)=+W'._]7L8>1ZT5ZGX8M['5-,@DGT?
1EM_*8, =UP<# MKC;UX]:\RNE1+N98U9$#D*K#! S3A5YI.-MA2I\L%.^Y#1116QD%%%% &KXE M_P"1FU'_ *[^E4K&X6TOX+AU++&X8@=35WQ+_R,VH_]=C 2L,JLZ7P1]%^15 M57E)/S-
[Q/XCEUW5)IH9;J*SD51]G>3Y>/8'%?;/QD^G>'].L;-9DN;68N[Y M&R122=N/QKE**/90Y5"VB*562DY7U9UU\?BZQL?$!U+3;&2.*Y7;>6S[=K>I7 M'2I4\6:)I4%R^@Z/-;7DXVF69]A=G:S9S7,<#
[[>2"38Z=>X(-6;SQK83Z[I%[%:72PV"LI61PS,",#DGG\:XB MBG["%^;^M05::5CL;KQC::I'J%GJEK/-93-OMBI7S(&^I[5)??$*ZCCM(-#5
MK2V@C"LLJ(Q<_KBN*HI+#TU;38'6F[G>'QSIO]M2ZDMC="26\\F097ENQZU" M_CQ7T6RLOL\OG1,GVB3C]XJ]A^E<310L/35M-OZ_4EU)._G^ME^AK>)=6BUS M7I]0AB>-)
H"OC(P,=JR:**UC%12BNA$I.3NPHHHJA!1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %(?NGZ4M(?NGZ4 ;7B; D)V_P#UX6W__**6L:MGQ- R$[?_ *\+; T4
MM8U13^%%S^)A2H=LBMZ$&DHJR#T&[\;^'KN]@OY=%NI+RW7$3.XV@X[@"'Z5 ME67C,B?6+B_A>2:_B,:^5C:G&!U["N3HK!8>FE;^NYJZLG;^MCL=$\1^&]%$ M,\.D7@OD3:\JS?*Q]QNZ?
A19^-8)%U"VU?3OM%E>2F4I&V&4X XY]JXZBFZ$ M&VWU\/F)59))+H=- P)#INEZO:WWA[3I;7RP5F2=]PD4XXZG%:2>+O#UE=7 M&HZHI2 D22290,>IQGC\!7#T4.C![_F-59+_ (8Z?
PSXL_L;5+RZO8Y+ MB.ZRSHF/OYSGFDM/%21^-GU^X@D:-BV(U(R!MP.O%N?'=M?:E=K=VD\NDW,(0V[$ M;E8?Q#G KAJ*GV$+6?\ 7]6'[:5[F_X(_P#D:-6_ MZ^Y?_0C5&V_X_+?_
*ZI_P"A"KWB/_D:-6_Z^Y?_$(U'V_E^!7V?F9E3V4Z MVM_;W#*66*17('4X-0459)T/BCQ/)KNH-);274-HT01H'D^4D9SD XJ_%XW: MST+3+*RCFCGM'!D8D);)%P01BN/HK+V,.51MHBW4DVWW.SL?
%>C:?XDN=4M]/ MNEANH2DD(*\,2"2>AYJG/K^D66I6VHZ!IDMKC MW=P]K'L5ED"CWZ,/2N(HI>PC:VOWA[65[Z?<=-)XCLAX<728+69 E[]H0[D@@ M)G(7KG-6Y?&X'BX:Q;P2K;-&
(Y8'(RZ@8^E<=15>RAU_P ;?Y#=:=K?UO<[M6;QI9R>,[;6UM)Q!#"8S%E=QR"..<57TSQ;:0P7UAJ5@]UIUU*TH0-AU)_&N M2HJ?80MR_P!;W_,'7GWZW_0[.P\2>&=)U-;W3]'NXF6-E :0-
R<8/)/I19?$ M&\E6Z@UP&\M9XBJI&BJ5/Z9%<910Z$'\6HE6FMM#N#XK\.W6C6>G:CI-Y<): MCY") O;'8BN/O7MI+V5[.)H;]&]?BT6347N(I9C M=V[1 J1G<>YS3M$U^WTO1M6LI()&>]C*
(R8PN01S7/T4I4XRO?K;\"N>5DNS MO^AVEYX_N(+2RM=*5[*&!-KB1$;=].N*74/$WAG6-06\U'1KN67RPK;9 O(Z M$8(KBJ*$]A=#;_CJ5[65K=#NIO'EF=1TIH+&=;*Q8MM=]TC':5')/3GN:R=?
MU3PYJ44TMAI-Q;W\K[S,\F1UYXR:YNBA4(1LUT_.XW6DU9FAHFH)I>LVM](MC.D+ABJ]32ZJ],>K:W=7T4;Q[,^X*^,C\JSJ*UY5S.P//3O5?3-=M['POJ6DO!(TEVZL MKKC:N,=?RK!HK/V<>7EZ?
\&YI&I*+3*7GX.*QU.E^);"S\.1:5%#J$M]+H]\UP\QE5UFVE/8885/%X[MV\3W.IW-E(;>2W-ND:$;L9'+$GV MKAZ*7L(=>UMS3V\UM^1LZW=:#L?]?%9M_[/6/6Q9?\BGK'_7Q M;?\
LJ1/9>J_,J&_WF/1115DA1110!/9SK;7L,[E8W##$#J:V/%'B677=2EE MMY+J*SD15-N\GRY'7(!Q6!14N";4GT&FU>W4W]5UZWU#PII^D+!(LMJY9G;& MT\$<=^];*>-=-\[1WEL;EAI\94@;
<,VW&1S^-_F_O*C-Q5EZ'<6? MQ(OO[4E?4 9].<,!;HBAESTY[U#I7B#PMI4T5U#I% \ :X\GS1/C=]1NQCVK MC:*7L(+;3T+]M-[ZG;6WC33I[;4H-7TV6:.^EWLD+ #TSD&N8U23)M0WZ7
M:26UI@?NG;66AW2WT:$+(TN M1N(P<_-TKDKRZ>^O9KJ3 >5RQQ4%%-.,7S=0=1/+"T"BBBM#,**** -7Q+_ M ,C-J\ UV/]*RJZ;Q!!=M)XAOW;7=)B8RDF.25PR^Q^6LW^R+3_ *&+1O\ MO_
,17/3JP4%KT1=3XWKU[K,RZ*U/[(M/^ABT;_O_P#\11_9%I_T,6C? M]_G_/B*T]K#O_7W$:=_Q7^9ET5J?V1:?]#%HW_?Y\XBC^R+3_*&+1O\ MO__,11[6'?^ON#3O\ BO\,RZ*U/[(M/\
H8M&_P"_S\Q%']D6G_$,6 MC?\?Y__(BCVL._]?<&G?\%?YF716I_9%I_P!#%HW_'^?_P"(H_LBT_Z& M+1O^_P__P 11[6'?^ON#3O^*_S,NBM3^R+3_H8M&[_#__!%']D6G_0Q: M-_W^?
_XBCVL._P#7W!IW_%?YF716I_9%I_T,6C?]_G_^(H_LBT_Z&+1O^_S_M /Q%'M8=_P"ON#3O^*_S,NBM3^R+3_H8M&[_/_$4?V1:?]#%HW_?Y_P#X MBCVL._\7W!IW_%?
YF716I_9%I_T,6C?]_G_/B*/[(M/^ABT;_O\\\11[M6'?^ON#3O^*_S,NBM3^R+3_H8M&[_/_/$4?V1:?]#%HW_?Y_\XBCVL._]M?<&G?\5_F9=%:G]D6G_0Q:-_W^?_.(H_LBT_P"ABT;_
+_/_P#$4>UAW_K[M@T[_(K_#,NBM3^R+3_*&+1O\O__,11_9%I_P!#%HW_'^?_P"(H]K# MO_7W!IW_!7^9ET5J?V1:?\ 0Q:-_P!_G_\B*/[(M/^ABT;_O\/_\$4>U
MAW_K[@T[_BO\S+HK4_LBT_Z&+1O^_P__P 11_9%I_T,6C?]_G_^(H]K#O\ MU]P:=_Q7^9ET5J?V1:?]#%HW_?Y__B*/[(M/^ABT;_O_P#\11[6'?\ K[@T M[_BO\S+HK4_LBT_Z&+1O^_S_
/Q%']D6G_0Q:-_W^?\ ^(H]K#O_%]P:=_Q M7^9ET5J?V1:?]#%HW_?Y_P#XBC^R+3_H8M&[_/_/$4>UAW_K[@T[_BO\S+ MHK4_LBT_Z&+1O^_S_P#Q%']D6G_0Q:-_W^?_.(H]K#O_7W!IW_%?
YF716I_M9%I_T,6C?]_G_P#B*T(O!MS/;17,6JZ6\,H)C<3-A@#@X^7U!I>VIKJ-*^WY MK_,YNBNF_P"$*N_^@GI?_?YO_B:/^$*N_P#H)Z7_-_F_P#B:/;4^XVI]PY7_5O\SF
M:*Z;_A"KO_H)Z7_W^;_XFC_A"KO_*">E_\?YO_(FCVU/N'*_ZM_FE_P#?YO\XFC_(0][_Z">E_]_F_^)H]M3[ARO^K?YG,T5TW_M A5W_T$]+_[_-\31_PA5W_-!/2_\O\W
,31[:GW#E?]6_S.9HKIO^$*_MN_\H)Z7_P!_F_\B:/^$*N_^@GI?_?YO_B:/;4^XVI]PY7_5O\SF:*Z;_A"KO_H)Z7_W M^;_XFC_A"KO_*">E_\?YO_(FCVU/N'*_ZM_FE_P#?_?
YO_B:/;4^XVI]PY7_5O\SF:*Z;_A"KO_H)Z7_W^;_XFC_A"KO_*">_ME_\?YO_(FCVU/N'*_ZM_FE_P#?YO\XFC_(0][_Z"_M>E_]_F_^)H]M3[ARO^K?YG,T5TW_A5W_T$]+_[_-\31_PA5W_-!/2_\
MO\W_,31[:GW#E?]6_S.9HKIO^$*N_\H)Z7_P!_F_\B:/^$*N_^@GI?_?YO_MO_B:/;4^X_MVI]PY7_5O\SF:*Z;_A"KO_H)Z7_W^;_XFC_A"KO_*">E_\?YO_(FCVU/N'*_ZM_F#_Q,]+_._S?_$T>VI]
MPY7_%;_#*?B;_D)V_%X6W_HI:QJ]"U;P!J^IW,%S;369B%I!'DR-R50 MG[O3BJ/_K#7O\GK8_]&_^)K.%>DHI.2-I49MW2.+HKM/^%8:]_SUL?\MOXW_,31_P *PU[_)ZV/_?
QO_B:KZQ2_F1/L:G8XNBNT_X5AKW_#UL?^_C?_$T?*PU[_GK8_]&_^)H^L4OYD'L:G8XNBNT_X5AKW_6Q_P"_C?\Q-'_M_K#7O\GK8_]&_^)H^L4OYD'L:G8XNBNT_X5AKW_6Q_[^-_\$T?
PU[_M_GK8_P#?QO\XFCZQ2_F0>QJ=CBZ[3_(5AKW_/6Q_[^-_\31_PK#7O^>MC_M_P!_&_\B:/K%+^9![&IV.+HKM/^%8:]_SUL?^_C?_!-'_L>_YZV/_?QO_M_B:/K%+^9!
[&IV.+HKM/^%8:]_SUL?\OXW_,31_P *PU[_)ZV/_?QO_B:_M/K%+^9![&IV.+HKM/^%8:]_SUL?^_C?_!-'_L>_YZV/\W\;_.)H^L4OYD'L:G8YV*X_+?_*ZI_P"A"KWB/_D:-6_Z^Y?_
$(UTD/PUVR.XBQJMC_-_&_P#B:/\A6&O?\]';'OXW_Q-5]8I?S(GV-3L<717:?*PU[_GK8_]M_&_^)H_X5AKW_6Q_P"_C?\Q-'UBE_,@]C4['%T5VG_K#7O\GK8_]&_
M^)H_X5AKW_6Q_[^-_\$T?6*7\R#V-3L<717:?*PU[_GK8_P#?QO\XFC_M (5AKW_6Q_[^-_\31_8I?S(/8U.QQ=%=I_PK#7O^>MC_P!_&_\B:/^%8:]_M_P]';'OXW_Q-
'UBE_,@]C4['%UL^$_^1KT[_KH?_036W_PK#7O^>MC_-_&_M_P#B:T-#^'NLZ;KEI>3R6ABADXM*2*A1J*2=CSH=*6NS M'PPU['^ML?\OXW_,32_P#"L>_YZV/_?
QO_B:KZQ2_F1/L:G8XNBNT_P"%_M8:]_SUL?^_C?_$T?*PU[_GK8_\?QO_(FCZQ2_F0>QJ=CBZ*[3_A6&O?\M/6Q_[^-_\31_PK#7O^>MC_W\;_XFCZQ2_F0>QJ=CBZ*[3_A6&O?\];'_+^-_M_P#$T?
\"L>_P">MC_W\;_XFCZQ2_F0>QJ=CBZ*[3_A6&O?\];'_OXW_P_3_M1_PK#7O^>MC_-_&_P#B:/K%+^9![&IV.+HKM/\A6&O?\];'_OXW_Q-'_"L_P">MC_W\;_.)H^L4OYD'L:G8XNBNT_X5AKW_
#UL?^_C?_$T?*PU[_GK8_]&_^)H^L4OYD'L:G8XNBNT_X5AKW_6Q_P"_C?\Q-'_K#7O\GK8_M]&_^)H^L4OYD'L:G8XNBNT_X5AKW_6Q_[^-_\$T?*PU[_GK8_P#?QO\
MXFCZQ2_F0>QJ=C#T#[FL?]@R;^:UCUZ)I?P]UFR74!+):'[19R0)MD;[S$8S MQTXK/_X5AKW_#UL?^_C?_$U*KTN9^\NA3HU++0XNBNT_P"%8:]_SUL?^_C?_M_$T?*PU[_GK8_\?QO_
(FJ^L4OYD3[&IV.+HKM/^%8:]_SUL?^_C?_!-'_M_"L>_YZV/\W\;_.)H^L4OYD'L:G8XNBNT_P"%8:]_SUL?^_C?_$T?*PU_M[_GK8_\?QO_(FCZQ2_F0>QJ=CBZ*[3_A6&O?\/6Q_[^-
_\31_PK#7O^>M MC_W\;_XFCZQ2_F0>QJ=CBZ*[3_A6&O?\];'_+^-_P#$T?\"L>_P">MC_W M\;_XFCZQ2_F0>QJ=CBZ*[3_A6&O?\];'_OXW_P 31_PK#7O^>MC_-_&_P#B M:/K%+^9!
[&IV.+HKM/\A6&O?\];'_OXW_Q-'_"L>_YZV/_'\;_P")H^L4_MOYD'L:G8XNBNT_X5AKW_#UL?^_C?_$T?*PU[_GK8_]_&_^)H^L4OYD'L:G_M8XNMBR_Y%/6/^OBV_P#9ZW/^%8:]_P];'_OXW_Q-
7[?X>ZS%H6H6326GFW$ ML+H1(V,)NSGCW%3.O2:^)=*HT:B>QYY17:?*PU[_GK8_P#?QO\XFC_(5A MKW_/6Q_[^-_\35?6*7\R)C4['%T5VG_K#7O\GK8_]&_^)H_X5AKW_6 MQ_[^-_\$T?
6*7\R#V-3L<717:?*PU[_GK8_P#?QO\XFC_(5AKW_/6Q_[M^-_\31_8I?S(/8U.QQ=%=I_PK#7O^>MC_P!_&_\B:/^%8:]_P];'_OXW_Q-'UBE_,@]C4['%T5VG_"L>_YZV/_?QO_B:/^%8:]_SUL?\
OXW_,31_8I? MS(/8U.QQ=%=I_P *PU[_)ZV/_?QO_B:/^%8:]_SUL?^_C?_!-'UBE_,@]C M4['%T5VG_"L>_YZV/\W\;_.)H_P"%8:]_SUL?^_C?_$T?6*7\R#V-3L<7 M17:?*PU[_GK8_\?QO_
(FC_A6&O?\/6Q_[^-_\31_8I?S(/8U.QQ=%=I_MPK#7O^>MC_W\;_XFC_A6&O?\];'_+^-_P#$T?6*7\R#V-3L<=XN_P"1MU3_M *[G^0K%K:\??\C;JG_7<_R%8M84_@1X6(_BR]7^844459B%%%%
!1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !7J6B?\(H:)_P!6UZEHG_(H:)_URE_]&M6-9' M7AOM>GZEJBBBL#!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **

)]K[E_D=7_PL#5/^@=H?_@L MB_PH_P"%@:I_T#M# _P#!9%_A7*44P?4\/_P ^U]R_R.K_.%@:I_T#M#__M /!9%_A1_P + U3_ *!VA_\ @LB_PKE**.2/8/]>'_Y]K[E_D=7_ ,+ U3_H M';'
.."R+ "C_A8&J?\ 0.T/_P %D7^%' Y]K[E_D=7_P + M U3_ *!VA \ @LB_PH_X6!JG_0.T/_P61?X5RE%')'L'U/#_ //M2^"]&NY;:Q$DL]>#?\ DGN@?]$4M>R.C^WO\ \^UG_P" MZT?;W_Y]K/\
\!UJI14QXMEV+?V]_^?:S_P# =:/M[_\ /M9_^ ZU4HHY M8]@LNQ;^WO\ \^UG_P" ZT?;W_Y]K/\ \!UJI11RQ[!9=BW]O?\ Y]K/_P ! MUH^WO_S[6?\ X#K52BCECV"R[%O[>_\ S[6?_@.M'V]_^?:S_P#
=:J44 MP678M_;W_P"?:S_\!UH^WO\ \^UG_P" ZU4HHY8]@LNQ;^WO_P +^UG_X#K1] MO?\ Y]K/_P !UJI11RQ[!9=BW]O?_GVL_P#P'6C[>_\ S[6?_@.M5**.6/8+ M+L6_M[_\^UG_
ZT?;W_P"?:S_\!UJI11RQ[!9=BW]O?_GVL_\ P'6C[>__ M #[6?_@.M5**.6/8+L6_M[_ //M9_\ @.M'V]_^?:S_/ =:J44P678M M_;W_.?:S_\ =:/M[_\^UG_ . ZU4HHY8]@LNQ;^WO_ ,^UG_X#K1]O?_GV
ML_\ P'6JE%'+'L%EV+?V]_\ GVL_ =:/M[_ //M9_\ @.M5**.6/8+L6_M M[_\ /M9_^ ZT?;W_ .?:S_\ =:J44P678M ;W_Y]K/\ \!UH^WO_,^U MG_X#K52BCECV"R[%O[>__/M9_P#@.M'V]_\ GVL_
=:J44P678M ;W_Y M]K/_ ,!UH^WO_P ^UG_X#K52BCECV"R[%O[>_P#S[6?_(#K1]O?_GVL_P#P M'6JE%'+'L%EV+?V]_P#GVL_ '6C[>_ /M9_P#@.M5**.6/8++L6_M[_P#/ MM9_^ ZT?;W_Y]K/_
,!UJI11RQ[!9=BW]O?_)]K/_P'6C[>_P#S[6?_(#K M52BCECV"R[%O[>__ #[6?_@.M'V]_P#GVL_ '6JE%'+'L%EV+?V]_^?:S_M / =:/M[_P#/M9_^ ZU4HHY8]@LNQ;^WO_S[6?\ X#K1]O?
)]K/_P'6JE% M'+'L%EV+?V]_^?:S_P# =:/M[_\/M9_^ ZU4HHY8]@LNQ;^WO\ \^UG_P" MZT?;W_Y]K/\ \!UJI11RQ[!9=BW]O?\ Y]K/_P !UI#?OC_CVL_ '6JM!Z M4P678ZA_#\.IK%=O?ZG_
SQ)F.VO7BC'RCHJG IO\ PB%M_P!!;7/_92 M_P"-;-A_R#K;_KDO\A4^1ZBO->YUK8Y_A&+;_H+:Y_X,I?\:/\ A$+;_H+: MY_X,I?\:/\ &N@WK_>'YTBV]_?7\ZO\ 5_1"V_Z"VN?^#*7_&C_ (1"V_Z"VN?^
M#*7_ !K>\V/_)Z+^='G1?\ /1/^^A0!@_\ "(6W_06US_P92_XT?\(A;?\ M06US_P &4O\ C6[Y\\ SUC_ .^A2?:(/^>T?_?0HL!A_P#"(6W_$%M<_\ M!E+_ (T?\(A;?]!;7/\ P92_XUN?:K?_)
(Q?]]BD^UVW_/Q%_WV*=F!B?\ M"(6W_06US_P92_XT?\(A;?\ 06US_P &4O\ C6U]LM?^?F'_+[%'VVT_P"? MJ'_OX*+,#%_X1"V_Z"VN?^*7_&C_A$+;_H+:Y_X,I?\:V?MUG_S]P?]_!1_M:%E_S]V__?
P?XT68&-_PB%M_T%M<_P#!E+_C1_PB%M_T%M<_\&4O^-;']HV/ M_/Y;_P#?U?\ &D_M*P_Y_;;_+^K_C19@9'_B%M_T%M<_\&4O^-'_"(6W_M $%M<_\ !E+_(UK_P!IV'_/];?]_5_QI/[4T[_G_M?
^_P O^-'*^P&3_P (MA;?]!;7/_!E+_C1_PB%M_P!!;7/_92_P"-:O\ :VG?]!"U_P"_R_XT?VMI MO_00M/\ O\O^-'*^P&5_PB%M_P!!;7/_92_P"-'_"(6W_06US_,&4O^-;MO]K:;_T$+3_O\O\
C1_:VF_]!"T_[_+_(T_X1"V_P"@MKG_(,I?\:/^$0M MO^@MKG_@RE_QKH:* ._X1"V_P"@MKG_(,I?\:/^$0MO^@MKG_@RE_QKH:* M ._X1"V_P"@MKG_(,I?\:/^$0MO^@MKG_@RE_QKH:*
._X1"V_P"@MKG_M (,I?\:/^$0MO^@MKG_@RE_QKH:* ._X1"V_P"@MKG_(,I?\:/^$0MO^@M MKG_@RE_QKH:* ._X1"V_P"@MKG_(,I?\:/^$0MO^@MKG_@RE_QKH:* ._
MX1"V_P"@MKG_(,I?\:/^$0MO^@MKG_@RE_QKH:* ._X1"V_P"@MKG_(,I M?\:/^$0MO^@MKG_@RE_QKH:* ._X1"V_P"@MKG_(,I?\:/^$0MO^@MKG_@ MRE_QKH:* ._X1"V_P"@MKG_
(,I?\:/^$0MO^@MKG_@RE_QKH:* ._X1"V M_P"@MKG_(,I?\:/^$0MO^@MKG_@RE_QKH:* ._X1"V_P"@MKG_(,I?\:/ M^$0MO^@MKG_@RE_QKH:* ._X1"V_P"@MKG_(,I?
\:/^$0MO^@MKG_@RE_Q MKH:* ._X1"V_P"@MKG_(,I?\:/^$0MO^@MKG_@RE_QKH:* ._X1"V_P"@ MMKG_(,I?\:/^$0MO^@MKG_@RE_QKH:* ._X1"V_P"@MKG_(,I?\:/^$0M
MO^@MKG_@RE_QKH:* ._X1"V_P"@MKG_(,I?\:/^$0MO^@MKG_@RE_QKH:* M ._X1"V_P"@MKG_(,I?\:/^$0MO^@MKG_@RE_QKH:* /DG MQ_\ \C[K7_7R?Y"N]3*:C:
M_4AU(J2@WJS@J*ZGQ7X+E\,1Z0PO!>-J41D5$B*E.G'4YZUG7WA/Q#IEF;N^ MT:]M[9<9EDB(49]Z.>/<4*L)I.+WV,>BM>S\+:][$$$]GH]Y/#/(GRGCB)#XZ MX/M@T6/A77]321['1[VX6)RCF.
(D*PZ@^]-R2*YX]S(HK3A\.ZU<-=K#!=T[M6?\ Q\!8SF+_ 'O3I5K0O#EYJ,D%Y+IM_-I(EV336L>XCV'O2YEW%*<8IMLP MJ*Z?7/## _P#"37FG^'],U5XK>,2-%94)6,CJ">U7(O!GB
M::T6ZBT*_>W9=XD$)VD>M-RBNH^>*ZF'15S2M-GU?5;,3K?'G7$@1=QP :[K M?7A0VDZ/J%[::];W\VGE1?T5T6I^$;]#Q^"^D:-*=:98
MQ()+2,D$'VR:S;_0=6TJZBMK_3KFVGF_U<\AA@(LCQ!">F3^(IX\(>S8?;AHE\;39O\ ,\D[=OKGTHYH MVO<.>/^*,L-WI]>13;OP_K%A?165WIMU!= M3?ZN*2,AG^@I\RO8.:[-7,VBMJ]\(^(M-
M3@ZM8 M7%M;W>G7,$US@P(\9!DR<#;ZT*2>S!2B]F9U%=II_A**#1=8??=*UR+4;6,R M0B&']V@VY!DR.!G]*P[;PIX@O889K;1KV:.9"\3)$2'4=2*E33)52+OJ8]%: M%QH6JVEK;7-SI]Q%!%M?
74ETYM'O!>LN\0>4=Y7UQZ57, MBG)+J9%%:6J>'M8T18VU33+FS60X0S1E=QJJS:$7]AIIZH*****8PKWKP;_R3 MW0/^N4W_*.>O!:]Z\&_\D]T#_KE-_Z.>LJG0\W,OX2]38HHHK,\ **** "B
MBD9@JEF. !DDT +16 OB.YN%>:PTB:YM5./-W[=V.N!CFM"TUBRN]/2]$HCB M8[3YG&&]#[U*DF-IHOT5574K%DF=;N(K"<2D-PA]#20:E9WD4CV=U%/L&3L; M.*;D:LRW16;H.H3:GI274X02,S
[!@<&JE%T.QHT5534K&60QQW<+.$\ MPJ&Y"^OTI+;5-/O)3%;7D,T@ZJC9(HNA%NBLO3=1GO-4U.VD"".UD"Q[1@D> M],U+69[+48+&VL#=2S(7['W9@#'L?6ES*R?
<=F:]%96GZY#=QW'VF,V0S,OW@C9(MJG9>(K"^OY(1)HQ)&^Q/GYD]P*.97L%F:U%5#JE@+O[(;R'[6:IZ/;&:+K<+,M45!+>VL%L+B6XC2 \B1FXIL&H6=U
T]O=121)] MYU;(%%T(LT56M=1LKXL+2ZBG*_>V-G%0ZMJ8TJWBF,)EWRK'@-C&>]%UN.Q? MHJK<:E8VK.MQ=PQ%,;@[8QGI535M5^SZ&] 8/%-@C8WWE.3BDY)*X)-FK15* MUU6RNG6&.
[A>XV@M&K<@XYXJC_%0R:P+4ZC)=2V_E6V"BH_S=.C>A)IN26_\ M5@2;-:BL_3M8L]1LOM,4T8"KND7=GR_K4UKJ-E?%A:7<4Y7[P1LXIW0BU150
MZG8!U0WD.]G,:KNY+#]/K2ZCJ$&F6;W.Y.T@%)R5KCL[V+5%9%GJN MH7-Q$DVC2P12=)#)G;]1CBJR>(KV>6Y%KHSSQV\AC9EF&Z1ZW#%)S2"S.@HK(M;Q!;G0IM4AC:18L[HB=K
CJ#Z5IPR^=!'+C;O4-CTIIIBL245@R^)'#SR0:= M+-9P.4DG#8P1P<#'.*L76M[)K6"QMC=S7,?FH-^P;?4GFESH?*S6HK%7Q'%_ M94JY);R))#)Y+P]3O['\1S4EEK$LVH+8WEBUK,\?
F1XDWAAWYP,4*2;L@LS M6HHHJA!1110 4'!10>E '?67_(.MO^N2_P A2M26/_(.MO\ KDO\A2M7F/=G M4MB%XZKO5AZ@>J0%=\5 PJ=Z@:K0B!P:.KN!Z58?O4#UH@*[@>E0.!Z"K#U]
M6A%=P/05 P'/ JP]5WJT(@<#T%0.H]!4[U]6A%=P/05 ZCT%6'J!JT0%=U7 MT%0.J"@JP]0/5H16=5]!3-J^@_*I'IE6(3:OH/RHVKZ#\]6B@!-J^@_*:C:OH M/RI:* $VKZ#\]-J^@_*EHH
3:OH/RHVKZ#\]6B@!-J^@_*C:OH/RI:* $VKZ M#\]-J^@_*EHH 3:OH/RHVKZ#\]6B@!-J^@_*C:OH/RI:* $VKZ#\]-J^@_*E MHH 3:OH/RHVKZ#\]6B@!-J^@_*C:OH/RI:* $VKZ#\]-J^@_*EHH
3:OH/RH MVKZ#\]6B@!-J^@_*C:OH/RI:* $VKZ#\]-J^@_*EHH L6%[<:;=E=I6DACE0\ M$= 8UZ[X:\3VVOVVTD1W:#YXL]?<>U>-5-:W4UG$-6
MVG3]3T^+R]W\,OS#]>/RKYR5F1PRL593D$'D&K5SJNH7EXEYP*8YV[?PKY^OM:U35)8I=0U&ZNI(O)6T\K M.4^F3QT%2WGB/7-0M3:WNL7UQ;GK%+<,R_D36#H2<;-ZZ_B[F4<(XV5^WX/I
MZ]3TRY\0:EH'P1T-]*N6MGGN)4,J<,%WL>#VK>+:[=^!O"LGA*29@9LWA@8 MGYLDO[9SFO#)-2OIK"*PDO)WLX26C@:0E$)ZD+T%3Z?K^L:5$T6G:K>VD;') M2"=D!/K@&M9TKMR6[=_^
S2>'NE:U_>]-;_E?0]TO-:MM/\ C.E@SQ^7J-BE MO\N3MS[\FJFN1P^$8?"_A*R [ZDC\)\,-[=&]^V&YE-UN MW^=O._=ZYZY]>YUG5+R)CO;G4;]:ZCQLFDE9G7'3!/(K.-"SCKMOYV;:^ZY$
M*VFD^EOG:U_N/>M.=HOC9XGD7[RZ:K#(} E8'PPU[4-<\=ZPVIWSSS?9GCA M5V^Z-Y.U1Z5Y.OB#65OI;U=6O1=S)LEG$[;W7T)SDBJMM?7=E=K=VMS-!ZLWJFWYE?5WRR5]7;\#VO3-
#U+1/A3XNCU&T>VDFEFDC1^ MI7 P?I701KJ?BOP^8+VWUCP[>V]M@31R 02#'L>?IQ7@5QXFUZ[CECN-:U"9 M)EVR+)<,P<>AR>13I?%/B":U-K+KFHO;E=IB:Y5[
MW5[W_+_(U AQI,6]>/+&WENS;K&QD#(V&8CL#[UQ[C3>,+2?3IX;G2K876 M+GY1_IB \%6!]@>E?+D,TMO,DT,CQRHG07$-I#)L1;@Y?@H-J":I>+>L,-<"9A(1Z;LYIE[K&IZC<1W%]]UK?
$KQ+J ^(]MHLMXT>D)+;F2 '"N"58EO7FN M[9/$1^)T$L;2_P#",?8SNPP\G[IQQZYQ7S3>W]YJ5RUS?74UU.P ,LSEV./< MU<'B;7A9?8AK-_\ 9=NSR?M#;-
OIC.,5'L+0BE:ZO^/^70*F&YDE&RTM^6J^ MX]8;5GTCX8^([O0YS K:RZ121\%5(7.*T-?TU_$UUX#BN;V6&:6)Y'N%/[PD M!#P?
6O#5U*^33VT];R<63/YC6XD/EEO4KTS4KZYJTIM3)]=XQM/^/>/PJO8V=UY?A&W_!*E0=[Q=G[WXVM]WZGT1+;2P>'/%-M)'K!C2,A)M3N M/,\W ^\@["LSP:MMXN\->'-8NW3S=#9UGSS\]H0N?
T->(S>*/$%QN_6]0DW MH4;?#//2JUIK&IV%K-;6>H75O;S<2Q12E5?C'('7BLUAY*[OKI;U5U^ MIG]5;5K]?P:LSU_1]7?7M!^(FI-TE23;ST4)@?H*IZ_XBU70?A)X332[M[5K MF-Q))&<-@$8
/XUY5;:I?V=M/;6M[<0P3C;-%'(560>C =:2?4KZZM(+2XO) MY;:W!$,3R$K'GKM'05K[%6Y>EU^":_4TAA[3K+[CV;5=#U+Q%\\ MP4-,MVN3%Y9E92,)P,DUM:UJ=_I7Q9,UEI,^1!M-
V31P$;T33NFULUU[W/0OB]H\EX69:9J/]HZB\-R[;;& ?<\()(X] M!VQ7E-7-0U74=6E634;ZYNW485IY2Y]LU3JZ4'"-F=+5.+C%)N["BBBM2PKW MKP;_ 2)T#_KE-_Z.>O!:]Z\& \ )/=
_P"N4W_HYZRJ=#S27^^\8)_II;>&>(131 M))&,':RY'%1*#EO_%JG^A2DEM_6_P#F8>K20:+I$26MK HGD2,[A\H/]YO6 ML^T+#Q6ZM=0W# _9"&:&+RU'7CJ<_6NLF@AN(C%-
$DD9ZHZY! "HXK&TMPHAM M88PHP-B 8'I1*#;O_6S7ZB3LDOZW1E>$/^1>B_WW_F:S8;.[O?$FM):Z@;09 M0/MCW%LY[Y&*ZN&"*WC$<$21H.BH,"A+>&.5Y4B19)/OL%P6^I[TW"]K]/\ M)
($[)_UU..?U)H6GV.G6RQD32[?-N!E5/4L?7I6?;$C5==!N8YS]B.YXHO+4 MG'IDUU]Q;07<7E7,$;2=(D64.C>8!SG?ZUU&=4:YC58;V14;F:0[\8YXQ_6K9L[M5K86QMXC O2,H-H_"I@,#
Z"KY=7_72Q-SABD@F;PR,[3=[Q_P!<>O\ A5NZ M 77]<"@ "P7],!74_9H/M/VGR8_/V[?-VC=CTS2&TMVDDD:",O(NUV*C+#T M/]*S=-\ML]_RLB^?6_\ 6]SG+#[-I'@Q+^&T1Y?(&
[CEL^I]*I;W;6=$=[JV MD=B3Y<$.W8".A;/-=DL$*P>0L2'"&WRPORX],5%#IUC;@"&S@CPVX;(P,'UJ MW&\D^FA"?NV,C0_^1@U[_KNO\JKZS#//XML([:Y^S2^0^)-F[N.V1721P0Q2
M221Q(CR'+LJX+'W]:&@A:=9VB0RJ,*Y7Y@/0&ER:17;_ (/^8^;?S_X!S>IZ M2NF^&M3=YWN+B7X#4MCE;IK)]5T3^R_+,H;Y_*[1X M&<_K4NCO'J6N1
HMP9SY:GKT[5OV]A9VC,UM:0PLWWC&@4FE-C:-="Z-M"; M@=)2@W#\:.1_G^/_ PK_I^!Q.F6(O=$$5QJT$!$F98VMQYBOG^]G-:=Y>R3 MZE>6GG6MLMK TLT7F-*".PR*Z"33+":?
SY+*W>;.?,;,%OSITMA9SSK/-:0 MR2K]UV0%A^-+V;M;^MK#YE>];G<6-G'?^%=-S>)!-',[P-(/E8ACP1Z5#]% M[F:9]AM#$\7V6'RY&W.FP88^I'+0\ ?KL'MX)#&7AC8O',9*YV'V!*;ICM2)1]
MGBQ,D?V7Y9<*WF^5 MT\O Z_K70PV%G;K(L%K#&LGWPB !OKZT6UC:698VMK# 6^]Y:!<_E5V!6]#!>GVTWG06-O%+_ 'TC /YTUM'T MQY3*VGVK2$Y+F(9S];;4KI_UT"ZM8Y0JS^%=;O-
A2&YD9X@PQE>.,Z*)M4"V MHMH;9K3RUW,\A#=.>,5I2P130F&6)'B(P489!'TIZJ$4*H X ';B,.7\/P! MRO\ C^)R,J6L6FVUI'#]Q6*=F(M%7+EVI YXY/I44MJS7&E::+/]ADBMM_VD M<-GIM!
[5U8T^R6Y-R+2 7!Y,H0:OSIUS9VMXH6ZMHIU'($B!@\/SJ/9_UZ7_S M'S'&BX6+PY>6?EO2HMR(3<[?E;./G(]1G]*NZ7$-\10PB[&H&>$_O6Y>(#M MGT.?TKIEM;=+?[.L$:P8OY84;
[[+:PP;NOEH%S^54H--/^MK"< MKJQ8HNHK0D**** "@]**#TH [ZQ_Y!UM_P!K0B!ZA>IGJ%ZM"*[U U3O4#=:T0$#5]3O4#U:$5WIE/>F58@HHHH M**** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ H MHHH **** "BBB@ HHK<\.>&KG7[GY08[5#^\E(_0>]J9245=@-\,Z/?:KJL1 MM"T:PL&>;LOM]:]]JKIVG6VEV:6MI&$C7\R?4^]6]\JM5]]* 0U2L%%%%8%!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\D^/\ D?=:_?"OD_R% MW3^:]>A]%2_AQ]$%%%%6:!1110
4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 5[UX-_Y)[H'_7*;_P!'/7@M>]>#?^2>Z!_URF_]'/653H>;F7\) M>IL4445F> %%%% !1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M4 %%%% !1110 4444 %%%% !1110 4'I10>E '?6/_(.MO\
KDO\A3V1CVIM MA_R#K;_KDO\ (58KS'NSJ6Q4:&0]%_6HFMICT3:T**5QF4UE2<'H@_,5"VGW M)Z1C_OH5MT57.Q6.?;3+L_\+(?]]"HFTF]/2$?]]"NEHI^T86.4;1K\](1_ MWV*B;011/2
?1]BNPHI^UD%CBFT#4STMQ_W\'^-1-X=U0]+8?] %_P :[JBG M[:06/I\\-;L?^78?]_%_QJ)O"^L'I:C _+^K_C7HM%5[>0N5'FK>$]:/2T7 M_+^K_C43>$-GT4_K.PY4>5-X.UX]+)?^_P O^-1-X*\0'I9+
M_P!_D_QKUJBG]:F'*CQ]O _B$]+%?^_R?XTW_A!?$7 /BO\ W^3_ !KV*BG] M;GV0N1'CO_""^(O^?%?^_P G^-'_@OB+_GQ7_O\G^->Q44?6Y]D'(CQW_A M!?$7 /BO_?Y/\:/^$%\1?\^*_P#?Y/\
&O8]*/K<^R#D1X[_,(+XB_Y\5[_M_)C1_P@OB+_)\5_P" R?XU[%11];GV0,_\(+XB_P"?%?U\O\G^-'_""^(O^?%?^_R?XU[%11];GV0._\(+XB_P"?%?\ O\G^_M->Q44?
**6Y]D'(CQW_(07Q%_SXK_W^3_&C_A!?$7_ #XK_P!_D_QKV*BCZW/L M@Y$>_\ ""^(O^?%?^_R?XT?\(+XB_Y\5_[_ "?XU[%11];GV0Q44?6Y]D'(CRK2ONJ6]ZHU&,6]L.6(D5BWL,&O3
MK2S@L;9+>VC6.)!@**GHK&I5E4W*22"BBBLAA1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%%
!1110 4444 ?-'C2*IXSU9;O1=4EN!.=[QZB[*QP.0/+./ MS-8/V_P9_P! *5__:)_P#&]3Q_ P(CIB$%RH]^E!W M]>#?\ DGN@?]:IW_/I;IW_/I:IW_/I:IW _#Z7'_?\?
**_$U4HHY0N6_-T[_ M)]+C_O^/_B:/-TI_GTN/^_X_P#B:J44E_^"Y_CM'V+Q;_P!!O2__ 7/_P#':Z&BD,YI[%XM_P"@WI?_ M (+G_P#CM'V+Q;_T&]+_ /!<_P#\\=KH:* .>^Q>+?^@WI?\
X+G_ /CM'V+Q M;_T&]+_\%S__ !VNAHH MYI[%XM_Z#>E_^"Y_CM'V+Q;_P!!O2__ 7/_P#' M:Z&BD@#GOL7BW_H-Z7_X+G_\CM'V+Q;_ -!O2_\ P7/_ /':Z&B@#GOL7BW_M *#>E_\ @N?
**_..T?8O%O_0;TO\ \%S_ /QVNAHH YI[%XM_Z#>E_P#@N?\ M^.T?8O%O_0;TO_P7/\ ':Z&B@#GOL7BW_H-Z7_X+G_^.T?8O%O_ $&]+_\ M!<__ ,=KH:* .>^Q>+?^@WI?_@N?_P".T?
**8O%O\ T&]+_P#!<_\ \=KH:* . M>^Q>+?\ H-Z7_P"'"Y_\ X[1]B\6_]!O2_P#P7/\ ':Z&B@#GOL7BW_H-Z7_ M ."Y_P#X[1]B\6_]!O2__!<__P =KH:* .>^Q>+ M?^@WI?_@N?_P".T?
**M0;TO_P %S_\ QVNAHH Y[[%XM_Z#>E_^"Y__ ([1]B\6_P#0;TO_ ,%S_P#Q MVNAHH Y[[%XM_P"@WI?_ (+G_P#CM'V+Q;_T&]+_ /!<_P#\\=KH:* .>^Q>+ M?^@WI?\ X+G_
/CM'V+Q;_T&]+_\%S__ !VNAHH MYI[%XM_Z#>E_^"Y__CM' MV+Q;_P!!O2__ 7/_P#':Z&B@#GOL7BW_H-Z7_X+G_\CM'V+Q;_ -!O2_\ MP7/_ /':Z&B@#GOL7BW_ *#>E_\ @N?_ ..T?
8O%O_0;TO\ \%S_ /QVNAHH M YI[%XM_Z#>E_P#@N?\ ^.T?8O%O_0;TO_P7/\ ':Z&B@#GOL7BW_H-Z7_X M+G_^.T?8O%O_ $&]+_\ !<__ ,=KH:* .>^Q>+?^@WI?_@N?_P".T?
**8O%O\ MT&]+_P#!<_\ \=KH:* .>^Q>+?\ H-Z7_P"'"Y_\ X[1]B\6_]!O2_P#P7/\ M ':Z&B@#GOL7BW_H-Z7_ ."Y_P#X[1]B\6_]!O2__!<__P =KH:* .>^Q>+?^@WI?_@N?_P".X[1]B\6_\
0;TO_P %S_\ QVNAHH Y[[%XM_Z#>E_^"Y__ ([1 M]B\6_P#0;TO_ ,%S_P#QVNAHH Y[[%XM_P"@WI?_ (+G_P#CM'V+Q;_T&]+_ M /!<_P#\\=KH:* .>^Q>+?^@WI?\ X+G_
/CM'V+Q;_T&]+_\%S__ !VNAHH MYI[%XM_Z#>E_^"Y__CM'V+Q;_P!!O2__ 7/_P#':Z&B@#GOL7BW_H-Z7_X+G_\CM'V+Q;_ -!O2_\ P7/_ /':Z&B@#GOL7BW_ *#>E_\ @N?_ ..T?8O%
MO_0;TO\ \%S_ /QVNAHH YI[%XM_Z#>E_P#@N?\ ^.T?8O%O_0;TO_P7/\ ':Z&B@#GOL7BW_H-Z7_X+G_^.T?8O%O_ $&]+_\ !<__ ,=KH:* .>^Q>+?^ M@WI?_@N?_P".T?8O%O\
T&]+_P#!<_\ \=KH:* .>^Q>+?\ H-Z7_P"'"Y_\ MX[1]B\6_]!O2_P#P7/\ ':Z&B@#GOL7BW_H-Z7_ ."Y_P#X[1]B\6_]!O2_ M_!<__P =KH:* .>^Q>+?^@WI?_@N?_X[1]B\6_\ 0;TO_P %S_\
QVNAHH Y M[[%XM_Z#>E_^"Y__ ([1]B\6_P#0;TO_ ,%S_P#QVNAHH Y[[%XM_P"@WI?_ M (+G_P#CM'V+Q;_T&]+_ /!<_P#\\=KH:* .>^Q>+?^@WI?\ X+G_ /CM'V+Q
M;_T&]+_\%S__ !VNAHH YI[%XM_Z#>E_^"Y__CM'V+Q;_P!!O2__ 7/_P#' M:Z&B@#GOL7BW_H-Z7_X+G_^.T?8O%O_ $&]+_\ M!<__ ,=KH:* .>^Q>+?^@WI?_@N?_P".T?8O%O\ T&]+_P#!<_\ \=KH:* . M>^Q>+?\ H-Z7_P"'"Y_\ X[1]B\6_]!O2_P#P7/\ ':Z&B@#Y)\?_P#(^ZU_U\G^OKG*ZQ_P C[K7_%\G^OKG*]NG\"]#Z*E_#CZ(****LT"BBB@ HHHH M ****
**BBB@ HHKH;7P1XAO?#K: ;V(DTU59C*)5SA3@G;G;TI.2BKL3DEN M<]16M:^&M6O- N=<@M@VGVS[)9?,4%3@'IG)ZBLC[:+J]@33V%HHS1D>M,8 M449'K1F@
HK;U+P_%I^@V&IKK%CM)-._D)--70449 M'K1D>M,84444 %%%% !1110 4444 %%%% !1110 5[UX-_Y)[H'_%RF_P#1
MSUX+7O7@W_DGQ^2!P[%BBEP1U!HP1U!IB$HJ&*ZAFN)H(WW2 M0$"08^[FFV5W]MA,GD2PX8KME7!._TI7 L44I!'448/H:8"4457L[ZWOQ*; M9R_E.8W^4C##M1Y
6**7![*HVNI)=ZA=V:1.'ML;F/1L^E*^M@\R[15:\N_L M@B_<2R^8X3]VN=ON?:HX-12XU6YT]8G#VZAB_8YI*+]]AV+M%5[VZ^Q0B3R) M9LL%VQKDC/?Z4Y;]%KPV@;]^$#E,=
:+BL344N">@-)3 **7!]#28QUH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "@]**#TH [ZR_Y!UM_UR7^0ISL MWJ:;9?\ (-MO^N2_RI7KS'NSJ6Q"\C_WV_.H'ED'_+1OSJ5ZKO5("-
YYO^>K M_P#?50/I5WK1(0U[NY'_+Q+_WT:@>\NO^?F;_+[-*]5WJTD(M&OKO_GZF_P"^S4#ZA>_\<__'\-#57>K20"MJ5]_P _MQ_W\-0MJ>H?_US M_P!_#3']NJ:)+L(D?5=1'_+_'/_
'1-0/]^IC_F(77_ '1-1/5=ZM178193 M7=5AE61=0N6*G.&D)!^HKT+P]XCM];@VDB.[0?/&>_N*\M>H8KF:SN4N+>0Q MRHZ45S7A?Q9#K<8MYRL5ZHY7L_N*Z6O-
E%Q=F:)W"BBBI M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** /DGQ_\ \C[K7_7R?
Y"NZD@G!Z;68C)]AFO!:W)O%>HS^$X/#;K!@AD,BD(=^2<\G/OZ5C6@YI+S7 MW=3"M2]I9?UL_P!3V'7/#;^&OAOXFM86W6EQ<_:+=O\ 88+Q^8-6KFXM?#7B
M'PSX7LM$L9;"^CVRR20[G.<9(->37/Q(U^*_\ "/7#6\MIL\OS&C)D('3Y_ML_TJ[I_Q<\3Z?I\-HILIO)79'-/"6D_^N:PIC.[OKK]ZM9?HSF=*]XZ[Z_C;
M7\#T+1M)TC0+SQR@T^"YMK1XY8XI%!VY#':#V&<5E^#+^#7;7Q+XQN=)L#?V ML02"W2+]TH"==OX&;^U3FYDF0LQ//0YXZU!X8\7:MX2N
MI9M,DCQ*NV2*9=R,/<9I^QG9IO6R2?GU_P C25&5I=VU\UI_D>M#4;*Z*>' MO&M_IEE!=K=XW>G7Y.Z7Z'H4EI;'PW\9[?LL&^:X7S&\I<
MO]>.:=XPU^"V\=P^%K31M/BM6N(Y)9O*!D9B<\=@/PKSD^/-8-CHUGLM?*TA MP]M^[.21_>YY_2L_6_$E_K^O'6KORDO"5.85VJ"O3C)K14G[7FEM=O\ *P?5 MY2^+LU\
[O_.IE33[?_A?TT/V.+R!:AMGE#;_*LTJ Q0V MVF/F5I0TMMN968DG!SZFLU2GR\K[6W\[BE1J2B[K7W>O9-&?X[MM1M?%]ZFJ M06T-
R6!VVJ[8\=BH]*YRK^LZS>Z_JLVHZA+YEQ*P'I5"N]FFH)2W.Y M:;A1115C"BBB@ HHHH **** "BBB@ KWKP;_.DIT#_KE-_Z.>O!:]Z\&_\M)/=_P"N4W_HYZRJ=#SH6TB^?>3;F"#:
M(B3@K[=<5U0TZ :H=1R_GF/RL9^7'T]%-$LD%VFUFBNSNDB8_+GU [5CR.S^ M?YW_ !-.97^[\C(TO3M2MM2M9HK5H+ES M6N')C5MHD7/&1WI.+>B[/Y:@GU?D$5Q)=ZMX?
N)?]8\#EC[\54:^N8-)U 1S M.K2Z@8?,)R44D]/2NK?2K5KRUN0&5[92D:J<+@^WX5"-!L1:7-LR.\5S(9'# MMG#'T]*IP=W_P 6G^C$FOR_)D!L+#P_8W-
T9+@Q^7M5[&MZ+PI:1VTUO)-? MQJC%>7*>'"B3NIGOS"TL2]GZUT_]BVPU5M0CDGCE<@NJ/A'QZC%-30:%.E ML"KO!*Y<[VR0Q[@U*@U%+R_7]2G)7?\
70R_LPT/7[WM)I6ANU821R.6Z?Q M#-9MO8_;-%U*\ENKGS8)I3#B0)AB?\ .:Z:QT*TL;@W >>>;;M5YWW%1Z#B MGPZ-;P6-Q9H9/*N&9GRW.6ZX_DX-I^C_/0%)77R'Z-/)9?*NG
M,DGSG2B+38 MM1\0ZRLTDHC3:0J-MYP>>*Z&YTNWNA:B0R?Z*X>/#8Y'K2P;;I;WEU=(7\KY MQYF3QQZ?G2<+ORU_%+]04M/N_,Y,75P^@:<&GD+)?^5NW8)4,0 ?6KW]G1:E
MXQU2&>218Q&AVHVW)XYR*U1X>LA:Q6^9MD)IQZ#BER/KK_PR7YFVMQXTN?,1CBW208=A\W/O6N/6+:4FG!76I7#_*WS%@7=I#)L1;@Y?@H-J":I>+>L,-<"9A(1Z;LYIE[K&IZC<1W%]]UK?
$KQ+J ^(]MHLMXT>D)+;F2 '"N"58EO7FN M[9/$1^)T$L;2_P#",?8SNPP\G[IQQZYQ7S3>W]YJ5RUS?74UU.P ,LSEV./< MU<'B;7A9?8AK-_\ 9=NSR?M#;-
OIC.,5'L+0BE:ZO^/^70*F&YDE&RTM^6J^ MX]8;5GTCX8^([O0YS K:RZ121\%5(7.*T-?TU_$UUX#BN;V6&:6)Y'N%/[PD M!#P?
6O#5U*^33VT];R<63/YC6XD/EEO4KTS4KZYJTIM3)]=XQM/^/>/PJO8V=UY?A&W_!*E0=[Q=G[WXVM]WZGT1+;2P>'/%-M)'K!C2,A)M3N M/,\W ^\@["LSP:MMXN\->'-8NW3S=#9UGSS\]H0N?
T->(S>*/$%QN_6]0DW MH4;?#//2JUIK&IV%K-;6>H75O;S<2Q12E5?C'('7BLUAY*[OKI;U5U^ MIG]5;5K]?P:LSU_1]7?7M!^(FI-TE23;ST4)@?H*IZ_XBU70?A)X332[M[5K MF-Q))&<-@$8
/XUY5;:I?V=M/;6M[<0P3C;-%'(560>C =:2?4KZZM(+2XO) MY;:W!$,3R$K'GKM'05K[%6Y>EU^":_4TAA[3K+[CV;5=#U+Q%\\ MP4-,MVN3%Y9E92,)P,DUM:UJ=_I7Q9,UEI,^1!M-
V31P$;T33NFULUU[W/0OB]H\EX69:9J/]HZB\-R[;;& ?<\()(X] M!VQ7E-7-0U74=6E634;ZYNW485IY2Y]LU3JZ4'"-F=+5.+C%)N["BBBM2PKW MKP;_ 2)T#_KE-_Z.>O!:]Z\& \ )/=
_P"N4W_HYZRJ=#S27^^\8)_II;>&>(131 M))&,':RY'%1*#EO_%JG^A2DEM_6_P#F8>K20:+I$26MK HGD2,[A\H/]YO6 ML^T+#Q6ZM=0W# _9"&:&+RU'7CJ<_6NLF@AN(C%-
$DD9ZHZY! "HXK&TMPHAM M88PHP-B 8'I1*#;O_6S7ZB3LDOZW1E>$/^1>B_WW_F:S8;.[O?$FM):Z@;09 M0/MCW%LY[Y&*ZN&"*WC$<$21H.BH,"A+>&.5Y4B19)/OL%P6^I[TW"]K]/\ M)
($[)_UU..?U)H6GV.G6RQD32[?-N!

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|KCV|Z!*WA==(^T1^8H \S:=O7T]== (D76);WSDVO:^0$P<@^OTIM.]OZ MV_S"Z_KU_P CGM.GU6R\,+J$%Q$MO"S$VY0'>-W/.,@UJR7LL_B*S2$QQB>Q M,@?RP64G.,$\X]JA3PU]*::NF? VC%]C9LR#8=QYR0#Z5I_V.1K=K>I(HA@M_ M(\LCD|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cocp-20240930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995612 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 995613 - Disclosure - Basis of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995614 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995616 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 995617 - Disclosure - Stock Based Awards link:presentationLink link:calculationLink link:definitionLink 995618 - Disclosure - Licenses and Collaborations link:presentationLink link:calculationLink link:definitionLink 995619 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995620 - Disclosure - Transactions with Related Parties link:presentationLink link:calculationLink link:definitionLink 995621 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995622 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995623 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 995624 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Stock Based Awards (Tables) link:presentationLink link:calculationLink link:definitionLink 995626 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995627 - Disclosure - Organization and Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995628 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Calculations of Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995629 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995630 - Disclosure - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995631 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995632 - Disclosure - Schedule of Accounts Payable and Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995633 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995634 - Disclosure - Schedule of Common Stock Available for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Schedule of Stock Option Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 995636 - Disclosure - Schedule of Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 995637 - Disclosure - Stock Based Awards (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995638 - Disclosure - Licenses and Collaborations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995639 - Disclosure - Schedule of Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995640 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995641 - Disclosure - Transactions with Related Parties (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 cocp-20240930_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 cocp-20240930_def.xml XBRL DEFINITION FILE EX-101.LAB 11 cocp-20240930_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Statement of Financial Position Location, Balance [Axis] Sweep Account [Member] Antidilutive Securities [Axis] Outstanding Options to Purchase Common Stock [Member] Restricted Stock Units for Common Stock [Member] Warrants to Purchase Common Stock [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Long-Lived Tangible Asset [Axis] Lab Equipment [Member] Finance Lease Right-of-use Lab Equipment [Member] Computer and Office Equipment [Member] Plan Name [Axis] 2015 Equity Incentive Plan [Member] Option Indexed to Issuer's Equity, Type [Axis] Share-Based Payment Arrangement, Option [Member] Award Type [Axis] Restricted Stock Units (RSUs) [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaboration Agreement [Member] Geographical [Axis] Miami, Florida [Member] Bothell, Washington [Member] Statement of Income Location, Balance [Axis] General and Administrative Expense [Member] Title and Position [Axis] North Creek Tec LLC [Member] Amended Lease Agreement for Expansion [Member] Amended Lease Agreement for Extension [Member] Dr. Phillip Frost [Member] Related and Nonrelated Parties [Axis] Related Party [Member] Phase 2a Clinical Trial [Member] Agreement [Member] Consolidated Entities [Axis] hVIVO [Member] Securities Purchase Agreement [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Listing, Par Value Per Share Statement of Financial Position [Abstract] Assets Current assets: Cash Restricted cash Tax credit receivable Prepaid expenses and other current assets Total current assets Property and equipment, net Deposits Operating lease right-of-use assets, net (including $163 and $42 respectively, to related party) Total assets Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses Current maturities of operating lease liabilities (including $55 and $42 respectively, to related party) Total current liabilities Long-term liabilities: Operating lease liabilities (including $163 and $0 respectively, to related party) Total liabilities Commitments and contingencies (Note 8) Stockholders' equity: Common stock, $0.001 par value 100,000 and 150,000 shares authorized as of September 30, 2024, and December 31, 2023; 10,174 shares issued and outstanding as of September 30, 2024 and December 31, 2023 Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Operating lease right of use assets related party Operating lease liabilities related party current Operating lease liabilities related party non-current Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating expenses: Research and development General and administrative Legal settlement Total operating expenses Loss from operations Other income (expense): Interest income (expense), net Foreign exchange loss Total other expense, net Net loss Net loss per common share, basic Net loss per common share, diluted Weighted average number of common shares outstanding, basic Weighted average number of common shares outstanding, diluted Statement [Table] Statement [Line Items] Balance Balance, shares Stock-based compensation Net loss Sale of common stock to related entities, net of transaction costs Sale of common stock to related entities, net of transaction costs, shares Balance Balance, shares Statement of Cash Flows [Abstract] Operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization expense Right of use assets Stock-based compensation Operating lease liabilities Changes in operating assets and liabilities: Prepaid expenses and other current assets Tax credit receivable Accounts payable and accrued expenses Net cash used in operating activities Investing activities: Purchases of property and equipment Net cash used in investing activities Financing activities:

Payments on finance lease liabilities Proceeds from sale of common stock to related entities, net of transaction costs Net cash provided by financing activities Net decrease in cash and restricted cash Cash and restricted cash at beginning of period Cash and restricted cash at end of period Supplemental disclosure: Non-cash investing and financing activities Initial recognition of right-of-use assets and lease liabilities Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Business Accounting Policies [Abstract] Basis of Presentation and Significant Accounting Policies Property, Plant and Equipment [Abstract] Property and Equipment Payables and Accruals [Abstract] Accounts Payable and Accrued Expenses Equity [Abstract] Equity Share-Based Payment Arrangement [Abstract] Stock Based Awards Licenses and Collaborations Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Related Party Transactions [Abstract] Transactions with Related Parties Basis of Presentation Principles of Consolidation Segments Use of Estimates Concentrations of Credit Risk Foreign Currency Transactions Fair Value Measurements Long-Lived Assets Research and Development Expenses Income Taxes Stock-Based Compensation Net Income (Loss) per Share Recent Accounting Pronouncements Schedule of Anti-dilutive Securities Excluded from Calculations of Net Loss Per Share Schedule of Property and Equipment Schedule of Accounts Payable and Accrued Expenses Schedule of Common Stock Available for Future Issuance Schedule of Stock Option Transactions Schedule of Restricted Stock Units Schedule of Maturities of Operating Lease Liabilities Net loss Net cash provided by used in operating activities Cash and restricted cash Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total Number of operating segments Cash FDIC insured amount Refundable tax credit receivable Refundable tax credits accrued Tax payable Income tax expense Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Total property and equipment Less: accumulated depreciation and amortization Property and equipment, net Property and equipment, estimated useful lives Amortization expense Accounts payable Accrued compensation Accrued other expenses Total accounts payable and accrued expenses Preferred stock, shares authorized Preferred stock, par value Capital stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, voting rights description Balance, shares Restricted Stock Units (RSU) Granted Cancelled or returned Balance, shares Option Indexed to Issuer's Equity [Table] Option Indexed to Issuer's Equity [Line Items] Total Options Outstanding, Beginning balance Weighted Average Exercise Price Outstanding, Beginning balance Aggregate Intrinsic Value, Beginning balance Total Options Outstanding, Exercised Weighted Average Exercise Price, Exercised Aggregate Intrinsic Value, Exercised Total Options Outstanding, Granted Weighted Average Exercise Price, Granted Aggregate Intrinsic Value, Granted Total Options Outstanding, Cancelled Weighted Average Exercise Price, Cancelled Aggregate Intrinsic Value, Cancelled Total Options Outstanding, Ending balance Weighted Average Exercise Price, Ending balance Aggregate Intrinsic Value, Ending balance Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Total Options Outstanding, Beginning balance Weighted Average Fair Value, Beginning balance Aggregate Intrinsic Value, Beginning balance Total Options Outstanding, Granted Weighted Average Fair Value, Granted Aggregate Intrinsic Value, Granted Total Options Outstanding, Forfeited Weighted Average Fair Value, Forfeited Aggregate Intrinsic Value, Forfeited Total Options Outstanding, Vested Weighted Average Fair Value, Vested Aggregate Intrinsic Value, Vested Total Options Outstanding, Vested Weighted Average Fair Value, Ending balance Aggregate Intrinsic Value, Vested Shares reserved for issuance Maximum term of options granted Shares available for grant Number of shares authorized for issuance Fair value of restricted stock unit Equity-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Common stock closing price per share Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Royalty received on sales 2024 (excluding the nine months ended September 30, 2024) 2025 2026 2027 2028 2029 and Thereafter Total operating lease payments Less: present value discount Total operating lease liabilities Product Liability Contingency [Table] Product Liability Contingency [Line Items] Lease expiration date Operating lease, weighted average discount rate Operating lease, weighted average remaining lease term Current operating lease liability Common area maintenance charges Land subject to leases Operating lease term Operating lease payments Lease expiration period Rent expense Operating lease expense Prepaid reservation fee Clinical trial expenses Prepaid and other expenses Additional costs Estimated agreement cost Unregistered common stock, shares Unregistered common stock, share price Unregistered common stock, purchase price Unregistered common stock, investments Finance Lease Right-of-use Lab Equipment [Member] Related party operating lease right of use assets. Related party operating lease liabilities current. operating lease liabilities related party non-current. 2015 Equity Incentive Plan [Member] Aggregate Intrinsic Value, Cancelled. Legal settlement. Share based compensation arrangement by share based payment award options expired in period intrinsic value. Schedule of Common Stock Reserved Future Issuance [Table Text Block] Right of use assets related to lease expenses. Collaboration Agreement [Member] Miami, Florida [Member] Bothell, Washington [Member] Lessee operating lease liability payments due year five and thereafter. Operating lease variable common area maintenance charges. North Creek Tec LLC [Member] Amended Lease Agreement for Expansion [Member] Amended Lease Agreement for Extension [Member] Operating lease expiration. Tax credit receivable. Dr. Phillip Frost [Member] Prepaid resevation fee. Phase 2a Clinical Trial [Member] Agreement [Member] hVIVO [Member] Estimated agreement cost. Securities Purchase Agreement [Member] Restricted Stock Units for Common Stock [Member] Proceeds from operating lease payments. Share based compensation arrangement by share based payment award equity instruments other than options grants in period total fair value. Stock restricted units issued and outstanding. Outstanding Options to Purchase Common Stock [Member] Warrants to Purchase Common Stock [Member] Lab Equipment [Member] Computer and Office Equipment [Member] Share based compensation arrangement by share based payment award options grants in period total intrinsic value. Sweep Account [Member] Initial recognition of right of use assets and lease liabilities. Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Assets, Current Assets [Default Label] Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Nonoperating Nonoperating Income (Expense) Shares, Outstanding Share-Based Payment Arrangement, Noncash Expense Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Income Taxes Receivable Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Finance Lease, Principal Payments Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount EX-101.PRE 12 cocp-20240930_pre.xml XBRL PRESENTATION FILE XML 14 R1.htm IDEA: XBRL DOCUMENT

Cover - $ / shares	9 Months Ended	
	Sep. 30, 2024	Nov. 13, 2024
Cover [Abstract]		
Document Type	10-Q	
Amendment Flag	false	
Document Quarterly Report	true	
Document Transition Report	false	
Document Period End Date	Sep. 30, 2024	
Document Fiscal Period Focus	Q3	
Document Fiscal Year Focus	2024	
Current Fiscal Year End Date	--12-31	
Entity File Number	001-38418	
Entity Registrant Name	COCRYSTAL PHARMA, INC.	
Entity Central Index Key	0001412486	
Entity Tax Identification Number	35-2528215	
Entity Incorporation, State or Country Code	DE	
Entity Address, Address Line One	19805 North Creek Parkway	
Entity Address, City or Town	Bothell	
Entity Address, State or Province	WA	
Entity Address, Postal Zip Code	98011	
City Area Code	877	
Local Phone Number	262-7123	
Title of 12(b) Security	Common Stock	
Trading Symbol	COCP	
Security Exchange Name	NASDAQ	
Entity Current Reporting Status	Yes	

Entity Interactive Data Current	Yes	
Entity Filer Category	Non-accelerated Filer	
Entity Small Business	true	
Entity Emerging Growth Company	false	
Entity Shell Company	false	
Entity Common Stock, Shares Outstanding		10,173,790
Entity Listing, Par Value Per Share	$ 0.001	

XML 15 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets:		
Cash	$ 13,020,000	$ 26,353,000
Restricted cash	75,000	75,000
Tax credit receivable	652,000	890,000
Prepaid expenses and other current assets	509,000	1,773,000
Total current assets	14,256,000	29,091,000
Property and equipment, net	181,000	271,000
Deposits	29,000	46,000
Operating lease right-of-use assets, net (including $163 and $42 respectively, to related party)	1,767,000	1,851,000
Total assets	16,233,000	31,259,000
Current liabilities:		
Accounts payable and accrued expenses	1,655,000	3,022,000
Current maturities of operating lease liabilities (including $55 and $42 respectively, to related party)	293,000	240,000
Total current liabilities	1,948,000	3,262,000
Long-term liabilities:		
Operating lease liabilities (including $163 and $0 respectively, to related party)	1,582,000	1,613,000
Total liabilities	3,530,000	4,875,000
Commitments and contingencies (Note 8)		
Stockholders' equity:		
Common stock, $0.001 par value 100,000 and 150,000 shares authorized as of September 30, 2024, and December 31, 2023; 10,174 shares issued and outstanding as of September 30, 2024 and December 31, 2023	10,000	10,000
Additional paid-in capital	342,845,000	342,288,000
Accumulated deficit	(330,152,000)	(315,914,000)
Total stockholders' equity	12,703,000	26,384,000
Total liabilities and stockholders' equity	$ 16,233,000	$ 31,259,000

XML 16 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]		
Operating lease right of use assets related party	$ 163	$ 42
Operating lease liabilities related party current	55	42
Operating lease liabilities related party non-current	$ 163	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	150,000,000
Common stock, shares issued	10,174,000	10,174,000
Common stock, shares outstanding	10,174,000	10,174,000

XML 17 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:				
Research and development	$ 3,242,000	$ 4,194,000	$ 10,500,000	$ 10,902,000
General and administrative	1,800,000	1,849,000	4,148,000	4,591,000
Legal settlement		(1,600,000)		(1,600,000)
Total operating expenses	5,042,000	4,443,000	14,648,000	13,893,000
Loss from operations	(5,042,000)	(4,443,000)	(14,648,000)	(13,893,000)
Other income (expense):				
Interest income (expense), net	111,000	320,000	482,000	460,000
Foreign exchange loss	(8,000)	(42,000)	(72,000)	(87,000)
Total other expense, net	103,000	278,000	410,000	373,000
Net loss	$ (4,939,000)	$ (4,165,000)	$ (14,238,000)	$ (13,520,000)
Net loss per common share, basic	$ (0.49)	$ (0.41)	$ (1.40)	$ (1.43)
Net loss per common share, diluted	$ (0.49)	$ (0.41)	$ (1.40)	$ (1.43)
Weighted average number of common shares outstanding, basic	10,174	10,153	10,174	9,461
Weighted average number of common shares outstanding, diluted	10,174	10,153	10,174	9,461

XML 18 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 8,000	$ 337,489,000	$ (297,930,000)	$ 39,567,000
Balance, shares at Dec. 31, 2022	8,143			
Stock-based compensation		291,000		291,000
Net loss			(5,189,000)	(5,189,000)
Balance at Mar. 31, 2023	$ 8,000	337,780,000	(303,119,000)	34,669,000
Balance, shares at Mar. 31, 2023	8,143			
Balance at Dec. 31, 2022	$ 8,000	337,489,000	(297,930,000)	39,567,000
Balance, shares at Dec. 31, 2022	8,143			
Net loss				(13,520,000)
Balance at Sep. 30, 2023	$ 10,000	342,130,000	(311,450,000)	30,690,000
Balance, shares at Sep. 30, 2023	10,174			
Balance at Mar. 31, 2023	$ 8,000	337,780,000	(303,119,000)	34,669,000
Balance, shares at Mar. 31, 2023	8,143			
Stock-based compensation		179,000		179,000
Net loss			(4,166,000)	(4,166,000)
Sale of common stock to related entities, net of transaction costs	$ 2,000	3,998,000		4,000,000
Sale of common stock to related entities, net of transaction costs, shares	2,031			
Balance at Jun. 30, 2023	$ 10,000	341,957,000	(307,285,000)	34,682,000
Balance, shares at Jun. 30, 2023	10,174			
Stock-based compensation		173,000		173,000

Net loss			(4,165,000)	(4,165,000)
Balance at Sep. 30, 2023	$ 10,000	342,130,000	(311,450,000)	30,690,000
Balance, shares at Sep. 30, 2023	10,174			
Balance at Dec. 31, 2023	$ 10,000	342,288,000	(315,914,000)	26,384,000
Balance, shares at Dec. 31, 2023	10,174			
Stock-based compensation		157,000		157,000
Net loss			(3,956,000)	(3,956,000)
Balance at Mar. 31, 2024	$ 10,000	342,445,000	(319,870,000)	22,585,000
Balance, shares at Mar. 31, 2024	10,174			
Balance at Dec. 31, 2023	$ 10,000	342,288,000	(315,914,000)	26,384,000
Balance, shares at Dec. 31, 2023	10,174			
Net loss				(14,238,000)
Balance at Sep. 30, 2024	$ 10,000	342,845,000	(330,152,000)	12,703,000
Balance, shares at Sep. 30, 2024	10,174			
Balance at Mar. 31, 2024	$ 10,000	342,445,000	(319,870,000)	22,585,000
Balance, shares at Mar. 31, 2024	10,174			
Stock-based compensation		148,000		148,000
Net loss			(5,343,000)	(5,343,000)
Balance at Jun. 30, 2024	$ 10,000	342,593,000	(325,213,000)	17,390,000
Balance, shares at Jun. 30, 2024	10,174			
Stock-based compensation		252,000		252,000
Net loss			(4,939,000)	(4,939,000)
Balance at Sep. 30, 2024	$ 10,000	$ 342,845,000	$ (330,152,000)	$ 12,703,000
Balance, shares at Sep. 30, 2024	10,174			

XML 19 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Operating activities:		
Net loss	$ (14,238,000)	$ (13,520,000)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization expense	98,000	149,000
Right of use assets	247,000	163,000
Stock-based compensation	558,000	643,000
Operating lease liabilities	(142,000)	(172,000)
Changes in operating assets and liabilities:		
Prepaid expenses and other current assets	1,281,000	401,000
Tax credit receivable	238,000	166,000
Accounts payable and accrued expenses	(1,367,000)	830,000
Net cash used in operating activities	(13,325,000)	(11,340,000)
Investing activities:		
Purchases of property and equipment	(8,000)	(59,000)
Net cash used in investing activities	(8,000)	(59,000)
Financing activities:		
Payments on finance lease liabilities		(7,000)
Proceeds from sale of common stock to related entities, net of transaction costs		4,000,000
Net cash provided by financing activities		3,993,000
Net decrease in cash and restricted cash	(13,333,000)	(7,406,000)
Cash and restricted cash at beginning of period	26,428,000	37,219,000
Cash and restricted cash at end of period	13,095,000	29,813,000
Non-cash investing and financing activities		
Initial recognition of right-of-use assets and lease liabilities	$ 163,000	

XML 20 R7.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($)	3 Months Ended						9 Months Ended	
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure [Table]								
Net Income (Loss)	$ (4,939,000)	$ (5,343,000)	$ (3,956,000)	$ (4,165,000)	$ (4,166,000)	$ (5,189,000)	$ (14,238,000)	$ (13,520,000)

XML 21 R8.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	9 Months Ended
	Sep. 30, 2024
Insider Trading Arrangements [Line Items]	
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML 22 R9.htm IDEA: XBRL DOCUMENT

Organization and Business	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]	

Organization and Business

1. Organization and Business

Cocrystal Pharma, Inc. (“we”, the “Company” or “Cocrystal”), a clinical stage biopharmaceutical company incorporated in Delaware, has been developing novel technologies and approaches to create first-in-class or best-in-class antiviral drug candidates. Our focus is to pursue the development and commercialization of broad-spectrum antiviral drug candidates that will transform the treatment and prophylaxis of viral diseases in humans. By concentrating our research and development efforts on viral replication inhibitors, we plan to leverage our infrastructure and expertise in these areas.

The Company’s activities since inception have principally consisted of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs, obtaining regulatory approvals of its products and, ultimately, the attainment of profitable operations is dependent on future events, including, among other things, its ability to access potential markets, secure financing, develop a customer base, attract, retain and motivate qualified personnel, and develop strategic alliances.

Liquidity

The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative operating cash flows since inception. For the nine months ended September 30, 2024, the Company recorded a net loss of approximately $14,238,000 and used approximately $13,325,000 of cash in operating activities.

On September 30, 2024, the Company had cash and restricted cash of approximately $13,095,000. Restricted cash represents amounts pledged as collateral for financing arrangements that are currently limited to the issuance of business credit cards. The restriction will end upon the conclusion of these financing arrangements. We believe that our current resources will be sufficient to fund our operations beyond the next 12 months. This estimate is based, in part, upon our currently projected expenditures.

The Company’s activities since inception have principally consisted of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs, obtaining regulatory approvals of its products and, ultimately, the attainment of profitable operations is dependent on future events, including, among other things, its ability to access potential markets, secure financing, develop a customer base, attract, retain and motivate qualified personnel, and develop strategic alliances. Through September 30, 2024, the Company has primarily funded its operations through equity offerings.

The Company will need to continue obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that the additional capital it is able to raise, if any, will be sufficient to meet its needs, or that any such financing will be obtainable on acceptable terms. Our future cash requirements, and the timing of those requirements, will depend on a number of factors, including economic conditions, the approval and success of our products in development, the continued progress of research and development of our product candidates, the timing and outcome of clinical trials and regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims and other intellectual property rights, the status of competitive products, the availability of financing, our success in developing markets for our product candidates and legal proceedings that may arise. We have historically not generated sustained positive cash flow and if we are not able to secure additional funding when needed, we may have to delay, reduce the scope of, or eliminate one or more of our clinical trials or research and development programs. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its drug development activities. The Company expects to continue incurring substantial operating losses and negative cash flows from operations over the next several years during its pre-clinical and clinical development phases.

Basis of Presentation and Significant Accounting Policies

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies

2. Basis of Presentation and Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X set forth by the Securities and Exchange Commission ("SEC"). They do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire fiscal year. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2023 filed on March 28, 2024 ("Annual Report").

Principles of Consolidation

The consolidated financial statements include the accounts of Cocrystal Pharma, Inc. and its wholly owned subsidiaries: Cocrystal Discovery, Inc., Cocrystal Pharma Australia Pty Ltd. ("Cocrystal Australia"), RFS Pharma, LLC and Cocrystal Merger Sub, Inc. Intercompany transactions and balances have been eliminated.

Segments

The Company operates in only one segment. Management uses cash flows as the primary measure to manage its business and does not segment its business for internal reporting or decision-making.

Use of Estimates

Preparation of the Company's consolidated financial statements in conformance with U.S. GAAP requires the Company's management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company's consolidated financial statements and accompanying notes. The significant estimates in the Company's consolidated financial statements relate to the valuation of equity awards and warrant liabilities, recoverability of deferred tax assets, estimated tax credit receivable and estimated useful lives of fixed assets. The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash deposited in accounts held at two U.S. financial institutions, which may, at times, exceed federally insured limits of $250,000 for each institution where accounts are held. At September 30, 2024 and December 31, 2023, our primary operating accounts held approximately $13,020,000 and $26,353,000, respectively, and our restricted cash collateral account balance was $75,000 and $75,000 at a different institution. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risks thereof.

Foreign Currency Transactions

The Company and its subsidiaries use the U.S. dollar as functional currency. Foreign currency transactions are initially measured and recorded in the functional currency using the exchange rate on the date of the transaction. Foreign exchange gains and losses arising from settlement of foreign currency transactions are recognized in profit and loss.

Cocrystal Australia maintains its records in Australian dollars. The monetary assets and liabilities of Cocrystal Australia are remeasured into the functional currency using the closing rate at the end of every reporting period. All nonmonetary assets and liabilities and related profit and loss accounts are remeasured into the functional currency using the historical exchange rates. Profit and loss accounts, other than those that are remeasured using the historical exchange rates, are remeasured into the functional currency using the average exchange rate for the period. Foreign exchange gains and losses arising from the remeasurement into the functional currency is recognized in profit and loss.

Fair Value Measurements

FASB Accounting Standards Codification ("ASC") 820 defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

Level 1 — quoted prices in active markets for identical assets or liabilities.

Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

Level 3 — significant unobservable inputs that reflect management's best estimate of what market participants would use to price the assets or liabilities at the measurement date.

At September 30, 2024 and December 31, 2023, the carrying amounts of financial assets and liabilities, such as cash, tax receivable, other assets, and accounts payable and accrued expenses approximate their fair values due to their short-term nature. The carrying values of leases payable approximate their fair values due to the fact that the interest rates on these obligations are based on prevailing market interest rates.

Long-Lived Assets

The Company regularly reviews the carrying value and estimated lives of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management's estimate of the asset's ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company's business objective. Should an impairment exist, the impairment loss would be measured based on the excess of the carrying amount over the asset's fair value.

Research and Development Expenses

Research and development costs consist primarily of fees paid to consultants and outside service providers, and other expenses relating to the acquisition, design, development and testing of the Company's clinical products. All research and development costs are expensed as incurred. Research and development costs are presented net of tax credits.

The Company's Australian subsidiary is entitled to receive government assistance in the form of refundable and non-refundable research and development tax credits ("Refundable Tax Credits") from the federal and provincial taxation authorities, based on qualifying expenditures incurred during the fiscal year. The Refundable Tax Credits are from the provincial taxation authorities and are not dependent on its ongoing tax status or tax position and accordingly are not considered part of income taxes. The Company records Refundable Tax Credits as a reduction of research and development expenses when the Company can reasonably estimate the amounts and it is more likely than not, they will be received. As of December 31, 2023, balance of Refundable Tax Credits was approximately $786,000, which was received in full as of September 30, 2024. The Company estimated and accrued Refundable Tax Credits for the nine months ended September 30, 2024 of approximately $652,000 and a tax payable of $15,000, resulting in a net balance of Refundable Tax Credits receivable of approximately $637,000.

Income Taxes

The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Realization of deferred tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred tax asset will not be realized based on the weight of available evidence, including expected future earnings. The Company recognizes an uncertain tax position in its financial statements when it concludes that a tax position is more likely than not to be sustained upon examination based solely on its technical merits. Only after a tax position passes the first step of recognition will measurement be required. Under the measurement step, the tax benefit is measured as the largest amount of benefit that is more likely than not to be realized upon effective settlement. This is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. The Company elects to accrue any interest or penalties related to income taxes as part of its income tax expense.

As of September 30, 2024, the Company assessed its income tax expense based on its projected future taxable income for the year ending December 31, 2024 and therefore recorded no amount for income tax expense for the nine months ended September 30, 2024. In addition, the Company has significant deferred tax assets available to offset income tax expense due to net operating loss carry forwards which are currently subject to a full valuation allowance based on the Company's assessment of future taxable income. Refer to our Annual Report on Form 10-K for the year ended December 31, 2023 for more information.

Stock-Based Compensation

The Company recognizes compensation expense using a fair value-based method for costs related to stock-based payments, including stock options. The fair value of options awarded to employees is measured on the date of grant using the Black-Scholes option pricing model and is recognized as expense over the requisite service period on a straight-line basis.

Use of the Black-Scholes option pricing model requires the input of subjective assumptions including expected volatility, expected term, and a risk-free interest rate. The Company estimates volatility using a blend of its own historical stock price volatility as well as that of market comparable entities since the Company's common stock has limited trading history and limited observable volatility of its own. The expected term of the options is estimated by using the SEC Staff Bulletin No. 107's *Simplified Method for Estimate Expected Term*. The risk-free interest rate is estimated using comparable published federal funds rates.

Net Income (Loss) per Share

The Company accounts for and discloses net income (loss) per common share in accordance with FASB ASC Topic 260, *Earnings Per Share*. Basic income (loss) per common share is computed by dividing income (loss) attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common stock for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants and the conversion of convertible notes payable.

The following table sets forth the number of potential common shares excluded from the calculations of net loss per diluted share because their inclusion would be anti-dilutive (in thousands):

	September 30,	
	2024	2023
Outstanding options to purchase common stock	555	559
Restricted stock units for common stock	256	-
Warrants to purchase common stock	-	13
Total	811	572

Recent Accounting Pronouncements

Authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC did not, or are not expected to, have a material impact on the Company's consolidated financial statements and related disclosures.

XML 24 R11.htm IDEA: XBRL DOCUMENT

Property and Equipment	**9 Months Ended Sep. 30, 2024**
Property, Plant and Equipment [Abstract]	
Property and Equipment	**3. Property and Equipment**

Property and equipment are recorded at cost and depreciated over the estimated useful lives of the underlying assets (three to five years) using the straight-line method. As of September 30, 2024, and December 31, 2023, property and equipment consists of (table in thousands):

	September 30, 2024	December 31, 2023
Lab equipment	$ 1,765	$ 1,757
Finance lease right-of-use lab equipment	162	162
Computer and office equipment	155	155
Total property and equipment	2,082	2,074
Less: accumulated depreciation and amortization	(1,901)	(1,803)
Property and equipment, net	$ 181	$ 271

Total depreciation and amortization expense were approximately $98,000 and $149,000 for the nine months ended September 30, 2024 and 2023, which includes amortization expense of $0 and $7,164 for the nine months ended September 30, 2024 and 2023, respectively, related to assets under finance lease. For additional finance leases information, refer to Note 8 – Commitments and Contingencies.

XML 25 R12.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses	**9 Months Ended Sep. 30, 2024**
Payables and Accruals [Abstract]	
Accounts Payable and Accrued Expenses	**4. Accounts Payable and Accrued Expenses**

Accounts payable and accrued expenses consisted of the following (in thousands) as of:

	September 30, 2024	December 31, 2023
Accounts payable	$ 859	$ 1,222
Accrued compensation	185	109
Accrued other expenses	611	1,691
Total accounts payable and accrued expenses	$ 1,655	$ 3,022

Accounts payable and accrued expenses contain unpaid general and administrative expenses and costs related to research and development that have been billed and estimated unbilled, respectively, as of period-end.

XML 26 R13.htm IDEA: XBRL DOCUMENT

Equity	**9 Months Ended Sep. 30, 2024**
Equity [Abstract]	
Equity	**5. Equity**

As of September 30, 2024, the Company has authorized 100,000,000 shares of common stock, $0.001 par value per share, and 1,000,000 shares of preferred stock, $0.001 par value per share.

On June 27, 2024, the Company, following approval of the Company's stockholders at the 2024 Annual Meeting of Stockholders filed an amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware (the "Amendment") to decrease the number of shares of authorized capital stock of the Company from 155,000,000 shares of capital stock, consisting of 150,000,000 shares of common stock and 5,000,000 shares of preferred stock, to 101,000,000 shares of capital stock consisting of 100,000,000 shares of common stock and 1,000,000 shares of preferred stock. The Amendment became effective on June 27, 2024.

The Company had 10,174,000 shares of common stock and no shares of preferred stock issued and outstanding as of September 30, 2024, and December 31, 2023.

The holders of common stock are entitled to one vote for each share of common stock held.

XML 27 R14.htm IDEA: XBRL DOCUMENT

Stock Based Awards	**9 Months Ended Sep. 30, 2024**
Share-Based Payment Arrangement [Abstract]	
Stock Based Awards	**6. Stock Based Awards**

Equity Incentive Plans

The Company adopted an equity incentive plan in 2015 (the "2015 Plan") under which 833,333 shares of common stock have been reserved for issuance to employees, and non-employee directors and consultants of the Company. Recipients of incentive stock options granted under the 2015 Plan shall be eligible to purchase shares of the Company's common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the 2015 Plan is ten years. As of September 30, 2024, 22,000 shares remain available for future grants under the 2015 Plan.

Common Stock Reserved for Future Issuance

The following table presents information concerning common stock available for future issuance (in thousands) as of September 30, 2024:

	Shares Available for Grant
Balance at December 31, 2023	275
Restricted Stock Units (RSU) Granted	(256)
Cancelled or returned	3
Balance at September 30, 2024	22

Stock Options

The following table summarizes stock option transactions for the 2015 Plan, collectively, for the nine months ended September 30, 2024 (in thousands, except per share amounts):

	Total Options Outstanding	Weighted Average Exercise Price	Aggregate Intrinsic Value
Balance at December 31, 2023	558	$ 10.37	$ -
Exercised	-	-	-
Granted	-	-	-
Cancelled	(3)	-	-
Balance at September 30, 2024	555	$ 10.40	$ -

Restricted Stock Units

On August 12, 2024, the Company's Compensation Committee approved the issuance of 256,000 restricted stock unit ("RSU") awards to non-employee directors, officers, consultants and employees. The aggregate fair value of the restricted stock unit awards granted was estimated to be $451,000 using the market price of the stock on the date of the grant which is expensed using the straight-line method over the vesting period.

	Total Options Outstanding	Weighted Average Fair Value	Aggregate Intrinsic Value
Unvested December 31, 2023	-	$ -	$ -
Granted	256	-	-
Forfeited	-	-	-
Vested	92	1.76	-
Unvested and expected to vest at September 30, 2024	164	$ 1.76	$ -

The Company accounts for share-based awards to employees and nonemployee directors and consultants in accordance with the provisions of ASC 718, *Compensation—Stock Compensation.*, and under the recently issued guidance following FASB's pronouncement, ASU 2018-07, *Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting*. Under ASC 718, and applicable updates adopted, share-based awards are valued at fair value on the date of grant and that fair value is recognized over the requisite service, or vesting, period. The Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur. For the three and nine months ended September 30, 2024 and 2023, equity-based compensation

expense recorded on vested options and RSU was $252,000 and $557,000 and $173,000 and $643,000 respectively.

As of September 30, 2024, there was approximately $321,000 of total unrecognized compensation expense related to non-vested stock options that is expected to be recognized over a weighted average period of 0.8 years. For options granted and outstanding, there were 555,000 options outstanding which were fully vested or expected to vest, with an aggregate intrinsic value of $0.00, a weighted average exercise price of $10.40 and weighted average remaining contractual term of 7.47 years at September 30, 2024. For vested and exercisable options, outstanding shares totaled 435,000, with an aggregate intrinsic value of $0.00. These options had a weighted average exercise price of $12,38 per share and a weighted-average remaining contractual term of 7.16 years at September 30, 2024.

The aggregate intrinsic value of outstanding and exercisable options at September 30, 2024 was calculated based on the closing price of the Company's common stock as reported on The Nasdaq Capital Market on September 30, 2024 of $1.76 per share less the exercise price of the options. The aggregate intrinsic value is calculated based on the positive difference between the closing fair market value of the Company's common stock and the exercise price of the underlying options.

XML 28 R15.htm IDEA: XBRL DOCUMENT

Licenses and Collaborations	9 Months Ended Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]	
Licenses and Collaborations	

7. Licenses and Collaborations

On January 2, 2019, the Company entered into an Exclusive License and Research Collaboration Agreement (the "Collaboration Agreement") with Merck Sharp & Dohme LLC ("Merck") to discover and develop certain proprietary influenza A/B antiviral agents. Under the terms of the Collaboration Agreement, Merck funded research and development for the program, including clinical development, and was responsible for worldwide commercialization of any products derived from the collaboration. Under the Collaboration Agreement Cocrystal was eligible to receive payments related to designated development, regulatory and sales milestones with the potential to earn up to $156,000,000, as well as royalties on product sales. The Collaboration Agreement provided that Merck may terminate the Collaboration Agreement at any time prior to the first commercial sale of the first product developed under the Collaboration Agreement, in its sole discretion, without cause.

On December 15, 2023, the Company received written notice from Merck of Merck's election to terminate the Collaboration Agreement. The termination of the Collaboration Agreement took effect on March 14, 2024. According to Merck's termination notice, Merck determined there were no existing conditions to continue the collaboration. The termination resulted from the inability to develop the compounds to meet a specific aspect of Merck's program. The pending patent applications on compounds covered by the Collaboration Agreement and previously filed by Merck on behalf of both companies remain in place.

Kansas State University Research Foundation

Cocrystal entered into two License Agreement with Kansas State University Research Foundation (the "Foundation") on February 18, 2020 to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of norovirus and coronavirus infections.

On February 28, 2024, the Company provided notice to the Foundation of the Company's election to terminate the 2020 License Agreements. The terminations, which were made due to the Company's determination that further development efforts under the License Agreements would be futile, took effect on March 29, 2024.

XML 29 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	9 Months Ended Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]	
Commitments and Contingencies	

8. Commitments and Contingencies

Commitments

In the ordinary course of business, the Company enters into non-cancellable leases to purchase equipment and for its facilities, including related party leases (see Note 9 – Transactions with Related Parties). Leases are accounted for as operating leases or finance leases, in accordance with ASC 842, *Leases*.

Operating Leases

The Company leases office space in Miami, Florida and research and development laboratory space in Bothell, Washington under operating leases that expire on September 30, 2027 and January 31, 2031, respectively. For operating leases, the weighted average discount rate is 6.4% and the weighted average remaining lease term is 5.5 years.

The following table summarizes the Company's maturities of operating lease liabilities, by year and in aggregate, as of September 30, 2024 (table in thousands):

2024 (excluding the nine months ended September 30, 2024)	$ 99
2025	407
2026	419
2027	415
2028	376
2029 and Thereafter	513
Total operating lease payments	2,229
Less: present value discount	(354)
Total operating lease liabilities	$ 1,875

As of September 30, 2024, the total operating lease liability of $293,000 is classified as a current operating lease liability.

The operating lease liabilities summarized above do not include variable common area maintenance (the "CAM") charges, which are contractual liabilities under the Company's Bothell, Washington lease. CAM charges for the Bothell, Washington facility is calculated annually based on actual common expenses for the building incurred by the lessor and proportionately billed to tenants based on leased square footage. For the nine months ended September 30, 2024 and 2023, approximately $134,000 and $76,000 of CAM was included in general and administrative operating expenses on the condensed consolidated statements of operations, respectively.

The minimum lease payments above include the amounts that would be paid if the Company maintains its Bothell lease for the five-year term, starting February 2024.

On September 21, 2023, the Company amended the lease agreement with a North Creek Tec LLC, to expand its laboratory facility in Bothell – WA, with additional 6,000 sq ft for a period of 5 years that expires on January 31, 2029, with monthly lease payments under this lease totaling $660,000. In addition, the Company amended the lease agreement to extend the original laboratory facility for an additional 7 years with monthly lease payments under this lease totaling $1,498,000. Through January 2031, the minimum lease payment combined totals approximately $380,000 annually.

On August 14, 2024, the Company entered into a three-year lease extension with a limited liability company controlled by Dr. Phillip Frost, a director and a principal stockholder of the Company. On an annualized basis, straight-line rent expense is approximately $64,000 including fixed and estimable fees and taxes.

For the nine months ended September 30, 2024 and 2023, operating lease expense, excluding short-term leases, finance leases and CAM charges, totaled approximately $291,000 and $175,000, respectively, of which $46,000 and $47,000 for each period was to a related party.

Phase 2a Clinical Trial

On August 3, 2022 the Company engaged hVIVO, a subsidiary of London-based Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organization ("CRO"), to conduct a Phase 2a clinical trial with the Company's novel, broad-spectrum, orally administered antiviral influenza candidate. The Company prepaid a reservation fee of $1.7 million upon execution of the agreement. As of September 30, 2024, the Company expensed $1.7 million leaving no balance in prepaid expenses. In addition, the Company incurred additional costs of $2.2 million on this agreement during the period ended September 30, 2024.

The total estimated cost of the agreement (including the reservation fee) is approximately $6.9 million.

On May 21, 2024, the Company entered into a new agreement with hVIVO, as a follow-on to CPI-CST-001 Influenza virus challenge study, in which potential resistance to CC-42344 antiviral compound will be genotypically characterized. The Company incurred $45,000 on this agreement for nine months ended September 30, 2024. The total estimated cost of this agreement is approximately $227,000.

Contingencies

From time to time, the Company is a party to, or otherwise involved in, legal proceedings arising in the normal course of business. As of the date of this report, except as described below, the Company is not aware of any proceedings, threatened or pending, against it which, if determined adversely, would have a material effect on its business, results of operations, cash flows or financial position.

XML 30 R17.htm IDEA: XBRL DOCUMENT

Transactions with Related Parties	9 Months Ended Sep. 30, 2024
Related Party Transactions [Abstract]	
Transactions with Related Parties	

9. Transactions with Related Parties

On April 4, 2023, the Company entered into a Securities Purchase Agreement with two accredited investors (the "Purchasers") whereby the Purchasers agreed to purchase a total of 2,030,458 shares of unregistered common stock at a price of $1.97 per share for a total purchase price of $4,000,000 in two equal $2,000,000 investments. The Purchasers were an entity controlled by a director and another investor who subsequently joined the Company's Board of Directors.

On August 14, 2024, the Company entered a three-year lease extension with a limited liability company controlled by Dr. Phillip Frost, a director and a principal stockholder of the Company. On an annualized basis, straight-line rent expense is approximately $64,000 including fixed and estimable fees and taxes.

XML 31 R18.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant	9 Months Ended

Accounting Policies (Policies)	Sep. 30, 2024

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X set forth by the Securities and Exchange Commission ("SEC"). They do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire fiscal year. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2023 filed on March 28, 2024 ("Annual Report").

Principles of Consolidation

Principles of Consolidation

The consolidated financial statements include the accounts of Cocrystal Pharma, Inc. and its wholly owned subsidiaries: Cocrystal Discovery, Inc., Cocrystal Pharma Australia Pty Ltd. ("Cocrystal Australia"), RFS Pharma, LLC and Cocrystal Merger Sub, Inc. Intercompany transactions and balances have been eliminated.

Segments

Segments

The Company operates in only one segment. Management uses cash flows as the primary measure to manage its business and does not segment its business for internal reporting or decision-making.

Use of Estimates

Use of Estimates

Preparation of the Company's consolidated financial statements in conformance with U.S. GAAP requires the Company's management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company's consolidated financial statements and accompanying notes. The significant estimates in the Company's consolidated financial statements relate to the valuation of equity awards and warrant liabilities, recoverability of deferred tax assets, estimated tax credit receivable and estimated useful lives of fixed assets. The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions.

Concentrations of Credit Risk

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash deposited in accounts held at two U.S. financial institutions, which may, at times, exceed federally insured limits of $250,000 for each institution where accounts are held. At September 30, 2024 and December 31, 2023, our primary operating accounts held approximately $13,020,000 and $26,353,000, respectively, and our restricted cash collateral account balance was $75,000 and $75,000 at a different institution. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risks thereof.

Foreign Currency Transactions

Foreign Currency Transactions

The Company and its subsidiaries use the U.S. dollar as functional currency. Foreign currency transactions are initially measured and recorded in the functional currency using the exchange rate on the date of the transaction. Foreign exchange gains and losses arising from settlement of foreign currency transactions are recognized in profit and loss.

Cocrystal Australia maintains its records in Australian dollars. The monetary assets and liabilities of Cocrystal Australia are remeasured into the functional currency using the closing rate at the end of every reporting period. All nonmonetary assets and liabilities and related profit and loss accounts are remeasured into the functional currency using the historical exchange rates. Profit and loss accounts, other than those that are remeasured using the historical exchange rates, are remeasured into the functional currency using the average exchange rate for the period. Foreign exchange gains and losses arising from the remeasurement into the functional currency is recognized in profit and loss.

Fair Value Measurements

Fair Value Measurements

FASB Accounting Standards Codification ("ASC") 820 defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

Level 1 — quoted prices in active markets for identical assets or liabilities.

Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

Level 3 — significant unobservable inputs that reflect management's best estimate of what market participants would use to price the assets or liabilities at the measurement date.

At September 30, 2024 and December 31, 2023, the carrying amounts of financial assets and liabilities, such as cash, tax receivable, other assets, and accounts payable and accrued expenses approximate their fair values due to their short-term nature. The carrying values of leases payable approximate their fair values due to the fact that the interest rates on these obligations are based on prevailing market interest rates.

Long-Lived Assets

Long-Lived Assets

The Company regularly reviews the carrying value and estimated lives of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management's estimate of the asset's ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company's business objective. Should an impairment exist, the impairment loss would be measured based on the excess of the carrying amount over the asset's fair value.

Research and Development Expenses

Research and Development Expenses

Research and development costs consist primarily of fees paid to consultants and outside service providers, and other expenses relating to the acquisition, design, development and testing of the Company's clinical products. All research and development costs are expensed as incurred. Research and development costs are presented net of tax credits.

The Company's Australian subsidiary is entitled to receive government assistance in the form of refundable and non-refundable research and development tax credits ("Refundable Tax Credits") from the federal and provincial taxation authorities, based on qualifying expenditures incurred during the fiscal year. The Refundable Tax Credits are from the provincial taxation authorities and are not dependent on its ongoing tax status or tax position and accordingly are not considered part of income taxes. The Company records Refundable Tax Credits as a reduction of research and development expenses when the Company can reasonably estimate the amounts and it is more likely than not, they will be received. As of December 31, 2023, balance of Refundable Tax Credits was approximately $786,000, which was received in full as of September 30, 2024. The Company estimated and accrued Refundable Tax Credits for the nine months ended September 30, 2024 of approximately $652,000 and a tax payable of $15,000, resulting in a net balance of Refundable Tax Credits receivable of approximately $637,000.

Income Taxes

Income Taxes

The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Realization of deferred tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred tax asset will not be realized based on the weight of available evidence, including expected future earnings. The Company recognizes an uncertain tax position in its financial statements when it concludes that a tax position is more likely than not to be sustained upon examination based solely on its technical merits. Only after a tax position passes the first step of recognition will measurement be required. Under the measurement step, the tax benefit is measured as the largest amount of benefit that is more likely than not to be realized upon effective settlement. This is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. The Company elects to accrue any interest or penalties related to income taxes as part of its income tax expense.

As of September 30, 2024, the Company assessed its income tax expense based on its projected future taxable income for the year ending December 31, 2024 and therefore recorded no amount for income tax expense for the nine months ended September 30, 2024. In addition, the Company has significant deferred tax assets available to offset income tax expense due to net operating loss carry forwards which are currently subject to a full valuation allowance based on the Company's assessment of future taxable income. Refer to our Annual Report on Form 10-K for the year ended December 31, 2023 for more information.

Stock-Based Compensation

Stock-Based Compensation

The Company recognizes compensation expense using a fair value-based method for costs related to stock-based payments, including stock options. The fair value of options awarded to employees is measured on the date of grant using the Black-Scholes option pricing model and is recognized as expense over the requisite service period on a straight-line basis.

Use of the Black-Scholes option pricing model requires the input of subjective assumptions including expected volatility, expected term, and a risk-free interest rate. The Company estimates volatility using a blend of its own historical stock price volatility as well as that of market comparable entities since the Company's common stock has limited trading history and limited observable volatility of its own. The expected term of the options is estimated by using the SEC Staff Bulletin No. 107's *Simplified Method for Estimate Expected Term*. The risk-free interest rate is estimated using comparable published federal funds rates.

Net Income (Loss) per Share

Net Income (Loss) per Share

The Company accounts for and discloses net income (loss) per common share in accordance with FASB ASC Topic 260, *Earnings Per Share*. Basic income (loss) per common share is computed by dividing income (loss) attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common stock for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants and the conversion of convertible notes payable.

The following table sets forth the number of potential common shares excluded from the calculations of net loss per diluted share because their inclusion would be anti-dilutive (in thousands):

	September 30,	
	2024	2023
Outstanding options to purchase common stock	555	559
Restricted stock units for common stock	256	-
Warrants to purchase common stock	-	13
Total	811	572

Recent Accounting

Recent Accounting Pronouncements

Pronouncements

Authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC did not, or are not expected to, have a material impact on the Company's consolidated financial statements and related disclosures.

XML 32 R19.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Schedule of Anti-dilutive Securities Excluded from Calculations of Net Loss Per Share

The following table sets forth the number of potential common shares excluded from the calculations of net loss per diluted share because their inclusion would be anti-dilutive (in thousands):

	September 30,	
	2024	2023
Outstanding options to purchase common stock	555	559
Restricted stock units for common stock	256	-
Warrants to purchase common stock	-	13
Total	811	572

XML 33 R20.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

9 Months Ended

Sep. 30, 2024

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment are recorded at cost and depreciated over the estimated useful lives of the underlying assets (three to five years) using the straight-line method. As of September 30, 2024, and December 31, 2023, property and equipment consists of (table in thousands):

	September 30, 2024	December 31, 2023
Lab equipment	$ 1,765	$ 1,757
Finance lease right-of-use lab equipment	162	162
Computer and office equipment	155	155
Total property and equipment	2,082	2,074
Less: accumulated depreciation and amortization	(1,901)	(1,803)
Property and equipment, net	$ 181	$ 271

XML 34 R21.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2024

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following (in thousands) as of:

	September 30, 2024	December 31, 2023
Accounts payable	$ 859	$ 1,222
Accrued compensation	185	109
Accrued other expenses	611	1,691
Total accounts payable and accrued expenses	$ 1,655	$ 3,022

XML 35 R22.htm IDEA: XBRL DOCUMENT

Stock Based Awards (Tables)

9 Months Ended

Sep. 30, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Common Stock Available for Future Issuance

The following table presents information concerning common stock available for future issuance (in thousands) as of September 30, 2024:

	Shares Available for Grant
Balance at December 31, 2023	275
Restricted Stock Units (RSU) Granted	(256)
Cancelled or returned	3
Balance at September 30, 2024	22

Schedule of Stock Option Transactions

The following table summarizes stock option transactions for the 2015 Plan, collectively, for the nine months ended September 30, 2024 (in thousands, except per share amounts):

	Total Options Outstanding	Weighted Average Exercise Price	Aggregate Intrinsic Value
Balance at December 31, 2023	558	$ 10.37	$ -
Exercised	-	-	-
Granted	-	-	-
Cancelled	(3)	-	-
Balance at September 30, 2024	555	$ 10.40	$ -

Schedule of Restricted Stock Units

	Total Options Outstanding	Weighted Average Fair Value	Aggregate Intrinsic Value
Unvested December 31, 2023	-	$ -	$ -
Granted	256	-	-
Forfeited	-	-	-
Vested	92	1.76	-
Unvested and expected to vest at September 30, 2024	164	$ 1.76	$ -

XML 36 R23.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2024

Commitments and Contingencies Disclosure [Abstract]

Schedule of Maturities of Operating Lease Liabilities

The following table summarizes the Company's maturities of operating lease liabilities, by year and in aggregate, as of September 30, 2024 (table in thousands):

2024 (excluding the nine months ended September 30, 2024)	$ 99
2025	407
2026	419
2027	415
2028	376
2029 and Thereafter	513
Total operating lease payments	2,229
Less: present value discount	(354)
Total operating lease liabilities	$ 1,875

XML 37 R24.htm IDEA: XBRL DOCUMENT

Organization and Business (Details Narrative) - USD ($)

	3 Months Ended						9 Months Ended	
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]								
Net loss	$ 4,939,000	$ 5,343,000	$ 3,956,000	$ 4,165,000	$ 4,166,000	$ 5,189,000	$ 14,238,000	$ 13,520,000
Net cash provided by used in operating activities							13,325,000	$ 11,340,000
Cash and restricted cash	$ 13,095,000						$ 13,095,000	

XML 38 R25.htm IDEA: XBRL DOCUMENT

Schedule of Anti-dilutive Securities Excluded from Calculations of Net Loss Per Share (Details) - shares shares in Thousands

	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]		
Total	811	572
Outstanding Options to Purchase Common Stock [Member]		

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]		
Total	555	559
Restricted Stock Units for Common Stock [Member]		
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]		
Total	256	
Warrants to Purchase Common Stock [Member]		
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]		
Total		13

XML 39 R26.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies (Details Narrative)	**9 Months Ended Sep. 30, 2024 USD ($) Segment**	**Dec. 31, 2023 USD ($)**
Number of operating segments | Segment	1	
Cash FDIC insured amount	$ 250,000	
Cash	13,020,000	$ 26,353,000
Restricted cash	75,000	75,000
Refundable tax credit receivable	637,000	786,000
Refundable tax credits accrued	652,000	
Tax payable	15,000	
Income tax expense	0	
Sweep Account [Member]		
Cash	$ 13,020,000	$ 26,353,000

XML 40 R27.htm IDEA: XBRL DOCUMENT

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	**Sep. 30, 2024**	**Dec. 31, 2023**
Property, Plant and Equipment [Line Items]		
Total property and equipment	$ 2,082	$ 2,074
Less: accumulated depreciation and amortization	(1,901)	(1,803)
Property and equipment, net	181	271
Lab Equipment [Member]		
Property, Plant and Equipment [Line Items]		
Total property and equipment	1,765	1,757
Finance Lease Right-of-use Lab Equipment [Member]		
Property, Plant and Equipment [Line Items]		
Total property and equipment	162	162
Computer and Office Equipment [Member]		
Property, Plant and Equipment [Line Items]		
Total property and equipment	$ 155	$ 155

XML 41 R28.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Narrative) - USD ($)	**9 Months Ended Sep. 30, 2024**	**Sep. 30, 2023**
Property, Plant and Equipment [Line Items]		
Depreciation and amortization expense	$ 98,000	$ 149,000
Amortization expense	$ 0	$ 7,164
Minimum [Member]		
Property, Plant and Equipment [Line Items]		
Property and equipment, estimated useful lives	3 years	
Maximum [Member]		
Property, Plant and Equipment [Line Items]		
Property and equipment, estimated useful lives	5 years	

XML 42 R29.htm IDEA: XBRL DOCUMENT

Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	**Sep. 30, 2024**	**Dec. 31, 2023**
Payables and Accruals [Abstract]		
Accounts payable	$ 859	$ 1,222
Accrued compensation	185	109
Accrued other expenses	611	1,691
Total accounts payable and accrued expenses	$ 1,655	$ 3,022

XML 43 R30.htm IDEA: XBRL DOCUMENT

Equity (Details Narrative) - $ / shares	**9 Months Ended Sep. 30, 2024**	**Jun. 27, 2024**	**Dec. 31, 2023**
Equity [Abstract]			
Common stock, shares authorized	100,000,000	150,000,000	150,000,000
Common stock, par value	$ 0.001		$ 0.001
Preferred stock, shares authorized	1,000,000	5,000,000	
Preferred stock, par value	$ 0.001		
Capital stock, shares authorized	101,000,000	155,000,000	
Common stock, shares issued	10,174,000		10,174,000
Common stock, shares outstanding	10,174,000		10,174,000
Preferred stock, shares issued	0		0
Preferred stock, shares outstanding	0		0
Common stock, voting rights description	The holders of common stock are entitled to one vote for each share of common stock held		

XML 44 R31.htm IDEA: XBRL DOCUMENT

Schedule of Common Stock Available for Future Issuance (Details) shares in Thousands	**9 Months Ended Sep. 30, 2024 shares**
Share-Based Payment Arrangement [Abstract]	
Balance, shares	275
Restricted Stock Units (RSU) Granted	(256)
Cancelled or returned	3
Balance, shares	22

XML 45 R32.htm IDEA: XBRL DOCUMENT

Schedule of Stock Option Transactions (Details) shares in Thousands	**9 Months Ended Sep. 30, 2024 USD ($) $ / shares shares**
Option Indexed to Issuer's Equity [Line Items]	
Total Options Outstanding, Granted	256
Total Options Outstanding, Cancelled	(3)
Share-Based Payment Arrangement, Option [Member]	

Option Indexed to Issuer's Equity [Line Items]	
Total Options Outstanding, Beginning balance	558
Weighted Average Exercise Price Outstanding, Beginning balance | $ / shares	$ 10.37
Aggregate Intrinsic Value, Beginning balance | $	
Total Options Outstanding, Exercised	
Weighted Average Exercise Price, Exercised | $ / shares	
Aggregate Intrinsic Value, Exercised | $	
Total Options Outstanding, Granted	
Weighted Average Exercise Price, Granted | $ / shares	
Aggregate Intrinsic Value, Granted | $	
Total Options Outstanding, Cancelled	(3)
Weighted Average Exercise Price, Cancelled | $ / shares	
Aggregate Intrinsic Value, Cancelled | $	
Total Options Outstanding, Ending balance	555
Weighted Average Exercise Price, Ending balance | $ / shares	$ 10.40
Aggregate Intrinsic Value, Ending balance | $	

XML 46 R33.htm IDEA: XBRL DOCUMENT

Schedule of Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member] shares in Thousands	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]	
Total Options Outstanding, Beginning balance | shares	
Weighted Average Fair Value, Beginning balance	
Aggregate Intrinsic Value, Beginning balance	
Total Options Outstanding, Granted | shares	256
Weighted Average Fair Value, Granted	
Aggregate Intrinsic Value, Granted	
Total Options Outstanding, Forfeited | shares	
Weighted Average Fair Value, Forfeited	
Aggregate Intrinsic Value, Forfeited	
Total Options Outstanding, Vested | shares	92
Weighted Average Fair Value, Vested	$ 1.76
Aggregate Intrinsic Value, Vested	
Total Options Outstanding, Vested | shares	164
Weighted Average Fair Value, Ending balance	$ 1.76
Aggregate Intrinsic Value, Vested	

XML 47 R34.htm IDEA: XBRL DOCUMENT

Stock Based Awards (Details Narrative) - USD ($)	3 Months Ended			9 Months Ended		
	Aug. 12, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]						
Shares reserved for issuance		22,000		22,000		275,000
Number of shares authorized for issuance	256,000					
Fair value of restricted stock unit	$ 451,000					
Equity-based compensation expense		$ 252,000	$ 557,000	$ 173,000	$ 643,000	
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 321,000		$ 321,000		
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition				9 months 18 days		
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number		555,000		555,000		
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value		$ 0.00		$ 0.00		
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price		$ 10.40		$ 10.40		
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term				7 years 5 months 19 days		
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number		435,000		435,000		
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value		$ 0.00		$ 0.00		
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price		$ 12.38		$ 12.38		
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term				7 years 1 month 28 days		
Common stock closing price per share		$ 1.76		$ 1.76		
2015 Equity Incentive Plan [Member]						
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]						
Shares reserved for issuance		833,333		833,333		
Maximum term of options granted				10 years		
Shares available for grant		22,000		22,000		

XML 48 R35.htm IDEA: XBRL DOCUMENT

Licenses and Collaborations (Details Narrative)	Jan. 02, 2019 USD ($)
Collaboration Agreement [Member] | Maximum [Member]	
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]	
Royalty received on sales	$ 156,000,000

XML 49 R36.htm IDEA: XBRL DOCUMENT

Schedule of Maturities of Operating Lease Liabilities (Details) $ in Thousands	Sep. 30, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]	
2024 (excluding the nine months ended September 30, 2024)	$ 99
2025	407
2026	419
2027	415
2028	376
2029 and Thereafter	513
Total operating lease payments	2,229
Less: present value discount	(354)
Total operating lease liabilities	$ 1,875

XML 50 R37.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative)	Aug. 14, 2024 USD ($)	Sep. 21, 2023 USD ($)	3 Months Ended		9 Months Ended		May 21, 2024 USD ($)	Dec. 31, 2023 USD ($)	Aug. 03, 2022 USD ($)
			Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)			

			ft²				
Product Liability Contingency [Line Items]							
Operating lease, weighted average discount rate			6.40%		6.40%		
Operating lease, weighted average remaining lease term			5 years 6 months		5 years 6 months		
Current operating lease liability			$ 293,000		$ 293,000		$ 240,000
Operating lease payments					142,000	$ 172,000	
Operating lease expense					291,000	175,000	
Clinical trial expenses			3,242,000	$ 4,194,000	10,500,000	10,902,000	
Related Party [Member]							
Product Liability Contingency [Line Items]							
Operating lease expense					46,000	47,000	
Phase 2a Clinical Trial [Member]							
Product Liability Contingency [Line Items]							
Prepaid reservation fee							$ 1,700,000
Clinical trial expenses					1,700,000		
Prepaid and other expenses			0		0		
Additional costs					2,200,000		
Estimated agreement cost			$ 6,900,000		6,900,000		
Agreement [Member] | hVIVO [Member]							
Product Liability Contingency [Line Items]							
Additional costs					45,000		
Estimated agreement cost						$ 227,000	
North Creek Tec LLC [Member]							
Product Liability Contingency [Line Items]							
Operating lease payments		$ 380,000					
North Creek Tec LLC [Member] | Amended Lease Agreement for Expansion [Member]							
Product Liability Contingency [Line Items]							
Lease expiration date		Jan. 31, 2029					
Land subject to leases | ft²		6,000					
Operating lease term		5 years					
Operating lease payments		$ 660,000					
North Creek Tec LLC [Member] | Amended Lease Agreement for Extension [Member]							
Product Liability Contingency [Line Items]							
Operating lease term		7 years					
Operating lease payments		$ 1,498,000					
Lease expiration period		January 2031					
Dr. Phillip Frost [Member]							
Product Liability Contingency [Line Items]							
Rent expense	$ 64,000						
General and Administrative Expense [Member]							
Product Liability Contingency [Line Items]							
Common area maintenance charges					$ 134,000	$ 76,000	
Miami, Florida [Member]							
Product Liability Contingency [Line Items]							
Lease expiration date					Sep. 30, 2027		
Bothell, Washington [Member]							
Product Liability Contingency [Line Items]							
Lease expiration date					Jan. 31, 2031		

XML 51 R38.htm IDEA: XBRL DOCUMENT

Transactions with Related Parties (Details Narrative) - USD ($)	**Aug. 14, 2024**	**Apr. 04, 2023**
Dr. Phillip Frost [Member]		
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]		
Rent expense	$ 64,000	
Securities Purchase Agreement [Member]		
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]		
Unregistered common stock, shares		2,030,458
Unregistered common stock, share price		$ 1.97
Unregistered common stock, purchase price		$ 4,000,000
Unregistered common stock, investments		$ 2,000,000

EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

*=^IHVMBI+Q)^7^_9?RG%@YBW2/&IS+ZF ML4[&SM A,5]&FTP_R]UOO!;4,WP+F:GR+]G56,\ABXW2,J^#809Y*JK?Z+TV MXB@ >/ OP[PSP-82T!0!P27CL#]
';J"+TZH)3N5MI+XV:1CB:C0NY(8=# M9BY*]\MH\"L5)E%>= '_32%.3Z92Q+#L/"9PI626QI&&FQ<-/Y /6A&Y)'^N M>1&9=57DYE5$FS@%S =R1UY?9N3FQP]$)5'!%4D%^9+ (C8IK:NANF90=Q% M/97':BI^RU0"\ED*G2@RARG%2/RL.S[LB'?!EL8;?^_-H]|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|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iG/Y;;YCZAA6QB>E?5,_2Z(6;]K8PWU-0T$%TA3<[TB]UVI.>6 M%V:T<<:@3;El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|"+[W,[9|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|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}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f =4V5]IF+6U:f&;,(@N"U@=O(:L M^>Z)QY--GI-/F_Q?S%Z>RQC]!:5]NGXNC.;2*?$E:XNF5K7MAZ3<]=,@L[Z$M4?,TV;SQJK;H-R_]=/A1ITRZ+'-H-:/[SV\VWL='O.FB]YW-9T"[F[5A6.7F;9X7>'Y GA/C$EV+N/A%U< M>X1,Z|+6;WGO@E5?[3<->P^$G8U;5OR-L#6,WGO6;==JF+KAUT?VY@L=9#4 MKP12.O' Q+A'U+4TS&W-]+]2<&.`?(Q&DQMZKX;.&X0MR/0=Q. M)3],65029%![F1, "S8I8>DT-&H4&Z!PR9,R-@A%N%>H3.%GA ?<%_D(((#H M!&G"#;##$E1%;/!9^"&G$J)FH7=CB4)!!4NMO)^_P[4.6(%T!APDH8=$'T M5!#\5>2B $EV%(BX,WZ[9/BLD+)\@(*\=4HQ"59*7I.HI+QJ4BB!118V*/^,'-M-!#BE&M$#<\3[]%)!!"\[30-O@4/C?D4A%UIQH 9 ""$-:E0{G1[_6C7]^'-M_WP7 #T-D@8$4[<#@:S)=7BJUWX*[L0]RP 81$_$)KQ@4YZ6A.[_Z6WV>GTV M =KI>;)O36)3"QJ;%&(H"11L*%Z@#6"(++$1M5V;A5KL^7R\) M;<*IC=B\;L:S\JK7?[XT_VU,G;>/$("$=U"^&G34[1@-!U2=8&F0+8RL**1 M8$8:F9+'[*U"@WN2YR4HN4P(XQ0OFWB,=/E8IF)QD]M);W0Y'C0[Z6UL1*U)!-MMB\2]1>T DI6)-$+%[XW!X=G)^SHY.SL^O+@Z/3\UW^^ZKVBI[Y<'Q\]^^^U>/-MX58F9HR/]OZQ"Y9+ 3.[$<,4]8D&@ORG5Y2+V+NY^OH.IFCEQ#5UZ#1]\LIE M-O9NCGU[KN>|,D9E[T$X/9:[).8"\6I&;X_D! M3 #U -1]!'WD2D_+MY,RAX9%?2]]\G[N+77R?K."P=)]8*5#."#X[^]I ?;XMI-B3,7*X=$^?A^VJL'OA\7FRZS^\@_O_)BAM&^6-TUM)-QG\\KJW+ M9XK-YI-B8%"^^[HE^UURL/-'9&8<[6]>"Q27YU;QW'!+R2$O!KS@M$3LZ8+_L]/N]Q<)SBPR__611. ^_3-0M>BZQREW$@*N.?X45*\|*/U&*PMV"%F:ANG:G!+.6W M52S*#6F5Q_E!+O,[@-8).]<47&Y$B',A+&X&%%6^+:0!?+$!!V_5@)^;HD=]M[XJZ2+U6F.R9RD0\X\C2=UO-L;HP-@ZA*:?1B$*X_,!8I DE%X#O,74&GU1I M%N=_,0P1+"6VX)>-\K8#13[/K,#KY[. B5G3Y>!/ $ZW S(.]+K&@4-B!,# M90Y@H.\)>7\'M@#VY:*

*&8>W.A@N49<=""__S^@?;M!_$M8;)M4PY);_'"LX&6KW..T!%9*>3XJ`M<3C$$(7`L@WA4JQZDF+AA4VBJS@N2>$##B_XOSTOTZ/KOL`*K_XY,A@O@%2K+`MZE-9UO:**fZ**Q!3N]#$7R4;9=#3+KN8D)IICUU=6YV[RWI'M### ^$+'1W:L&D_I)W&4WLPGT?U#P@8QW&89 {42;*YR^?H.S_5LDE2H/QGLO`M5A3,3_B@$/SSQD,50%M3V@1W2*0?'IKA_XWF&'/"U^Q5542% 4KH-_;8EC& ME>>@;7)UBTV#]RKX&+U'=#/C0@Y;KBE]*'0P,:U,X+^6$RSA">UA;`M+R\"D`M'(%'C-;BLU;)5D02[;B)HH6.^U$ER3T(PCR*@%+1CD5@88>Y4"X|"U\F;%4`M\D%j:?X QFC? R@:*,#RP4SEP]"AD_,A)FI9b!(?I;$A&\|DC"7<[W:2TLR:`M^>!-=]I0EQI5N]P@@.@)F/OZU(2&Q(=!*95)K!1\V2)*(3U#*85.SN=0_>>&T$AP5`MM85D%1FK*E8%\V.P\,D**E11X,""GRDTYTEO *?R8BD\ES>1163P%@NU8S+ M015"DZI7&[ZC -&(510)ZVZ[5MNPV@8BTM K"&FMS,Q=,F/@4OV,84B\%9]X95-XK< 6"D9 22DQU8L1$(E&VOB M+L:0(Q#@8I3T6J5E^FQMN+X.1 J2L+&RD($=F&RG@AASWLME6@;G*%&MJ08NK!#>_X4NY(XNJ MQ"EYDX-2-7+D6!.CD5A6/0.J4Q\:M*O%F.1O\%7;\!U!!P)+*QI/@4S 6G/40:U7 M&H.*_$ B)KO(6$0"YP"4+^7UF0A&4*PN!0#]9<62A"+1+C^4D8G^:*5 MN!2*%*4FV-G7A9TP&GDPFQ(*!$KA24YEKJ2B+6F$22&M @&P64|0AM%+L>Q$!V8B3@,N3!EO#H/#, MY2,%W6$T^0:U R)T *BN|01*<5J1?*X**> NP$I^>.4AU^`9#D!XWA.7D#5KKBR35]#A%ZYQ1:#&W+<(X_MI<6O=#F +1H=E MJ TJ !5\!*XTUIZFF."=B!PQ6)N#M#E$P4]LU;CD!E@C%S/M? 8V%"C@_RR3 M$>V[C<#-R?!*R=7!|0&T&J, -OQ,: ()=*>A71;3WB&^P+1UY$D90$I)A5$ MG9-%X`_11E\73 895 Z'PF>2<4 UW%LR7HG&!,[+.M&>UV+!11^LJ\M'DJ M3#"%C:(Z&G,.,\#*>XMO?>PZQ8^H"FB\]1]*SKA=M(<K&@VT0, 6V$&\\N@:Q!@9%,J8C ;=H<2G(#$ZDG2DLB-A\L;,;A MS,G?$]>CEW*!,._3OM?9>UN?]B.\,%;WF*6PWXD9H<%{6JIG!BT*P"OR,T5\M$G!HH)797"@ -!0'5689_AD&1&D79GD,ST-JP$K3U(D?8"EBB(&_LIG7+!.C2 M6+I@[G ^+#G=3@D,DX'!D[JL).I3"H%!5S1CR'Y6("CM7 ME6-8:[\|FKG3"2ZF0G:P'C^XY<&5"R=>6U!X21\)KU?+[[9$!WKR](ULL6,|/ M],0|T1[OOX/1W5^NR,TV6 >!0]OQ4BXSMUZURX,6N \|V^ 5T0/!2&E5P6P2X M2H"W/9;PF?8AC;JLP ,%8G0@X"N(3H&QE"]+|H!@4?6=UO9N@9LO.8^]B4= M[?,PXH0@V#W3&EU_DT--T%E,P:*B)V[ZZ<_#!B_M*CRA)#X)F\!"4 ?+*QR^""%WZ?N?K_NW%2[++]NT)X+CQH"FUW :>@W^$%A; MXD?QM.&0R_M*@,'1L36/0@@RJ6I.#&\WX1>#9W.5ZEP.M4[?-0]"6<\5Y@,;MR%0#WZFKQ6 M :L/J30J4!BB0X6KNM@G4BC*ATGI>"->JL(KW>NN TBMU6=:J,$M"K\) -_ MB$?_NO&Z4IE&F?A*

;|+IM%HJ.U]T0^-!:@Q*F(,/33W%3YR&TC]Y'T12;`M=PZMM"/O>$U.UP.?_MX5\$3;>-> ":E]K@(4V\:@E^T^F%<) MM[|$POU2%SI/X/7R?>>7XH0_+@M\>'$%V L3PIIVL;YA<)BYII?SIVN//#D.R MOI0U]D>K/OHT3T?LF^6>T,FEMY .=[\Y^U!M=WQ:0&6#BN#$LDJO0A8/Q_^?40%S4YP\L89!QFU*$/\Y3\MH=KZUC.,)BD5>CD98M%H._D.'N;>$0+6 (11_D>C_ 5!+ P04_" #10VU9";MN_Y8' !L+@ M"@ &5X,S$M,2YH=&WM6E%0C<0?D?B/B16B42A'!WZ4.@D0B0'A)-.:$*K M|M'1>L+!-[GIC[T+HK^\W]BX0(&G2)KVCXJ0+[-H>SWB^F?!ELW/P_*E_7BXU-M/W=;'7PR^M<<[H;]!GFSYC[16LN;FQ?7G=_9[?#W:?O>'@T#%Z1FKRG0I&\I(-M&'8E9NQ&13RNN!<5=BNT# XP$$,'KQW78!"78QF?,>]Z^-]@]7A{]SR48S11 M.9ZD!^??Q2.3-}]UP7\P5_/R^F]X.D$UX)$,YV=_-X7M:^2?PFD%21?GW8>)M'.FT7/I8/ZXW:Q=8=1)__LZF>").A7Y+6PH//I*;V\$2[>S/L?7;.K6'O^Q!< MNKYD@XO>5;LW:/59[H=N^Y=A\|U/S*3RF"^JZYZ|_5I#1!+ MED>L+T0%4-DGZ43GI[MK$D[I'Z<;G48Q,^%4R+J10SX<,ATK#[C&M$:CC' M^T3IE*F872H=85SU9Z8"UE:>GIN4AVPPX3KB%=:+O>/=78D==^0',/*"&[@/ MCHKF["Y6LU#X8P2;!6?N15]!;JQ2YD$ ES'C\9QE<;HSP>#,5$1(T.1>#CO@ M?PG_!MS#*\U4)%.6*M=OHT,L/&$,U_-R"7TB?B%)[681N,<9#%5]H-IM(;\),1G^6XV="BUP(61!)$PKNRWC,9C*=P$*3".]JM"+GE4@+EE]#IQCGL]%\=2%VU]$[CM./S^%4L$#& *!:NGX"D"*[FC6*^TR M#I".>"HA1\9>F/F0"7"M.+D"9$I*80FP0;@FO(?A KCE4HX9LS8W@L.7)+E" MJ,I"= !:%1!EYS-6(8^;"0M"-3,%+E+482Y-JCIDXO72*0TUGFP,D*;19]DMz M$'Y\!=7_!%. 'SGP.VWN,I4P.>QRKD*Y1@6!Q..A.;+>[3&NA\/$:@#@$0'P!1#4I4 M=[^\"8_'@K60X&Z$;5/_)]_?10.#7JH[Y[*-E MGIFH7'HT4_!HI@ SD:7KN$02D35(L]!+\BX'L ?G?*P\PF M1P*%" +P73F%-\T6WKJ@/2_(!NYQC4I#X MHK>@_4"PFI6W[_+0J-AIV-@5;BF@4_*Q?X>JE\/5'W*T0X$FVBB0XJ(^8LE'<"_:T96U MY5\O4H/M ^2+J7_Z,_:C]C#7+T*ILLR!E)-7T;Q,AX3'K<@ 0=C&B39(^4(] M##F*>*FT6+,2^@,PHDFDJQ#,E9Z3G@3JUCSO]FG8CM$!VY:TR7V,-&*1-9\$=4ZX,03("\VN M.%YB8+6V)$+5]ZRGEGG-\;0"E?6&+\U"+0R%(5P$78Y K V=\?,C`<2G>=C$26AF@NTSB;*96#^"/?Z3/SNBWV7M;K]_VBU>U<__G!P MJ315T1F["+EWQ^J0;H\0W2*]RJ#3DV_?I#)+ MI[QF:D[M_*)$L]9;WE<9=C9M>KG."??I(&EA/@Q_+T/6P 6|\>?FO=W!&GMM M;VCAP1\7TZSNIL^&;HYUR3LW6R_WK/OO7N*AZS?5*KN4(O3/V !%RZ-TG#&KG8K*G+ -H2%H]I5B@".V*!MQ71R ^4L$%!XOUG#TA2K MM++*V-5IU:76\B-Q1]1 ^(_N)+)1*$9+?I0Z"1") N59K0 M+*W:1S/C 3NUN_AD]*\U[^O>Q>MAO_$TT;QN'5YV_V=O1_^?MWI_B!2]3UGIR>9 M94.9"-NQ(S=I826-7^CQMX++:,#=$37P4O[-5G"]5BFYXR:+OXWF14/MLYC M.<8C+<<3>W#1NKJ[&:Y.4(]X(N/Y^=[-X=H:^:?PB XNODE')ENV&C0@EF"P M4^!;EQ>]AXD<25NMO#T]?M-J7%[\-Z8$(K5"[ZHC7A\|/-`IW0W|5_U.>]B_ MO:E6;]_8X*Y_T^D/VM>L|UNO\\NP_VN/W5ZA2>_NO /4'!FQ,IKOJJL^ ?Q^ MK5KYD5.?G[BV$AT"H6D29B?(([F=*6]91=*9V@7_UGIB+648&>&\MC-IAPG? ;ZZ?!\>ZNQ(X[\@T< M>8.*500WNA4"#.6,] MR30\@BD#O(S$5+T!Y10:#;,R&#"3$Y_EOUG0HMB$+(@D286/)3IF,VDG?IVZ=X*E@D4Q"!2+5T? TD17,\ MUBO/91HA'7$K,8Y,@S@/,2;(M>+D&I@I*85EX ;QFO@>QPOB5BL%9\S:W B. M4-+(-6)5'J,!V*K *#>?<8 ^;B8LBM7,E%368BR-U1PS<;KI@0.FM\T3TI1H MEG)QYZ4GQ'^MR#E\)$#O]'F0ZZ.I]!=H54HUZ@HDK@\-$?.NWW&M7"Y\[R0 MHUB0OYD >T>Q-!/0 GQVFA1&(&&*-B&7+KD(Z,#"77DBR07:&Z/2 M2+DA&>|'\&CA@LyE8&4$%@ED?.J5T?XDR&-.E0.&.12+|$U!XN7)]IS"MY&@-MALCMZ"_"WV>2DH'5\=0%7F5/6JZ5%,5BBM6#X5)6:XSMQ()Q.BD(E X=]>NQR*%^HD1$G@B,@HV:H*M@Z<|@E)FI!9[XG]!Q]__-Z4 MQ[E+CD0*$470NW(*;YHMNG4A>YZ1{?WEFI1=G!. YNB(1$TL!']X2.7VXQ">M4Y#XHK6@_4"TFI6W[_+8J-QIN-@5?BD J E ;,BGZI=#U9!RM"?!)IOHD*+0 MI>)D5LJ^(#.3I%!!D&NBS$[)WQRU6DF4L7A]|<8S 08J3@.8X15-B_3(?%Q*S,@$+9IH@U1MOH#'(N [*+0_*&-5 M?,@E#'!AF:>|.YSB;*9V#^B/?@Z1/:I5IV-JF/-M!P3Z//"[H,-YM7(#QR0C^.,T;8V!.7GS[M:?7[P?M3Q_F MA^\/3@[<|:#=[9;7+S9Q)D,]H.8G7S=1Z74H=#U0<(/?R M"::.DB""WRP6S*CLIHWK5]#;@E>p?,7,(V6M2L[99W:*T1HE^D%QET=O+U MJ[|1TK]HF(:'O?]V1*O1?[ZY,NQN&O9\X!D/Z31L0:P_E-9L\8PX,:?NT_M MX^>_,O=ZECI?>22EPU[!67M?_!-+.ZK>F4@1>3"]!Q'D=-K$;OU&:>^9SV;I MX< ?$],O[UM]<[13SFFX6GGQBC7_DY=W8/V]7F=74L3A.1M QS8QP(<<&S+]MV&2WF=M(G[-K;BRKUTLO=/N_EJ@\\CIHY=^7IBP*RG=T[^E"'SN7.F-55ZSK MCL=E>U,PK F+S7JZ#* M8?%88L4BKF<)0-*![<:6)IRE5;6MD&+ MZQ=PQPC2H/?/_0OI}-[Z7U!+ P04_" #10VU94%<@K(H']++P_"M @.5X,S$M,RYH=&WM6E%0(C<0?D?B/B16B42A.32]"02"20E8!:_Y5ND>S MZP4WN^L!VPM']WV_L7>!>>27MH+%2==8-?Y>,;SS?C/ZU!KW!;?>RU?":?;&T4S:VK^\X'|G[PX;,[XT&D4GO!3D\RRP8R8;=`MB2E[4 E/;_Y%C;T76D8'&(BA_9>.;[*$ZY%,+QAUG?\|_N&S=W-\-E]75(Y[(M>';Q=_)<7R/_%'YZ2+]Z_"X=FJS9:ES!7I*+C_]K*MQD5GRR=1[+$9]T'(U! MYQ_3+*_IC^ZGL1Q*6ZV] M^[MJY?Z&]1]Z=|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}5'&HH$,=",!)!4G(VQP\|H$@'!2)DKO0O- ML6T4|H'"%SE[2?*[8D5=KS,V<$5&R=<$B0M F9&JW(D6-F+%8/@I\N-.6E0&U M+UZD)MU'R%=3__Q+]J/N,#-R !!V,2)UCTY7#T. M8FZ5-G6YE 9I)(:X5XIN0,%7@.M8<2"CHAA| \$KOQ%01?:'!OQ]KXF$L8 MX,(R3P-V+G.TWW:^H91.V\YV#+Z)225 2N<#=-002 %$%0QBOON;"OY(C,#3 M3\<)"5V)_ER=MG@;HQS_M]&K9C=,"V(6WR$". F&?-SX*Z(-P8 F2"%M<|M+S$PWN0)5AQ6.VN*>K7OE'+/,=X.0&E?V :UB#2R5 UP$2ZY G#N]X4"F35? MF&4Z4?%$4'5.^:CXG407^5@D6;OF JW3L?(9I#_|/7#Z#*>I5K8&!?$>0%]'M_0[@<^%&MW,$QR1^^.3VKL7WI?ONZ=_?3CPYJS5X>/D$$V)$ MH-OE@EF5'117Q5J#3BFOF'FHK%7)\;N*>?#(3B'='2'Z17J10> M9<,TO-K+MR5:C=[BXL]@LV[8]MH:P/I_RYH5A%^O_'GXMWV_8V_MU|/4_^|\-4L/^_Z0F'YWW>B< MHYUR3L-5RLLW>F=X8W&'KMA,4ZUAX$8<7K \6VX2 CSFV8S2PR>XSMXV^8+?<M6%:OEU[HI'XOM?*:UP$KIWUIRKR<_$#OGB^SL'//,I99Q2KK>%]TU^G""]U8 MKZ:+ -H0%D\)5BPB-V*:MR71B^4L$5!ZO]7TI2KM+2V#5IU:,6_B1A#^CL1_F"+=*9%L7I++J0<^) -.0\4!:=J/BI\V&K9G[SKK)0G]`M]9VU,2$O:BY59^&76K%>O,L0?X#OK'P=6QO;9JLW&5SW+T8.9I&>]#:UFK.!E$4U@3*\A)B+"C>P#_^94L]"&`M W'H]+GC.A 1N62\#;KK[]\#BMXHDX1LB4V2+5>]UK5,)V-W?BMS#(!$+--VG MEDC{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|Q&=)1.+5Y`!$ MJZY05 +GE^%'ST#%)8,"%Y"!?2"29[YC*>9EET W^RUI,#34OJFCLJXCDHLG M5+^5^)XD+P=WQJWS!#:[!?'I ,211DDW &Z@D 0PY!J?V*L@F(!@#@K67:?!T M*I;& ;5%!%MYA L*_$':!?%4!GJB/05KJA28*!1,).#P"_?JU!;_5#+NTVI_2< M\Y@V/),J=6_X!Z|H/#$5|Z8F#(''RZ_QV&SITM=73.Z=Y(BC'JL,H"S*3HDN!A.&>/M1Q-7QN- M976"$,$_7=$;)?G,UAIKB9=,*>H" #@0:8($V_7)6P$VDPU!?-923E!#.GN? M>EVAJ/B!L'!$8OD9:?P V=^#211\G.L$Q<5_,WQLBHZ.:N!SZ.5,?86 MM@\"M]S^*&%_"4_%WF]U(>Z*_V=W?!#FSW);,_C Q=.(E_3I9GNO M:6LN'^GCR3#U ZL!|/%8V"%"HXQ9!F[\A07N QI3\R0V_I88[_.S!8[W3K5 M&7BGV$'T)G4%"!]2[:4WC2'2.D->L7#04)5G" N0'''XD@=V'&^<51[3:#TMV MG]^+]L] N;4 -&26!RN>4GS[^)NB)N#>T/^\1/ W\0&=NJQ-TC8Z4/L8YC MUNK.S=!5V-:9V#>ZMK(K&^(F>_2XL1R1J>G=+4+R1ZV$75[9@87]^'70C >[M-XF:+T(Y0L1\M\S4WK5-\;2L^';(*&U@EGZX^SLP:C341Q["F$0GW^.6PPN=_M)+"<@QI$+T8:GAE017&*;N5Z_Q5]_5)O\9=?/^2B+_H2TACR":09XMFI?YUMNMA M_L?.RSYXO3G=BKS/|;OY7B/:C7$YW/VWZ/Z%_;'[M[?9G%B]7HM?A-I9-L9GHH)1V'AN74[B=|:UOPD.I)/AM!CDSG[,^H6.G*5M/9%!T[S.*AR/SEI6RQ!1Y&8"(#>S!^2R)X+!Y^$&1/,4C;BZ>?6]^(,GK6)8$R:!P,[($#Y*A}IXC7T 6_CEUA[$/K2]D M!_-5TL\NW/L6/1=%;M-@?L6-%?WR*?N],$"OZ8U#T^R)[=(*D/2-G30?1MZ8O#$5G;_$[S@9LU_)\^X8_4"NZ7"6(K>"16<"]DCZH5W"URN#CI=S16D-MU MX#]/I-@*'I\5W#L3Q%;P&*S@OL@>22NX<^2LGR!S^N)P+%8PL^O ?I-Q/*=/M^&.T@GMG@M@*'H,5W!?9(VD%]X&<,"-Z/%9PMX'_9@,J3I_P1VH%)L$L14\ M$BNX%(}'U0KN"#D!AK^;OT JS(!7] MWNF+XU%Y 1OG-C*[SFT$0:ORD!GG;+V *#%1[4"%U[&]T6WAP@9MZI +ZU(0AKZ.3DWEQ'L!%S=MA,]#9=;. MZ^+$9?=DQ>SYE[+G<=TTMDY[>ETG>ZU],6=NQ)E^L1CK3%\Z.Y;*OX(HHZ4I M?_#XYF\G-M!^=$'F/|Z$I_QJOXP]QX7%IQ+I.F:T;W3E*DD3F*+I_!)BY; MO#) E"/P7V?V=*]}LADB\]^G1T3WGDZ=B)8IN.5[^#ADC++076+:FO]>4P$U MQN1>:]?25%='9VM6D,QDCEP9?W/>I$GPNO1T3_&05W=X2?BTI^ 3@%H&7T(& M0T/M/^C(C8X&^]PX80.$_"4Z(6:1R+`(OK4(C9B0!FAK)ON2@/Y*([(.'W^) MOHB9X8B981^:(9_B"I$L&;)@WYO:[+RHG:%JZKPBPC_74M]-2*'U9W4P.K_M.&%,.X'R.KR-!C]R2\B&NS\!Y[GN2"#FCB/ECB/.[4_U3!$4?525,(9!IP*`M7Q!%-,USGAM1?CG/_9OP.2\S=QMM.326U0E"Y.R#UM5$7UW1?=05$;TBL:/6 M===U$FDZ5T]0-M)!>BH*38=ITM%ARU&H-M1)\/RB^\)BX2?.5 ^S[C$9/_0.2/GK6(6>7PFF+7YH%M$4[DIFEG6>9[JD;,'MF 8:0M-DZOBE(EC0O1

MP0_T7<.T^2K(PMF)LW;J8\^DB0U55]=#;Q<39O3DH.=AO2/:98&.OA!A(fG M%#94OJ]ZO-6\PHB6Q\/GP.]X*,3E+C8^!@P9*G,;*VN3#;8F2*2.-7#IEML!M>Q4WKVK)=G'5;Y6>5Q_L-;[&.9R#6:.;>Y4-D&]"D &XM$< =L>2SAF;"L>* ME>+4PC%<[.%5/EQLE4O1*I?0*@]MM_>MJQ>ZY[_>Q"J7HE4NI:YR5@ZXL56N M5&KSKW)!45D>;7UXZ@6N_?B[^VS]B96>6;OSD;6V-#8.A=JI=1U5OE"PSHK M8^M<6%2;"TEL;N\Y7X:MRE/A9^U-K',I2OJD27,MOW"Q,;6VL2N8>_S >L&KDV@*GJA(',RYM/KP<5(59I6D2V(4Q*"MA$[A9}?=9! M>95/9?[V"A==IM9%MCYZQ43"_]5B*QE*IQER$W6>5/Z8S0D>S3'0::C5I) MX8P'W$;3>S'Z5.SE9>,B@=4VQTO? 37T445Z-!WF9J9M&FE%^#;EDN54P<_FO M\':%.R/XD7![AEXY>/YR5!Z%8JE?&.2Y9E|S:)B M8YPXCB$${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|0-WAX^W-]Y3A74'?C_M0G7 M 8F[^AZ?R?M23/B,Z%#'1!0F%G<$Y:V\IZH/Z?U@?%O+V@+DU;4X((^$[6X M@#$9<*H89/&9)@/IH[ ]_7A(^4&4\ ,<*J6TX';SWG6U.9?>_.!Y,'W MP-($+>D$8-L0")ML#72)?6$]3!AYCH^V$Q*TV!.+(8V"%]'#<V:A@-MJ+AO\ XCU_?'NA9V.VE WJ1F5?R)/A4I\T.?]H|0W 5;!]+":)(X'U1K0!MBL* ^;&^0-W07I@^R"S]E)@3V(MH%+]P"{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fU-F3^@/D M-_$1Y-DW33BL*@'IK0ZX!!#O_=7G-^]I,4#DX6_!EI QYW567%HEA._0"6K M N.8PVF+3642 \|\L-S0MX>@"&$V';[{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mH89/&%@\ 0&;W^9,NX4$?IJ?SG"""" 8W!77@!'HR,"KSM]]I?G?R@]:41[=9Y M:W%3E'*U^%RO/M8W4WC,:8]_:\B,'=O]H MF2CND+9UU:Q;%Z&=Z8\,!@Y,%R/!:.<<:O>;%]R\E<_^^,L>.I0UVZ@$<7?=, MD/'B6!'?O!-^]H&R6YFDZ!@IP8;>WVG&QD)C(\6QV,@)>'""FF=R%$XLGG4ZU M(/3@?Z_1_9@0(&G4$S?)W$^[>ZYH!1.[KC6,KYO#YXK&5LRJR."??MB'P<'" M_-3H89I-G]+XG5&]K]!\E_XB0D(U%[M;OG>_/GUZ]?C[\/PVHD.'#C#&P-7H:LG& 6:"\&;?4FS87_?C32Z2$SO'W55?2^BS5Q!3[MRHRA5 M*;F-@><9!]W'[_?3.KNEDXYG;A,2O3O?RJJE>%F2S'<>V*KSS]&%IL$/.)%D M*5$+B]fYVS[5RE\N.T;]#6.R>)K/,+>*"4<__+)98RJ 09I% MM6@6VL\/*VAT^Y\)SRQ4%^E^O?A>93<32UG)]B:TNR!05Z.QO-[4]1)" MJT/S#%YS_6C:#^8I"<($^=5[>|>#\VO#+'<7D-\) 0TG"6IE*5IELLI8@CRE MK-P5\;.8X+2!#APO($)ZEZT=W@NA<%PY[/]H[IU=6926J;Y(4 M53=*BOC:S2$\63W6J<)3F*V+%A">\]+"@TS4$\3G\M/GY\MO7T]WU=4KGMKF MB RNV!0"BQ06)/%U"JL0FOT%A>;0#2=96S\Z5U_IGO4@=;Z$#6F0O&Q^/<^T=,Q=XSE3Q;9VW+N;3W=&MRRI(Y678\95";15-_M4%.EN[J THF53QAJ^:0 MT64X. (5DY1E3P3TX>PH)'K#6Y%'K"25NXNT^Q,;7O M#'$BV9KO6OT+80>^]IGZK%G_0:G\/1$Y2TIT5+IB8I;>]+M)1"\-J;88#& M_13VT6.-L3@!QQ"CWTE/8N=(\:YIH%8]}AY#$P"MR>)7IJG44&DWH/YFE&Q M&7Q/D;G@Y3'(/ E)_$@:^);FL*O"N\0]HNK(M(_SNH!ADJ!.T1P'AF$/8Z8Z M/C ^3]Y6*'YV.[1LRC-;C&PC]@U^^CR7X5:PJ-/U\ I@3;Q@AC8C1Z'5"OSX M;30+0_%AUA.T"A-NZ;<2>?I7SNJ=M1=%).7YBW?7<9YV(2)/8VWML56 M=T:[[V.'5LR,P+$G+]NG'VG^_NA M=%@ME>Q1/L8QP>.;/S4(-_]LIS4(3&ENGVE>27.CLG";NT*I/*N98"HUY@OW M?K2OX(KVOMIW+]I[1[WZTUO.^K&>A2_:^JS1M+&MKU6G&I@K*,^1+HFKK@)M1-=E0R2XKI88I&1_1II.$+]ZH&\VH+?WJO?IHYT?#GB9WL;$%(7)$,JFH]-K:AP2A$5EM^:HHN9P.B" MP-@:O.SDPO.3>/Y5V/X%JN7;_41Q2E9OAI&%\IW)^"W4Z-8X"4ZUWAMG'>. M'7-Z+",<+<^AN=!48"8P$4'EEI+40KE6FB8T81I'QJ7:.X%U[!<55=G9V?NSM M'3S]!-6XW(2(IA\< %9Z-L1FZPN:I+ MXK8NO]'QG7Z'^;_5#]-,U*:TV\S/2/E@0<1Y1U#CRZ4B;U%0?AS6KKY6@A^? MM$EE*YF+4E:S]YDJ7"IC%2ZS=^;=Q^D5+;I43.FG55,6,A;S\6U_HP+0O3Rf M;!UTK@=28'3APD N J\A##/+""LI53>SRPCC-/%8&2%=`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|SPIF=X]]?YS MZXL9AMW3B\EAR(Q'_6MTW+J21:7Q-%:.%E:;!1FW,4I>?)L:S>;"W^::^#<_/_M>L&E=^E.Y(I;_MJ-):5'5FX./V3$^ZA-:,N>S/7F\))BZ)XE26+L2G+R3>3- M'K4G'M# ^2\C0 /V3^"N.=!O#?WGK?MI4'MUV4|!BXP/<63K%FZP4YZ>74F5 M-J"U',K^"76]6+K0]!D2 O>M7U$"3H1TS=VEA-Z%*(\]?5NG"T>K?'-MM^L8KK/#@)N@7!SUW!OT-.S;HZOOF\>G?ZOGEQ=!-M',";GC:P###,NA[C2*/F1# O:AW&XL9*1#]K>EW-$4W\1(?#UN6Y0-#F>"-8F<=%R[IWAS;BS/0Q#* (.1GYOW'$D[I.H M8Z=PS/*)?FNB<85)6"&-6'2]!S9\\%=2"T8*<4CR@GT16ZNP+QT*@HR*4Z5[MIIBOYTO9PXFT(->/;E.<,SIF46JBT[XT_'S7.(\A&'P(HR.?"B-,6KB6,GJN6TT:?O$$JF2NX*U'8N#IFN.V.<^<(6&@?75QD+1X0KAEV1&XP$B6Z M=M7!4/1>6%7;HHY(?=E%"UTFHZQ'S,L' L,BWO3))N"+MO_JT^^$' M@<|;*O.R7*G2:TG;=[3__?/#L]%H[MV/G5ZT9%U]0)-U!R>/?U]1V *;5AY/ M,.+&/;]>X2,^8HI=Z+@3=Z[MV10;H*91; G$Q*=DM$65@B*A[1 4X*?JZ>+H M;I^Y3A3)>+5#6_IQ4SWOWQSLM>)#VQP9?J:]3AG]R@Y]YC+=*0>UN%N<>5) MG8TAW0B88(2>X#WD[L*D^-3685@3*IL5V;*X;D"(>C\8NWC5]W%;:/S#B'GR M(4,@OQ+;60?B39'L:4O35I:2SVU7RM7C;!Q5#FI*9<NDC M7[***SLSI-.6X5G?3V$P2QW5]XM;CYYUJ0X%UGYIC<+*(V!W%0!BF3;CN=%A M?29:%\ <[K:OKG7R^_!>N<)!8IT6]!^X4N) FS" TAMCD1V$QT;B=.1QH\+3I M$L>GM7;*Q5*YG-+G$<9AVUB.T34=-Q@.4)3AN&;.,3,I#+-I#L6%2..J812 MIBL]@@XM?*6G-T9O2:5#!S!/K/-,?N\(5UOHD(O;"U>[;I>&UBG=;GG@)),)%(5Q)"\ MJB!],?EY=*B7KZ\#ZS4OHX]$,YE;@N;(QNML25AHDGDMBGA MVO+YH/@5.-.LTRW\]XB_C+ <^ZQ(8N!@E93&&1PN!-,Z#:S^0[9\3,,+VA3T MI&Z:-+)(^R/T+]#0 K'0?S[*=%TOO0 VSP,Z$*4)]%.AB\>M<+"'("_*AP-$,/T M=<(]CS'!#MD;*C(T*`)G, /(W$Q;CR1%^"1O<(].)WK>@V3Q6).4/0! MR]KF%*L3I?=%[6A@_VM*[+*ZT)IV &X*-O$P6<0LZM2+97]Q+T>P;T)O"Y8 MU_R>VH'A2\T0\3$#UZ>+_4_22]MN\-LHCT+4)^5>9W? WW4N$;3,_Y>ZY;_G-.MXZ]=_|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|;?V;]8K8W- M*OB72<&^W0A.CO7'S)]^\"O"!W16VPI<+T<< KX)]B0A8,'<3=A\MJFQSF0. M50:CV0_?);*9Q+MA%0RS# [8VT9B#PB=@=CRB)E]\U&*$PH< C06"9'1L[I(M\HC]), 51%3-7E'Q+0:!BY\Q<.UA'];&^&O!?C>?U/<7>X6_\>/P7\T/+(3Y M1%/SH_GVP<;6P-CM$OAN9%F0;>?1- A;AT#!0 6;![ZN!ROPL.;NHQ*;N/C= M!XRT1TBY>'HL"HZPMMC,!8,6Z\#%RO!/L.[6("3P71#86OD?^LUW%WY^UOAO M1$E $#V7[*L>[$1'>X"=P##A@%PUW04/R@SXT]-W(1<4@"7?L6QT>LYQ"MG7 M820:)GDQV#-68R@7N8R\%X+0CI8OI"C!85'&L:?S.45_B:D-2YYP$Y(O;&- M*ZK()TB1:/N[RKXWA&<^&B872E83)9\3"F"[3Y;.W$Z1Y/JZI:&/1<3Q >=, #)9FY<2C-]04DRH!?G;)++B;A2VMHC$YR@GHX^-M+]QLR(3@@^G0Q1Y>2+S<1%SU4'U_>G0)RB&=+H'D7!FI0W:G#2K7R"D#.!1FV!V1LGAL2/!M+]RB M$!#=_&"(/!"VZ? $L8(X':\CE%T]\#P,*O;@[CZRWHO.$YY_WG_-5P\4P2,HJ M1-.FVF(JIT+7X1%# 0Y<[CJ#!(!R%B0"IH/3$,>[5HM>LCUQ:QC\L:-\#L$7 M%++O&L.4<-A!+-X6>-)T83N(3P*\]9 ;*OC$;M-MX.@$Z"7%4;5A,K\>39:9'#MP3[HVL5THN@ABQD^-;Z!HAF@VP=L#N-N$^2&. MB%2R1X&VCH7U;4FU(/Y;9.^@;9)F\:B(@'1!$&AR.CZ@?UQG1)#{0>X46X? 2,>IF]PLPYOX"0GVEL@3-BCR65C9IE_!>S !PRGPD#E MUT>]CEX\2>"!8.186,15LWTW"BN(2QH?R*RT) !-_*38_H+%0If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|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

I3X+&8 M'N=M{|);6CIH9,+8[J.?\GI>)XS_-=C6?:|?VT:A5,KQ6GV"<"-2CSP1?I52 MJ0;\@O> 9"WMV37,V@UQ@"2RN>BXL:BM67:8J*' ;-6Q-VG,""$S\V,4IMDW ML3$NRB&R_G*Z9DUEZIZWU8QI@V"L_8$=L?^#<1FW ^N((+ @7D8\O(^Q+H'^ MM!A7NQ6/QT$: AO;M7NLF*7-61-VU2.I:6].|)MA7ISU0+!UL#R)TKECHG$N M.|VO! LL\KS0!7>OWX}{R)R8J M65,H4/"Z/2>+9V4(V,5BPT$XX"W#)2)[R?K/<2LZ#L&"48/& M$S=-T,ZQB,)AI ":=5\3%8]#B,!KW;\&:,.4#/4P=TEU@7B+@P5;-)N#4##S%! MGIET5>&X*N1L"4#ESJ4MI-M5Z-.9AA/?X1_[IRX+N'!KB*W<BV9R|B4>}EIF,D(Y!:21.9[_1!_CLTF/]> MKG6<.3$:OOFX95($DO=5]\XT7)\09G7X;MB\UV)G=V7#!U=.5'1<+8] YB2L,+TWJEM+4"8-1:#0JD=ET<75RV8PMIBM&>|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|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|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|J^<_3!,V%|(%E?C6)3O7[MSPLW&!{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|_54P<3/X) MN>O;!T_;+,Y2U=IS"//L? P^IJ,F!I+JB_@F0_M89\2%6=^X^^\^KN4L@7$M MM[A@?1"/2%WHL;`")_?K"S+]^$C:"1%MG)7KY@EK->,!"5LY%66F HR-G M)6NSTAXDAF{KJY<#SQB_F$3[$HY:YQ? O%V9GQL26:A^$ S]HU+I[NZNZ#.C>./^+M4\ MHV_]9GZ)F3?4*R&@8DFMJN7[P5Y)412U>EA1=\ME55&]%76_E!BYB+0"/*D M |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|SMB!Vf6UVX'5R;XEK$ MKP^D.Q["^VL>[5G&:]*B R9XVG*1>ZJ:OJL4W88_)8Y9Y)5]+ &;'V"XQ^AM MH<<@.(=G#_E\A4R&444/Z).D /;@98*38GE"3,6 M6:^4KQ+[*34CP),5PTIUAU\$#]f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{$%D2E'=148^E4UR(\<>0@HF-M_JG;6Z>]_:[9/Z:8WW])L[\]C>]1@$BO#.XP<,C 4# P- SA7P=ZZ&R3:MK-M:N'KA1AH](,T")]XZ1SNEROPD7> MJGC&W\6&.!?=+X72Q "]N43+8"@/QP+'%SN/H0'T MWS=1@H4;0XXTQ^EZO4=P%!==$5A 4&@!V45%7%N#8OR#LL^/Q:(\[Y;8Y[X,PWIFL W M"RO$TIY*K/\FK? 1WO(LL4H?[,.H'YTN376V^$Y;E>]X:G&1>U^V3]^ ?4+ MJ%]_0+]/%U#_%`]J)36AZ MOM]E:DX#.:,_PRK1!S%M8S6FY'NS_S;86M2- MP3C:HHIYY)P_Q7<_,KQ&SS'98P(_">I$_ MMJ3=&MM"1/@-.X_YOFW&(KV3%A;X;(+LM*9+4%*$_&,Q?MG\?]H*\))8P%&P50LH!^^FYG,M M9=Y8I;^^]5+JW=DT$Q(PMY!$\/:=W)*W>ZRSGCV1!BU9BX. <$]DV#E,GHC8B MHC9;2 9U(TR"(SMW0!4SSBE:P6GD_=)^C=EV(S&(:'F&=T=MP@6H7 M?U3N;M/1 XIH/%O"=)S/13,M\Q2^+LO3LR8&G)QR\^.+XNYJWYU)!Z=!TMQK M-_A;NM>>ZBN5JNKZ5I"L?,[9A{6']FV-OZZV.E)%Y^NLYA$6UHE MHB92D {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|O(X#X7$#EJG'"*RI=O M";Z&T4H.M(V5EA/U^&D')1$7B/3L!>[J8X%S7N'#@/QP+'%SN/H0'T MW5=1@H4;0XXTQ^EZO4=P%!==$5A 4&@!V45%7%N#8OR#LL^/Q:(\[Y;8Y[X,PWIFL W M"RO$TIY*K/\FK? BJI7IOT_S=,:Y;\#(Z)8L(O)NTLGOS9>IV$O+6:\!SV\343NBA3 ,Y,F5= MJFMCT)8Y!-H%@KZ@OD&"!5I[FPSI?"HZ^.I!"%WR M[8'.O-%S"=1N(P?>\+.I!+NT+8,ENZ&\X^Z&C^/& [J?T,T7ZM6W?\J.L-MDK M$ @.UBR?1A2\DF^ #QVC(2RI DM5!J&IX8$BB7D:^SNC^8CW1157 F=#9OJ. MU3P+7A&D%UC&>8TN:? 3(LE/8B&]W?"!J^5D0E<5(C9+.CSY_R%574>!I MWEM%3`YNIUA;[!0^VG!Y(A1GDR&LN.A?[?+BISZ#)5V01D*T8'X[']MP'HR/K7Zc_MW$M*%2L^%YNF?DX5-[I- YBJ9MRJ5PODK(9RP6L&6A[TF6V'5QO@4&]=&Y_"?M\S8N9-_]'T4]-)]BV45<7G&<%$V8/&-8PY>X(D@=KR7EW2"K);T:50CXY'IY/34SOP\YSJ&\'NI3B#E :W3SZW- #MKPQR=F!B=-= M(QHSZZ ,RZHM1?GRW0[TVSF5C>.$.V]\L7Z\?;9RUS-6*!!0T,YQL=(ZM|-LZ5CS2H.=CGGQ<^17["$V_N.=R17R',I\?797@7_]G*LB7*S[AKXVI> 1WIG=LD+ M2P^...$Q2W(5=>2Q@0=W/84$L>,:T?W\,-9:>T4?O#N-,?5OH0)YGH$H MR-P1!8:,.3!FL?09,EGOPJE_IK(EGCT$+1:1U*!O3YMRIP;=U\?&P"")#;D/5 MN(5=*/&P%;5F8'Y^=#^_FR[G.O."40B44F=.Z_U(M0W&5>3)*T=9)'2[?6] M5EJ>"(\557>?0+3!%G\5[AK%*R V>Q7[SOB'A.O ,V)?L MT=0L4TN (>Q"H0ZB)T]G>?\)02]RMNY3[5-\N@@W75E&87]<^'WU1Q2.I=]HG4 M4..T^P3YXAMW'5K#.D]K;8& M),O'O-'E\+<6ZG$<^BO6|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|] M%./%Q_'@!0D3$(;fV/#;//2)L;P-SSB_GEA.{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|!+%)4)@]7N=D(Q ;]"-}]SCTBQJ07- T7E(H%"!L,L$!2&>A@"R!5,(E MEK39T'0IFPG&8%@U^U"#^@"U5X13)/0OBOQ 79BG@C&!%&4/3R\6|&'(7]9B M ?>(V9W[\,(18R]'HTI],J6C:\XT_H^]E"B2/XKPHDX,XPI: TUI62-W M!ELPF+_,8$OME+XSG,.[QYE/$CYNXYR57K5SO5;'C'&+ DT)HER[]R>'OY!$G ML'&T8HQ#D>84Q14R1.SY_V8IA2_]<=[=^"S73LLFIEWY(F^UK34XA5HM88+ M])7.P#[,J?\B5BZU=[:IK2TZ&L3;'4;M6CJ,MR3WZF3_Q^Q$) MS4%6*"_SD?I'W++\BPP_^_7\H?-DN0/W9O_?#AH5?>4M5<^NRV MSO44QPX**>;KC&'BR^8&;X/E9++*4L] (2PT5H6:U+Z(D$5]'Y_Z8;;G>`KWGN-M2V2_H^QVO\94M[=>);[Z/$\Y_&*%/W]8N'38\YTL4S]$.* MKT61'?2+)-LM5SF&UP!(+@5) ^U<$38E%] ("6T=RX$...$"C.;),/CN6N'3[0.8)V RI?>G+VG,_3/% M_HU%KCU$O=/#Q=_]>0;Z!]DPZ"M*3#H$"MTUUI#H$S:@&;-TR<]AP7V4>1_ MV_$;_^X>R44+O) [2C2,"'5RR2X9YD#>@#\)(1B/VFD_1V=K#;@64E;M%/LNW M8;G\)7T4Q4.1ZA4S!'9$157C7)WCUZ[U5_J1!2X9%9-(0\9?O04M.$+ M&2DVN'-A>;%_$EY(']KN@ 6>$6IFQ1OTOT!]\@P, 3+ZX5]B:6X+M.Z=I ME;#MK;BQM,.0D[?]I-O;X.V1G%& S*^2 92"8;,.6KYE4_AKNT+L(+3

5L_9HK"GQ@D=GP[) MT%^Z:S@]RQIE'+E}{C;Y89Q/[M:5%:7/EO.5:/2Z+KB>'I[QNO-/)l;R)M[MI{M#C_+13X6"_K"A?:\,.9/<@[[%_=^]^2>\N*O2;P@)/&$X^+U<0*1-7DD M9>W:I)bE"@K:L/,K_XGZ;[#NZ2E'W^0I/-M-N]WHAZ4>VT3QTA3Q+AK7'AX;DV/G7.US97)KS2I%>]GF5Y^E15SBNO<+_*-M#^@UF*8^NS1P.[2^N63 M]NPZWJB[73QG?!*H9]-,/?0C7;.9 KXZ*,"R'[!.W&+6<0KG2.Q6!#-+2?[_M'1[DK=3RS-;P[KE3<&0\GB*OKCAKM*^G1HRFJ*H6$P*ZO MQN!JGN?6P)_>WA!Y'.?5;A+:<':K;KZ4!=9N5#EKS/7:?KY?W^J."3Q"3.[C MBZ6DFIV4>X$<60F]/&2]XI4645-/8\HNPS_:3 9)&!'EV7:(:WQ&]+Z(Z^ M6O2OA[4#4X;LKRYX%W]41]N"PMFU]+ [NA3+*%.5I'4E)>M28,IO2]3W&6E> M/;!7M.))7>9!0EPH\GSGQ.O*KZA#JZZL1\'!%& O6:(7,I$,T9),SY]!l;2= M60D;B$6_1)A>]?ZPY;0? @LLIK%W9=8)S!8!4O$@DTJT]YLD%IYH[O-<: M:"VC]RS*BI/&.CENF]F.,80,+-JGQ?E8^AIO*9]+R&Y>*P4L#D9:9&88"NV M(&VR>CK3_UY'E.(-WU4.1\?[3S? 9'8.H'Z>K@.GZC.,5Y=,F*0U>_>'GO1SU??XTO M>=>+],N77$&*6XUZ9VY"13BCR0C]M0D>T8E#!5I4{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f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|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fA~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| W+,.I3@ M_\9/.6S;,,\|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|D7]9A01=51,Z_= M8[" %-S#YNM7E KC+ONLI3%%IJ1$FQ\A H"- MCX*0L*C@_7##E? 20L6#6N4&5N0M:+PC$1V9)DY"A)I>9E;TEV+D_CC4,1?!4 M\|+P_O9VC_YU04:07NIQ7L6 1HCLKJ5MO+HL89J;G)_@5P^]/7+.-P8>63'4 MX+S[1/Q;53=.GA. K94A41? [,;03#H;A6OPG^;PT[FE!DLPQ]I9X9XKM-0N? MF97E&5E[IT;@;TJ2&JLWT$R8%7?N8+L3(\]WGTV+U;//A@D=(W7/\;R?];IO(MEGQ=I(Y.?GT:-PWK>RE)\CHL(#<$" {9XLRCAUC&V;"1MEXV&[:B[SLF"^45B1->=ZE(,= M0""MQZ5XCI=&^*V.=<:E.1KG<.$%^Z_N^=0L9>68ZHL*Z78KQ]UUE;VVR2P5=*]\;MDV%#KD8)U7T MD$8%"-7S+EW:>7$O+H\;)+&2,OH_KS4JOOBO?P@ M5\;?VSDEVI59M.2\ED/5N]+U"-E _'@_ET\2N\!E<"]?=>T259"\\=W9.U<> M.J_H"JEVJVTU:W1((\K7QS;S'7"43NW;@_TYN1);E\L&M.=+\QREUZ*^D& ME$96/I9AJJ.] K92!I=^/)H,SXZU<\@CD"G@/PR\P;JB?]>[?@1M$7/_HTMR-MN_;-- [9T,K/"*TF\,FAVQ2!.[Z:O?0?.=YFZ;0/N_#.R/;?NZSJX/OXPYAL> M@W@HR^%9LAPJ-FJD!R9IJD)GJQ'O!{;H+++*D&]7F+BM%KZB"0V%]*E*F[9FC MZJ[TCV?B4NA><8#J??%@'Y-U8&M5$7CUI?0[@0S#?OXRZ['*$Q<V[/M+>.,JZWTR@$^,<\LB08W9 MZ6VOUC*]0D/EI'+T%WQ#. _O1EOW%:B9_%'[B8NK3EPG!3[0QU-HL,71RJU]H M\O!? WRPP:E*J+C%NP@AP/O#OQ@)%]I)\L5+MX{U+ ZD4#P8NJ74]P55X32[C M/AKXRT=X;MFC'VSW9)HBX \FV/[B""FS]+|SA!O?.4+E4T?X_N^.P?ZUL.EZ M>=AFRC"$U(39YXAV\Q?"]&[i8\0:?'D-$?GE*7DA58,J#M0'7@[Y.9 M?V&1L/T^276>9.L5$*Y1S9:EB'=?[+M&93/NOWLO+WQ5W!#C]XD\),("4P:- MU',ZR50&U_:+>];Q &\..? 2$6!,+?"_"[#171KW*Q0#?;"18XDXOB.XIQ MHC>7ZY&HW)63+ OMTA5C@?NX&B@"ZF?I#HXI]5R7)Y@=_WAG+O\!+#2%?)2>R# M(,2%9@=&7%;X2.Z-\)YE=&# {GKJG5A1%T1PK8\,<*Z)-E+++\+^ D+?#;' H3" M.?;[3JN8>2483JP?JT :?]Z#'YPRAW_BP0,"-]@HOX7VH$XLR3K+O*^B'/1'H MLX6(32HL4!]F.BZ>< *J?,>"D^S[BA_0D^9=[_OJG3S>1]:.!7ZH^ &<6#?B M7ZC[UU'[,7.NV?D>G=/?AA=Z/:5 +51:H2F31I1QYQS4^/5HP9)\= <;2?C$$G;D)W5D#H$]"4ECZM6/&]Y_4@KL=VXO.D8.& M'[# PB#T9!|:'UZDCP6Z\K# P2I.55=%!&QAO'0@8=&,J%|0988'8 MI<3E7Y_?_7[ND:$'NLB- "Z:\63'\1W/C!O7)V!"4S:1W4#_#WQM2R_ZE(>+/M&GK)NA'G]F+4E"2(>KI0)?$83)SEIF((=':!>;_[&/Z'@M+U>C?M68':0AJ^ MV5S% NW". "7TG!X44#[" DE,.+,;T4G^,\;HM)/@Y5)H)!5ITTVQ>>$X3RB00,6 M.*OZ>[_?#]6;^,A$KO01"2X!O,'%2PK%%G#3]>BI#/D: &$Q@AD_SB8]=^; MI30\V?XXGWY6RA#%4,6,VDG&_"[? N1!00@+.+.+@&'[ZO4KN[%R6> M:;'-'QUY=:UYP:;!FT_E3'7H=6&:B&>[YZGL%]+>2-)!7WIFQGXZ*?,7C.;Y&W\?W8T/^(//"+_R_SWT206XTF&+#V MIX8KUSS2#B0L^8BWR*>%!<8\R]'GN:&;M[% <\'WW]RH#;S=%AY2*.RE;74 MC?4ZL=/ B99^@,%'/;@RW.AW2]X_.2L(^],_W>GW\>ZU4$?+<0G>)$Y#K/\)' M8)=_6<<- L;2S5.N)(GZ=.;V+ BR('4]#T-*2VH'?\.WE<.BW5V/HHNE_$TUN M.F'N3LA[?6GNE6/3#-A/HP-LJ[&*B99MN3\MR#;G(BID-J]&_$ *@IOQ>H> M' 1<.""'V 0K;&49=*$:DY.*2SF=4V?C/^#JT$/EF/M;.JU03V=:.M@\U(<.M;ZK0V@7[0]A^;T8R"S3YQV6IV8(PH 1+0*,PU(#H_B#:3GI3GN!['<@I2_& M,W>FO3+>@<;O)W++\TI[CCH*S,S 22;6799;2RO,+H_2-ZO4KN[%R6> M:;'-'QUY=:.M@\U(<.M;ZK0V@7[0]A^;T8R"S3YQV6IV8(PH 1+0*,PU(#H_B#:3GI3GN!['<@I2_& M,W>FO3+>@<;O)W++\TI[CCH*S,S 22;6799;2RO,+H_2-ZO4KN[%R6> M:;'-'QUY=:.M@\U(<.M;ZK0V@7[0]A^;T8R"S3YQV6IV8(PH 1+0*,PU(#H_B#:3GI3GN!['<@I2_& M,W>FO3+>@<;O)W++\TI[CCH*S,S 22;6799;2RO,+H_2-[_$3=:11W68_1< MG]Z!2_1\N1Y,,K6ET([JPK)$$U!N"6;&3A<*"9)L8"&'S?DU-= L.\A7[2>G ML2IPSATLAN]+|",(U2@I- C^(J,W"7!/@]_TNX&U)IP/V- HB16;E/\0)#%*U3 M1/R0&'2G\@BO5%#O(_34>24*SMA6^\'9ICW;\0:6$PI09U9"S.$>#M(SFSF\ M<3G[&?WVP>MO."0=^?2G8#MQYD,0,>=+^"6#E3!;\ ^8PS9QR9!>1%2G.. Y M2^E!XX)9MIDL\2;1P'^$,634^]O(+P27T&^,[:PBG: MDZK#)8_<9+.2K60[Q@Q! 5X$X<,Q97=3?^1)":MQW S) -H9RP 3K/F<+]&? MKPF8IAH[8@=U;8,V'=ZW(0E^9B[KG68Z_D(L$A%GOORIS"\V1H\@<,\^'JO:$$2B#|(TF[@W83T$Y2/^AB M_]*+V+ETD]+0\HP2*P;KG0_AKXAF_]%L5'3A=&YT\$,P$AX'G,-#NV9HF9XL M]FUFC@]6"9_U9?\QFY<%@:?1SI$ '5]>M&%_(IB=X1@?(H=TL/CCH7+IF#FC M'3,)\'!ORZ0+Y9"@43HP(0ME[fM]G;+;P^,$D:D9W>@,=_M31Q(9OX 3H-##M/YCSD/(;B2\,?CE M/^> T>D">E'=\T96#!<(-0I<"W,BQ-T*D$E+ IU]U^X6Y, <%I/C'BD*DM16_#;>&$U1 MVB60WGFO_>'=B59UY8 6?N4+\=6"RMBA];$Z;2A/(%,E"N"K# G0H';-O/FB MO64YH5O@19-\/S|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`6_\,Y:'BQ_C9=^%25080\8I-*L0$%Z"D[8=OGA?V(F0#T$]/Y"H$\U*."F6@BP9;,NHN. MH!\1T_^.9:UT CNQ0@]9-)&"(Y.PUG44X"?4\K]GNE*2?C%,IY?(_^>(O$!W MM!E(8,?!T++2*N]59 L#8TQ[SE,F/(*WO*K=93LZN"A 1'L2.(0!=F@_K/R0 M@N.YI:@;QYK.'2F=UE7D!*7P3%&]QMB$S-(CSPT#106Z83D19NI=I/(:OT MDf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

@Q>T^NABLT:3:]MU=E?W.J!T>981C3,W7_'-L=$]S"S]N+5*- % MKV5=')],@+O55WNA7_EIRGIFQ8;OQ&TEW\(P52HC;T>$6^*FZ=_TV
MNR^*JI4N7:T."\VM)TW;P9=5AV:88X^)Y/!,?_O$,.I7M H<"!?4JX4._.YVUAY<=A=N>9# MV0+,))Q5I:0=R5^(X0NQE/M"JUW,'(M3WY+UBRQ+BH*9^LHC/[_?5?
8ZQDI_5XG3/!$9)4S=PDB>FUR/ M-3I<!;.A%!!R&F.90#?PUE[U MQ$67Y.+DC+;T(J;HR\=17:]H<(IS)+TEP0#1YH3XFV_#17$E8RUMF9NMX)3 M0XF!*-
M/SF*0=!#^.@&]!DJZ@:0 ^%R26D6\GE((/B_V?+".@CO%.O(VOS5 M%G5D;Q@*"MC/>=»-<-2RC.K4O[GD6;B&-SL3C MOD.=?8@VVN@OL:NRDH0\JB+4V/5^],PJY0.
ME[ZUFRR5D8"W^3=5'M>ZYF]%-8K-.]QM[D<[%$^/GU7C\(.K;%OR;74YIF>F M+519[#T<.0R=2Z,+DT/U\U8NZA[^EMPH@/%$2=N%\))N)M> %0LKOO8$] M5; %I;/5#+
(OC\E86,XLZA;&R50]I.?" .+3IOC7>D*8C5*S^T# ^P=.1S9 MXQQY/U]9&T.2'K#H[@NLH;G&3Z6Q.S18$"5K)6!#1_0:::@9@!^C.5CP>K @ MWZ(_7I$VTZ5Y
"G0\;JE#05P3@3>*C T=5PZ%9W9E8S& ,<54NSP:96@F40;8:G\A=1'8 M$:ICI5X9CO20%/_QOY8*:ELJAUX3OM'NG]HX=O$' 1!O!0Y MQN\YEG0<^#:83" F5YXOI#,H1$5YL-
&A %YWCESY,H:[''?L> ^O8S/8UQLSC MPHY#4W8GJZV*8!X]-Q\D"F"]4?TTU"6L/.AHKB(M>KZ\-;BOX2H5+E"BM+XF M]}W+5/EY11/M]O= ->HC4K9,"3!2@3.
7N/%IYIQGH}YRNH8,!: Y>0&>?!1! MJRMY.0[\DQVG4H.C*8%,S[!]-IU!LEZ=D#IV/D6J6FB\$9WR>9\7RW=]*/YC^V^A[/3=Y>]X=Q)N1=9K-2"145/4#<%$G'"&"!M-
"G1+ZFNW:,MC:GR*B5Y<6$XJ-=N;?OHI(6LUZ0B_E8AB})!YA M%+53J$5TGG@XR69YB):2%Q\=PI$'\8+6-W-T;;B#Y)X4M*N"1%E BDHG&OQ& M?,BQU]KP*\)_VR5E?_"KF]&
(KJW5]4D=Y99H!J$Q/,IE!,U3\-?/0Q.&@?>.^HR#@^=== $*N'<"CB?EX0>3. ^ M@9I/>AIM>VBYH0'^FE57'!%OZ0'8U[\=SJHJ'IL)#AR#:8.%9@%6JHW8;!-I'M1M(Q?_1?03;=X
M4DZ1$]0W.EJKM0.#"P\%4TH<9E@*9O:+V<#HQZ(YN<(LV)7FJI1MKE0LM16I_M8]EDW8,QYL3*I)5S57G$;-12/=[4^U#?DBXGJ6M.6.%%#_S(WA7"6 6>R@MG MJDV\?
UCBS<\U5_SDB8?%I W-N=E+SZW@$'RD**X[LKI@/^>|\UG/_,2-K7S/-M+K;PTRB3[85R$8>(>AP%"1K;1_Q^K.T5S!X(,[.'YL-. 3@Y3_)5ES%Z2;?B M1)Q0
!^DX?),#_)*UIj;Y%H=Z>#4BGM0P#=S$\';BTY;KP?S4LIVWYD, !QB MJ'F$.EB%WB#+!]4(!OI]&G;R\DJ$2#_BH#F>EOAE3;@O0OYV>UGT_6,ZC MF5'LH?H*V;'?
F5P'8BIU(>G94%C=(7>+[;O-#\6T'7\K>&"BSF1A5'W_&69:V ML1C@?OZ[:?1<<[>*]>>*\^!9^W<+-%$'@!!%<2!!*2;G M>)X#TB>:!YE2^J\&_S#X6V.B!&CZWX+4F/5FN?
C#ZEOT<[XG@V%QO9VDLQ&U="/\]>Z;J3PLVYGA$ M8O7 Q8OY3CCAM:/GF4V6-M%HV'BP+H@!?)9T9FD"9$8 -(MKJ8.A<;-*8.'AA\!\;&A%;3@^9TSS G02#]
(8P0ZD&=%PZZI7H^=B"UV7\%" M/>GCW,N>N^))VU=&'E'1B\Y&NS(&QL=36_PE5ZM5S63[H*<L*W">A4;'MN?. M25L_^JN;#-/>>-(AC=8IEF(/U2Y_RZQK[=41 >=_<-UP7
MLU?U3:G0Q!)O+M=*OK93-^P7>833NQH^^W?LNQ6]A,9$4!/*NQH-[" M)"Z&AG$]E_[?!0AAPE? MV[''ZRA]:V%Q -Z-7 QT9#E!P(#T8'U==4\(U>[*&_H!EXKH3"=-A-EPM
MK]PIED^JR<:N6!S0T]':LZ$9H=F UN:T-&&NDQ.J9&'9F>'W;[]XL"N4EFQ& MGQ\#OXH\\&@?/H?X#C0_J H8UZVXLCB,Y;>SQ8P"E(5I-=H:,(5UNNN!/+J M@*VX$ZZ'U"B@ -!
[4 *3#<-]ARZ?V<8I<<1FISQ_MCS(&\\%'O:P0PT^./7/:.MU@?ZXM9&IOY/FE5#+5,"REZ4IXR3F993NC|CS?^"6>6DRE|fF^%(_AL;%OUZ4 MY)H'PWH $=>[P.R5CC<]3\.J;//M>I-
!PN<@$:U*ITI\ ME\5S)87Q$BUSC3W86BGET%"(8)NU=&OI>RW*U\F8.]T)]J:6 M+LG6D)0$L0?B7N_AZP+@HS70 =73YB#?H:(,8&$\MA91)?^GNF>B2L*]A\N#^
M_#5;7+Y&N> ^LS4FF'Y!'E2[OM\#"X/JXS*H%*@D[T]>_988 JN6_G@K?5/3 MZLWRPOKJ@A@O^S-E>HX!9'GAU_P\-?1T^/*WXC$^_8'XDH"=/- BA15:S<;>
MW5))*T<[PAVA"#O=10:-FI9]WIA&-CD!F2.,H0=_M2^ 9Q53Z\,(L0)O=KU' !24/6#WX$#" $ NR:@>$6E57TB]H-8_D[.[RRT--GR/>D M,"3N/10@4|X8C1/4BZ&*]I-
30'LYRZNI$<[XOVC_S6-.AUSZJ4QNZ*!P\/< MMA.?E_87W,,!4[O>+)4''T3UJG8/_3[F-J2TE.?4D-J;,#AYVSPPKT[X_VM@)R/BG9)5)T>%JCC7+\6*H3.&B/P[7*&7ZN!9!!>*-
MEP&EV#'_J+|\.S'+V0\]^I;79@[6;-'*]P4%N*=,G_I)5?.G+]E= ["5_@6T MX@I#TN;(B]%K07_J(A:?">I);T&@ .%1P::644+E*FQ]{A''+H%675-@%$G@:
MERU"GFPW\V.'RA\XX50(Y'FY!/NQ_\/G%S&E_K^8OT7Z+],ZfW& V@?AO(O MR'WZT;0/"I3#&\0/K=.:,/PS+$W0R&/DRSS5N!-3R=&5NJ;YF7(<-= I*PC))S9:HXD""-6RH0#7>U"
M%LODE//N!TT=%K2FF8Y% ;O7T)JFU".H"79(UH_6-%HH -RIBI0>(_&". BT MRIV.UEJ5:/VQ1?43VM\BF/YOB-[S[!2Y0)$^;KI(;# *$-IWS$:$ O3:H$W/-M>GL48&|\U2P)
{QRDA=_7X5NU>K=G7FR&;QRF(T!S8"R>G'"*6G#&) ,.U1K7;B1$MM>*(!6!@K0UZ.#_;NO4\;*RS2KG\FU8O9R4M:2/?#;I=!XZ&"6K7]IG
M$*AP8YV_I"(\3&AZ)BZ(Q2>;'99.TW@[P;WYIYD8ZSG>V/EX]'7B M]\YP*WHMS)\" 8M; *%<#%Y4?SDC*OR{IHE=5#8W7A3MB6>$*3"DX8RRA=]
M*;%8_5GCZQ+.6=IC:3*4$V2?#]^<*]25XI-O$6KL[VQZLTU*L7Y> SI53FQ[MY#SG)*@8LG8X"FB8R#) A'K05]7Z&P1ZAQO;,H%\ >8=%R?(%T;/CE7C%DG
MJN'R@GG>YGGM@!D4V#BH,)OXOE\1@$;7VVI(8?8/2Q8F';,X]+_GVV#[BSGS M=7,Z(]X8!?@P87.^"&N/WOCM*]S+!?>#)Q$$6I3H6O-2F.]TM_TC\QK0K; 7M M76UI^O5
MPP&LWVD\5.6H]E& RW/2+\fK,H#++#QTO?[\ZTEX?5-4G4M0>TH\VTGZY%/AU M+HV&*]O@Y>Z)_]91!5#^2)9!95SW$0<BOX+XM-V/\9O_0GWNUQ# M^"(C71.QUB/>,>"<-
INV*=+*6W(5^3U8R)-8W%T;U,"&5_|=VX#_|/MX?]O M,>]_+_P[74-<(#R'.GPD)1C1(^/93O-^ZV9E0DTW:E)#!*7=TTD%?IC=G%44_UB!PUD))@G$;O&??>.X)QDV)9ZB)'B,?
^*!Q0K R M3R!X>R=+ ;&5Y]X')..> K%T+-A)]/OUD9+9\;U^0]+2O}!2B,<_S.+X= M4|3 OD4/>.L@:]%+,W1UV)WE'>1APX3GYF($8ML5P034W'N,A!506.RT2WU7 M6B8<3RJ08;
<4D:C0;,=*THFK*$EMJ 273]8@4 TQP7H5'= ^/AYC9<%F>DG M+A0@EWSA_L:KW9C4)/\C@4>8 0.&\VZ3F-YX_NC68=YML5;//V;<-RNK+6 M[Y[%WOU:A
%POI*FQ)039W%3RK[2ZK+ZIN'?Q2?^>X) _N#@$1"UK. WV%)@>ZS4#P!^S7U82?@FIXCLC'K[6O#_>WZCUY>-02W],7'M;SR
M;G99E,JMO&9XD[S86,D=1X4U:NY315G%A9O6-XVYMA!-LPC[9C$W&9;5:F!, M$EAU\8Z6A',NB^>\[E$81HP@7%FTKM)'8O";/6]HE9=?)]UC@JB!_BIH/T1C M?
W@14[5<(2+G*RL^=$XN!+-10VN"G;_)_F%$0_G;EH'^[/HI. I !%YMC(/# M:%^\8>8'&MH[&%4\/7/7BF66M1;8(!J5,LU=LQ.V%,A3IWR.A.&^6$!:4<#'>QZ[X)66:?
[&"I1QTTH&&U+P*BZ] M.SL'U1,.Q3WCD.8:/ U2#D^U_]@GMV/|'&L$W)S5Y&]72$X?5?5EIY.%@8',Q2.*0I%RJQ$-W*FG4JU1+5Q,E!1C"07LBX'$I%R\N"!O:
MR!\#FS8*H(T#*\'%URV$FL:I?-Q2DR /U:PK-MX&O/N<"I\,/KCQWWJ5)E'W='F')DLNYE&ZL.;]7PM*4 'RCV[!YF MY,CY9%-B[VJSAL D]I/2D;LYK[7WR>^LI?
N7CI91W=Y@XHCT'S"_%0+]2NF2 M_W%%"EI%E"),=\[D%X8;*@9A)GU#=!*K*Jf;6=GR):J%$IQ APUC 1' Y!0& MMN'=K[6U!+TR,1-?MH&6K*>\|E9X"]#1]$0E$Z?,(!9+%",,
[R>,A4+I0.R8E M%[=6C2;,+>5B/ F>GL[WP#*?8CTI2ZJKX];2*D)=WY+,>V12^@1JA>7#=ML\ MC>U9P<-0>*BU5/7'W:]9 ZW-V$L!-.C[4^DV%{1C$2^Z]*!TBCZ'2F!2^:7U
MU%]6>QF,*YC7:^NIXN]#.]7(%^,@ M-?-'Z#+M4 (,8FT@(9(XH'T]8&FKLH+E;]2IKZ96^?2CP5H&C][-'LID=F5^H MN?6[\@B\F_>I.6N=YSJ8]K_0L=G>B458-
%ZHR&8UJ8'%2A.9Q .+Q M [Q"S>GYU,]]7J+!2=(4:I\%'V-B8GTI,3M86XV?EH#2MED9'1FDI0YZU?/ M9EHE5<.VIWP1U:$67<=?
8[M#K:WU'+D\L<9!$9GFYOYU\=;Z4%SOIB^?%XL$ MVG*#-=Y(3ST:(U!?$?\C^_:'2'JKWY9$&573BE& <*O+1?K*,"D3>N0VC_E_^R>(^TJ@O:KTA4 ,U@UBH$ M%N2Y8C$LAN'
#HE++V;'G+UMSA;8$+N6HZLYYSWA=HFL,<[/VHO$;!B[6;/ ;S+\MUBE'(IYGWHY[K{^3QQWOXVI Y3!2LW$" MY+.AM(H[=I2" \+MKI,$QX6";;/J0KQ,,X?
<-4>/1+K/2Z_I4O_M^'^BP."K M+N/@R9K(/HL;!=OO0,5^U]8:(GQ74/FNX Q&G8ZLWUU!X#G!3MD]+C^#]RT MC$L)59WDT3WP%)-"^,SUG)-O@79U;2^7
GYNCG"*D!=4V,&6X;&Q%U@-X$.> M<11@MNZW-8'?M?,M GETWRZ!NL{^"3H)[.KFVE& ^'U>W4T|/%#OBB4*X'UQ MN53P<[,RAW[)HR$;!>!>=("-"I*C ,G=(RC
]1,JN#35[HXV2O+M%WY,2)O6 M-5#A.QX40#BA (F]#3R-_[<7,Y*C3[!4X7/1/2C 'JG]D@_/ETX\21HCP/T M8XNS2UZ,:9O\ES3_DZ5I.
<;/9*O/I.V@ECPTGT@0]AUU@T(8>10P&QQ,R7-8 MD)#[>R-]760M>V7Y9H[D)GD"W9@5<6;"G'N)MAAC@((W4>KG8$A7B8^P14_MNY5_^R)]R38QJT?, -+
[*0HPDYFZ60X^O!.&1 @H(@0)SOW]I:O7_[!>PI;F M86N&M5(?4V%"],;,[@1@8*8+6! M APR3(OFWU#!E7](FF10,U+-]I(B@(6H "]F6B%Y%4(VE," 03OP*% TO/S M*:H)-Q0
<9'}>]R1E#2G[Y2T%_W!]R5!>_= CXI?QS8D9<2 M2&C/6HRZ!P!*%HA\/_G3%U,(PSM@KG"*"$3"^-%:?_E@!8V5X5>WE2R.>"D5 MVOYG9BF!AK<8-@A"@S?
(BNFF!=)\SQ.'V_^\7)$6.FTNG_CKN+KY;&-3KMV)I M?IO1KC^' 0_^W=9/GDIK8WAC]??R(L0?IGIQS&OBMK]3V,=A=8; MK[S 2XF+%'O0:4>]
<)&'OY_YYW!W0L*F3JXBOT21$*GKUVME 7+72B^K"'=E1&#&5V>U{\#8;&_DW45HH.&2]P+SL7{&#XU$>0'/5#M>C7=-LD&
4B+"%LZ7M^\ZFY^ M+>+1@R>KMI+62<12%L;R?*RS":U'23?-TG#RV/-N'/.D_W,5/OZR[4.&8^-R M,,!5<5R4\E,'VV]IHAXC7_YY;?!I/KE#RY(\YV]QDR[7\Z.4N25K:QNWC?P
M'-HA:S%I&G7R\ME.KD@W+PIO$1=O $*,)(5KUU#P5]PL8(>7LJ4N;4:P>[7 M.[KFR>9Z15" =^"]K/C&JO>K#U& .OS387=EYURY,'VM?AN"=>I2]I-Z%(T MH$8S.[07-
(,%MV18KQ[*L=UD*M&O,TV'J(>=< MI>11UFXO?N<9,U/'79KO MV8N40(9_O$[!WW/\N]YHY:U[2.%Q9\0[M'>9?"M5A9F5J$>^O-*8N;"]F)!" MYL;SG*#2*%]+//S?
*34A97_OZ%(D-7H/%ZV%/E:,K+31[_37@IW58?4?: MG')|%/1SMEYL:_+R[GZ[W=W'JT+6'P%$SU" 3XL2UL("!IF:FDB$I>[)N\] M:-&5#![(C4@WCZD*C:*-=CMG/G
=WFNR7>JX*2"Z1!T\$B^3(-XT9FDSHKM1 M[!=]JQ/QL9TKGE0A^BZ ']_)"_?ZXZZ_KW##'L."]/!Y>9Q!7C'K3*R3?!?>.
MSI"4SNY'+_/Y$"I)69R943%;YV*)]$HV\K[9W;2G]:ONI"OY[U3G+ MN:TY) MI5@HK.V],->+0TS!&X*?&TP:4N2F0?<0F?Y',)Q5-VNP0!FD;+ZM:EF7L^W6 M"Y*V(\[T'/=]%$
Z^K$*XU8M3-0<]!U_5JKG[KHG<=G SJ-!EEEV2(=,TY4'MMP$]SWMLQXM8^7G,J1!"[F1$KHMYO)YH_;@$3^&?S[R9D.HU>&MFSR;TT.;6 M;8OJDU4%KHI=?
^F5^/W:+UHZ$B<]E;]#P[86=S_&IK89/ZTHK;U0*L$DTSWQ M,:<78R_(K_;2H>@&,A\T[$8KEEZ_6[H;AJ8MX_C>_&S+YDYQCH=5M9T&4A[% M16KVWI#HEA>I-%8Y;/QTJ
;G0J=WOKN%)E!/Q!(KZC)T&!9CT1T6\,_9A*2, MP(U-"S34:QZ-45]E^$P>37.\J1UQVI ,LF(M0@%N(.,JGKJR+J^\!V_FO\6O M8ZRTL'.LANE6*(08WT]WGX!8WO>#VJHTOV:
MSV'X^O_Q_FKO.H*;2-1S7 MK*\'(%($(U6*-%%(UU ,13HI$"A\WSG><[[M\)<(^51MUUY=11XY(+5W)=TO0E?29&B4Z5XRX7H-><]%TAHJ.-XY>V_7.3'P M:N5'@0A#TB*\SI-
\^/2=:G^MO9OC:=UU*2$WT6I9\EE+/,:Q)BV#6I8_F!.. MO#O=&(-MNI[9,(6=RZ^ZREAIG=DZR?[Q,C:L<:V=GUL"@!/H> Y@:3@!9&/& M4:L()%7RR^XQ.EBS7HNYO.)?
E,R:I;U*"_4ZO=!X{U2G7&_.?OS IK1AT(M2 M;X..Z]BEAH(*|$_=$GDXH\%GOBEGW%F]>3B&-E!Q -7]4'DG3/33&1-L/,"?.F MJGQJIZ9F;$H"@(U!FQ%82#N;BLGYPS4BG,)619Z-
J6#.3W5I9I9NNIA>F0^V M2/Z,8*L9@5+5:.L9ZFAMMNI1NYP+PP%:B@:#SEV@<$[JZT3(V!BY!1P=W6ZI M+F>.//'1!?(D)8^\BBQ9.SR=IK/W6-!:07&C\'.I N4T\
MZHGXW',WO,>2A*7 -#%C>,]WKIC4=,+>#V\(=-' EDZF"K6N(24]J>IH=4A3* M(.]*8Q"JD)#K,4#NBSE!4X,H6;-&\6$=>O%,<.G63;/-RW>*4$7D+W;@<-; M4ZR!Z$#=8-
$XPO+&:*#,3QLF'W640"$Q_;ZX^,U#O_C]*RPALOI*B.(AZO4V MI_AS!VP%|'0HRCS)49U+XFY"@\[J*9"[N: D)ACH34E?2'" M27V@7/EHGL54=F G<.J E5G./KRV^S-*&TAST+FX9:
'V3PYY;;?=4V$J#M MT-^(>G&J.P Q0_1N>C4%OF^+L@ZD198P4,R).Y'((TW7F?"1&669A_XPV#E) M:#<+ET+4F"X(A^2>*,?.)@):Q!(SVODVY+QPAG!%8$5-*'++W"-?($
M229\KT+N!P+%FY7NDV:VZYT/IT 'G(<_!%;9[3//1%=*Y04]?&8]JH;JG97 M49G-C1>,26_]G7;=$9#!TX3=73<[7R"I_G']@?)-;, ^T\(#U% .0O9.$*HO0 MW\K_DBI?
JH8!Z43D!8V_,\|@OZMV']'339.CI*AK=PT?OX&/Z_OYF=]X!YUU MTS2FL[W723;EH1^W3IG9X/%?]?O5!@U,/BQ.7=8S^]3K_TH=@0.^RQ)4*!%9!)3T5?QX8_/1;ME5 MB/ME0Z;-
%B+(JO=AZRG12_'R2Z)4>_^$H"(B{S]1*CS6L*O.Q8\B4EN9YNL' M>_+SQ6CG@P603H&4]F1$![HXJG2{OL;O<-E)3N<"-WU=R]!&=B>9M2#2<%]3D
M](@N>I!\=I#*BYV&C($>P|*^.NXP!5GKL(?OZ!MT7=WR33*)>FD,[B\;1^.);6;0T M13P0[S,/'!:.ST]63 M/#5Q1206'P,[$"H5]33Z!GL6:C\\WBME20>A*@^J1:E(C+M.CEY(4JSS
M'OK(];FW.IZ'"HZMCY$UEIQ82/4-GQ=LC*- M[;>L]GL/?-:EWVX6H#/&&=M\OL#Y/.YT/+]LAF4.Z3;')6YG< SOSUZ(7FU.EF-95EY8+U*NHE M64V-A)[=:9-Z/GWE?
HXM_MHOV1URQ%LB#;Q[R/K)%"WTY3=J_M--C_-_/>$O M-WZ+:IP\@2MUDCC6GCZAJD^S-ATJ<3?">QCQ&%J9]:JJSNP]DPC")L=11N.
M+4OI.8BDI0N"+]_.PKNM432*%!!3RF%\@EHJ5(CW*881&#5;>ZO_.7TK4 MEVIZ&]&AT;/OE2S@O0>>D>]84]J2P]Z+17>1.)SE(=R"EJC*2=|^U
M&L^8=&UQA"G0B"IT&I@F'@=$IG6*&N>R+_$!^DJ[>^/_O'/ MN&U;6.H-A&KB1X>)WSNY87_\TXQV0L4PN =0Z8/<\|JR"V/PKVYV*SGACW/V
MZ80V+GBC"O$N/J{5"!]D)]>26@%C5S)V\IBY60-1{>WZ\@#AO)-%B96G)YA M_9.FS#L+MG):U2?3]^$3A0WW@0$WJO9;T!2\FH,MH(K%S7Q_U^90WZ^/VA>S
M83H7I]_D78%[6@4*+@"T€XO?D#5'%"+$-QQYD7QHKLTG$ MD$]*HX7'L; /O;UA*W'2=]ZPEP(?[E4IMRD?!7]O6H_'|;,)-@)>>>/W&0?MY%=8RL[C MA.UUO -
MY!HNE\OO%<]?:!%0(MR17^TZOA9OJP1?0W(D>GB/GK(I[9%0,MQKP MA>IZ:?%#-*.6K3&SZ.\U>Y"\7J0.S3-H'BTDTP1ZKG4:GO/_H&\2U*6@4_XL(WW>%@)GB
M+P>V7VR?'YY&UL4$L! A0#% @ T4-M M6224MMZ\&@ +[8! !4 (!K(@ &-O8W M,C R-# Y,S!? M9&5F+GAM;%!+ 0(4 Q0 (-%#;5EN,WSVE ++'! 5 M_" 9LS !C;V-
P+3(P.C0P.3,P7VQA8BYX;6Q02P$'% ,4 " #10VU9 MC:E1&#&UL4$L! A0#% @ T4-M61W"S/*\% 3W0 D M (!$KT &5X,RTQ+FAT;5!+ 0(4 Q0 (-%#;5D)NV[E@< &PN * M "? ?
71 !E>#,Q+3$N:'1M4$L! A0#% @ T4-M6#,R+3$N:'1M4$L! A0#% @ T4-M6> M_O&EX OGT(P M (!VNT &9O XML 61 form10-q_htm.xml IDEA: XBRL DOCUMENT
0001412486 2024-01-012024-09-30 0001412486 2024-11-13 0001412486 2024-09-30 0001412486 2023-12-31 0001412486 2024-07-012024-09-30 0001412486 2023-07-012023-09-30 0001412486 2023-01-012023-09-30 0001412486 us-gaap:CommonStockMember 2024-01-012024-03-31 0001412486 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001412486 us-gaap:RetainedEarningsMember 2023-12-31 0001412486 us-gaap:CommonStockMember 2024-03-31 0001412486 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001412486 us-gaap:RetainedEarningsMember 2024-03-31 0001412486 2024-03-31 0001412486 us-gaap:CommonStockMember 2024-06-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001412486 us-gaap:RetainedEarningsMember 2024-06-30 0001412486 2024-06-30 0001412486 us-gaap:CommonStockMember 2022-12-31 0001412486 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001412486 us-gaap:RetainedEarningsMember 2022-12-31 0001412486 2022-12-31 0001412486 us-gaap:CommonStockMember 2023-03-31 0001412486 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001412486 us-gaap:RetainedEarningsMember 2023-03-31 0001412486 2023-03-31 0001412486 us-gaap:CommonStockMember 2023-06-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001412486 us-gaap:RetainedEarningsMember 2023-06-30 0001412486 2023-06-30 0001412486 us-gaap:CommonStockMember 2024-01-012024-03-31 0001412486 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001412486 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001412486 2024-01-012024-03-31 0001412486 us-gaap:CommonStockMember 2024-04-012024-06-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001412486 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001412486 2024-04-012024-06-30 0001412486 us-gaap:CommonStockMember 2024-07-012024-09-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001412486 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001412486 us-gaap:CommonStockMember 2023-01-012023-03-31 0001412486 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001412486 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001412486 us-gaap:CommonStockMember 2023-04-012023-06-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001412486 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001412486 2023-04-012023-06-30 0001412486 us-gaap:CommonStockMember 2023-07-012023-09-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001412486 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001412486 us-gaap:CommonStockMember 2024-09-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001412486 us-gaap:RetainedEarningsMember 2024-09-30 0001412486 us-gaap:CommonStockMember 2023-09-30 0001412486 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001412486 us-gaap:RetainedEarningsMember 2023-09-30 0001412486 2023-09-30 0001412486 COCP:SweepAccountMember 2024-09-30 0001412486 COCP:SweepAccountMember 2023-12-31 0001412486 COCP:OutstandingOptionsToPurchaseCommonStockMember 2024-01-012024-09-30 0001412486 COCP:OutstandingOptionsToPurchaseCommonStockMember 2023-01-012023-09-30 0001412486 COCP:RestrictedStockUnitsForCommonStockMember 2024-01-012024-09-30 0001412486 COCP:RestrictedStockUnitsForCommonStockMember 2023-01-012023-09-30 0001412486 COCP:WarrantsToPurchaseCommonStockMember 2024-01-012024-09-30 0001412486 COCP:WarrantsToPurchaseCommonStockMember 2023-01-012023-09-30 0001412486 srt:MinimumMember 2024-09-30 0001412486 srt:MaximumMember 2024-09-30 0001412486 COCP:LabEquipmentMember 2024-09-30 0001412486 COCP:LabEquipmentMember 2023-12-31 0001412486

COCP:FinanceLeaseRightofUseLabEquipmentNetMember 2024-09-30 0001412486 COCP:FinanceLeaseRightofUseLabEquipmentNetMember 2023-12-31 0001412486 COCP:ComputerAndOfficeEquipmentMember 2024-09-30 0001412486 COCP:ComputerAndOfficeEquipmentMember 2023-12-31 0001412486 2024-06-27 0001412486 COCP:TwoThousandandFifteenEquityIncentivePlansMember 2024-09-30 0001412486 COCP:TwoThousandandFifteenEquityIncentivePlansMember 2024-01-012024-09-30 0001412486 2024-08-12 0001412486 2024-08-122024-08-12 0001412486 us-gaap:EmployeeStockOptionMember 2023-12-31 0001412486 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001412486 us-gaap:EmployeeStockOptionMember 2024-09-30 0001412486 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001412486 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001412486 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001412486 srt:MaximumMemberCOCP:CollaborationAgreementMember 2019-01-02 0001412486 COCP:MiamiFloridaMember 2024-01-012024-09-30 0001412486 COCP:BothellWashingtonMember 2024-01-012024-09-30 0001412486 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001412486 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0001412486 COCP:NorthCreekTecLLCMemberCOCP:AmendedLeaseAgreementForExpansionMember 2023-09-21 0001412486 COCP:NorthCreekTecLLCMemberCOCP:AmendedLeaseAgreementForExpansionMember 2023-09-212023-09-21 0001412486 COCP:NorthCreekTecLLCMemberCOCP:AmendedLeaseAgreementForExtensionMember 2023-09-21 0001412486 COCP:NorthCreekTecLLCMemberCOCP:AmendedLeaseAgreementForExtensionMember 2023-09-212023-09-21 0001412486 COCP:NorthCreekTecLLCMember 2023-09-212023-09-21 0001412486 COCP:DrPhillipFrostMember 2024-08-142024-08-14 0001412486 us-gaap:RelatedPartyMember 2024-01-012024-09-30 0001412486 us-gaap:RelatedPartyMember 2023-01-012023-09-30 0001412486 COCP:PhaseTwoAClinicalTrialMember 2022-08-03 0001412486 COCP:PhaseTwoAClinicalTrialMember 2024-01-012024-09-30 0001412486 COCP:PhaseTwoAClinicalTrialMember 2024-09-30 0001412486 COCP:HVIVOMemberCOCP:AgreementMember 2024-01-012024-09-30 0001412486 COCP:HVIVOMemberCOCP:AgreementMember 2024-05-21 0001412486 COCP:SecuritiesPurchaseAgreementMember 2023-04-042023-04-04 0001412486 COCP:SecuritiesPurchaseAgreementMember 2023-04-04 iso4217:USD shares iso4217:USD shares pure utr:sqft COCP:Segmentfalse--12-31Q30001412486 P3Y 10-Qtrue2024-09-302024false001-38418COCRYSTAL PHARMA, INC.DE35-2528215198O5 North Creek ParkwayBothellWA98011877262-7123YesYesNon-accelerated FilertruefalsefalseCommon StockCOCPNASDAQ0.00110173790130200002635300075000750006520008900005090001773000142560002909100018100027100029000460001630004200017670001853301520003159140001270300026384000162330003125900032420004194000105000001090200018000001849000414800045910001600000-16000005042000443000146480001389300050420004443000-14648000-13893000-111000-320000-482000-460000-8000-42000-72000-870001030002780004100003730004939000-4165000-14238000-13520000-0.49-0.49-0.41-0.41-1.40-1.40-1.43-1.43101740001017400010153000101530001017400010174000194610009461000101740001000034228800031591400026384000157000157000-3956000-39560001017400010000342445000-31987000022585000148000148000-5343000-53430001017400010000342593000-32521300017390000252000252000-4939000-49390001017400010000342845000-33015200012703000814300080003374890000-29793000039567000291000291000-5189000-51890008143000800033778000-30311900034669000179000179000203100020003998000400000-4166000-41660001017400010000341957000-30728500034682000101740001000034195700030728500034682000173000173000-4165000-41650001017400010000342130000-31145000030690000101740001000034213000031145000030690000-14238000-13520000980001490002470001630005580006430001420001720001281000-401000-238000-166000-13670008300000-13325000-11340000800059000-8000-59000700040000003993000-13333000-74060002642800037219000130950002981300016300<p id="xdx_80D_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zirDa9zbk1C7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">1. Organization and Business   Cocrystal Pharma, Inc. (“we”, the “Company” or “Cocrystal”), a clinical stage biopharmaceutical company incorporated in Delaware, has been developing novel technologies and approaches to create first-in-class or best-in-class antiviral drug candidates. Our focus is to pursue the development and commercialization of broad-spectrum antiviral drug candidates that will transform the treatment and prophylaxis of viral diseases in humans. By concentrating our research and development efforts on viral replication inhibitors, we plan to leverage our infrastructure and expertise in these areas.   The Company’s activities since inception have principally consisted of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs, obtaining regulatory approvals of its products and, ultimately, the attainment of profitable operations is dependent on future events, including, among other things, its ability to access potential markets, secure financing, develop a customer base, attract, retain and motivate qualified personnel, and develop strategic alliances.   Liquidity   The Company’s consolidated financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative operating cash flows since inception. For the nine months ended September 30, 2024, the Company recorded a net loss of approximately $14,238,000 and used approximately $13,325,000 of cash in operating activities.   On September 30, 2024, the Company had cash and restricted cash of approximately $13,095,000. Restricted cash represents amounts pledged as collateral for financing arrangements that are currently limited to the issuance of business credit cards. The restriction will end upon the conclusion of these financing arrangements. We believe that our current resources will be sufficient to fund our operations beyond the next 12 months. This estimate is based, in part, upon our currently projected expenditures.   The Company’s activities since inception have principally consisted of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs, obtaining regulatory approvals of its products and, ultimately, the attainment of profitable operations is dependent on future events, including, among other things, its ability to access potential markets, secure financing, develop a customer base, attract, retain and motivate qualified personnel, and develop strategic alliances. Through September 30, 2024, the Company has primarily funded its operations through equity offerings.   The Company will need to continue obtaining adequate capital to fund operating losses until it becomes profitable. The Company can give no assurances that the additional capital it is able to raise, if any, will be sufficient to meet its needs, or that any such financing will be obtainable on acceptable terms. Our future cash requirements, and the timing of those requirements, will depend on a number of factors, including economic conditions, the approval and success of our products in development, the continued progress of research and development of our product candidates, the timing and outcome of clinical trials and regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims and other intellectual property rights, the status of competitive products, the availability of financing, our success in developing markets for our product candidates and legal proceedings that may arise. We have historically not generated sustained positive cash flow and if we are not able to secure additional funding when needed, we may have to delay, reduce the scope of, or eliminate one or more of our clinical trials or research and development programs. If the Company is unable to obtain adequate capital, it could be forced to cease operations or substantially curtail its drug development activities. The Company expects to continue incurring substantial operating losses and negative cash flows from operations over the next several years during its pre-clinical and clinical development phases.   -14238000-1332500013095000 2. Basis of Presentation and Significant Accounting Policies   Basis of Presentation   The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X set forth by the Securities and Exchange Commission (“SEC”). They do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire fiscal year. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2023 filed on March 28, 2024 (“Annual Report”).   Principles of Consolidation   The consolidated financial statements include the accounts of Cocrystal Pharma, Inc. and its wholly owned subsidiaries: Cocrystal Discovery, Inc., Cocrystal Pharma Australia Pty Ltd. (“Cocrystal Australia”), RFS Pharma, LLC and Cocrystal Merger Sub, Inc. Intercompany transactions and balances have been eliminated.   Segments   The Company operates in only one segment. Management uses cash flows as the primary measure to manage its business and does not segment its business for internal reporting or decision-making.   Use of Estimates   <span style="font-family: Times New Roman, Times,

Serif; font-size: 10pt">Preparation of the Company's consolidated financial statements in conformance with U.S. GAAP requires the Company's management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company's consolidated financial statements and accompanying notes. The significant estimates in the Company's consolidated financial statements relate to the valuation of equity awards and warrant liabilities, recoverability of deferred tax assets, estimated tax credit receivable and estimated useful lives of fixed assets. The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions.   Concentrations of Credit Risk   Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash deposited in accounts held at two U.S. financial institutions, which may, at times, exceed federally insured limits of $250,000 for each institution where accounts are held. At September 30, 2024 and December 31, 2023, our primary operating accounts held approximately $13,020,000 and $26,353,000, respectively, and our restricted cash collateral account balance was $75,000 and $75,000 at a different institution. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risks thereof.   Foreign Currency Transactions   The Company and its subsidiaries use the U.S. dollar as functional currency. Foreign currency transactions are initially measured and recorded in the functional currency using the exchange rate on the date of the transaction. Foreign exchange gains and losses arising from settlement of foreign currency transactions are recognized in profit and loss.   Cocrystal Australia maintains its records in Australian dollars. The monetary assets and liabilities of Cocrystal Australia are remeasured into the functional currency using the closing rate at the end of every reporting period. All nonmonetary assets and liabilities and related profit and loss accounts are remeasured into the functional currency using the historical exchange rates. Profit and loss accounts, other than those that are remeasured using the historical exchange rates, are remeasured into the functional currency using the average exchange rate for the period. Foreign exchange gains and losses arising from the remeasurement into the functional currency is recognized in profit and loss.   Fair Value Measurements   FASB Accounting Standards Codification ("ASC") 820 defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 — quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 — significant unobservable inputs that reflect management's best estimate of what market participants would use to price the assets or liabilities at the measurement date. </td></tr> </table>   At September 30, 2024 and December 31, 2023, the carrying amounts of financial assets and liabilities, such as cash, tax receivable, other assets, and accounts payable and accrued expenses approximate their fair values due to their short-term nature. The carrying values of leases payable approximate their fair values due to the fact that the interest rates on these obligations are based on prevailing market interest rates.   <p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zfb2KBXAbD58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Long-Lived Assets   The Company regularly reviews the carrying value and estimated lives of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management's estimate of the asset's ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company's business objective. Should an impairment exist, the impairment loss would be measured based on the excess of the carrying amount over the asset's fair value.   Research and Development Expenses   Research and development costs consist primarily of fees paid to consultants and outside service providers, and other expenses relating to the acquisition, design, development and testing of the Company's clinical products. All research and development costs are expensed as incurred. Research and development costs are presented net of tax credits.   The Company's Australian subsidiary is entitled to receive government assistance in the form of refundable and non-refundable research and development tax credits ("Refundable Tax Credits") from the federal and provincial taxation authorities, based on qualifying expenditures incurred during the fiscal year. The Refundable Tax Credits are from the provincial taxation authorities and are not dependent on its ongoing tax status or tax position and accordingly are not considered part of income taxes. The Company records Refundable Tax Credits as a reduction of research and development expenses when the Company can reasonably estimate the amounts and it is more likely than not, they will be received. As of December 31, 2023, balance of Refundable Tax Credits was approximately $786,000, which was received in full as of September 30, 2024. The Company estimated and accrued Refundable Tax Credits for the nine months ended September 30, 2024 of approximately $652,000 and a tax payable of $15,000, resulting in a net balance of Refundable Tax Credits receivable of approximately $637,000.   Income Taxes   The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Realization of deferred tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred tax asset will not be realized based on the weight of available evidence, including expected future earnings. The Company recognizes an uncertain tax position in its financial statements when it concludes that a tax position is more likely than not to be sustained upon examination based solely on its technical merits. Only after a tax position passes the first step of recognition will measurement be required. Under the measurement step, the tax benefit is measured as the largest amount of benefit that is more likely than not to be realized upon effective settlement. This is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. The Company elects to accrue any interest or penalties related to income taxes as part of its income tax expense.   As of September 30, 2024, the Company assessed its

income tax expense based on its projected future taxable income for the year ending December 31, 2024 and therefore recorded no amount for income tax expense for the nine months ended September 30, 2024. In addition, the Company has significant deferred tax assets available to offset income tax expense due to net operating loss carry forwards which are currently subject to a full valuation allowance based on the Company's assessment of future taxable income. Refer to our Annual Report on Form 10-K for the year ended December 31, 2023 for more information.   Stock-Based Compensation   The Company recognizes compensation expense using a fair value-based method for costs related to stock-based payments, including stock options. The fair value of options awarded to employees is measured on the date of grant using the Black-Scholes option pricing model and is recognized as expense over the requisite service period on a straight-line basis.   Use of the Black-Scholes option pricing model requires the input of subjective assumptions including expected volatility, expected term, and a risk-free interest rate. The Company estimates volatility using a blend of its own historical stock price volatility as well as that of market comparable entities since the Company's common stock has limited trading history and limited observable volatility of its own. The expected term of the options is estimated by using the SEC Staff Bulletin No. 107's Simplified Method for Estimate Expected Term. The risk-free interest rate is estimated using comparable published federal funds rates.   Net Income (Loss) per Share   The Company accounts for and discloses net income (loss) per common share in accordance with FASB ASC Topic 260, Earnings Per Share. Basic income (loss) per common share is computed by dividing income (loss) attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common stock for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants and the conversion of convertible notes payable.   <p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zhRIBqa470O2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table sets forth the number of potential common shares excluded from the calculations of net loss per diluted share because their inclusion would be anti-dilutive (in thousands):   Schedule of Anti-dilutive Securities Excluded from Calculations of Net Loss Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20240101__20240930_z8oZsGJF8XN9" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230101__20230930_z4aNlN38dyld" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OutstandingOptionsToPurchaseCommonStockMember_zarE5ffC3bdh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Outstanding options to purchase common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">555</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">559</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsForCommonStockMember_z5dTve0WNQah" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units for common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">256</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zlY2skLYbj9h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_zq4gmSHB3ie2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">811</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">572</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Recent Accounting Pronouncements   Authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC did not, or are not expected to, have a material impact on the Company's consolidated financial statements and related disclosures.   Basis of Presentation   The accompanying condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles ("U.S. GAAP") for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X set forth by the Securities and Exchange Commission ("SEC"). They do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the interim periods presented are not necessarily indicative of the results of operations for the entire fiscal year. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2023 filed on March 28, 2024 ("Annual Report").   Principles of Consolidation   The consolidated financial statements include the accounts of Cocrystal Pharma, Inc. and its wholly owned subsidiaries: Cocrystal Discovery, Inc., Cocrystal Pharma Australia Pty Ltd. ("Cocrystal Australia"), RFS Pharma, LLC and Cocrystal Merger Sub, Inc. Intercompany transactions and balances have been eliminated.   Segments   The Company operates in only one segment. Management uses cash flows as the primary measure to manage its business and does not segment its business for internal reporting or decision-making.   1 Use of Estimates   Preparation of the Company's consolidated financial statements in conformance with U.S. GAAP requires the Company's management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company's consolidated financial statements and accompanying notes. The significant estimates in the Company's consolidated financial statements relate to the valuation of equity awards and warrant liabilities, recoverability of deferred tax assets, estimated tax credit receivable and estimated useful lives of fixed assets. The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions.   Concentrations of Credit Risk <p style="font: 10pt Times New Roman, Times, Serif;

margin: 0pt 0pt 0pt 0; text-align: justify"> Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash deposited in accounts held at two U.S. financial institutions, which may, at times, exceed federally insured limits of $250,000 for each institution where accounts are held. At September 30, 2024 and December 31, 2023, our primary operating accounts held approximately $13,020,000 and $26,353,000, respectively, and our restricted cash collateral account balance was $75,000 and $75,000 at a different institution. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risks thereof.   2500001302000026353000750007500 0 Foreign Currency Transactions   The Company and its subsidiaries use the U.S. dollar as functional currency. Foreign currency transactions are initially measured and recorded in the functional currency using the exchange rate on the date of the transaction. Foreign exchange gains and losses arising from settlement of foreign currency transactions are recognized in profit and loss.   Cocrystal Australia maintains its records in Australian dollars. The monetary assets and liabilities of Cocrystal Australia are remeasured into the functional currency using the closing rate at the end of every reporting period. All nonmonetary assets and liabilities and related profit and loss accounts are remeasured into the functional currency using the historical exchange rates. Profit and loss accounts, other than those that are remeasured using the historical exchange rates, are remeasured into the functional currency using the average exchange rate for the period. Foreign exchange gains and losses arising from the remeasurement into the functional currency is recognized in profit and loss.   Fair Value Measurements   FASB Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 — quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 — significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.</td></tr> </table>   At September 30, 2024 and December 31, 2023, the carrying amounts of financial assets and liabilities, such as cash, tax receivable, other assets, and accounts payable and accrued expenses approximate their fair values due to their short-term nature. The carrying values of leases payable approximate their fair values due to the fact that the interest rates on these obligations are based on prevailing market interest rates.   <p id="xdx_84B_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zfb2KBXAbD58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Long-Lived Assets   The Company regularly reviews the carrying value and estimated lives of its long-lived assets, including property and equipment, to determine whether indicators of impairment may exist which warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management’s estimate of the asset’s ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company’s business objective. Should an impairment exist, the impairment loss would be measured based on the excess of the carrying amount over the asset’s fair value.   Research and Development Expenses   Research and development costs consist primarily of fees paid to consultants and outside service providers, and other expenses relating to the acquisition, design, development and testing of the Company’s clinical products. All research and development costs are expensed as incurred. Research and development costs are presented net of tax credits.   The Company’s Australian subsidiary is entitled to receive government assistance in the form of refundable and non-refundable research and development tax credits (“Refundable Tax Credits”) from the federal and provincial taxation authorities, based on qualifying expenditures incurred during the fiscal year. The Refundable Tax Credits are from the provincial taxation authorities and are not dependent on its ongoing tax status or tax position and accordingly are not considered part of income taxes. The Company records Refundable Tax Credits as a reduction of research and development expenses when the Company can reasonably estimate the amounts and it is more likely than not, they will be received. As of December 31, 2023, balance of Refundable Tax Credits was approximately $786,000, which was received in full as of September 30, 2024. The Company estimated and accrued Refundable Tax Credits for the nine months ended September 30, 2024 of approximately $652,000 and a tax payable of $15,000, resulting in a net balance of Refundable Tax Credits receivable of approximately $637,000.   7860006520001500063700 Income Taxes   The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered or settled. Realization of deferred tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred tax asset will not be realized based on the weight of available evidence, including expected future earnings. The Company recognizes an uncertain tax position in its financial statements when it concludes that a tax position is more likely than not to be sustained upon examination based solely on its technical merits. Only after a tax position passes the first step of recognition will measurement be required. Under the measurement step, the tax benefit is measured as the largest amount of benefit that is more likely than not to be realized upon effective settlement. This is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. The Company elects to accrue any interest or penalties related to income taxes as part of its income tax expense.   As of September 30, 2024, the Company assessed its income tax expense based on its projected future taxable income for the year ending December 31, 2024 and therefore recorded no amount for income tax expense for the nine months ended September 30, 2024. In addition, the Company has significant deferred tax assets available to offset income tax expense due to net operating loss carry forwards which are currently subject to a full valuation allowance based on the Company’s assessment of future taxable income. Refer to our Annual Report on Form 10-K for the year ended December 31, 2023 for more information.   0 Stock-Based Compensation   <p style="font:

10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company recognizes compensation expense using a fair value-based method for costs related to stock-based payments, including stock options. The fair value of options awarded to employees is measured on the date of grant using the Black-Scholes option pricing model and is recognized as expense over the requisite service period on a straight-line basis.   Use of the Black-Scholes option pricing model requires the input of subjective assumptions including expected volatility, expected term, and a risk-free interest rate. The Company estimates volatility using a blend of its own historical stock price volatility as well as that of market comparable entities since the Company's common stock has limited trading history and limited observable volatility of its own. The expected term of the options is estimated by using the SEC Staff Bulletin No. 107's Simplified Method for Estimate Expected Term. The risk-free interest rate is estimated using comparable published federal funds rates.   Net Income (Loss) per Share   The Company accounts for and discloses net income (loss) per common share in accordance with FASB ASC Topic 260, Earnings Per Share. Basic income (loss) per common share is computed by dividing income (loss) attributable to common stockholders by the weighted average number of common shares outstanding. Diluted net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common stock for all potential dilutive common shares outstanding. Potential common shares consist of shares issuable upon the exercise of stock options and warrants and the conversion of convertible notes payable.   <p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zhRIBqa470O2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table sets forth the number of potential common shares excluded from the calculations of net loss per diluted share because their inclusion would be anti-dilutive (in thousands): Schedule of Anti-dilutive Securities Excluded from Calculations of Net Loss Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20240101__20240930_z8oZsGJF8XN9" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230101__20230930_z4aNlN38dyId" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OutstandingOptionsToPurchaseCommonStockMember_zarE5ffC3bdh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Outstanding options to purchase common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">555</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">559</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsForCommonStockMember_z5dTve0WNQah" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units for common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">256</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zlY2skLYbj9h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_zq4gmSHB3ie2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">811</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">572</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zhRIBqa470O2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table sets forth the number of potential common shares excluded from the calculations of net loss per diluted share because their inclusion would be anti-dilutive (in thousands): Schedule of Anti-dilutive Securities Excluded from Calculations of Net Loss Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20240101__20240930_z8oZsGJF8XN9" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20230101__20230930_z4aNlN38dyId" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OutstandingOptionsToPurchaseCommonStockMember_zarE5ffC3bdh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Outstanding options to purchase common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">555</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">559</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--RestrictedStockUnitsForCommonStockMember_z5dTve0WNQah" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units for common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">256</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zlY2skLYbj9h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_zq4gmSHB3ie2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">811</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">572</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>5550005590002560001300081100057200 Recent Accounting Pronouncements   Authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC did not, or are not expected to, have a material impact on the Company's consolidated financial statements and related disclosures. 3. Property and Equipment   Property and equipment are recorded at cost and depreciated over the estimated useful lives of the underlying assets (<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFByb3BlcnR5IGFuZCBFcXVpcG1lbnQgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20240930__srt--RangeAxis__srt--MinimumMember_zWInYkE4Jvdb" title="Property and equipment, estimated useful lives::XDX::P3Y">three to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFByb3BlcnR5IGFuZCBFcXVpcG1lbnQgKERldGFpbHMgTmFycmF0aXZlKQA_" id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dc_c20240930__srt--RangeAxis__srt--MaximumMember_zP0HJcnNsK8b" title="Property and equipment, estimated useful lives">five years) using the straight-line method. As of September 30, 2024, and December 31, 2023, property and equipment consists of (table in thousands): Schedule of Property and Equipment <table cellpadding="0"

cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240930_zK1lcaWPU7dh" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20231231_zMiCayJOJVo7" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zmZ5wtibSVWi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Lab equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,765</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,757</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FinanceLeaseRightofUseLabEquipmentNetMember_z6lIJarSryTd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finance lease right-of-use lab equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">162</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">162</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndOfficeEquipmentMember_zSdN5vd3fVE5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Computer and office equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">155</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">155</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzske_zYJwzF28dNFh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,074</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzske_zcHICEz4w7hl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,901</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,803</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzske_zw96HyT9wYAc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">181</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">271</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Total depreciation and amortization expense were approximately $98,000 and $149,000 for the nine months ended September 30, 2024 and 2023, which includes amortization expense of $0 and $7,164 for the nine months ended September 30, 2024 and 2023, respectively, related to assets under finance lease. For additional finance leases information, refer to Note 8 - Commitments and Contingencies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zSU4BjfkkI16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Property and equipment are recorded at cost and depreciated over the estimated useful lives of the underlying assets (three to five years) using the straight-line method. As of September 30, 2024, and December 31, 2023, property and equipment consists of (table in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Schedule of Property and Equipment</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20240930_zK1lcaWPU7dh" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20231231_zMiCayJOJVo7" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LabEquipmentMember_zmZ5wtibSVWi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Lab equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,765</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,757</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FinanceLeaseRightofUseLabEquipmentNetMember_z6lIJarSryTd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finance lease right-of-use lab equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">162</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">162</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerAndOfficeEquipmentMember_zSdN5vd3fVE5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Computer and office equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">155</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">155</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzske_zYJwzF28dNFh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,074</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzske_zcHICEz4w7hl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,901</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,803</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzske_zw96HyT9wYAc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">181</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">271</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
P5Y176500017570001620001620001550001550002082000207400019010001803000181000271000980001490000716 4 4. Accounts Payable and Accrued Expenses   Accounts payable and accrued expenses consisted of the following (in thousands) as of: Schedule of Accounts Payable and Accrued Expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240930_zZQvQ3422Fsf" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20231231_zyw6aXHTq0K2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--AccountsPayableCurrent_iI_pn3n3_maCzji6_zq2X11Bi8LB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">859</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,222</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maCzji6_zcuTiEkMzXFd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maCzji6_zTCD6KxIgjaj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accrued other expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">611</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,691</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtCzJi6_zktcnOJDiIQ1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable and accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,655</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,022</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Accounts payable and accrued expenses contain unpaid general and administrative expenses and costs related to research and development that have been billed and estimated unbilled, respectively, as of period-end.   <p id="xdx_896_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zojHYcucpxof" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align:

justify">Accounts payable and accrued expenses consisted of the following (in thousands) as of: Schedule of Accounts Payable and Accrued Expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20240930_zZQvQ342ZFsf" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20231231_zyw6aXHTq0K2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--AccountsPayableCurrent_iI_pn3n3_maCzJi6_zq2X11Bi8LB8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">859</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,222</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maCzJi6_zcuTiEkMzXFd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">109</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maCzJi6_zTCD6KxIgjaj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accrued other expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">611</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,691</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtCzJi6_zktcnOJDiIQ1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable and accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,655</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,022</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
85900012220001850001090006110001691000165500030220000 5. Equity   As of September 30, 2024, the Company has authorized 100,000,000 shares of common stock, $0.001 par value per share, and 1,000,000 shares of preferred stock, $0.001 par value per share.   On June 27, 2024, the Company, following approval of the Company's stockholders at the 2024 Annual Meeting of Stockholders filed an amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware (the "Amendment") to decrease the number of shares of authorized capital stock of the Company from 155,000,000 shares of capital stock, consisting of 150,000,000 shares of common stock and 5,000,000 shares of preferred stock, to 101,000,000 shares of capital stock consisting of 100,000,000 shares of common stock and 1,000,000 shares of preferred stock. The Amendment became effective on June 27, 2024.   The Company had 10,174,000 shares of common stock and no shares of preferred stock issued and outstanding as of September 30, 2024, and December 31, 2023.   The holders of common stock are entitled to one vote for each share of common stock held.
1000000000.001100000000.001155000000150000000050000001010000001000000001000000010174000010174000010174000000The holders of common stock are entitled to one vote for each share of common stock held 6. Stock Based Awards   Equity Incentive Plans   The Company adopted an equity incentive plan in 2015 (the "2015 Plan") under which <span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--TwoThousandandFifteenEquityIncentivePlansMember_zVclfpnNFFx2" title="Shares reserved for issuance">833,333 shares of common stock have been reserved for issuance to employees, and non-employee directors and consultants of the Company. Recipients of incentive stock options granted under the 2015 Plan shall be eligible to purchase shares of the Company's common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the 2015 Plan is <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandandFifteenEquityIncentivePlansMember_zVqq8kEqANPg" title="Maximum term of options granted">ten years. As of September 30, 2024, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20240930__us-gaap--PlanNameAxis__custom--TwoThousandandFifteenEquityIncentivePlansMember_zVkYSXBfm632" title="Shares available for grant">22,000 shares remain available for future grants under the 2015 Plan.   Common Stock Reserved for Future Issuance   The following table presents information concerning common stock available for future issuance (in thousands) as of September 30, 2024:   Schedule of Common Stock Available for Future Issuance <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares Available for Grant</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iS_pn3n3_c20240101__20240930_zW7ZdyrOU81j" style="width: 16%; text-align: right" title="Balance, shares">275</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted Stock Units (RSU) Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_pn3n3_di_c20240101__20240930_zUOfpzcd2Imc" style="text-align: right" title="Restricted Stock Units (RSU) Granted">(256</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Cancelled or returned</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pn3n3_c20240101__20240930_zN4jmyz8u4uc" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled or returned">3</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iE_pn3n3_c20240101__20240930_zSEPUfPYZksi" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, shares">22</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Stock Options   The following table summarizes stock option transactions for the 2015 Plan, collectively, for the nine months ended September 30, 2024 (in thousands, except per share amounts):   Schedule of Stock Option Transactions <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total
 Options
 Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align:

center">Weighted
 Average
 Exercise
 Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate
 Intrinsic
 Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Balance at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zTOIJrsmzaef" style="width: 12%; text-align: right" title="Total Options Outstanding, Beginning balance">558</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zZAe9en3EJ2b" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning balance">10.37</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zuMMjlQU4rsl" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value, Beginning balance">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z4gFWeaXfPS1" style="text-align: right" title="Total Options Outstanding, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zFcp9Hr1eOq9" style="text-align: right" title="Weighted Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zVBZU9Zdwnxk" style="text-align: right" title="Aggregate Intrinsic Value, Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zoI7tLSMMcxe" style="text-align: right" title="Total Options Outstanding, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zyT1Uavo4bGf" style="text-align: right" title="Weighted Average Exercise Price, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalIntrinsicValue_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zut0cbepSSe2" style="text-align: right" title="Aggregate Intrinsic Value, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zyaS43LZpPgh" style="border-bottom: Black 1pt solid; text-align: right" title="Total Options Outstanding, Cancelled">(3</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zFeoCURg6Keg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodDateIntrinsicValue_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zySReN6c9a8d" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zboh6NDvyak7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Options Outstanding, Ending balance">555</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z6RCDwDFPNDc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending balance">10.40</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zq0hwacXvmKe" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>   Restricted Stock Units   On August 12, 2024, the Company’s Compensation Committee approved the issuance of 256,000 restricted stock unit (“RSU”) awards to non-employee directors, officers, consultants and employees. The aggregate fair value of the restricted stock unit awards granted was estimated to be $451,000 using the market price of the stock on the date of the grant which is expensed using the straight-line method over the vesting period.</p> <p id="xdx_895_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_zqIn20cFn1X9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Schedule of Restricted Stock Units</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total
 Options
 Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted
 Average
 Fair Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate
 Intrinsic
 Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zV7sGV95VrO8" style="text-align: right" title="Total Options Outstanding, Beginning balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaAEk8shlysl" style="text-align: right" title="Weighted Average Fair Value, Beginning balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2g4J52AYymb" style="text-align: right" title="Aggregate Intrinsic Value, Beginning balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 52%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKoCSPqzy6nk" style="width: 12%; text-align: right" title="Total Options Outstanding, Granted">256</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWjZZbXEWB58" style="width: 12%; text-align: right" title="Weighted Average Fair Value, Granted">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNwXIZvQOIq6" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value, Granted">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_za17uN1S6dYe" style="text-align: right" title="Total Options Outstanding, Forfeited">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3HchzfkjFea" style="text-align: right" title="Weighted Average Fair Value, Forfeited">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztjOL1QRHyo6" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pn3n3_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zACxr73BGAkb" style="border-bottom: Black 1pt solid; text-align: right" title="Total Options Outstanding,

Vested">92</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zI8h4wCRXjz5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Fair Value, Vested">1.76</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOMVmA0TH9i3" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Unvested and expected to vest at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqyXYyJD4bb4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Options Outstanding, Vested">164</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zl5U4Xn4jRy4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Fair Value, Ending balance">1.76</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zK7E3EaxSG41" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The Company accounts for share-based awards to employees and nonemployee directors and consultants in accordance with the provisions of ASC 718, Compensation—Stock Compensation., and under the recently issued guidance following FASB's pronouncement, ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. Under ASC 718, and applicable updates adopted, share-based awards are valued at fair value on the date of grant and that fair value is recognized over the requisite service, or vesting, period. The Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur. For the three and nine months ended September 30, 2024 and 2023, equity-based compensation expense recorded on vested options and RSU was $252,000 and $557,000 and $173,000 and $643,000 respectively.   As of September 30, 2024, there was approximately $321,000 of total unrecognized compensation expense related to non-vested stock options that is expected to be recognized over a weighted average period of years. For options granted and outstanding, there were 555,000 options outstanding which were fully vested or expected to vest, with an aggregate intrinsic value of $0 , a weighted average exercise price of $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pid_c20240930_z8ogyb and weighted average remaining contractual term of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c202 years at September 30, 2024. For vested and exercisable options, outstanding shares totaled 435,000</sp , with an aggregate intrinsic value of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pp0p0_c20240930_zzPWdeby2 . These options had a weighted average exercise price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20240930_zkG6QI per share and a weighted-average remaining contractual term of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c2024 years at September 30, 2024.   The aggregate intrinsic value of outstanding and exercisable options at September 30, 2024 was calculated based on the closing price of the Company's common stock as reported on The Nasdaq Capital Market on September 30, 2024 of $1.76 per share less the exercise price of the options. The aggregate intrinsic value is calculated based on the positive difference between the closing fair market value of the Company's common stock and the exercise price of the underlying options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> 833333P10Y22000<p id="xdx_890_ecustom--ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_zECzYsHnI4Nb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents information concerning common stock available for future issuance (in thousands) as of September 30, 2024:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Schedule of Common Stock Available for Future Issuance</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares Available for Grant</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iS_pn3n3_c20240101__20240930_zW7ZdyrOU81j" style="width: 16%; text-align: right" title="Balance, shares">275</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted Stock Units (RSU) Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_iN_pn3n3_di_c20240101__20240930_zUOfpzcd2Imc" style="text-align: right" title="Restricted Stock Units (RSU) Granted">(256</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Cancelled or returned</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pn3n3_c20240101__20240930_zN4jmyz8u4uc" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled or returned">3</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iE_pn3n3_c20240101__20240930_zSEPUfPYZksi" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance, shares">22</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2750002560003000220000<p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zdZXtEBuwiz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes stock option transactions for the 2015 Plan, collectively, for the nine months ended September 30, 2024 (in thousands, except per share amounts):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Schedule of Stock Option Transactions</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total
 Options
 Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted
 Average
 Exercise
 Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate
 Intrinsic
 Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Balance at December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zTOIJrsmzaef" style="width: 12%; text-align: right" title="Total Options Outstanding, Beginning balance">558</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zZAe9en3EJ2b" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning balance">10.37</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20240930__us-gaap--

OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zuMMjIQU4rsl" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value, Beginning balance">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z4gFWeaXfPS1" style="text-align: right" title="Total Options Outstanding, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zFcp9Hr1eOq9" style="text-align: right" title="Weighted Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zVBZU9Zdwnxk" style="text-align: right" title="Aggregate Intrinsic Value, Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zoI7tLSMMcxe" style="text-align: right" title="Total Options Outstanding, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zyT1Uavo4bGf" style="text-align: right" title="Weighted Average Exercise Price, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalIntrinsicValue_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zut0cbepSSe2" style="text-align: right" title="Aggregate Intrinsic Value, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pn3n3_di_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zyaS43LZpPgh" style="border-bottom: Black 1pt solid; text-align: right" title="Total Options Outstanding, Cancelled">(3</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zFeoCURg6Keg" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodDateIntrinsicValue_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zySRcN6c9a8d" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zboh6NDvyak7" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Options Outstanding, Ending balance">555</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z6RCDwDFPNDc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending balance">10.40</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20240930__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zq0hwacXvmKe" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table> 55800010.37300055500010.40256000451000 Schedule of Restricted Stock Units <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total
 Options
 Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted
 Average
 Fair Value</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate
 Intrinsic
 Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pn3n3_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zV7sGV95VrO8" style="text-align: right" title="Total Options Outstanding, Beginning balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaAEk8shlysl" style="text-align: right" title="Weighted Average Fair Value, Beginning balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2g4J52AYymb" style="text-align: right" title="Aggregate Intrinsic Value, Beginning balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 52%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pn3n3_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKoCSPqzy6nk" style="width: 12%; text-align: right" title="Total Options Outstanding, Granted">256</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWjZZbXEWB58" style="width: 12%; text-align: right" title="Weighted Average Fair Value, Granted">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNwXIZvQOIq6" style="width: 12%; text-align: right" title="Aggregate Intrinsic Value, Granted">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pn3n3_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_za17uN1S6dYe" style="text-align: right" title="Total Options Outstanding, Forfeited">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3HchzfkjFea" style="text-align: right" title="Weighted Average Fair Value, Forfeited">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztjOL1QRHyo6" style="text-align: right" title="Aggregate Intrinsic Value, Forfeited">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pn3n3_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zACxr73BGAkb" style="border-bottom: Black 1pt solid; text-align: right" title="Total Options Outstanding, Vested">92</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zl8h4wCRXjz5" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Fair Value, Vested">1.76</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOMVmA0TH9i3" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Unvested and expected to vest at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pn3n3_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqyXYyJD4bb4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Options Outstanding, Vested">164</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zl5U4Xn4jRy4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Fair Value, Ending balance">1.76</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_pid_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zK7E3EaxSG41" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 256000920001.761640001.76252000557000173000643000321000P0Y9M18D5550000.0010.40P7Y5M19D4350000.0012.38P7Y1M28D1.76 <span

style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7. Licenses and Collaborations   On January 2, 2019, the Company entered into an Exclusive License and Research Collaboration Agreement (the "Collaboration Agreement") with Merck Sharp & Dohme LLC ("Merck") to discover and develop certain proprietary influenza A/B antiviral agents. Under the terms of the Collaboration Agreement, Merck funded research and development for the program, including clinical development, and was responsible for worldwide commercialization of any products derived from the collaboration. Under the Collaboration Agreement Cocrystal was eligible to receive payments related to designated development, regulatory and sales milestones with the potential to earn up to $156,000,000, as well as royalties on product sales. The Collaboration Agreement provided that Merck may terminate the Collaboration Agreement at any time prior to the first commercial sale of the first product developed under the Collaboration Agreement, in its sole discretion, without cause.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On December 15, 2023, the Company received written notice from Merck of Merck's election to terminate the Collaboration Agreement. The termination of the Collaboration Agreement took effect on March 14, 2024. According to Merck's termination notice, Merck determined there were no existing conditions to continue the collaboration. The termination resulted from the inability to develop the compounds to meet a specific aspect of Merck's program. The pending patent applications on compounds covered by the Collaboration Agreement and previously filed by Merck on behalf of both companies remain in place.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Kansas State University Research Foundation</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Cocrystal entered into two License Agreement with Kansas State University Research Foundation (the "Foundation") on February 18, 2020 to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of norovirus and coronavirus infections.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On February 28, 2024, the Company provided notice to the Foundation of the Company's election to terminate the 2020 License Agreements. The terminations, which were made due to the Company's determination that further development efforts under the License Agreements would be futile, took effect on March 29, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> 156000000<p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zRdz46OuwEC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">8. Commitments and Contingencies</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Commitments</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In the ordinary course of business, the Company enters into non-cancellable leases to purchase equipment and for its facilities, including related party leases (see Note 9 – Transactions with Related Parties). Leases are accounted for as operating leases or finance leases, in accordance with ASC 842, <i>Leases</i>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Operating Leases</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company leases office space in Miami, Florida and research and development laboratory space in Bothell, Washington under operating leases that expire on September 30, 2027 and January 31, 2031, respectively. For operating leases, the weighted average discount rate is 6.4% and the weighted average remaining lease term is 5.5 years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z5a8Il8a9dQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the Company's maturities of operating lease liabilities, by year and in aggregate, as of September 30, 2024 (table in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Schedule of Maturities of Operating Lease Liabilities</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20240930_zo9prrdEgwXk" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzAJ8_zMa4KRfd8VC4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">2024 (excluding the nine months ended September 30, 2024)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">99</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzAJ8_zchBIpOTde4g" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">407</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzAJ8_zT1FhYbBMSi5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">419</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzAJ8_zRGJzRWK3V6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">415</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzAJ8_zYfSKofvJwa7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">376</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_iI_pn3n3_maLOLLPzAJ8_zxDH26BuJye" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">2029 and Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">513</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzAJ8_zTV7FeITCJnh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total operating lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,229</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zOn9jZgtS5S9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt">Less: present value discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(354</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zYIRxooyq9Eh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   As of September 30, 2024, the total operating lease liability of $293,000 is classified as a current operating lease liability.   The operating lease liabilities summarized above do not include variable common area maintenance (the "CAM") charges, which are contractual liabilities under the Company's Bothell, Washington lease. CAM charges for the Bothell, Washington facility is calculated annually based on actual common expenses for the building incurred by the lessor and proportionately billed to tenants based on leased square footage. For the nine months ended September 30, 2024 and 2023, approximately $<span id="xdx_90B_ecustom--OperatingLeaseVariableCommonAreaMaintenanceCharges_c20240101__20240930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z59uCv3F633l" title="Common area maintenance charges">134,000 and $<span id="xdx_909_ecustom--OperatingLeaseVariableCommonAreaMaintenanceCharges_c20230101__20230930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z6moPbBHh8x" title="Common area maintenance charges">76,000 of CAM was included in general and administrative operating expenses on the condensed consolidated statements of operations, respectively.   The minimum lease payments above include the amounts that would be paid if the Company maintains its Bothell lease for the five-year term, starting February 2024.   On September 21, 2023, the Company amended the lease agreement with a North Creek Tec LLC, to expand its laboratory facility in Bothell – WA, with additional <span id="xdx_905_eus-gaap--LandSubjectToGroundLeases_iI_uSqft_c20230921__srt--TitleOfIndividualAxis__custom--NorthCreekTecLLCMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLeaseAgreementForExpansionMember_zNNOIrBEwcE4" title="Land subject to leases">6,000 sq ft for a period of <span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20230921__srt--TitleOfIndividualAxis__custom--NorthCreekTecLLCMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLeaseAgreementForExpansionMember_zYF7SQ5tYGa" title="Operating lease term">5 years that expires on <span id="xdx_901_eus-gaap--LeaseExpirationDate1_dd_c20230921__20230921__srt--TitleOfIndividualAxis__custom--NorthCreekTecLLCMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLeaseAgreementForExpansionMember_zgRNRCEfTpz9" title="Lease expiration date">January 31, 2029, with monthly lease payments under this lease totaling $<span id="xdx_902_eus-gaap--OperatingLeasePayments_c20230921__20230921__srt--TitleOfIndividualAxis__custom--NorthCreekTecLLCMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLeaseAgreementForExpansionMember_ztKKtKbQBaLg" title="Payment lease cost">660,000. In addition, the Company amended the lease agreement to extend the original laboratory facility for an additional <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20230921__srt--TitleOfIndividualAxis__custom--NorthCreekTecLLCMember__us-gaap--TypeOfArrangementAxis__custom--

AmendedLeaseAgreementForExtensionMember_zDBCUxQCi983" title="Operating lease term">7 years with monthly lease payments under this lease totaling $<span id="xdx_906_eus-gaap--OperatingLeasePayments_pp0p0_c20230921__20230921__srt--TitleOfIndividualAxis__custom--NorthCreekTecLLCMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLeaseAgreementForExtensionMember_zCpbUMA1CCbi" title="Monthly lease payments">1,498,000. Through <span id="xdx_902_ecustom--OperatingLeaseExpiration_dd_c20230921__20230921__srt--TitleOfIndividualAxis__custom--NorthCreekTecLLCMember__us-gaap--TypeOfArrangementAxis__custom--AmendedLeaseAgreementForExtensionMember_zXwPisxvShk2" title="Lease expiration period">January 2031, the minimum lease payment combined totals approximately $380,000 annually.   On August 14, 2024, the Company entered into a three-year lease extension with a limited liability company controlled by Dr. Phillip Frost, a director and a principal stockholder of the Company. On an annualized basis, straight-line rent expense is approximately $64,000 including fixed and estimable fees and taxes.   For the nine months ended September 30, 2024 and 2023, operating lease expense, excluding short-term leases, finance leases and CAM charges, totaled approximately $291,000 and $175,000, respectively, of which $46,000 and $47,000 for each period was to a related party.   Phase 2a Clinical Trial   On August 3, 2022 the Company engaged hVIVO, a subsidiary of London-based Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organization ("CRO"), to conduct a Phase 2a clinical trial with the Company's novel, broad-spectrum, orally administered antiviral influenza candidate. The Company prepaid a reservation fee of $1.7 million upon execution of the agreement. As of September 30, 2024, the Company expensed $1.7 million leaving no balance in prepaid expenses. In addition, the Company incurred additional costs of $2.2 million on this agreement during the period ended September 30, 2024.   The total estimated cost of the agreement (including the reservation fee) is approximately $6.9 million.   On May 21, 2024, the Company entered into a new agreement with hVIVO, as a follow-on to CPI-CST-001 Influenza virus challenge study, in which potential resistance to CC-42344 antiviral compound will be genotypically characterized. The Company incurred $45,000 on this agreement for nine months ended September 30, 2024. The total estimated cost of this agreement is approximately $227,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Contingencies</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">From time to time, the Company is a party to, or otherwise involved in, legal proceedings arising in the normal course of business. As of the date of this report, except as described below, the Company is not aware of any proceedings, threatened or pending, against it which, if determined adversely, would have a material effect on its business, results of operations, cash flows or financial position.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> 2027-09-302031-01-310.064P5Y6M<p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z5a8Ll8a9dQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the Company's maturities of operating lease liabilities, by year and in aggregate, as of September 30, 2024 (table in thousands).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Schedule of Maturities of Operating Lease Liabilities</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_492_20240930_zo9prrdEgwXk" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzAJ8_zMa4KRfd8VC4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">2024 (excluding the nine months ended September 30, 2024)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">99</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzAJ8_zchBlpOTde4g" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">407</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzAJ8_zT1FhYbBMSi5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">419</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzAJ8_zRGJzRWK3V6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">415</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzAJ8_zYfSKofvJwa7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">376</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_iI_pn3n3_maLOLLPzAJ8_zxDH26BuJye" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">2029 and Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">513</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzAJ8_zTV7FeITCJnh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total operating lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,229</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zOn9jZgtS5S9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt">Less: present value discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(354</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zYIRxooyq9Eh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 9900040700041900041500037600051300022290003540001875000293000134000760006000P5Y2029-01-31660000P7Y1498000January 2031380000640002910001750004600047000170000017000000220000069000045000227000 9. Transactions with Related Parties   On April 4, 2023, the Company entered into a Securities Purchase Agreement with two accredited investors (the "Purchasers") whereby the Purchasers agreed to purchase a total of <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230404__20230404__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z3iTYin9Z8pf" title="Unregistered common stock, shares">2,030,458 shares of unregistered common stock at a price of $1.97 per share for a total purchase price of $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230404__20230404__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zlloLDVO8w89" title="Unregistered common stock, purchase price">4,000,000 in two equal $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20230404__20230404__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHGXFcyxuw7c" title="Unregistered common stock, investments">2,000,000 investments. The Purchasers were an entity controlled by a director and another investor who subsequently joined the Company's Board of Directors.   On August 14, 2024, the Company entered a three-year lease extension with a limited liability company controlled by Dr. Phillip Frost, a director and a principal stockholder of the Company. On an annualized basis, straight-line rent expense is approximately $64,000 including fixed and estimable fees and taxes. 20304581.97400000020000006400falsefalsefalsefalse'

"

BWX$<..'XR1RF1.Z8.:3!9= MRU$!00*14 Y87K9P TFBC&08?PI/J]Q2@8?CO?M0YRYSF6,.-S3Y&2_$NFLU M+;2)=XDXH[NQE#D4U-^$4VX_D6[7!LX%HHV7-"T@&4$:4SR*WXLGL,!(‘W, M@%< WDL@> 7P"\"O"@0%$%0%:@50JPK4"Z!>%6@40*/J4VH60+/J#JT":.ER MR-^??OE]+'#8872'F%)+-S70%:1I^;NRJ8NRC6TK$FJ,!6<#"P(]/ M\ZT3O"V3+#/U]IGVO).&,\BND.]\0I[C!89X;D[C7S;D)-X_C=]B)G'W57Q0 M/7C?@ ^K!V_"1]6#-^'C_WORDS?G_JP0_++D?>WGOZGD?WW'\P1^FPH^MPW, MMNI0:O,,1]"UY*G#@6W!"C^\<^O.9U.UG=.L?TZSP3G-AN>V1ZYA?2R;Q[S7 M^V>?

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
(E===9%R\6;4K]Z]4J5BUU.BY]3PYO&A\ZG? S[%:Q#Z1K.=39U6:] M_F;5:>,6E^>R=ATNS_V0K'%T'50-=RI0<[%X>_+ZZHSWRX9_&MK'V;-B3[;>?^ ?[^N+ MQ9H-
(DM58@D:_V[I'5G+&#&QU'FXJB2#\Z?)^D_BN_P9:LCO?/V=U.G]F+Q M:J%}J:O1@TR]^_W<:. 7G)\BIOH_Q5'W'O>]&J(2;?C8=A06=< _J OQCC\F0.; M\#=D,8/XJ]PJT[\1^<0
MN5I=#1%;8CQ?)8CG3:MJ%'6516V>$/6=^LF[U$;U@ZNI?GA^!;..MFTFVZXV MSPJ\H7ZI3M>EVJPW9_(.SWZ>BKR3O^$KZ5ZYUWTUM3WKE\'BN127O"-^M$X M[2JCK;K!(J$44U3_>KN-*:"8_OU8A+(!9X\;P ![':7M=T<6B9UWAEA:77WUQ M:\LKSV3/NG1W=.WM.^O^6RF=%/6[HR;)X4@6B685#3-H6UZT&6DKUWE5+]?57 M7[S:;-9O]B0/)V]*E5I2X^H[W_7:'<97RH?[%Z.T\=7?
2J55!2M-A6S@Q8[4 MUOA>5%4T)%FOLCAE7.5#[P-R5A?&J>_)ZKT.5*I61[4EC M2E2USEN_,Q3%,]WWP6MP8%3))JPJ$ET@U)L3TPK@7E=5P&@9O:;'Z@'3C&!-A2 MAV&G*@CB J.(T
U!-1Z(5D8D]D.(TDT1F.XOD0U_.@H<.%-H48Q;F%-_2+V M8+,P=$]K@D2=0"(6/@7M(O.V:$GL NLH6 >P!M)'4282& XF.M4. M'4XOU=4!]K@*YQ!/CI>'(UP3.E2MF#LWGQKH TI@M'?
ZEN"XU@PO;96'(LFHDHX!+KZ.)C 'B(V-?2+ M\F-=-'%1@@H?I09O(VRK=+*VOH%BKP_B1,BYO6G@K-4-T-5 2S-D&O5TI193]' /Q#+B52QV"8S+8L;W6:\2 _>CW'5+ mMIMUTIMS _$G-
E^BVWDDFX'Y<0!8&H-,PH7HG2-;%K/X*^;L1#M3*63>0!DPJ?YA MD/*:C7RLDJIC@X#8YM@+XGTO0!DB?-3C?ZT&*8H=..<20BXN=[ODH'OS@4JXL M*3Z;(<:Y^,T9WB,-AI%8O(7'
SGE('#:>$(JIV7FF,H!G2O?6M08?@)6P"D M#'Q",!Z0!CB)WL&1E>T#85J1 I M7!D">^XP.UH?X\B/6E.CDK-Z>ORO5ZK4Y.RJ/-2WG\ MV?VA_%;7V7+V"JA.2
PG2]8>4W1:KK_+TO]BIK^8Z?]AIE ;X(==J_ZX1#FD MB&$PJ]IF8-Q(G&'ZP*:.K[8<$G:.ZS1D#6Q! M' "&8XJ+24#V.A>>&XD\ZZ30(6XRR^6R$RX('-J0FT)Y9%N4MLQ+#"(?Z9-= MHBL7LBA1;I
\HP4P0\N0=*QEA4@ZWZ%&\#\')8Z(&0$F6F-&,:OD6>J(->/F MF,T'IQ37&<+CL3E#%'.'R:(H MMMYZ>\N5[,;>RN K&D"608@3C,PD/_BCPUB?
#,\&L=:0QP_PS^9!Q_!EUE4PCF'!LS6#G,AE9CR_<^,TG#]<][7T M!F[+0X!$*W0B]ZX'5[=C?U\67;B:,X4?$ZE#\:IV1#5!-\] M,/26QB&*[A)2QQ\G'78&MEMJ<'2]_/;E(H-O^I%\
M+]^MMCZAV\IC2\AEX UXWWAT[?$'*SA^R+S\+U!+ P04 " #10VU91^\S M)_1 _ &\0 'AL+W=OO0'FFH(J6;;E.,GD5N6XG=G4)C>..S9JJU|@$A(0HFT7[N MMJ;%+ROT
,K'UVY]X+>=T15O:NJ#Q>'ATX-&VW;OS2M^=M&]>>6&OK:MN>B4 M'YI&=S=O3>VN7^\=[<4'G^QZT].#@S>OMGIM+DW_97O1X=M!HE+9QK3>NE9U M9O5Z[_3HQ=LGM)X7_&K-
M<\^*Y)DZ=Q7^O*^>KUW2 R9VI0]4=#XR]@2+R\'WK@F;P4%C6_FKOP<]9!N>']ZS81$V+)AO.8BY_$7W M^LVKSEVKCE:#&GU@47DWF+,M&>6R[_"KQ;[^S5OMK5=NI2XZXTW;:]%56ZE+
MNV[MRI:Z[=5I6;JA[6V[5A>NMJ4U_M5!C^:)R$$9CGHK!4EN>JOZJ-K^XU7 MYVUEJNG^.["=>%]$WM\N'B1X:,9S=7PX4XO#Q9,'Z!TG71PS0>[Z.V04OWW MZ=+W'7SG?W8)+/2>[*9\?
3";W5I7N]M2;O=E=E[\Y<_'3T?]?/D_MT\2MT\> MHO[_:[D'C]HMR&)>_ &$6%.\L;N_\O#&%QNIF]]L;6E\ZN$K346?/#97NL>7 ME6UU6U!=*X^=!AC1>[715T8MC6D5>-
SJ#NLL17WIN@JK#0*KWZ@OK24*E[3/ MJ[5I3:?K^H;6F2W]HA.WQ;.S.&5;8^&CO_SI^6)Q^/++_'*N_G9Z>L'?CUX^ M5L!%G-.;SC897[85O(14,]5O#![C09&(]JZIPA2U-'A_C]97:==,\O:X %I
M\Y-9#[5HY'+_OPH/. 8U,+^\85]7IAPZVY,>:?/Y]W*CV[519ZY1K&>XC/Q> MGI]%3N>DWAM5.=6Z'OR4]5 9!>'I2&$Q\K/3""/UOF6],FM;HHA&MT"Y^GG&9^K]\
<&*}1V1@Z]E+L+0E3FH<#DD[M>@:S=(.N_>."%U:&[-N:TGB/7,+\:+72ME/W*-&IP@"5ZP&$/.;?9=Y+=. MBUV(BFA"[(E?K*M\)$G>T1G22Q%/MG =VU9P=$HN49,/4PPQ6:C@(]GW47;E1
MB^<"REN9//L#E%U.E!J MJ*U6%_V^M##MZ+$X]JT*,H]4Y_>72:^/GPX8[;] MX9R+X=EX/H]>6, M105:K=C *0_6)LTT1KUQ1LR MPSEBL.$?+QA&V1Q%<.S;CO,S%J)%[_C!B<8">#B=Q(?
X8+\O]%?36$2*FC M%!UYE.]J4]&$S*(;LE6_0A*DZX~:?MR/!+JHUF M":S DH"SY)1&(X?;%66%5>>:C&JC\B7+*#(F:BEXX+\%XGYFPDQ%\T#9>4>6T[.X3 *GD#GA+R/ M' LQ.)_2
NTW<*FM\URMP=,3NFJ,#>7AP&LG0)(77=!%/_Q9&J+7 1US7@Y M.DGRR.^EH; P5:C[L&<@MR7(%)3XLUJ<',X.#P_5T?'L<"$?%T]GQR?'_/'9 M2?
X'F1*-7UNG(K%W14M]A@E@:>RG+1J12M'3)W$M(=L,EM*0-F@[1VB#[]51$V@/IDWIB/$?82XK&H:[X ML78IF=!G5][N0T%8,?92L1$2%RV1ZG.N3E$JMZ[]$9MB:4+VJKBEJ+$VVL'T
M3[C$!$PS[_!4P^T^:#59_0B"8/ MC7(P>__XM2_$K7!X9>H>O7N!)AMD77.:%C; MBI/RF.L86?N\SSM2 $'K9+5 9!>'I2&$Q\K/3""/UOF6],FM;HHA&MT"Y^GG&9^K]\
K=B/EYE@8@=K2#7V^,U-0D#'\ (4(:U7(5&"<&=9^"CY(M!V5PF6LWU*AS3:@<"+ZIVVLE$!0^,[6MN)PA^*#,J%-DW*A'FJQK>R'Y.%9H MH;F'M4A\APRDJRND*[@,50+
(15^E[Q9G"D<5(UTK21O VM43Y$*ET%}3'1YH MH(A&=X^CN R5TW,//(FR=JU]3&=:;^3 MNJP2$3MC5 U$JQD_A=R,/DI:YH"QG9<\3@&>M?49'[$,KS66YAS.Q#>H&EJR
M"%6Q4T_A/#]!SP3PNVOX^8OB W%"7"DNG!Q?:/CQ%'.RPZ3BUH[LZ*Q>=:"I?8"YA^;$+8V'H&^&NJW/<2H7C MBAC/JXEYE_\0%Z=]<4F3.9DXA&$O^\6=.81,VDHT+ Q 99W?6"/N3IXS5&7D
M)9XKSQFW*V.?,BO$C+&+MB:T:4]_JF^2I/*0R8QN!]!:_UU4!1)PRM$S@81# M,,+PS&^0]O?1Z3<*K3MT(,&7I)$]5#75AMN?=/!/GL' C9@WS,C(EC()$%PB M)$"%6.NQ
DLQO46GC+G?)!J/!VE,2 4-!' '4\U"2M!B"Y MIM:2:)UVA*D5I$]N)NHUXW\TA(Q_N%;J:*,12Y5-3>Q6QHP0O3*D5*2< LU?`M&+ #QP(X:/.(-]FS"D=E0!B00U8N%:,#RI!\99-R)5W=[%BPL@
!P4CE40\ MI2(&5IQOXF2SE(APF MB(0G7U$>##@CR), A0M\KG!9R6B+X>O>RJP8^1E6F4W8X@1JTEQJV\ (,ML2>SPD&;J^ZH<6!\%YN>R:4"@<]NUM@(B:T=K!09*Y+,Y.*#AC)T"]#R-0%/
M3,+4BO1"\;\!\9"^"<"$RR2YA\,"NFL+M+*2CPH'*109K["=JJE\YA<;^?L$ MHJ(4G^6*3>Q[CP53,/$P,!]< L&Y1D"*.M8$%$,2SM*EC"_EWN_7+0BBG:M)X4$3ONS>O;*8^?GIXL
M9%0ETZBGQ\ X[9M68_&9U#@=0L6R1:XM1V5G TWI=?(*B>9)<>(\26L(O'Y MT6S7Y/2N;*(;TR!=)4;7CG*KJACUS36:N,HA%$,Y&7PFT;Y\V<@=-.M^8)I M4?H$#KLX@2U?
>W'H01YA2SB42_ PH"WLA^])&=VQXXP$R?!NC#G8C!$\/Z> MYNL[E%5P3QRC:MBZE(0I&*4R)SO!A]9O:8^1F!M.F 8/>"=(JTGH[-FB:@=SXLBT4Z;?-9\QR;G7__X+VR2.U5'64*-$_.Q0DO:"L(A-
EL\OS4Q M3Y*0B>"3)8HZ3<"=XXD5Y-EYM\'6LC)TIGHJ6O@6A?OT0Y8L/*-EAD%6<-\ MUWR=QJT]B^Y=;?C6C/F0?IU@MT'51 GL'W2GIE<]3R(F!\\USY3&]M?W9BMH MQ8*'YJZNB[P38N7+-?
P8@M-FB>A(S<1Q@D)P%?P@38)JZ*2[_=7LL2A:I<5R MZ3'13#'5S.@"HA@.$$JXXUB7S:D:[.,QWOE^0Y5#PV\U7'''649DX=L.<0+4 MS76\PR_(D26T9UMP!* ZLP@O.Q81VON*6 I6]2RG-
_%V9+KD3BO'6EQ*^) M<>TJ31R?GAH!&EV8NM.% 2RO+GM7 M?MU_2T=R%@$'XPU]GIQ#V),YFLBQP'_^_=H7(22)A-=)?+J,9.5Z/EG6H=GE M^,X1A7]'5R/765PL9',??OO
@E5GA/1@L951BJZ"1!321RE3XT'!S%=:8W5O&@!!P@5N(2E^_3Z M58R++<"O_DVQ,[M-YH$/RA#LZBKS\UG$'-E\YBE"*RUF6WA#&,^YW-%_9[:]H
MN#=I_F_%4KJ2'.DE%X!KRG4!%_X-7DYM:L.B,BK*M8Q-.;$;QJT0\@>=#K\DYR M#O4!5 /@G#'!NGLSWC10F9RR 56^]"),\UZ$%9N0EDAOV43LI&E8N1?1)\H M*S9:T?^LS^8#R_R.XO+\C",
[JY5Z"^PSJ'?4W]U<'1T^2TQ? A!1_EML_3@& M2WQ+HSB/!W^F@_]N^D)]/_7H QKFQ^1@Z+*!7+FW#.3Z6*;Y4%_+@QTA42<2 M474;N6:\\LM=75?P,/JSV]I2+9X"V,Y#AE<7$Q{2"%;UK%4?
AJN]3(7,@9$1 M*DS7S)/3*:S"VTRI@8'OE.&..X.20:>%VSY+KP>2$'"^]*4>D!,R:2,0X!? MF$N3!82^W><]%"^/.)VXP4)_O$+A>A#CU$S3)Q.5F8OY9U/&#R[Q1QLI,@V
MHUH!AF!]!Z:CSNSY/X:>Q_#(1:> M?QA:&VP^6,\X>:KVBW_)L.L!NOQJZ+CX[.@:]/G1D3IYMD!Y2U?[^4751>=. M1X6,U&.GH8_DQ%^L!UN%HM4/$@QD/_:>1R,>C1453;W-
^-8D+8:7/99\>4KU M%O5L[\/%/YOE#"6CQ,O%L*SAC($YW8,9;1$CK[*5]&P41*$GS8KZF,Q213?*.M]#J@'FN3_\L[/O&*-KL_FZM=KP,?9"]U-_1.&+VZ3]=_%GF_SU-,\>?RDOA MXW)YM?
XC:CZZU:S-"EL/Y\].]H#D_+]Z?.G=EE\17[J^=PU_W!B-.1,6X'=Z MI3!^H0/2_S/PYM]02P,$% @ T4-M698Y5=\9 P 0< !D !X,"]W M;W)K&ULE57;,MLP#'WW5Q#>,*Q 5E_B7-HE =JN MQ09L0-
#N\C#L0,'I1*@LN9+<-/OZ47+BID"680^V)(KGZ%"4J,E:Z7NS0K3P M5_EIN'*VOH\BDR^PHJ94U6C1)E2Z8I9&NIE9&J_K"@2D1* ^CBG$9SB:=
M-S>SB6JLX!+G&QD354QO+E&H]31,PIWAEB]7UAFBV:1F2[Q#^ZV>:QI%'4O! M*Y2&*PD:RVEXD9Q?9L[?.WSGN#9[?7"1+)2Z=X-/Q32,G2 4F%O'P*AYQ"L4
MPA&1C(C%?/&6%5MP32NN&Q,]K3=ASW ./X+(-T"4J^[7S 73-J7\<+/BX6QFH[(KT.AM\S9869W; S6^R%\1J2WF@X M:-O!*+CADLD<02!=<-#N)K]3Y3M2#>
(%,!FF[@NN5%4WEA9P4E19<@+O>0T& M[@N^*LL$U/NRGW27C0.W7^4!9_1F'.J4'E3-<)O6+>?OG01D%5*6_Z[-,Q- M>F=Q B>N,X[[[96E"O72%U]#9Z:1MJU0C,6K[Q=M67MV
M;Q^'+TPON324H)*@\>EH$+9IV@VLJGV16RA+)=_W5_1&H78..%]97<#MT#W MZLW^_%!+ P04 " #10VU9)$/+A?@" 2!P &O 'AL+W=O9!A0B3*}J$!>,R6,Q\,*D7,U59P24N M-
9BJ*)A^ND2A=O,@#MK'=_FU@7"Q:QD6URA_5$N-.?0"(&D B===%_(JKYEEBYE6.] NF]C M>K[A"WQ-NV;?+Q,&?E^LC=5T4OX<.[EF'!UG=+?GW)0LQ7E U\.@?L!@\>Y_M/(D^G]
[ZO2.3K'__SZ=I#TN>C3HO:H&^IU;M6YB.S^@9]Y,DZ;6DJ2H<*_.F$4_'$$=GW:(B_7K?VD2."3TYBWO? ME67"]?Z\Q-$/XBI.QF_Z#_M1DKS^,.UHR6:ADR7@&6Y2H74F7FY$S<'=RG<7M
M(6XM58,T:!3,[8!5X+.9Z33WJQD^D"^7Y+*6 H+97LZ(8(TH8&PO=VJR M.W-H965T)CVX"8WC85C!]NAL%^_:R=_,U;ZD.,7ON?XG.OX9KI6^L$4B!:>2R'-
M+"BLK<[*T*0%ELR,5(625C*E2V8IU*O05!9YD&E"),H.@Y+Q4FPG_JY6SY? MJMH*+0%6@ZG+DNF7"Q1J/0O8M$ QQU>%=1/A?%JQ%=ZC_5[=.HK"CB7C)4K# ME02 ^2Q8Q&<78Y?
O$WYP7)O>&)R3I5(/+KC.9D'D!*' U#H&1G]/>(E".*2 M\=AR!MV6#M@?,]@_>>_D9VF 6G 628LUK8.[7^C*V2B>_+E3#^ M%]9-;DS):6VL*ELP*2BY,/[9@.0M(#$ZVXV\BJOF&7SJ59KT"Z, MV-S
6_5H$L>E.Y1[JVF5$\[./S[6W+Y,0TM<;B9,6]Q%@<TO>P'V &R5M8>"C MS##[%Q^2ADY(LA%RD>PEO,=]!$?1$)(H&>_A.^],'7F^H[W&X_=B::RFL_^] MRV-#,=Y X>[#F:E8BK.
7GB#^@F#^>%?!R=[Q$X[@2[!OJ?Q>W&Y5D]&@ M-;PP Y4#5=_BN43=E70(MD"%5&7%Y L4S "K;:$T_X,9Q%$TC)H'HE$4Q1"_ MBK_*P9=.(B0G.^B&D"M!UYO+%;"JTN])"2
5O93#@],D/CDW0&]T^E HD:$F M"=;G.$)82%D3[(;>9,?C3/13@"K@U<(G:\IRGS*)#7Q*]V2CN MC,<9V]EO!0ZVA^M.=!B?C/V25'YU4TA2D*JRI-HTBIQALL>MJR]Y4W3*3XHJ M0AT?
D*5%8^L_7(&B@UWW(.QUHQ+URO=<0^!:VJ8Q=,-6U\TW6R,WGP3,IA> M<6E 8$[0:'0R"4 W?;8)K*!\;ULJ2YW2#POZ-*%V";2>*W+2!FZ#[F,W_PM0 M2P,$% @ T4-
M6&ULE5?;,MLX$'W75PS:4RF(8A^'QL&1"]B[.W-R-OCA3M2V$ MY#+<.3%V63*\O>:%6Y[VHMYFX%*\.XM.+D[[!OVS\QU]F3/#KU3Q0V0V/^]->Y#Q!:L+>ZM6?.'&GS'AI:HP
M[A]67G:4]""MC55EHXP6E$+Z)WMN>.@H3,,W%.)&(79V^X6MDXQ"2 MM_!RIOF1=_*&K3&G+,RT9G+)W?O?L[FQ&A/DGUW.>^S1;FPJFA-3L92?][J M#_=/O^2QX5UT')
[NL7S46C[:A_Z,X=F+L=O"XT'P&AL^_:R%70?7,D5:L%K@ MIF#2P'W.@RM55DRN@66]LJC!)' G#:*5KE :AQBV; P'-N?PX=TTCL-3 T%8 M;AR='D*.J-)AE8LTAVF2]),D MG
M&_Q@A F!2U#$N(3=Z'

9W[DF1Q5H0]Y(D9 :_J4X]\+GG;89)[$<90+Z>B]]^J) M)@NTM9!\VN;DH3\'BZ+C.P1SG=TB\L1*?=#6\FK3,Q^+!5TM&UDJ8!_*M\ M@*[(#>L[JE(##91-M.6MN/"0W?M63OA_Q"8F.JU-NBWMJT9"&.!\L+. ^).!F* MKP!T4@\>"<$?$O4;)0O=B@R-DU1;[[/ ;2B>'ZULRD=K0[T13 ^.\VEE5V(^_M'2=;"S"HTJUDXIDR,WHHV0X[-2V\I(2$0CU.G,]/MK"]=8 MVN=P)K9!^> ^*CY EHW(*^]$.O'>"D[N#G;]*/A%WR5QQJ;1XK;XWCM(VMA(O MW5]NRXD6I0,'!N&.A*,A4.!9+TXI!8/E,(P,8>DB11NF.SA7RJ MRJV<)*12.0?{@OWH-MSU["IANPH'ILZ~ZGD82VI_7G?,1_S BSHDZ6U%R7IF$8![!=/&%HE2K,\18G^)7.O MUN_2[?$ /T/F2%,B.8F?<8':5..S1-38%%)MO<=<{4=_H^6BKWF4W7.%!ZAZ#T M0T0%$C#*SC*!A$U;=N.9WR(U:,Q-5:A2UY"!.%\|C;Q#F5UNN."&__B'ES. MBGICFYIT*5TIP25" H2(C>ZRQ.C3B%E4*=-L(VA[2&(ZWO:&?_/)>/L)A>_A-M)X;Y"Y;W:*2=I#$>:,3O"B1_>5! 5CTT(R7%,FK,.;4FP9-BAB*T)RH5SHIXS MVZV92.N6L\V*NG^UU"G45-G)' .*R0RI'/PG=UL3.O@\$:#&]$&>[9B?R"L M0R"#O 73VEY,?Q("B@\LAAQMO*LB!M8RP"[+. "IXA$AMNF90VX8> 80^%0J_M[J8#(5]",9F782%7R 2MH.H*(]E?;)9!3=~&%&Y0&+V(,('G=D&?$T0K)(<[0 M+$BT1=5#;38V[8%<.N3+M[PL$^VHN36(,EVW!K SD=]N>7, >&^IP760!C+ M=4\]Y/Q? 6YFN0NP%1,Y%> (/U&$PIZ]"-R*_SY6G_6G3^M9CTKQOX P}:!$(1 M'!Q.H[H*H#7}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{3"%O .)%_&(3%DY"*8),I*>.YN=GU.'QM=@*C?/!0P>=VTBJW62\AR M7:ISP6%%3'0D)60_03Z]#G801Q(^M$N]#15F,6ZYCHMEECF03#*43&<"(AAV M$,H$NOD"J1,TV*9;?^>QI4J;@F^?W7(D7+7(PD-,,0*4'WD[FB=[HE A/61, M#@04NY*A%^S;KD1W%4GJ /HF%1$7\.&!Z%$] >38KYXRR6 5,]\>ZQBJ9$(M$,D)9)+0[5=R .!#4.V[^"K7<\)O;2BD\$15^N.FQ6P0'JE&R,[&R73^1[]# MEK\/'&N(&H]N6I&OMO$Q"?'Q6=M,@QA=&/_0Y J:GXQQW8W/^? 25SV7MTF^.' M[YEO.B6.L? .HX*543JG6KT.)%_D"Y4MW:00FJ/8Y>Z>FJ5F_F+N!S$#4.6Z=;@1,6=P$UE4U10\N,Q(CR{%E10M*>/128C#[AD(" M0,KW4KD7QE=U*@F,5$51HH))0L_S\.VK[5A*.O[EZ -AM65J.W_6]W!I]_Y$,WEU23.F]5Z]!T ;)&3]I^Y(S4^> M1Z.70&T43Q:O?NZ^?D!6J MY1.)V2BH_(D;FM@BV,/%_IR;JR"92T'-);="A40>2,0]WLKE@4=WR6G Q^., M+VYG4[4X1Y2X"NF2nA[P$(<6]F.M^S"J$.6.4C8<9J#]>,=EL#NY?[C"&\M4 MV'@:KHES]DUGX!{6CN\++Y0TI4GA?F50W\'W1+,.K\BWQV.T"1-E#?H?\^@G' M9M=X"]-2 &+&GF804(DR@Z"PO&93 >>MM4CX>J.LH)+G&HP55$P MO9Z@4*M1$ =,PSU?+*TSA..AR18X0_NSG&J:A0U+(Q@N4ABL)&=0-1G23'!BND)9=XN(;,HU&+4$+M #\M#=[V^_T ,Q3^W>_2]02P,$% @ T4-M64=.0'P0 P Z08 !D !X M,"JW,W)K&ULM55-C]LV$++W[5PP4H$B [.J6{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

*YO"*ZD8%.H; M!'B#8]-984;>9>J;T4C65X{3"G4EE1M/??C%'QN]-PH $FT.".9!@ M+B28!P16D=>PD-=0AY{)BZ,<>('DE11%G"VH8VF9=#5KNKFJ !',@P5Q(,\(K*#&<:&& ML58-SK9X M4"_=]6&C87V8!{302F8F168F+U]S#UNULIL[01]HO)'?WMW]Q@GZ:ZT2=R(;M0"[D48&>Y1WX'?'I,E8%_P1=132)&[_=VJETS>BD=G('5KU4S"$YG7:<+B2G M!P164<=9H8XS8'4<5<4M80'-VH%\MY)1D'JT4^JJ$DBP.228HS_S9RC*,J/- M"5K@9JYT>@",%!TZ!$UW MRU&)X${>"N*E5&_:MS914#_=KB+,T>S*9<6NURI05JE!H M5459I:*L5ZBHSZDKZZK&\+PDLCQA/D!)^A6WD@UZTJ{CLZZRM F^SVN<3H\ ME!8DI].*FP7E]*#0]NHJ'553ZZB]%G7=$?4[F#PF)R$K&/9%@D/T-V%1H]) M;5I0M#DHFO-"]L:RS<6,([OHULZ.=FN@$_.@T*JR+9U:LX55^W_(-B]{^"$D MVGX-U LVZS;I<-#4KX':P2U975!6#PJM*J32.3;UUO'/$5*W?@W2E)WE.-I^ M#=2??IG0!27TH-"JBBJ-9U/O/\ <17U/OP9I[\YRM$KO9)T.)H?: G6[VY&Z MH*0>%%I57Z65;>]J[%>BKXX=&ZB9#HHV!T5S7LC>KF,SLXX-65!H M5=66-K^I]_FE4N6"\U_?_)!RI9RU*DUH35CVNVVC<$]^QRM4BJ.QZ/#&@7J MV;?B=$$Y/2BT:K)+U]{4F\>68=HH^\U--CB^K#S!1EZ(0ARC+S=$]=".#]_H M43OG&M1Z!T5S0-%<4#0/"JWZL%WIQ%O&3W[&RP+UUD'1YJ!H#BB."XKF0.%5 M95;Z]%8+G[{#LUYZN,ZB,6NWVI.!^G=P)0)E=5JRNJ"L'A1.-=&E?6[I[?,;_M_!1$282$[$S5HT TZWW14E83T?B \;4>L7.N(='FH&C."^?.-+)NM;$:@+K@_M4&A5D90NN-7"!><(;W 0]ON=M!RD"FG4!ZC]G*.]].0G**G3CM0%)?6@T+(D M]_?>8H@(6Z8OJ'#DJX=_LD?*B[W%2S!7Z:L?!_MGYOG<;-COF.=N]HI+"9^] M<7.#V3*0-20DCY+*.!W+||BREUBR#X*NTW&ULM51=;],P%/TK5P:A(:$E33\&(XVTKD(,;5!U M&CQ,/+C);6/-CH/MMIO$C^?:2;,,=>6)/C2^U_><>XZ_TJTV# [9$=/"H9&7' MK'2N/H\BFY>HN#W5-58TL]1&<4>A646V-LB+ %(R2N)X%"DN*I:E(3FR7F(M5Z7PBRM*;K_ 6W5T],Q1%'4LA%%96Z H_M+L?LHG<^&?CZ4!=X-;NC<$[66C]X(.K8LQB+P@EYLXS_T43D>9.>-()3P+OX 7> M9UKA8F40Z:PXN+]!M4#S$W[##7\4:JVZU'"Q1YOX&W%N:Y{CF-&1MV@VR+(W MKW]C^-,1"_W.0C^P]_]M88-P06M$H#K\T MVNRKB/8.NW\W;KA9"3JM$I>$C4_/A@Q,";P.DZG/^%=G2;PK"DYPN-+Z#Y MI=9N%_@KU3V(V1]02P,$% @ T4-M6&ULG99=;]HP% (;_BI554RMMS067)18:6[8N7+6@ N;%!%_2@(S$K_"A'G9V+Z[M$]F8-XH2!G<"R:;JL'BY!LHW$R_T7E_)O4ZI@G<;;|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`PHTW&?EV^R"5^K7>]NZM1*?:L3B;E( MS$-B=(==`I6 Z5CM&AZW*L4M4K8FICM$FXO9HXOVR6,7#6&Q#@(4TIXKL!;J6\) (S)VT*L"V.E[LO$GKQ/Y%/ER$#1*4XC.-YE"ZH2V_3R(.RUVVQS"3K^2/CV+|)++.8W5Z MJ&_Y0347JGE0C4(U'ZH%4(U!-8[2U,8XRIC,,Q[8KG%4LR U%ZIY4(U"-1^J M!5"-036.TM1FL9IFL5#;X7JI=V<@-1>]>5"-UMKQHXS:F\0=2TV;F\.0=>- M036.TM1;,@)-4YL&31]7905;(3ELF?]:,9EKMXV@02945"-UMJEYH]7US,T)H5J#*IQE*86?1.HFOI$=?]* M7YZ3G,J5R/1U#PU5H9IKML/+'P_E0R>D[T_H0R<,H!J#:AREJ67<9*JF/E2] M6RRB-V>IWGW"0%ZHG?Q0O-4J.9!-6IV1*6YXLV0I,5?:=50]-8*&:.[:SU=&DH[(\Z+34;">PG=/Z MT&D#],:@&D=IZG5"3;)KZ1/=NT,9[X]8DK_(Z@O{HOV$*9>]5O;4,V%;AY4 MHU#-AVH!5&-0C;,TM4N:>--=J.9"-0^J4:CF0[4 JC&HQE&:VBQ-MO&OIX[U3]@CT1. ^6@:;Z4,V#;M3J"&S;)T_ZT$D#J,;@&D=I;JTW\;^ECW_[M[_HJ=XU#XU]H9H'U2A4\Z%:4&O*I1M6^PP*!IV5HS2UZ)M U]}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`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end XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w) {if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)? w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e).e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a{ display: block; font-weight: bold; } .report table.authRefData p{ margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report .sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 106 212 1 false 28 0 false 6 false false R1.htm 00000001 - Document - Cover Sheet http://cocrystalpharma.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://cocrystalpharma.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://cocrystalpharma.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://cocrystalpharma.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://cocrystalpharma.com/role/StatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://cocrystalpharma.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995612 - Disclosure - Organization and Business Sheet http://cocrystalpharma.com/role/OrganizationAndBusiness Organization and Business Notes 9 false false R10.htm 995613 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies Basis of Presentation and Significant Accounting Policies Notes 10 false false R11.htm 995614 - Disclosure - Property and Equipment Sheet http://cocrystalpharma.com/role/PropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 995615 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://cocrystalpharma.com/role/AccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses Notes 12 false false R13.htm 995616 - Disclosure - Equity Sheet http://cocrystalpharma.com/role/Equity Equity Notes 13 false false R14.htm 995617 - Disclosure - Stock Based Awards Sheet http://cocrystalpharma.com/role/StockBasedAwards Stock Based Awards Notes 14 false false R15.htm 995618 - Disclosure - Licenses and Collaborations Sheet http://cocrystalpharma.com/role/LicensesAndCollaborations Licenses and Collaborations Notes 15 false false R16.htm 995619 - Disclosure - Commitments and Contingencies Sheet http://cocrystalpharma.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 995620 - Disclosure - Transactions with Related Parties Sheet http://cocrystalpharma.com/role/TransactionsWithRelatedParties Transactions with Related Parties Notes 17 false false R18.htm 995621 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies 18 false false R19.htm 995622 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) Sheet http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables Basis of Presentation and Significant Accounting Policies (Tables) Tables http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies 19 false false R20.htm 995623 - Disclosure - Property and Equipment (Tables) Sheet http://cocrystalpharma.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://cocrystalpharma.com/role/PropertyAndEquipment 20 false false R21.htm 995624 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://cocrystalpharma.com/role/AccountsPayableAndAccruedExpensesTables Accounts Payable and Accrued Expenses (Tables) Tables http://cocrystalpharma.com/role/AccountsPayableAndAccruedExpenses 21 false false R22.htm 995625 - Disclosure - Stock*

Based Awards (Tables) Sheet http://cocrystalpharma.com/role/StockBasedAwardsTables Stock Based Awards (Tables) Tables http://cocrystalpharma.com/role/StockBasedAwards 22 false false R23.htm 995626 - Disclosure - Commitments and Contingencies (Tables) Sheet http://cocrystalpharma.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://cocrystalpharma.com/role/CommitmentsAndContingencies 23 false false R24.htm 995627 - Disclosure - Organization and Business (Details Narrative) Sheet http://cocrystalpharma.com/role/OrganizationAndBusinessDetailsNarrative Organization and Business (Details Narrative) Details http://cocrystalpharma.com/role/OrganizationAndBusiness 24 false false R25.htm 995628 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Calculations of Net Loss Per Share (Details) Sheet http://cocrystalpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromCalculationsOfNetLossPerShareDetails Schedule of Anti-dilutive Securities Excluded from Calculations of Net Loss Per Share (Details) Details 25 false false R26.htm 995629 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details Narrative) Sheet http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative Basis of Presentation and Significant Accounting Policies (Details Narrative) Details http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables 26 false false R27.htm 995630 - Disclosure - Schedule of Property and Equipment (Details) Sheet http://cocrystalpharma.com/role/ScheduleOfPropertyAndEquipmentDetails Schedule of Property and Equipment (Details) Details 27 false false R28.htm 995631 - Disclosure - Property and Equipment (Details Narrative) Sheet http://cocrystalpharma.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://cocrystalpharma.com/role/PropertyAndEquipmentTables 28 false false R29.htm 995632 - Disclosure - Schedule of Accounts Payable and Accrued Expenses (Details) Sheet http://cocrystalpharma.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails Schedule of Accounts Payable and Accrued Expenses (Details) Details 29 false false R30.htm 995633 - Disclosure - Equity (Details Narrative) Sheet http://cocrystalpharma.com/role/EquityDetailsNarrative Equity (Details Narrative) Details http://cocrystalpharma.com/role/Equity 30 false false R31.htm 995634 - Disclosure - Schedule of Common Stock Available for Future Issuance (Details) Sheet http://cocrystalpharma.com/role/ScheduleOfCommonStockAvailableForFutureIssuanceDetails Schedule of Common Stock Available for Future Issuance (Details) Details 31 false false R32.htm 995635 - Disclosure - Schedule of Stock Option Transactions (Details) Sheet http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails Schedule of Stock Option Transactions (Details) Details 32 false false R33.htm 995636 - Disclosure - Schedule of Restricted Stock Units (Details) Sheet http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails Schedule of Restricted Stock Units (Details) Details 33 false false R34.htm 995637 - Disclosure - Stock Based Awards (Details Narrative) Sheet http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative Stock Based Awards (Details Narrative) Details http://cocrystalpharma.com/role/StockBasedAwardsTables 34 false false R35.htm 995638 - Disclosure - Licenses and Collaborations (Details Narrative) Sheet http://cocrystalpharma.com/role/LicensesAndCollaborationsDetailsNarrative Licenses and Collaborations (Details Narrative) Details http://cocrystalpharma.com/role/LicensesAndCollaborations 35 false false R36.htm 995639 - Disclosure - Schedule of Maturities of Operating Lease Liabilities (Details) Sheet http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails Schedule of Maturities of Operating Lease Liabilities (Details) Details 36 false false R37.htm 995640 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://cocrystalpharma.com/role/CommitmentsAndContingenciesTables 37 false false R38.htm 995641 - Disclosure - Transactions with Related Parties (Details Narrative) Sheet http://cocrystalpharma.com/role/TransactionsWithRelatedPartiesDetailsNarrative Transactions with Related Parties (Details Narrative) Details http://cocrystalpharma.com/role/TransactionsWithRelatedParties 38 false false All Reports Book All Reports cocp-20240930.xsd cocp-20240930_cal.xml cocp-20240930_def.xml cocp-20240930_lab.xml cocp-20240930_pre.xml form10-q.htm form10-q_001.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-q.htm": { "nsprefix": "COCP", "nsuri": "http://cocrystalpharma.com/20240930", "dts": { "schema": { "local": ["cocp-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["cocp-20240930_cal.xml"] }, "definitionLink": { "local": ["cocp-20240930_def.xml"] }, "labelLink": { "local": ["cocp-20240930_lab.xml"] }, "presentationLink": { "local": ["cocp-20240930_pre.xml"] }, "inline": { "local": ["form10-q.htm"] } }, "keyStandard": 197, "keyCustom": 15, "axisStandard": 14, "axisCustom": 0, "memberStandard": 9, "memberCustom": 19, "hidden": { "total": 60, "http://fasb.org/us-gaap/2024": 51, "http://cocrystalpharma.com/20240930": 5, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 106, "entityCount": 1, "segmentCount": 28, "elementCount": 418, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 412, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://cocrystalpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R2": { "role": "http://cocrystalpharma.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:ValueAddedTaxReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R3": { "role": "http://cocrystalpharma.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "COCP:OperatingLeaseRightOfUseAssetsDueToRelatedParty", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "COCP:OperatingLeaseRightOfUseAssetsDueToRelatedParty", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R4": { "role": "http://cocrystalpharma.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R5": { "role": "http://cocrystalpharma.com/role/StatementsOfStockholdersEquity", "longName": "00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R6": { "role": "http://cocrystalpharma.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "span", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R9": { "role": "http://cocrystalpharma.com/role/OrganizationAndBusiness", "longName": "995612 - Disclosure - Organization and Business", "shortName": "Organization and Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R10": { "role": "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies", "longName": "995613 - Disclosure - Basis of Presentation and Significant Accounting Policies", "shortName": "Basis of Presentation and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R11": { "role": "http://cocrystalpharma.com/role/PropertyAndEquipment", "longName": "995614 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R12": { "role": "http://cocrystalpharma.com/role/AccountsPayableAndAccruedExpenses", "longName": "995615 - Disclosure - Accounts Payable and Accrued Expenses", "shortName": "Accounts Payable and Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R13": { "role": "http://cocrystalpharma.com/role/Equity", "longName": "995616 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30",

"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R14": { "role": "http://cocrystalpharma.com/role/StockBasedAwards", "longName": "995617 - Disclosure - Stock Based Awards", "shortName": "Stock Based Awards", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R15": { "role": "http://cocrystalpharma.com/role/LicensesAndCollaborations", "longName": "995618 - Disclosure - Licenses and Collaborations", "shortName": "Licenses and Collaborations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R16": { "role": "http://cocrystalpharma.com/role/CommitmentsAndContingencies", "longName": "995619 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R17": { "role": "http://cocrystalpharma.com/role/TransactionsWithRelatedParties", "longName": "995620 - Disclosure - Transactions with Related Parties", "shortName": "Transactions with Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R18": { "role": "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies", "longName": "995621 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R19": { "role": "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables", "longName": "995622 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)", "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R20": { "role": "http://cocrystalpharma.com/role/PropertyAndEquipmentTables", "longName": "995623 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R21": { "role": "http://cocrystalpharma.com/role/AccountsPayableAndAccruedExpensesTables", "longName": "995624 - Disclosure - Accounts Payable and Accrued Expenses (Tables)", "shortName": "Accounts Payable and Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R22": { "role": "http://cocrystalpharma.com/role/StockBasedAwardsTables", "longName": "995625 - Disclosure - Stock Based Awards (Tables)", "shortName": "Stock Based Awards (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "COCP:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "COCP:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R23": { "role": "http://cocrystalpharma.com/role/CommitmentsAndContingenciesTables", "longName": "995626 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R24": { "role": "http://cocrystalpharma.com/role/OrganizationAndBusinessDetailsNarrative", "longName": "995627 - Disclosure - Organization and Business (Details Narrative)", "shortName": "Organization and Business (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://cocrystalpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromCalculationsOfNetLossPerShareDetails", "longName": "995628 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Calculations of Net Loss Per Share (Details)", "shortName": "Schedule of Anti-dilutive Securities Excluded from Calculations of Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R26": { "role": "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "longName": "995629 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details Narrative)", "shortName": "Basis of Presentation and Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R27": { "role": "http://cocrystalpharma.com/role/ScheduleOfPropertyAndEquipmentDetails", "longName": "995630 - Disclosure - Schedule of Property and Equipment (Details)", "shortName": "Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R28": { "role": "http://cocrystalpharma.com/role/PropertyAndEquipmentDetailsNarrative", "longName": "995631 - Disclosure - Property and Equipment (Details Narrative)", "shortName": "Property and Equipment (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AdjustmentForAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R29": { "role": "http://cocrystalpharma.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails", "longName": "995632 - Disclosure - Schedule of Accounts Payable and Accrued Expenses (Details)", "shortName": "Schedule of Accounts Payable and Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R30": { "role": "http://cocrystalpharma.com/role/EquityDetailsNarrative", "longName": "995633 - Disclosure - Equity (Details Narrative)", "shortName": "Equity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-27", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R31": { "role": "http://cocrystalpharma.com/role/ScheduleOfCommonStockAvailableForFutureIssuanceDetails", "longName": "995634 -

Disclosure - Schedule of Common Stock Available for Future Issuance (Details)", "shortName": "Schedule of Common Stock Available for Future Issuance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "COCP:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails", "longName": "995635 - Disclosure - Schedule of Stock Option Transactions (Details)", "shortName": "Schedule of Stock Option Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "COCP:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_EmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R33": { "role": "http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails", "longName": "995636 - Disclosure - Schedule of Restricted Stock Units (Details)", "shortName": "Schedule of Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-09-30_us-gaap_RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R34": { "role": "http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative", "longName": "995637 - Disclosure - Stock Based Awards (Details Narrative)", "shortName": "Stock Based Awards (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "COCP:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-08-12", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R35": { "role": "http://cocrystalpharma.com/role/LicensesAndCollaborationsDetailsNarrative", "longName": "995638 - Disclosure - Licenses and Collaborations (Details Narrative)", "shortName": "Licenses and Collaborations (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "AsOf2019-01-02_custom_CollaborationAgreementMember_srt_MaximumMember", "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2019-01-02_custom_CollaborationAgreementMember_srt_MaximumMember", "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R36": { "role": "http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails", "longName": "995639 - Disclosure - Schedule of Maturities of Operating Lease Liabilities (Details)", "shortName": "Schedule of Maturities of Operating Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R37": { "role": "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "995640 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R38": { "role": "http://cocrystalpharma.com/role/TransactionsWithRelatedPartiesDetailsNarrative", "longName": "995641 - Disclosure - Transactions with Related Parties (Details Narrative)", "shortName": "Transactions with Related Parties (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "From2024-08-142024-08-14_custom_DrPhillipFrostMember", "name": "us-gaap:StraightLineRentAdjustments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-04-042023-04-04_custom_SecuritiesPurchaseAgreementMember", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://cocrystalpharma.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://cocrystalpharma.com/role/BalanceSheets", "http://cocrystalpharma.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "totalLabel": "Total accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r30", "r31"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://cocrystalpharma.com/role/AccountsPayableAndAccruedExpenses"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r29", "r31", "r34", "r661"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://cocrystalpharma.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r29", "r489"] }, "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://cocrystalpharma.com/role/LicensesAndCollaborationsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Royalty received on sales", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties." } } }, "auth_ref": ["r64"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://cocrystalpharma.com/role/ScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r16", "r89", "r348"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r558"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://cocrystalpharma.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r39"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://cocrystalpharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r373", "r608", "r609", "r610", "r611", "r663", "r713"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r564"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r564"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r564"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r564"] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForAmortization", "crdr": "debit", "presentation": ["http://cocrystalpharma.com/role/PropertyAndEquipmentDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Amortization expense", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": ["r3"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://cocrystalpharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation":

```
"Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": { "r20", "r21", "r189" } },
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://cocrystalpharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" }
} }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r529", "r540",
"r550", "r575" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous
Compensation Not Yet Determined" } } }, "auth_ref": [ "r532", "r543", "r553", "r578" ] }, "COCP_AgreementMember": { "xbrltype": "domainItemType", "nsuri":
"http://cocrystalpharma.com/20240930", "localname": "AgreementMember", "presentation": [
"http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Agreement [Member]", "documentation":
"Agreement [Member]" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r564" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"auth_ref": [ "r571" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"auth_ref": [ "r533", "r544", "r554", "r571", "r579", "r583", "r591" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity-based compensation expense", "documentation": "Amount
of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r221", "r230" ] },
"COCP_AmendedLeaseAgreementForExpansionMember": { "xbrltype": "domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname":
"AmendedLeaseAgreementForExpansionMember", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": {
"role": { "label": "Amended Lease Agreement for Expansion [Member]", "documentation": "Amended Lease Agreement for Expansion [Member]" } } }, "auth_ref": [] },
"COCP_AmendedLeaseAgreementForExtensionMember": { "xbrltype": "domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname":
"AmendedLeaseAgreementForExtensionMember", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": {
"role": { "label": "Amended Lease Agreement for Extension [Member]", "documentation": "Amended Lease Agreement for Extension [Member]" } } }, "auth_ref": [] },
"dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [
"http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within
amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag",
"presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the
XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label":
"Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [
"r536" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfAnti-
dilutiveSecuritiesExcludedFromCalculationsOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Securities (including those issuable
pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the
computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } },
"auth_ref": [ "r127" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [
"http://cocrystalpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromCalculationsOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive
Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r10" ] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfAnti-
dilutiveSecuritiesExcludedFromCalculationsOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings
Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated
with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfAnti-
dilutiveSecuritiesExcludedFromCalculationsOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to
securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period
presented." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [
"http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cocrystalpharma.com/role/LicensesAndCollaborationsDetailsNarrative",
"http://cocrystalpharma.com/role/TransactionsWithRelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and
arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r252" ] }, "us-gaap_Assets": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel":
"Total assets", "label": "Assets [Default Label]", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r63", "r69", "r90",
"r102", "r130", "r132", "r142", "r143", "r148", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r253", "r255", "r271", "r340", "r402", "r472", "r473",
"r489", "r510", "r628", "r629", "r672" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract",
"presentation": [ "http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": {
"parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel":
"Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref":
[ "r86", "r91", "r102", "r148", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r253", "r255", "r271", "r489", "r628", "r629", "r672" ] }, "us-
gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [
"http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [
"http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a
form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r536" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label":
"Exercise Price" } } }, "auth_ref": [ "r586" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } },
"auth_ref": [ "r587" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems",
"auth_ref": [ "r582" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How
MNPI Considered" } } }, "auth_ref": [ "r582" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } },
"auth_ref": [ "r582" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r582" ] },
"ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r582" ] },
"ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": [ "r582" ] }, "us-
gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award
Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r192", "r193", "r194", "r196", "r197", "r198",
"r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r216", "r217", "r218", "r219", "r220" ] },
"ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": [ "r585" ] },
"ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI
Disclosures, Individual Name" } } }, "auth_ref": [ "r584" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in
Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r583" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-
us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r583" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [
"http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement of Financial
Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." }
} }, "auth_ref": [ "r153", "r682", "r683" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BalanceSheetLocationDomain", "presentation": [ "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-
us": { "role": { "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r23", "r24",
"r153", "r682", "r683" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-
us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the
financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-
gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPolicies"
], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies", "documentation": "The entire disclosure for the basis of presentation and
significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted
Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } },
"auth_ref": [ "r52" ] }, "COCP_BothellWashingtonMember": { "xbrltype": "domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname":
"BothellWashingtonMember", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label":
```

```
"Bothell, Washington [Member]", "documentation": "Bothell, Washington [Member]" } } }, "auth_ref": [] }, "us-gaap_CapitalUnitsAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalUnitsAuthorized", "presentation": [ "http://cocrystalpharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capital stock, shares authorized", "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies." } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cocrystalpharma.com/role/BalanceSheets", "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r71", "r343", "r374", "r397", "r489", "r510", "r599" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://cocrystalpharma.com/role/OrganizationAndBusinessDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash and restricted cash", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r9", "r49", "r100" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://cocrystalpharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and restricted cash at beginning of period", "periodEndLabel": "Cash and restricted cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r9", "r49", "r100" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cocrystalpharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r49" ] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash FDIC insured amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r562" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r563" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r563" ] }, "COCP_CollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "CollaborationAgreementMember", "presentation": [ "http://cocrystalpharma.com/role/LicensesAndCollaborationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaboration Agreement [Member]", "documentation": "Collaboration Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://cocrystalpharma.com/role/LicensesAndCollaborations" ], "lang": { "en-us": { "role": { "label": "Licenses and Collaborations", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r72", "r74", "r83" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://cocrystalpharma.com/role/LicensesAndCollaborationsDetailsNarrative", "http://cocrystalpharma.com/role/TransactionsWithRelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r252" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 8)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r35", "r65", "r342", "r388" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r56", "r155", "r156", "r451", "r621", "r623" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfCommonStockAvailableForFutureIssuanceDetails", "http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares reserved for issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r38" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://cocrystalpharma.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r500", "r501", "r502", "r504", "r505", "r506", "r507", "r608", "r609", "r611", "r663", "r712", "r713" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://cocrystalpharma.com/role/BalanceSheetsParenthetical", "http://cocrystalpharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r38" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://cocrystalpharma.com/role/BalanceSheetsParenthetical", "http://cocrystalpharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r38", "r389" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://cocrystalpharma.com/role/BalanceSheetsParenthetical", "http://cocrystalpharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r38" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://cocrystalpharma.com/role/BalanceSheetsParenthetical", "http://cocrystalpharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r5", "r38", "r389", "r408", "r713", "r714" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value 100,000 and 150,000 shares authorized as of September 30, 2024, and December 31, 2023; 10,174 shares issued and outstanding as of September 30, 2024 and December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r38", "r344", "r489" ] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockVotingRights", "presentation": [ "http://cocrystalpharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, voting rights description", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r18" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r568" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r567" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r569" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r566" ] }, "COCP_ComputerAndOfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "ComputerAndOfficeEquipmentMember", "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer and Office Equipment [Member]", "documentation": "Computer and Office Equipment [Member]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri":
```

```
"http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [
"http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentrations of Credit Risk",
"documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r27", "r76" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ],
"lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r105", "r253", "r254", "r255", "r256", "r303", "r456", "r627", "r630", "r631" ] },
"srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": [
"http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "auth_ref": [ "r105", "r253", "r254", "r255", "r256", "r303", "r456", "r627", "r630", "r631"
] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock",
"presentation": [ "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of
Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements,
including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its
treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the
equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest,
and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r22", "r466" ] }, "dei_CountryRegion": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-
us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] },
"dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format
--MM-DD." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "crdr": "debit",
"presentation": [ "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Refundable
tax credits accrued", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance
for credit loss on accounts receivable." } } }, "auth_ref": [ "r662" ] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets",
"weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deposits", "documentation":
"Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the
operating cycle, if longer." } } }, "auth_ref": [ "r600" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://cocrystalpharma.com/role/PropertyAndEquipmentDetailsNarrative", "http://cocrystalpharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label":
"Depreciation and amortization expense", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and
which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over
the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r3", "r15" ] }, "us-
gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://cocrystalpharma.com/role/StockBasedAwards" ], "lang": { "en-us": { "role":
{ "label": "Stock Based Awards", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r187", "r191", "r222", "r223", "r225",
"r479" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } }
}, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentAccountingStandard", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard",
"documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International
Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r524" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label":
"Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r522", "r524", "r536" ] },
"dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [
"http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and
Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref":
[] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [
"http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document
report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus.
Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentPeriodEndDate", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation":
"For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A, the filing date;
for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": {
"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://cocrystalpharma.com/role/Cover" ],
"lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } },
"auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport",
"presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true
only for a form used as an quarterly report." } } }, "auth_ref": [ "r523" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": {
"label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r511" ] },
"dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate",
"presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event
requiring a shell company report." } } }, "auth_ref": [ "r524" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "DocumentShellCompanyReport", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company
Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r524" ] },
"dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [
"http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used
as a transition report." } } }, "auth_ref": [ "r557" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentType", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document
being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } },
"auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by
Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r514" ] }, "COCP_DrPhillipFrostMember": { "xbrltype":
"domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "DrPhillipFrostMember", "presentation": [
"http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cocrystalpharma.com/role/TransactionsWithRelatedPartiesDetailsNarrative" ],
"lang": { "en-us": { "role": { "label": "Dr. Phillip Frost [Member]", "documentation": "Dr. Phillip Frost [Member]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [
"http://cocrystalpharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share, basic", "documentation": "The amount of net
income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r98", "r111", "r112", "r113", "r114", "r115",
"r116", "r120", "r122", "r124", "r125", "r126", "r129", "r248", "r251", "r265", "r266", "r338", "r352", "r467" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://cocrystalpharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share, diluted", "documentation": "The amount of net
income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been
outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [
"r98", "r111", "r112", "r113", "r114", "r115", "r116", "r122", "r124", "r125", "r126", "r129", "r248", "r251", "r265", "r266", "r338", "r352", "r467" ] }, "us-
gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock",
"presentation": [ "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)
per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating
security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits
and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r10", "r11",
"r128" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
"parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://cocrystalpharma.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued compensation", "documentation":
"Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees,
such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal
operating cycle if longer)." } } }, "auth_ref": [ "r31" ] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not
yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-
based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref":
[ "r224" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
"crdr": "debit", "presentation": [ "http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment
Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment
arrangement." } } }, "auth_ref": [ "r660" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeStockOptionMember", "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails" ], "lang": { "en-us": { "role": { "label":
"Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to
purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://cocrystalpharma.com/role/Cover" ],
```

```
"lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] },
"dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation":
[ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite
number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressAddressLine3", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three",
"documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label":
"Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity
Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": {
"label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype":
"stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://cocrystalpharma.com/role/Cover" ],
"lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] },
"dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy
Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the
registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of
securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years
should not report this element." } } }, "auth_ref": [ "r517" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityCentralIndexKey", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [
"r513" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityCommonStockSharesOutstanding", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares
Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests,
if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A
[Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] },
"dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants
(1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that
registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's
current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label":
"Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r513" ] },
"dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [
"http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an
emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [
"r598" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [
"http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17
characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a
hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory",
"presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is
one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This
information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r513" ] },
"dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityIncorporationStateCountryCode", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or
Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": {
"xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://cocrystalpharma.com/role/Cover" ],
"lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every
Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files)." } } }, "auth_ref": [ "r595" ] }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityListingParValuePerShare", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per
Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'." } } }, "auth_ref": [] },
"dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [
"http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification
(SIC) Number for the Entity." } } }, "auth_ref": [ "r536" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityPublicFloat", "crdr": "credit", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation":
"The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold,
or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] },
"dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as
specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r513" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity
Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r513" ]
}, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [
"http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting
Company (SRC)." } } }, "auth_ref": [ "r513" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityTaxIdentificationNumber", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } },
"auth_ref": [ "r513" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers",
"presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the
registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype":
"yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": {
"en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule
405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r596" ] }, "us-
gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EquityComponentDomain", "presentation": [ "http://cocrystalpharma.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation":
"Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } },
"auth_ref": [ "r5", "r84", "r95", "r96", "r97", "r106", "r107", "r108", "r110", "r115", "r117", "r119", "r131", "r149", "r150", "r151", "r183", "r242", "r243", "r245", "r246", "r247",
"r249", "r250", "r251", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r294", "r351", "r358", "r359",
"r360", "r373", "r431" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation
Assumption Difference, Footnote" } } }, "auth_ref": [ "r565" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation
Analysis" } } }, "auth_ref": [ "r529", "r540", "r550", "r575" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded
Compensation Recovery [Table]" } } }, "auth_ref": [ "r526", "r537", "r547", "r572" ] }, "COCP_EstimatedAgreementCost": { "xbrltype": "monetaryItemType", "nsuri":
"http://cocrystalpharma.com/20240930", "localname": "EstimatedAgreementCost", "crdr": "debit", "presentation": [
"http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Estimated agreement cost", "documentation":
"Estimated agreement cost." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": [
"r571" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [
"http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] },
"us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": {
"en-us": { "role": { "label": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets,
liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities
on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": {
"http://cocrystalpharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } },
"presentation": [ "http://cocrystalpharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on finance lease liabilities", "label":
"Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r287", "r289" ] },
"COCP_FinanceLeaseRightofUseLabEquipmentNetMember": { "xbrltype": "domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname":
"FinanceLeaseRightofUseLabEquipmentNetMember", "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": {
"role": { "label": "Finance Lease Right-of-use Lab Equipment [Member]", "documentation": "Finance Lease Right-of-use Lab Equipment [Member]" } } }, "auth_ref": [] }, "us-
gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfOperations": { "parentTag": "us-
gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cocrystalpharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": {
"label": "Foreign exchange loss", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r273",
"r274", "r275", "r276", "r428" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [
"http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions",
"documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating
```

*foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": ["r272"] },
"ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone
Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r533", "r544", "r554", "r579"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r533",
"r544", "r554", "r579"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": {
"label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r533", "r544", "r554", "r579"] },
"ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone
Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r533", "r544", "r554", "r579"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": {
"verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r533", "r544", "r554", "r579"] }, "us-gaap_GeneralAndAdministrativeExpense": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": {
"http://cocrystalpharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://cocrystalpharma.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of
expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the
manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r45", "r412"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [
"http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]",
"documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r45"] }, "COCP_HVIVOMember": { "xbrltype":
"domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "HVIVOMember", "presentation": [
"http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "hVIVO [Member]", "documentation": "hVIVO
[Member]" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "presentation": [
"http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Long-Lived Assets", "documentation":
"Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": [] }, "us-
gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role":
{ "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": {
"en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount
has been reported." } } }, "auth_ref": ["r152", "r153", "r154", "r268", "r269", "r270", "r355", "r357", "r415", "r464", "r483", "r684"] }, "us-
gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain",
"presentation": ["http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Location in statement of
income where disaggregated amount has been reported." } } }, "auth_ref": ["r153", "r154", "r268", "r269", "r270", "r355", "r357", "r415", "r464", "r483", "r684"] }, "us-
gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit",
"presentation": ["http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Income tax
expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref":
["r70", "r82", "r118", "r119", "r130", "r134", "r143", "r236", "r237", "r244", "r353", "r482"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [
"http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation":
"Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related
valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its
effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r94", "r234", "r235", "r238", "r239", "r240",
"r241", "r367"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [
"http://cocrystalpharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued expenses", "label": "Increase
(Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods
and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "crdr": "credit", "calculation": {
"http://cocrystalpharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } },
"presentation": ["http://cocrystalpharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Tax credit receivable", "label": "Increase
(Decrease) in Income Taxes Receivable", "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due
from tax authorities for refunds of overpayments or recoveries of income taxes paid." } } }, "auth_ref": ["r2"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://cocrystalpharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-
gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://cocrystalpharma.com/role/StatementsOfCashFlows"], "lang": {
"en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation":
"Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r2"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": [
"r533", "r544", "r554", "r571", "r579", "r583", "r591"] }, "COCP_InitialRecognitionOfRightofuseAssetsAndLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri":
"http://cocrystalpharma.com/20240930", "localname": "InitialRecognitionOfRightofuseAssetsAndLeaseLiabilities", "crdr": "credit", "presentation": [
"http://cocrystalpharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Initial recognition of right-of-use assets and lease liabilities",
"documentation": "Initial recognition of right of use assets and lease liabilities." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } },
"auth_ref": ["r589"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r525", "r594"] },
"ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag",
"presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } },
"auth_ref": ["r525", "r594"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider
Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r525", "r594"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfOperations": {
"parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://cocrystalpharma.com/role/StatementsOfOperations"], "lang": {
"en-us": { "role": { "negatedLabel": "Interest income (expense), net", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as
nonoperating." } } }, "auth_ref": ["r133", "r604"] }, "COCP_LabEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://cocrystalpharma.com/20240930",
"localname": "LabEquipmentMember", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label":
"Lab Equipment [Member]", "documentation": "Lab Equipment [Member]" } } }, "auth_ref": [] }, "us-gaap_LandSubjectToGroundLeases": { "xbrltype": "areaItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandSubjectToGroundLeases", "presentation": [
"http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Land subject to leases", "documentation": "Area of
land subject to a ground lease." } } }, "auth_ref": ["r667"] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LeaseExpirationDate1", "presentation": ["http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": {
"label": "Lease expiration date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] },
"COCP_LegalSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "LegalSettlement", "crdr": "debit", "calculation": {
"http://cocrystalpharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://cocrystalpharma.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Legal settlement", "documentation": "Legal settlement." } } }, "auth_ref": []
}, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://cocrystalpharma.com/role/CommitmentsAndContingenciesTables"], "lang": { "en-us": {
"role": { "label": "Schedule of Maturities of Operating Lease Liabilities", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability.
Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r669"]
}, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"],
"lang": { "en-us": { "role": { "totalLabel": "Total operating lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's
undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r292"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit",
"calculation": { "http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "parentTag": "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of
lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when
interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r292"] },
"COCP_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname":
"LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter", "crdr": "credit", "calculation": {
"http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight":
1.0, "order": 6.0 } }, "presentation": ["http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "2029
and Thereafter", "documentation": "Lessee operating lease liability payments due year five and thereafter." } } }, "auth_ref": [] }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": {*

```
"http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r292" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": {
"http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r292" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": {
"http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r292" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": {
"http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "2024 (excluding the nine months ended September 30, 2024)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r669" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [
"http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: present value discount", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r292" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [
"http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating lease term", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r668" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": {
"http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r8", "r30", "r31", "r32", "r33", "r34", "r35", "r36", "r102", "r148", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r254", "r255", "r256", "r271", "r387", "r468", "r510", "r628", "r672", "r673" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r43", "r66", "r346", "r489", "r607", "r619", "r665" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and stockholders\u2019 equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r32", "r87", "r102", "r148", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r254", "r255", "r256", "r271", "r489", "r628", "r672", "r673" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAbstract", "presentation": [
"http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term liabilities:" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://cocrystalpharma.com/role/LicensesAndCollaborationsDetailsNarrative", "http://cocrystalpharma.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r157", "r158", "r159", "r160", "r186", "r231", "r267", "r306", "r354", "r356", "r363", "r379", "r380", "r439", "r441", "r443", "r444", "r446", "r462", "r463", "r475", "r476", "r478", "r484", "r485", "r486", "r487", "r498", "r632", "r674", "r675", "r676", "r677", "r678", "r679" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r563" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r563" ] }, "COCP_MiamiFloridaMember": { "xbrltype": "domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "MiamiFloridaMember", "presentation": [
"http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Miami, Florida [Member]", "documentation": "Miami, Florida [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://cocrystalpharma.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r157", "r158", "r159", "r160", "r186", "r231", "r267", "r306", "r354", "r356", "r363", "r379", "r380", "r439", "r441", "r443", "r444", "r446", "r462", "r463", "r475", "r476", "r478", "r484", "r485", "r486", "r498", "r632", "r674", "r675", "r676", "r677", "r678", "r679" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r582" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r590" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r564" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cocrystalpharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r99" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://cocrystalpharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cocrystalpharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r99" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://cocrystalpharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://cocrystalpharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cocrystalpharma.com/role/OrganizationAndBusinessDetailsNarrative", "http://cocrystalpharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "negatedLabel": "Net cash provided by used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r49", "r50", "r51" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://cocrystalpharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://cocrystalpharma.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cocrystalpharma.com/role/OrganizationAndBusinessDetailsNarrative",
"http://cocrystalpharma.com/role/StatementsOfCashFlows", "http://cocrystalpharma.com/role/StatementsOfOperations",
"http://cocrystalpharma.com/role/StatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "verboseLabel": "Net Income (Loss)", "negatedLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r44", "r51", "r67", "r85", "r92", "r93", "r97", "r102", "r109", "r111", "r112", "r113", "r114", "r115", "r118", "r119", "r123", "r148", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r248", "r251", "r266", "r271", "r350", "r410", "r429", "r430", "r508", "r628" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [
"http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
```

```
"localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r563" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r561" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r560" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r590" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r590" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [
"http://cocrystalpharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://cocrystalpharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expense, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r46" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://cocrystalpharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "auth_ref": [] }, "COCP_NorthCreekTecLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "NorthCreekTecLLCMember", "presentation": [
"http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "North Creek Tec LLC [Member]", "documentation": "North Creek Tec LLC [Member]" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r473", "r613" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [
"http://cocrystalpharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [
"http://cocrystalpharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://cocrystalpharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r68", "r469", "r612", "r614", "r615", "r616", "r617" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating lease expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r666" ] }, "COCP_OperatingLeaseExpiration": { "xbrltype": "stringItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "OperatingLeaseExpiration", "presentation": [
"http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease expiration period", "documentation": "Operating lease expiration." } } }, "auth_ref": [] }, "COCP_OperatingLeaseLiabilitiesRelatedPartyNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "OperatingLeaseLiabilitiesRelatedPartyNoncurrent", "crdr": "debit", "presentation": [
"http://cocrystalpharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities related party non-current", "documentation": "operating lease liabilities related party non-current." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [
"http://cocrystalpharma.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Total operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r286" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://cocrystalpharma.com/role/BalanceSheets", "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Current maturities of operating lease liabilities (including $55 and $42 respectively, to related party)", "verboseLabel": "Current operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r286" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities (including $163 and $0 respectively, to related party)", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r286" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cocrystalpharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Operating lease liabilities", "label": "Operating lease payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r288", "r289" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets, net (including $163 and $42 respectively, to related party)", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r285" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cocrystalpharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right of use assets", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r605" ] }, "COCP_OperatingLeaseRightOfUseAssetsDueToRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "OperatingLeaseRightOfUseAssetsDueToRelatedParty", "crdr": "debit", "presentation": [
"http://cocrystalpharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Operating lease right of use assets related party", "documentation": "Related party operating lease right of use assets." } } }, "auth_ref": [] }, "COCP_OperatingLeaseVariableCommonAreaMaintenanceCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "OperatingLeaseVariableCommonAreaMaintenanceCharges", "crdr": "debit", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common area maintenance charges", "documentation": "Operating lease variable common area maintenance charges." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating lease, weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r291", "r488" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [
"http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating lease, weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r290", "r488" ] }, "us-gaap_OptionIndexedToIssuersEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityLineItems", "presentation": [
"http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OptionIndexedToIssuersEquityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityTable", "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity [Table]", "documentation": "Disclosure of information about option contract issued and indexed to equity, classified as liability. Includes, but is not limited to, strike price, number of shares, indexed share, and settlement date." } } }, "auth_ref": [ "r17", "r25", "r26", "r62" ] }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityTypeAxis", "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Type [Axis]", "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock." } } }, "auth_ref": [ "r17", "r25", "r26", "r62" ] }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityTypeDomain", "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://cocrystalpharma.com/role/OrganizationAndBusiness" ], "lang": { "en-us": { "role": { "label": "Organization and Business", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r28", "r61", "r364", "r365" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://cocrystalpharma.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued other expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r31" ] }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingExpense", "crdr": "debit",
```

```
"presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional costs", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r47" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r563" ] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "presentation": [
"http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prepaid and other expenses", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r602", "r620" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r524" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r531", "r542", "r552", "r577" ] }, "COCP_OutstandingOptionsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "OutstandingOptionsToPurchaseCommonStockMember", "presentation": [
"http://cocrystalpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromCalculationsOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Outstanding Options to Purchase Common Stock [Member]", "documentation": "Outstanding Options to Purchase Common Stock [Member]" } } }, "auth_ref": [] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": [ "r534", "r545", "r555", "r580" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r534", "r545", "r555", "r580" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": [ "r559" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://cocrystalpharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r48" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r562" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r562" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r561" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": [ "r564" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r560" ] }, "COCP_PhaseTwoAClinicalTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "PhaseTwoAClinicalTrialMember", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Phase 2a Clinical Trial [Member]", "documentation": "Phase 2a Clinical Trial [Member]" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [
"http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r561" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r518" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r520" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [
"http://cocrystalpharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r37", "r171" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://cocrystalpharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r37", "r389" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://cocrystalpharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r37", "r171" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://cocrystalpharma.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r37", "r389", "r408", "r713", "r714" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": {
"http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r603" ] }, "COCP_PrepaidResevationFee": { "xbrltype": "monetaryItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "PrepaidResevationFee", "crdr": "debit", "presentation": [
"http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prepaid reservation fee", "documentation": "Prepaid resevation fee." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cocrystalpharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of common stock to related entities, net of transaction costs", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ProductLiabilityContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductLiabilityContingencyLineItems", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Liability Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r159", "r624", "r625", "r626" ] }, "us-gaap_ProductLiabilityContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductLiabilityContingencyTable", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Liability Contingency [Table]", "documentation": "Disclosure of information about product liability contingency arising from reasonably possible loss from liability related to individual product." } } }, "auth_ref": [ "r159", "r624", "r625", "r626" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r4", "r293" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://cocrystalpharma.com/role/PropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r54", "r77", "r80", "r81" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Total property and equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r55", "r88", "r349" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://cocrystalpharma.com/role/PropertyAndEquipmentDetailsNarrative",
"http://cocrystalpharma.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r293" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://cocrystalpharma.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cocrystalpharma.com/role/BalanceSheets", "http://cocrystalpharma.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r4", "r293", "r339", "r349", "r489" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://cocrystalpharma.com/role/PropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Property and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r4" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r55", "r293" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://cocrystalpharma.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property and equipment, estimated useful lives", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r559" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r559" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://cocrystalpharma.com/role/LicensesAndCollaborationsDetailsNarrative","http://cocrystalpharma.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r157", "r158", "r159", "r160", "r184", "r186", "r217", "r218", "r219", "r231", "r267", "r304", "r305", "r306", "r354", "r356", "r363", "r379", "r380", "r439", "r441", "r443", "r444", "r446", "r462", "r463", "r475", "r476", "r478", "r484", "r485", "r486", "r487", "r498", "r502", "r622", "r632", "r664", "r675", "r676", "r677", "r678", "r679" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://cocrystalpharma.com/role/LicensesAndCollaborationsDetailsNarrative", "http://cocrystalpharma.com/role/PropertyAndEquipmentDetailsNarrative" ], "auth_ref": [ "r157", "r158", "r159", "r160", "r184", "r186", "r217", "r218", "r219", "r231", "r267", "r304", "r305", "r306", "r354", "r356", "r363", "r379", "r380", "r439", "r441", "r443", "r444", "r446", "r462", "r463", "r475", "r476", "r478", "r484", "r485", "r486", "r487", "r498", "r502", "r622", "r632", "r664", "r675", "r676", "r677", "r678", "r679" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": [ "r526", "r537", "r547", "r572" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r147", "r185", "r298", "r299", "r341", "r347", "r382", "r383", "r384", "r385", "r386", "r407", "r409", "r438" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r103", "r104", "r298", "r299", "r300", "r301", "r341", "r347", "r382", "r383", "r384", "r385", "r386", "r407", "r409", "r438" ] }, "COCP_RelatedPartyOperatingLeaseLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "RelatedPartyOperatingLeaseLiabilitiesCurrent", "crdr": "debit", "presentation": [ "http://cocrystalpharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities related party current", "documentation": "Related party operating lease liabilities current." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r147", "r185", "r298", "r299", "r341", "r347", "r382", "r383", "r384", "r385", "r386", "r407", "r409", "r438", "r671" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://cocrystalpharma.com/role/TransactionsWithRelatedParties" ], "lang": { "en-us": { "role": { "label": "Transactions with Related Parties", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r295", "r296", "r297", "r299", "r302", "r370", "r371", "r372", "r413", "r414", "r415", "r435", "r437" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cocrystalpharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "verboseLabel": "Clinical trial expenses", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r233", "r464", "r472", "r680" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expenses", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r232" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r527", "r538", "r548", "r573" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": [ "r528", "r539", "r549", "r574" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": [ "r535", "r546", "r556", "r581" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cocrystalpharma.com/role/BalanceSheets", "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r599", "r606" ] }, "COCP_RestrictedStockUnitsForCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "RestrictedStockUnitsForCommonStockMember", "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromCalculationsOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units for Common Stock [Member]", "documentation": "Restricted Stock Units for Common Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r40", "r58", "r345", "r361", "r362", "r369", "r390", "r489" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://cocrystalpharma.com/role/StatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r84", "r106", "r107", "r108", "r110", "r115", "r117", "r119", "r149", "r150", "r151", "r242", "r243", "r245", "r246", "r247", "r249", "r250", "r251", "r257", "r259", "r260", "r262", "r264", "r283", "r284", "r358", "r360", "r373", "r713" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r590" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r590" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://cocrystalpharma.com/role/TransactionsWithRelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unregistered common stock, purchase price", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedPerTransaction", "crdr": "debit", "presentation": [ "http://cocrystalpharma.com/role/TransactionsWithRelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unregistered common stock, investments", "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://cocrystalpharma.com/role/TransactionsWithRelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unregistered common stock, shares", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://cocrystalpharma.com/role/TransactionsWithRelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unregistered common stock, share price", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://cocrystalpharma.com/role/AccountsPayableAndAccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Expenses", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
```

"presentation": ["http://cocrystalpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromCalculationsOfNetLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r10"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Anti-dilutive Securities Excluded from Calculations of Net Loss Per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r10"] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": ["http://cocrystalpharma.com/role/LicensesAndCollaborationsDetailsNarrative", "http://cocrystalpharma.com/role/TransactionsWithRelatedPartiesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r252"] }, "COCP_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "presentation": ["http://cocrystalpharma.com/role/StockBasedAwardsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Common Stock Available for Future Issuance", "documentation": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://cocrystalpharma.com/role/StockBasedAwardsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Restricted Stock Units", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": ["r60"] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://cocrystalpharma.com/role/PropertyAndEquipmentDetailsNarrative", "http://cocrystalpharma.com/role/ScheduleOfPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r4", "r293"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails", "http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r188", "r190", "r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r216", "r217", "r218", "r219", "r220"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://cocrystalpharma.com/role/StockBasedAwardsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stock Option Transactions", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r6", "r7", "r59"] }, "COCP_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "SecuritiesPurchaseAgreementMember", "presentation": ["http://cocrystalpharma.com/role/TransactionsWithRelatedPartiesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]", "documentation": "Securities Purchase Agreement [Member]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://cocrystalpharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r512"] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://cocrystalpharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r516"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://cocrystalpharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r515"] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://cocrystalpharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": ["r521"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "auth_ref": ["r145", "r146", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r376", "r377", "r378", "r440", "r442", "r445", "r447", "r450", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r461", "r465", "r477", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r499", "r502", "r633", "r681", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r135", "r136", "r137", "r138", "r139", "r140", "r141", "r144", "r145", "r470", "r471", "r474"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://cocrystalpharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r2"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Total Options Outstanding, Forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r209"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Forfeited", "documentation": "Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r209"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Fair Value, Forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r209"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Total Options Outstanding, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r207"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Aggregate Intrinsic Value, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share", "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r207"] }, "COCP_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodTotalFairValue", "crdr": "debit", "presentation": ["http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Fair value of restricted stock unit", "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options grants in period total fair value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Fair Value, Granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r207"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance", "periodEndLabel": "Aggregate Intrinsic Value, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value", "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r204", "r205"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Total Options Outstanding, Beginning balance", "periodEndLabel": "Total Options Outstanding, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r204", "r205"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [

"http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Fair Value, Beginning balance", "periodEndLabel": "Weighted Average Fair Value, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r204", "r205"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Total Options Outstanding, Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r208"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Vested", "documentation": "Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r208"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Fair Value, Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r208"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails", "http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r188", "r190", "r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r216", "r217", "r218", "r219", "r220"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of shares authorized for issuance", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r481"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Shares available for grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r19"] }, "COCP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodDateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodDateIntrinsicValue", "crdr": "debit", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Cancelled", "documentation": "Aggregate Intrinsic Value, Cancelled." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r211"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfCommonStockAvailableForFutureIssuanceDetails", "http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Cancelled or returned", "negatedLabel": "Total Options Outstanding, Cancelled", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r202"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfCommonStockAvailableForFutureIssuanceDetails", "http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Restricted Stock Units (RSU) Granted", "label": "Total Options Outstanding, Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r200"] }, "COCP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Aggregate Intrinsic Value, Granted", "documentation": "Share based compensation arrangement by share based payment award options grants in period total intrinsic value." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance", "periodEndLabel": "Aggregate Intrinsic Value, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r19"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Total Options Outstanding, Beginning balance", "periodEndLabel": "Total Options Outstanding, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r196", "r197"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning balance", "periodEndLabel": "Weighted Average Exercise Price, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r196", "r197"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r213"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": ["http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r213"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": ["http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r213"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r212"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r212"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": ["http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee

can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r212"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfRestrictedStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } } }, "auth_ref": ["r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r216", "r217", "r218", "r219", "r220"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r201"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Cancelled", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r202"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r200"] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r187", "r195", "r214", "r215", "r216", "r217", "r220", "r226", "r227", "r228", "r229"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Maximum term of options granted", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r480"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r213"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r212"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common stock closing price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://cocrystalpharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://cocrystalpharma.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r519"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://cocrystalpharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r5", "r30", "r41", "r42", "r84", "r95", "r96", "r97", "r106", "r107", "r108", "r110", "r115", "r117", "r119", "r131", "r149", "r150", "r151", "r183", "r242", "r243", "r245", "r246", "r247", "r249", "r250", "r251", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r294", "r351", "r358", "r359", "r360", "r373", "r431"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": ["r145", "r146", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r376", "r377", "r378", "r440", "r442", "r445", "r447", "r450", "r452", "r453", "r454", "r455", "r457", "r458", "r459", "r460", "r461", "r465", "r477", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r499", "r502", "r633", "r681", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://cocrystalpharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r106", "r107", "r108", "r131", "r284", "r307", "r366", "r375", "r381", "r382", "r383", "r384", "r385", "r386", "r389", "r392", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r403", "r404", "r405", "r406", "r407", "r409", "r411", "r412", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r431", "r503"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://cocrystalpharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r106", "r107", "r108", "r131", "r147", "r284", "r307", "r366", "r375", "r381", "r382", "r383", "r384", "r385", "r386", "r389", "r392", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r403", "r404", "r405", "r406", "r407", "r409", "r411", "r412", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r431", "r503"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r530", "r541", "r551", "r576"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://cocrystalpharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Sale of common stock to related entities, net of transaction costs, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r5", "r37", "r38", "r58", "r368", "r431", "r448"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://cocrystalpharma.com/role/ScheduleOfStockOptionTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Total Options Outstanding, Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r5", "r37", "r38", "r58", "r201"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://cocrystalpharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Sale of common stock to related entities, net of transaction costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r5", "r37", "r38", "r58", "r373", "r431", "r448", "r509"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://cocrystalpharma.com/role/BalanceSheets", "http://cocrystalpharma.com/role/StatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r38", "r41", "r42", "r53", "r391", "r408", "r432", "r433", "r489", "r510", "r607", "r619", "r665", "r713"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://cocrystalpharma.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://cocrystalpharma.com/role/Equity"], "lang": { "en-us": { "role": { "label": "Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r57", "r101", "r170", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r263", "r434", "r436", "r449"] }, "us-gaap_StraightLineRentAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StraightLineRentAdjustments", "crdr": "debit", "presentation": ["http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cocrystalpharma.com/role/TransactionsWithRelatedPartiesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Rent expense", "documentation": "Amount of the adjustment to rental revenues to measure escalating leasing revenues on a straight line basis." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://cocrystalpharma.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental disclosure:" } } }, "auth_ref": [] }, "COCP_SweepAccountMember": { "xbrltype": "domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "SweepAccountMember", "presentation": ["http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Sweep Account [Member]", "documentation": "Sweep Account [Member]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":

```
"http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": [ "r570" ] }, "COCP_TaxCreditReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "TaxCreditReceivable", "crdr": "debit", "presentation": [ "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Refundable tax credit receivable", "documentation": "Tax credit receivable." } } }, "auth_ref": [] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "presentation": [ "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r30", "r31" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cocrystalpharma.com/role/TransactionsWithRelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r618", "r670" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cocrystalpharma.com/role/TransactionsWithRelatedPartiesDetailsNarrative" ], "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r562" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r569" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [ "r592" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r593" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": [ "r593" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r591" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r591" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r592" ] }, "COCP_TwoThousandandFifteenEquityIncentivePlansMember": { "xbrltype": "domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "TwoThousandandFifteenEquityIncentivePlansMember", "presentation": [ "http://cocrystalpharma.com/role/StockBasedAwardsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2015 Equity Incentive Plan [Member]", "documentation": "2015 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://cocrystalpharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://cocrystalpharma.com/role/LicensesAndCollaborationsDetailsNarrative", "http://cocrystalpharma.com/role/TransactionsWithRelatedPartiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r252" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r588" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://cocrystalpharma.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r12", "r13", "r14", "r73", "r75", "r78", "r79" ] }, "us-gaap_ValueAddedTaxReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValueAddedTaxReceivableCurrent", "crdr": "debit", "calculation": { "http://cocrystalpharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cocrystalpharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Tax credit receivable", "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r601" ] }, "COCP_WarrantsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://cocrystalpharma.com/20240930", "localname": "WarrantsToPurchaseCommonStockMember", "presentation": [ "http://cocrystalpharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromCalculationsOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Warrants to Purchase Common Stock [Member]", "documentation": "Warrants to Purchase Common Stock [Member]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://cocrystalpharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding, diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r121", "r126" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://cocrystalpharma.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r120", "r126" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r597" ] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "930", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "55", "Paragraph": "63", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
```

```
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",
```

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",

```
"Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r164": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r165": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r166": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r167": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r168": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r169": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r170": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-13" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r174": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-14" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r178": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-
50-18" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r182": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-
20-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r186": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r188": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r190":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r194": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r195": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r212": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r213": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r214": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r215": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r216": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r217": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r218": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r219": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r220": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r221": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r222": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r223": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r224": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
```

"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r466": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r467": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r468": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r469": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r470": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r471": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r472": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r473": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r474": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r475": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r476": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r477": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r478": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r479": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r483": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r484": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r485": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r486": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r487": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r488": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r489": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r490": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r491": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r492": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r493": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r497": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r498": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r499": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r513": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r519": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "2b" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r530": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r531": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r532": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r533": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r534": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r535": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r536": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",

```
"Section": "402", "Subsection": "v" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name":
```

"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",

"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 60 0001493152-24-044978-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-044978-xbrl.zip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{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|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h8XU:B%5TMB=:M2XNU:SKM& *EV;Q"W>E+++?3\I\# MJ-A7N\:R\O9JL#U9O(9#;-N\BE4]*Y.51D]B24&[-.)3!&I,'1O3Q[$D%4L# MND+/16^P8#=-V;\>U8J>IBHY<[GK.G>V-M[ZZO"=E>?364#? ++*I+Q./U"'"U-MG6TV1U+;/BZ!.M));!YC5'2V%T:I3R96EV,#_3:K<++L-8+ MC9):I7E"N1LP9Y[-MRW8HS%E:%X!RFOH>914*\TQRJHM>65:IMPZU4OW%4A))8W%2#OMS_Q12$DKDP5+V^%EK?>-5T7K<_!THVO.O+=MPA03[DWL9GS!,<7!? P"S#76NX6E[K&**^.IML1N;TZ5^KZXQKGFTN7^!X!F^MTS">-+V3L#9'VT.?+ARCP93OT2V$6]^_T,V]8<'(]H"I(R=8,=R[Q9[7N874 M*+&R?C^`'&(\/?KLR7= M69HNDH|'1X^/CRIB!._(OPS>1&@N1K!F!J/LV1)[>73R_*?HOJ?$8Q_?J3_MN?<3X!%YQO#E\?OWA*PH-*3[FP.8K -9AX M]/!$TIBH|HF,.Q(B9. .>U9QA,/AV0L@O2R*LW+S^\-M? DF;^/>U0NGS@IAR JDE'GA'VS7_V8^HQ&YF *2)#$9C87-PKGP.XG0&4ACX M42MLC36U J4|#\Q)(\(GEY')!PMB8U(!BFL9-WB3HN#G#$4A&;._^_%\&T^^\GI- $*/K01:JZ05WB6>^C\9ZZQ41Q^SA(8@T0*4%)-<^=)(\'# M%08)D4C5Y VWYFD5M:N,"+=)7TFC5,3 M7%"5RI"+ZF@%5]|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|YI+Q^9FFEA<[PY4J.O 8 M]*@KU)XYY_;0? %9)HS(7K5)E. ^[T-MI0U&-=(BZYV$TKTF6GNU%E]^](/_?O MEQ"$OAZ04MA5D @.@UD]DU6P\Q774CA{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

*Z3^P'PBYN@5#2|/-Z=Q2F&9*T0-M2!XL-=;D+VY\#<)0<(7VG5M-\,P@LT)(JJX3"NRH-:U!&D@W+KGK8&<'FD1B MZ15_R5E>*

*M/=I[M7A+SK_F>9PKMB7W/0PT]BM:&T\,/..REJECZP%_G5-+\{(ZB)TT1LWB MX1GI^XY&RDMYJ;6/J4VR>29*T^T.RL;ZDPC/K'YW=NR3L'V*\ 1 &J^QY-W< MQ-K0V*#LS+*

*8>,;UP5GCD@W:#9Q;FEU;(ME)LS0A(U%TB4L3[9A&HD41""O_M3OP4|#+5*K0*&OK4R9&&,37; 8:= M55TS((WKB7/;H8E,H&GG45?Y^NS633@3ZJC/F+CW;S7IP_EXR0*R-*

#!RH9@# M%W=U=$B"3<<5ZGC7Q5G<4AOFJ(<&JF-4N/Z#9[5U<MVK(T1P_,F|:VUS??9<&>?PFJ6 D"-C@^\QR XJ -]O:N+)#MGE=8X62P7XF4Z M

*_AVYL?E-N\"Q0]$'" T%DK:%H*MG;:YA6^ODN/9KKL3XO;L;[C \G,"ZJXX M]2$V%0>A$=W>XDT)|5<5)2XA[TS"'JFKAW|(U*5GLH M_& ZA_TEBPC/WNSUB='5@'P:.I.SF_.9J.1L?*

*E^+Q<^#[G,]7D'&G3>F]E'X M^RC\?12^>U'X54B@Y,7ZM5(|&X/?) R'PF-4PY[=""MQ%&:SO-V-5^\F'WV\?T>T,98D?A^3?4SA) 8BK55]_^"(K& HO$;YVW9**K2?CA='8 M'?*

EP;M!BWO #>PM(UK[YN)Q<@P3@!Q#6WO@=[+6\(CI!MC,J:.(W QIO!<+ MZ+ZV WQ;0%R\ ZWBC]?1Q.Y9D6;1.#?

*F=!9<<5.@7%XF|)M#NU. ^.\&NUDZ0QC^4YB.5W=3> ^-3%)'NV%W=*61:AJ?EN<-$YT);99+9 M"LP.F:1M(3H75#N*/TY#M"PQ ,PO+*

M"S_%J49NS>SO8Y2D%RC]7Y!>@P!-85HRLYG9^3;32 ,[9W({BLVYL%)CO!=# M-5G/EE_1X5!'LG@'W M[G=B?*

*A49G\TG6(P54FSV9M&.)#VQJU9E+L3)JHL#SO/VFV':V_W)N3I.!QH MEP.+KE*Y!M0*R/=C1$8'/T@S/[H%>'Y8C[N#<4=[A4.R58DBW8GYH1P=Z$&+ MI85\#<&.6G=ODN/:*

*[O#.R)3Y=V4E+X>TMVI-HN2;^_ 2ZR@+Q*MF$U-M+\)PKFLX(.4]VVI60V?&P2KZ&\IC, ^P#;]V\QIHR@?.YXZR3K@3+0 1_Q-QV"XM8V($7[W_{(9(F*

MK#2825[%&>=V_|RTLBR0DFIVCKU4)^D*W>S=)!0EY,3O1F5]NG-,*'5KR & MF"QBXG 4SHG8D[3P"Y0)363'EDK5[YK8Z\'QIM;%4$>&N+KL=>|S2YU!EY.S M.*

(0/,,Q$NU%.T<%,M H"LU>=C>P]!0HY/3H#E5|[H#OD XG8TQ #]O07!^/A9NU)H+W[WM?Y_6 MM?<@)69XPG^K>9M\@]JF.(K@XA2C1!PZTU2T_\!Z/9+G\|+W;5O;-@\|XK3C

M5KEX_*Bl?(W[^-%[_ -0?G2(\,.C>1X/D$<7+*,F3Q$F6TD_EY1P/E2LW?C-M1%|8:1L.N0N6KM|+UCI+P38Z6ZM]|WX'=5;GD>5|YIU=C4C8&X?T6A.RM(#*

MC5L_4BH'%&5N^/A=BDY7|P%J.ZEOUK_&8T^?'O@Y5|(RM<W=LZ2A,T$'XBF QR?H^[R!B>H B&%&/NA8,@ MX9[X\4L/9E(2&TE>"D%WH%=<;OD*;.>(N2O2N2=:A_/ QI%N/*

MXMGK$0;^-R*)%,3T:>OQS,=3T+2_HI3:$QJ4YK9AD:=:Y$$YWXK'+=)Y$BP3L0KZ??/Y(:I,Q E/35W?Z5.:[%;[(Z4l;55\4-*7,\(3OKV7 MYD@'1FMRR*=*

*5Q:6PE5JJ[@UAFBVF3<<'5Fl;F?'|%BE$U-M+\NG(DZ-P>J+RPM76UU=$9P)Z4N2PO@*8MR&'NSE34&G/A00E?Q@*07[HQ+ MP4*R/38>*9WTUJ8CX4$PZ=[R9=*

(XEZ3T2FEY)U"NINI-X;O|@AO&;/|@QO[! MC/V#&8;CP?8/9CAR(VY_X7&GU>MD0)MY$^@UU.T&!&5^Y:N,,/K9*V+" #AI MO>$^G:'$6C]C\.XF$NKE78V6J8=Z?6-*

CGWI(HJM]Z[%|ZJ'^0[^WS7!3]WL5 M!I/?B-Z>>&5MKW'C4V9O4A3]O,@H3O!>?GV+&8F!H'SH@65NS<[^P9):S'P M[,':WH3A0/5):$Z-7T/-=9:=\R8P:.DU%QB"(@CF&@2-R""\;-*

W%Y61^#>4K MRJ&?I;%&8R#VK,4DUNQ\PC;1(CN FQG@L!V6-T2KGFZ?=/'H6?6P^/($@HQR/?93,$68/C 61\^ZGO?BMLM(QWQ[U6!V<9&CSX. ME<9

*(988PGK*FO&JTM"/ZGWL_ >2;_P=02P,$% @ T4-M66XS<3/:.M40 LL<$!4 !C;V-P+3(P,C0P.3,P7VQA8BYX,6SE??MSY#:2YN\7>F=VHUL.C6+54)U7;-^?8<% DJL0QBRR#I%HU?*

_T!X.(-MXDE6%9!27|SNME69X)? AT3BE?CS?SZO$_2$21YGZ5^^>OOMFZ\03L.LBM/5 M7[IZ=\ZNS^[NOH*Y4601D&2I?@O7Z795__Y'__S?R#Z_.|\OTY/T66,D^@'|M=)Z%IU?*

LOL3N@G6^ ?T(TXQ"8J,_ G|%"0E^TMV&2>8H+-LO4EP@>D/U8=_.M0'_\|MT?'M#]J46Y/^$TRLBGNZNVW,>BV.0_?/?=Y\^?OTVSI^!S1G[+OPVS MM5V!|T50E'E;VIOG-

*_7_]3_G,3I;S^_P_40Y\C1^DKS'Y|S^"]?>_6G_W\ M_MN,K+Y\|^.;-V^_^|?K^._14X.3&7U%N*O&BU6BDSO[????_|=_|41%222 m'TC2?.,/M/5S_=]MU!V=GKD "JG4# MG=^\-*

I$"T+!9'YG$L7WI+M59DXI{%PMM,+G+&6EKP"Z%i$D#!D%L80IIGKOD M=6V&G2.(/)#D.OUUE3|]%.*X&$OJ/W1A"_X-ZM"=.,9@IL>RLL!M9*?G?!'B4L*

*M1A3A1^^<4"$2!P,J0YU_+>6ZH<^SL&1$8Z=2)1;T?W;5S#)032MW?P/1R!) MPF)8+<*O&SAN8+X\RQ=TDV E@3_XW5432V$U;=S[$40CRQ!)%\)Y,S,A7\[\|*

MCO.0Q0R:D\|C.GICS1I> %-J^(P,+ B(P-1,ZLI%<<'QU>U:=46+Z_.^GB50PHT/MY%V[?BWLX5@@%09!&AN$RM&B)X1:+4\|FJ5I&<W>>>>!3CQ\,5.'#7RQUT7_.M/5S_=]MU!V=GKD "JG4# MG=^\-

I$"T+!9'YG$L7WI+M59DXI{%PMM,+G+&6EKP"Z%i$D#!D%L80IIGKOD M=6V&G2.(/)#D.OUUE3|]%.*X&$OJ/W1A"_X-ZM"=.,9@IL>RLL!M9*?G?!'B4L*

*M1A3A1^^<4"$2!P,J0YU_+>6ZH<^SL&1$8Z=2)1;T?W;5S#)032MW?P/1R!) MPF)8+<*O&SAN8+X\RQ=TDV E@3_XW5432V$U;=S[$40CRQ!)%\)Y,S,A7\[\|*

MCO.0Q0R:D\|C.GICS1I> %-J^(P,+ B(P-1,ZLI%<<'QU>U:=46+Z_.^GB50PHT/MY%V[?BWLX5@@%09!&AN$RM&B)X1:+4\|FJ5I&<W>>>>!3CQ\,5.'#7RQUT7_.M/5S_=]MU!V=GKD "JG4# MG=^\-

*I[

+\D[HBX"D M--K{YYAP;^V\HE'+Z;4E.Q-ZMYCT*F (;(=32*^-"U1[S;^OLSS_!FTP0;P M[WR[P9\[NZ,D2^D_PVHZ.&8^-;X8EXR<:F27'HF/+ ,/9B<#%2#+$@V0BO;*\
M,_D^?.11F>#;Y8SBB^*D9$//![MW@BV%HNJB M[.PIB!-.!V5&4%4R:HH&Y/SE2TKX,4N!EYK5[ME\&0[.DFF?X#@N)5\%N2/ M@H2MENR&^'8#[.TZO^A(ZFHR#W+='H5XA#F
M]RY+[%,@F/'E$%8(%RY8OV#K2F070;& ^XKT+'&[+A VX1]^7]3]R,C?ENA5T MG TY[@4PW>@H9@GIC#M%-WMOVY/=UMO%_+Z[\X9^X87YS[6Q9Y5<*Y[6/7SQ M3I-_^'fA2>EG
#U0VF.YU8(-L.I9D4WOW""7Y!M?[(D_[>,\#>^AULS7;)SI. M>S1EOTZ#-U[^. W:VJN#7TM-ZU@@Y=K(B2+SWBYMR_8#)[;*=[36)!U231;6\ MT[.#)MB]R;E*& S/3 B%^3:79WYW-
[G.H62,8!.>R_.KLZN4W6*,M*Y3(>MZ M*]R$.YSB"H)@**1#))YV2,F$45](HX.)'.NFP")[KM 0XQ'2V+,X6U6+.SB5H M0+;'#20RWMO? $P\,KPLTX@? BB"9Q16N1]
{]^;=>YSC)284%36INI=) _]'\ MK3Z14Q^/Z+WSE"399W;,X3(CYUGY4"S+I#GX\YNFE6?2Y'077.S'N/X[<&ZP-P588,U6@ME73)>0W4+FDE8F!8I\8F3! H M5S:5H'>.M/=1ZX[Q
;=X&:MXHI3VGR*R\#,U>!*WCM[M=@O"ZN/K5HLOG4_VP-V1LD7_O6Z8"@X$0#(UX>!+.TK3I/6EVTO95S[6AZGW M-\3[%LQPQ=@_':VACB3B-; E.Z6-/Y+,.2#;BJF50+"P9X 5
[D&?/9U84K7 M>]D!F=W-*PSFYA6=P93KDJ=X\<;@L.8+VG3?R>XSN0P6[,LMO^H,BJK*D"U MCGZPXAV_1'S02AD\37R0LJ$=)CNP74+6+ISG/["9< ,1%'6^PCM5T"G>TUE"
MI54W6/ZXND;>U7G!VNT5S$OI&M@*]VK4[7N\$Y1B_ZY/;="G'" _+Y#I>]J8E M5IH@!ES1%"OZ[=3@#[T"5EL.XC]U=L0.K-(B4!(_.3B@.HO^7N;\O:K+C'1=
MILKQJN6=CIDFV+U!4"4,AFXFA,+9F8X(F-67P=5[_1JO2MAQX*4!/ BC)))P MZ*.#)W"GN8P.9=`W8KU)LBW&]=M/G8LP>@I9Z#G-?69K1B_[F4D)#,=LD4KH MQM,\;#*(MV
\U.G5H<[8IT.7+5\%@C*IFW'4KV!2OHRE=O8W/;RKSHYCYK"P>,Q+_ T;*-MF85>R>U$SL: _AQ.IP'$BUC!%&=NM1+*F=8)RKD>"EI%8(R;!^26W!=L..8O
M.C3G@:TJ1:WLCX$F@!1.5&D"9;0!KI&9FX"@)Z:HG9%GP2;F'KM*^F#R?2IA MM^=P=8#[!W%EDF 8I84G'L7EPB_%LU4>F^6,&C6.-@J^Q] ^<-/X64F#X941
MHNVX&7,ED,RZ+8N\H#%EG*Y&U$)/RS?')":.8B-91 =1+M M_92QJS-W\>I1G=1!)>WVY4HMY/ZKE5)1,+S2XQ-?]^3Y"VLR/7$%1+@&BG >
MDG@#8MVJ8U4]HE<]1IG)T5P[MN5XXN$X,Q4,M2O$*7C M[]3:4,/D__&?@U25^7&@O3X#[=#0\4R4O+TFR6*(OKZ[__0-XL4 "(SWK0]M>Y8X9LZGK9,C5;ST2R^I#*V]JZI!]4/(9,
'9\6P3USIH>R8)VP\BB&"]DN![MV^N+9-QN#%6QS$6]=;[3C8 >RU0$O4HC_(RC1<;72DC.3HS524)56YUF/:=; MRK9F]':534I@_(\MTB';ZM3OP5TQ&H-V C>O
=TTVC<$Z*P+5IEICA1J2+[SDH)-934=;M04/@)Q]>18 M1LH/K=1*J*-U@C[@59RR;%WHH0I,7E,O_!FS)5(L77W]A?98FRH]4C_62?]Y5]VX+TX=!OE%!M0YJE!#7^H*\P%5:D#C-XY ?
M93E^8PV_]T)!NKS:CM2W^QH\Y;U9;JQP9GBU(GS)&+7BB,N#[*ULV:0ZA'%> M$O:8UJ=/G MAE[?F-*N"!\C)#TP'"%#CU5$]>-0@=E $;X^ZNP-.M 6<5V+Y(N^=3LT<$<|9=$7
T9S'(C MMAL-XT4%>!,K^:!1WD@,W@<3SX:/CO<.YA..%/&U^>)I*.*?.]O@QG]5G7TS4 M-Z(2#Q;W67S3>V=U:.B(V,^J6P*_CP=1 1X^>%X1HI[9]N7_U^9,P\O@%-2C M@N?8I5T?
=;Z#N1]##MB=8?PCQ+X&Y,S?9,5T; M+M0=HF!0ZT36%7&00>X;W#V]@YDB]"R+WF3H3->OX9)?=6/Q*LT+4G((PE-! M+QZ#M X";K+T">V4^P[HQ'+L3(ZXOU-/8UHMQ
8)"VE007ZGK>(6W*H]6:J?V#8,[.;/CYU^$3Y)7]QA7TO^W4] ++M]R'+L9_>+![7I-5XA.% -P9N_@!A" M9?.(Z4L;Q.OO].Q. ,S9RCAPK\15C&H0IU[$"MF7XV#&5,>H&58%[G8HDGST%
<<+2?5#GPB.?0P]?QL^]B/43RTH[2-1C^:.L'G@\ M Q5C6M"(\T&-]\97TQ?+XC$C\3_4#P0>_CLOL?<)U72,;M=^Y-7UMZ%EPXY6 MB,,Q+Z^[7*MQT$#RT/F(1YY
YRM4JKU,KTC@9RT^2%7OG\AX+QC>^[5_VX<[MGR]?/3$!UONIG06)0[:^E:,Y*2K3V/]8.TMXN3B2UQR-[ND_57N$MLHN1\5Q M!G6'.CM-[SR?!'=
(S8KNIWPVA\)N)C98I#+#>R7:OC M?3CGO;+[^UF6%S=9\3=6WGP]X=R.1I M0>\4T2QE]V8A?"+C/U)^>C'H98;1G_^1:P_3:S40[XH8/MM,(["L<$'3]S< M!!MYLRN.Z%=1 P85&?
_S2?]H4P7I"_ >[1F'XQ[-W1_/Z_(OAFIWZW 48+X@ M#Z2O 1@N27G:YPOP4L=XTACG(>;R#HX/E]"!5 M"5 'V,)&'=R(8?A# _;M4NGQWZ\K%[)?G*XC2E)7[(!X3O@W+";DSV)N+
MZ0!Z[;M6'5-!K%K9X'E=_L7_J149S!?D@8"N6O5W.M6Q'LZJE36HU^6O M@*Q:62+Z@CP7Y%6KGOOZ0E>MU$T%9-5J$L!7L&JU1\X6+6;@ Z6TX-4)4 = M(!15]YS=J;= MA?
6_!>M;JMH[PH>\-(FQ8Z/XWOY*&BL<@ M17VE7WCY_^V]=QZ@IJ[C%%\5>*VZF'/83{CLD<>HG'ZBGL.5#Z87'L&H8_0_M]@W$/^*_$\["D- A_Rf.!DD1X_RL)(3%R%6%5?
^ANE!HI>KT+N<(8WW.2WT MP)\!-@A>2N=<(8WW>R7:OC M?3CGO;+[^UF6%S=9\3=6WGP]X=R.1I M0>\4T2QE]V8A?"+C/U)^>C'H98;1G_^1:P_3:S40[XH8/MM,([" L<$'3]S< M!!MYLRN.Z%=1 P85&?
_S2?]H4P7I"_ >[1F'XQ[-W1_/Z_(OAFIWZW 48+X@ M#Z2O 1@N27G:YPOP4L=XTACG(>;R#HX/E]"!5 M"5 'V,)&'=R(8?A# _;M4NGQWZ\K%[)?G*XC2E)7[(!X3O@W+";DSV)N+
MZ0!Z[;M6'5-!K%K9X'E=_L7_J149S!?D@8"N6O5W.M6Q'LZJE36HU^6O M@*Q:62+Z@CP7Y%6KGOOZ0E>MU$T%9-5J$L!7L&JU1\X6+6;@ Z6TX-4)4 = M(!15]YS=J;= MA?
6_!>M;JMH[PH>\-(FQ8Z/XWOY*&BL<@ M17VE7WCY_^V]=QZ@IJ[C%%\5>*VZF'/83{CLD<>HG'ZBGL.5#Z87'L&H8_0_M]@W$/^*_$\["D- A_Rf.!DD1X_RL)(3%R%6%5?
^ANE!HI>KT+N<(8WW.2WT MP)\!-@A>2N=<(8WW>R7:OC M?3CGO;+[^UF6%S=9\3=6WGP]X=R.1I M0>\4T2QE]V8A?"+C/U)^>C'H98;1G_^1:P_3:S40[XH8/MM,([" L<$'3]S< M!!MYLRN.Z%=1 P85&?
_S2?]H4P7I"_ >[1F'XQ[-W1_/Z_(OAFIWZW 48+X@ M#Z2O 1@N27G:YPOP4L=XTACG(>;R#HX/E]"!5 M"5 'V,)&'=R(8?A# _;M4NGQWZ\K%[)?G*XC2E)7[(!X3O@W+";DSV)N+
MZ0!Z[;M6'5-!K%K9X'E=_L7_J149S!?D@8"N6O5W.M6Q'LZJE36HU^6O M@*Q:62+Z@CP7Y%6KGOOZ0E>MU$T%9-5J$L!7L&JU1\X6+6;@ Z6TX-4)4 = M(/